<tstset trglang="any" setid="test" srclang="any">
<doc sysid="Edinburgh" docid="doc">
<seg id="1">This document is a summary of the European Union's application report (EPAR) which will be explained as the Committee for Humanities (CHMP) to enter recommendations regarding the application of the medicines.</seg>
<seg id="2">"if you need further information about your illness or treatment, please read the parcel service (also part of the EPAR) or contact your doctor or pharmacist."</seg>
<seg id="3">"if you wish for more information about the basis of the recommendations of the CHMP, please read the scientific discussion (also part of the EPAR)."</seg>
<seg id="4">"it is available as 5 mg, 10 mg, 15 mg and 30 mg tablets, as a 10 mg, 15 mg and 30 mg tablets, as a solution to take (1 mg / ml) and as a injection solution (7,5 mg / ml)."</seg>
<seg id="5">"B. Biophysical thinking and speech, Hallucinations (hearing or sight of things that are not present), misstrating and reality; • Biophysical I disorder, a psychic disease which have not been present in the patients with periods of periods."</seg>
<seg id="6">"do you have any questions or suggestions? if you want to send us a question about this product, simply complete all the fields marked * and click" "Send". ""</seg>
<seg id="7">The injunction solution is used for fast control of increased unrest or behavioral disorders when the orale is not possible.</seg>
<seg id="8">"in both diseases, the solution to take the solution to take or the melt-tabletins are applied to patients who suffer from tablets difficulty."</seg>
<seg id="9">"for patients who take advantage of other medicines, the same as Abilify, should be adapted to the dose of Abilify."</seg>
<seg id="10">"this causes the signal transmission between the brain cells by" "Neurotransmitter", "i.e. chemical substances that enable communication of the nerve cells among each other."</seg>
<seg id="11">"Aripiprazol is probably mainly known as" "full-piece" "for the receptors for the neurotransmitter Dopamine and 5-hydroxytyptamin (also serotonin)."</seg>
<seg id="12">"this means that Aripiprazol like 5-hydroxytamin and Dopamine, but in less measurements than the neurotransmitter to activate the receptors."</seg>
<seg id="13">"dopamine and 5-hydroxytyptamin with schizophrenia and bipolar disorder in schizophrenia and bipolar disorder, contributes to normalize the activity of the brain to normalize the activity of the brain, making psychological or manic symptoms."</seg>
<seg id="14">"the efficacy of Abilify, the re-determination of symptoms, was examined in three studies over up to one year."</seg>
<seg id="15">The effectiveness of the injections solution was compared in two studies at 805 patients with schizophrenia or similar diseases that have been increased to a period of two hours.</seg>
<seg id="16">"in another study, Abilify the efficacy of Abilify and Placebo, in a different study the efficacy of Abilify and Placebo, in a different study the efficacy of Abilify and Placebo, which have been stabilized with Abilify."</seg>
<seg id="17">The effectiveness of Abilify injecting solution was compared in a study on 301 patients with bipolarable disorder that was increased by Lori (another antipsychotic) and Placebo via a period of two hours.</seg>
<seg id="18">"in all studies, the change of symptoms were investigated using a standard skala for bipolar disorder or the number of patients treated to the treatment."</seg>
<seg id="19">"the company led to studies, in order to investigate how the body can take the melt-tabletins and the solution to take action (up)."</seg>
<seg id="20">"in the two studies with the injection techniques, patients showed a significant reduction in doses of 5.25 mg, 9.75 mg or 15 mg, a significant reduction of symptoms increased more than the patients who received a Placebo."</seg>
<seg id="21">In the application for the treatment of bipolar disorder in four of the five Kurzzes studies in four of the five Kurds studies are effective as Placebo.</seg>
<seg id="22">"posted in English, International, International, Sea Powers | Tagged aircraft carrier, China, Sea Control | Leave a comment"</seg>
<seg id="23">"do not describe your experience with the dispatch or the buying process. if you want to send us a question about this product, simply complete all the fields marked * and click" "Send". ""</seg>
<seg id="24">"the most common side effects of Abilify to take (observed in 1 to 10 of 100 patients), smitis (maternation), slaughter (maternation), slaughter (lemon), salipation (amorphew), salipation (amorphew), salipation (amorphew), salipation (amorphal), salipation, Insompation, Insomnie (sleeping disorders) and anxiety."</seg>
<seg id="25">"the Committee for Humanities (CHMP) was carried out to the conclusion that the benefits of Abilify in treatment of schizophrenia and severe pain in the treatment of schizophrenia and patients with Aripiprazol, against the risks associated with Aripiprazol."</seg>
<seg id="26">"in addition, the Committee came to the result that the benefits of injections for patients with schizophrenia or patients with schizophrenia or patients with patients with schizophrenia or patients with manic infections in patients with schizophrenia."</seg>
<seg id="27">"June 2004, the European Commission reported the European Commission in Otsuka Pharmaceutical Europe."</seg>
<seg id="28">ABLE FY is for the treatment of heavy up to heavy mantastic episodes of the bipolar disorder and for the prevention of a new manic episode in patients who had previously worked for the treatment with Aripiprazol. (see section 5.1).</seg>
<seg id="29">The recommended initial dose for ABLE FY is 10 or 15 mg / day at a reduction rate of 15 mg / day one day independent of meals.</seg>
<seg id="30">An increased effectiveness in dosing over a day dosis of 15 mg has not been proven, although individual patients can benefit from a higher dose. "</seg>
<seg id="31">The recommended initial dose for ABLE FY is 15 mg once daily, regardless of the meals as monotherapy or combination therapy (see section 5.1). "</seg>
<seg id="32">The efficacy of ABLE FY in treatment of schizophrenia and Biophysics - disorder in patients with 65 years have been proven.</seg>
<seg id="33">"with regard to the bigger sensitivity of these patients, a lower initialdosis should be drawn if clinical factors should justify this (see Section 4.4)."</seg>
<seg id="34">"if the CYP3A4-inductor can be removed from the combination of combination, the Aripiprazol dose should be reduced to the recommended dose (see section 4.5)."</seg>
<seg id="35">"the appearance of suprevalence of psychological diseases and affective disorders and was reported in some cases after the beginning or after change of an anti-psychotic therapy, also with Aripiprazol (see section 4.8)."</seg>
<seg id="36">"results of a epidemiological study showed that in patients with bipolar disorder, no result in patients with bipolar disorder in comparison with Aripiprazol in comparison to other antipsychotism."</seg>
<seg id="37">"Aripiprazol should be used with the treatment of patients with known kardiovasculariatric diseases, diseases that are used for hypotony fracture, hypovolution, treatment with blood pressure sensing treatment) or hypertension (including aqueous and maligne)."</seg>
<seg id="38">"3 late dyskinesia: in clinical trials which was a year or less, there was no reports about during treatment with Aripiprazol Dyskinesie."</seg>
<seg id="39">"when using ABACFY patients, signs and symptoms of a late dyskinesie should be moved to reduce the dose or treatment."</seg>
<seg id="40">"if a patient signs and symptoms developed on a MNS, or inclear high fever without an additional clinical manifestation of MNS, all anti-psychological manifestation including ABLE FY."</seg>
<seg id="41">"therefore, Aripiprazol were used in patients with crampons in Anamnese or for states that are used with crampings in connection with caution."</seg>
<seg id="42">"56 - 99 years old with Aripiprazol in patients with psychosomal patients, patients who were treated with Aripiprazol were treated with Aripiprazol."</seg>
<seg id="43">"however, in one of these studies, a study with high dosage, a significant relationship between the dosage and the use of unpredictable events in Aripiprazol patients."</seg>
<seg id="44">"hyperglycemia, in some cases extremely and associated with Ketoazide or hyperosmolarem Compa or death, was reported in patients who were treated with atypical antipsychotic substances, including ABLE FY."</seg>
<seg id="45">There is no precise risk assessment for hyperglycemia-related events with ABLE FY and other atypical antipsychotic substances which allow direct failure.</seg>
<seg id="46">"polydipans, polyphagy and weakness) are observed and patients with diabetes mellitus or with risk ofdiabetes mellitus should regularly be monitored using diabetes mellitus or with risk factors for diabetes mellitus."</seg>
<seg id="47">"in general with bipolar patients and patients with bipolarized patients and patients with bipolar bears, the application of antipsychotics, the application of antipsychotics, the use of antipsychotics, which could lead to serious complications and could lead to serious complications."</seg>
<seg id="48">"because of the primary effect of Aripiprazol on the central nervous system, when Aripiprazol in combination with alcohol, or other centrally effective drugs can be taken with excessive side effects (see section 4.8)."</seg>
<seg id="49">"the H2-Antagonis Famotidin, a Magicic acid-blocker, reduces the Resorpchart rate of Aripiprazol, with this effect as a clinically not relevant."</seg>
<seg id="50">"in a clinical study with healthy subjects, the auc of Aripiprazol for 107%, while the Crate remained unchanged."</seg>
<seg id="51">"it is expected to expect other highly effective inhibitors of CYP2D6, like fluoxictin and paroxettin, similar effects and therefore should be similar to similar Dosisreinducement."</seg>
<seg id="52">"in addition to CYP2D6 'bad' (=" "T" ") Metabolism the common application with highly effective inhibitors of Aripiprazol result in comparison to CYP2D6 extensive metries."</seg>
<seg id="53">"if you consider the common gift of Ketoconazol or other highly effective cYP3A4 inhibitors, the potential benefits potential potential risks for patients."</seg>
<seg id="54">Other highly effective inhibitors of CYP3A4 like Itraconazol and HIV-proteins have similar effects and therefore should be similar to similar Dosisreinducement.</seg>
<seg id="55">"depending on the CYP2D6- or 3A4-inhibitors, the dosage of ABLE FY is on the Dosisheight before the beginning of the accompanying therapy."</seg>
<seg id="56">"Diltiazem or Escaffopram) or CYP2D6, together with ABLE FY, can be found with an increase in Aripiprazol- concentrations."</seg>
<seg id="57">"clinical trials showed a significant effect on the metastasis of the substrates of CYP2D6 (Dextromborphan / 3-methodology), 2C19 (Omeprazol) and 3A4 (Dextrophiphan)."</seg>
<seg id="58">Patients should avoid their physician if they are pregnant or pregnant during treatment with Aripiprazol.</seg>
<seg id="59">"due to inadequate data, it is not only used in pregnancy and due to the reproduction studies in the pregnancy, unless the possible benefit of the potential of potential is able to increase the potential risk of Föp."</seg>
<seg id="60">"in addition to other antipsychotics, patients should be aware of dangerous machines, including strength vehicles, including strength vehicles, until they are sure that Aripiprazol will have no negative influence."</seg>
<seg id="61">The following side effects were more frequently than in Placebo or with a possible medical-relevant side effects (*).</seg>
<seg id="62">"the frequency of the above side effects is defined according to the following criteria: often (&gt; 1 / 100, &lt; 1 / 10); occasionally (&gt; 1 / 1,000, &lt; 1 / 100)."</seg>
<seg id="63">"results appear ordered" "by relevance" "or" "by date" "(publication date),"</seg>
<seg id="64">"in a Placebo-controlled study on 26 weeks, the incidence of EPS 19% in patients under Aripiprazol treatment and 13.1% in patients under Placebo."</seg>
<seg id="65">"in a different controlled study period, 26 weeks were treated by EPS 14.8% in patients that were treated with Aripiprazol and 15,1% of patients at Olanzapin therapy."</seg>
<seg id="66">In a controlled study with Biophysical I disorder - In a controlled study of EPS 23,5% in patients under Aripiprazol- Treatment and 53.3% in patients under Haloperiosis treatment.</seg>
<seg id="67">"in a different study about 12 weeks, the incidence of EPS 26,6% in patients under Aripiprazol treatment and 17.6% for those under lithium-treatment."</seg>
<seg id="68">"in the long time period, over 26 weeks with a Placebo of EPS 18,2% for patients under Aripiprazol- Treatment and 15,7% for patients under Aripiprazol- Treatment and 15,7% for patients."</seg>
<seg id="69">"a comparison between the patient groups of the Aripiprazol and Placebo, where potential clinically significant changes of the routines, have not been a serious problem."</seg>
<seg id="70">"evidence of the CPK (creatine-phosphokinase), generally temporarily and supplements were observed in 3.5% of the Aripiprazol patients were observed in comparison to 2.0% of the treated patients."</seg>
<seg id="71">"on the side effects that occur in connection with Aripiprazol, the maligne neuroleptic syndrome, late dyskinesie and crampings in older dementia patients, hyperglycemia and diabetes mellitus (see section 4.4)."</seg>
<seg id="72">"clinical trials and since the market launch were unintended, unintended or aberrations with Aripiprazol alone in adult patients with estimated delivery of up to 1260 mg and without death."</seg>
<seg id="73">"however, there is no information about the efficacy of a hemmodified lysis in the treatment of an overdose of Aripiprazol, as Aripiprazol is a high plasma treatment."</seg>
<seg id="74">It is assumed that the efficacy of Aripiprazol in schizophrenia and Biotonin 5HT1a receptors and a antagonist effect on Serotonin 5HT2a receptors.</seg>
<seg id="75">"Aripiprazol showed a high impact on Dopamine D2- and D3-receptor in 5HT1c- and 5HT2a -5HT2c- and 5HT7-, for alpha-1-adrenches and the histamine-H1receptor."</seg>
<seg id="76">"with the gift of Aripiprazol in dosing, from 0.5 to 30 mg once every day via 2 weeks to healthy subjects showed a high-dependent reduction of the binding of 11C-Racloprid, a D2 / D3-receptor, on the Nucleus caudatus and the Putney."</seg>
<seg id="77">"in three Placebo-controlled short time studies (4 to 6 weeks), Aripiprazol in comparison with positive or negative symptoms showed, Aripiprazol in comparison to Placebo has significant improvement in the psychotic symptoms."</seg>
<seg id="78">"in a Haloperidium-controlled study was 52 of the proportion of the individual patients who were similar to the study mediator, in both groups (Aripiprazol 77% and Haloperides 73%)."</seg>
<seg id="79">"current values from measured values, which were defined as secondary research goals, including PANSS and the Montgomery-Assam-scale, showed significantly more intense improvement than with haloperials."</seg>
<seg id="80">"in a Placebo-controlled study of 26 weeks to stabilized patients with chronic schizophrenia, an significantly higher reduction of return rate which is at 34% in the Aripiprazol group and at 57%."</seg>
<seg id="81">"in a Olanzapin-controlled, multinational double blind study with Schizzol (N = 18 or 13% of the primary patient listing), under the average weight of at least 7% compared to the output value (i.e. a increase of at least 5,6 kg) at a average weight of ca."</seg>
<seg id="82">In two Placebo-controlled monotherapy studies with flexible dosage for 3 weeks with patients with a manic or mixed choir of the bipolar-I disorder.</seg>
<seg id="83">"in a Placebo-controlled monotherapy study of 3 weeks with high dosage for patients with a manic or mixed choir of the bipolar-I disorder, Aripiprazol were not excessive."</seg>
<seg id="84">"in two years of patients, Aripiprazol showed a bipolar disorder in two weeks with patients with a manic or mixed choir of a bipolar-I disorder, with or without psychotic conclusions."</seg>
<seg id="85">Aripiprazol proved to be a comparable proportion of patients with symptomatic remission of Manie as lithium or Haloperials.</seg>
<seg id="86">"in a Placebo-controlled study of 6 weeks with patients with a manic or mixed choir of a bipolar-I disorder, with or without psychological features, the accompanying therapy with Aripiprazol has a higher efficacy in the reduction of hormonal symptoms compared to monotherapy with lithium or Valproat."</seg>
<seg id="87">"10 In a Placebo-controlled study on 26 weeks, followed by a long-term expansion of a long-term expansion of 74 weeks with manoeuvol during a stabilisation phase, in regard to the prevention of a bipolar return, mainly with the prevention of a return in the prevention of a return."</seg>
<seg id="88">"* Understand the competitive environment, the market's major players and leading brands; * Use five-year forecasts to assess how the market is predicted to develop."</seg>
<seg id="89">The average amount of surplus value is approximately 75 hours for Aripiprazol in extensible Metabolition via CYP2D6 and with approximately 146 hours at 'bad' (= "" m ") Metabolishing on CYP2D6.</seg>
<seg id="90">"in Aripiprazol, there is no differences in the pharokinetics between male and female healthy subjects, as shown at a pharmacokinetical investigation."</seg>
<seg id="91">A pop-specific evaluation for the pharokinetics have no reference to clinically significant differences regarding the ethanol or the impact of smoking on the pharokinetics of Aripiprazol.</seg>
<seg id="92">The pharmacokinequalities of Aripiprazol and Dehydro Aripiprazol were similar to patients with severe kidney disease.</seg>
<seg id="93">"the study investigates the impact of non-take-up for two hypothetical scenarios, namely increasing and decreasing the base amount of social assistance in Germany by €100 per month. IAB-Discussion Paper 20 / 2015"</seg>
<seg id="94">"based on conventional studies on safety spicology, toxicity with repetition of repetition, reproduction of reproduction, genotoxicity and the channel potential have no particular dangers for people."</seg>
<seg id="95">"ecologically significant effects were observed in dosing or expositions in which the maximum dosage or position in humans, so that they have only limited for clinical application only or no importance."</seg>
<seg id="96">The effects include a high-dependent adjunctions (Lipofuscin-pigment-accumulation and / or paratrophy) at the recommended maximum dose of 50 weeks to 60 mg / kg / day (the 10times of the middle Steady State Exposition (auc) at the recommended maximum dose on people).</seg>
<seg id="97">"in addition, a Choleliac has been found as a result of the intestinal tract of hydroxy- Metabolzol in the Galle of Monpiprazol in the Galle of Monpiprazol in the recommended clinical dose or 16- to 81owing to the recommended maximum dose for people based on mg / m2)."</seg>
<seg id="98">"however, however, there is no more than 6% of the concentration of the recommended daily dose of hydroxy- Aripiprazol not more than 6% of concentration camps that were found in the study about 39 weeks in the study (6%) of the in vitro solubility (6%) of the in vitro solubility."</seg>
<seg id="99">"in rabbits, these effects were to dosing, which led to expositions of 3- and 11cent of the middle Steady State auc at the recommended clinical maximum dose, observed."</seg>
<seg id="100">"with 2 x 1, 28 x 1, 28 x 1, 49 x 1, 98 x 1 tablets."</seg>
<seg id="101">"15 late dyskinesia: in clinical trials, a year or less, there was no reports about during treatment with Aripiprazol Dyskinesie."</seg>
<seg id="102">It is assumed that the efficacy of Aripiprazol in schizophrenia and Biotonin 5HT1a receptors and a antagonist effect on Serotonin 5HT2a receptors.</seg>
<seg id="103">"22 In a Placebo-controlled study on 26 weeks, followed by a long-term expansion of a long-term expansion of 74 weeks with manoeuvol during a stabilisation phase, in regard to the prevention of a bipolar return, mainly with the prevention of a return in the prevention of a return."</seg>
<seg id="104">"27 late dyskinesia: in clinical trials, which was a year or less, there was no reports about during treatment with Aripiprazol Dyskinesie."</seg>
<seg id="105">It is assumed that the efficacy of Aripiprazol in schizophrenia and Biotonin 5HT1a receptors and a antagonist effect on Serotonin 5HT2a receptors.</seg>
<seg id="106">"34 In a Placebo-controlled study on 26 weeks, followed by a long-term expansion of a long-term expansion of 74 weeks with manoeuvol during a stabilisation phase. in regard to the prevention of a bipolar return, mainly with the prevention of a return in the prevention of a return in the mania."</seg>
<seg id="107">"39 late dyskinesia: in clinical trials, which was a year or less, there was no reports about during treatment with Aripiprazol Dyskinesie."</seg>
<seg id="108">It is assumed that the efficacy of Aripiprazol in schizophrenia and Biotonin 5HT1a receptors and a antagonist effect on Serotonin 5HT2a receptors.</seg>
<seg id="109">"data coverage: market sizes (historic and forecasts), company shares, brand shares and distribution data. why buy this report? * Get a detailed picture of the Baby Food market; * Pinpoint growth sectors and identify factors driving change; * Understand the competitive environment, the market's major players and leading brands;"</seg>
<seg id="110">The recommended initial lift for Aripiprazol is 10 or 15 mg / day at a reduction rate of 15 mg / day one day independent of meals.</seg>
<seg id="111">Patients suffering from ABLE FY tablets can take the melt-tabletins to ABILIFY tablets (see Section 5.2).</seg>
<seg id="112">"in some cases, psychological diseases and affective disorders have been reported in some cases after the beginning or after change of an anti-psychotic therapy, also with Aripiprazol (see section 4.8)."</seg>
<seg id="113">Late dyskinesia: in clinical trials which was a year or less, there was no reports about during treatment with Aripiprazol Dyskinesie. "</seg>
<seg id="114">"clinical manifestations of a MNS are high fever, muscle stimulation and signs autonomous instability (irregular or blood pressure, troughing, sweating and heart rhythm disorders)."</seg>
<seg id="115">"in general, patients and patients with bipolarized patients and patients with bipolar bears are observed in patients with bipolar disorder, the application of antipsychotics, the use of antipsychotics, which could lead to serious complications and could lead to serious complications."</seg>
<seg id="116">Patients should continue to inform their physician if they are pregnant or pregnant during treatment with Aripiprazol</seg>
<seg id="117">The following side effects were more frequently than in Placebo or with a possible medical-relevant side effects of the drug using (*).</seg>
<seg id="118">In two Placebo-controlled monotherapy studies with flexible dosage for 3 weeks with patients with a manic or mixed choir of the bipolar-I disorder.</seg>
<seg id="119">"58 In a Placebo-controlled study of 6 weeks with patients with a manic or mixed choir of a bipolar-I disorder, with or without psychological features, the accompanying therapy with Aripiprazol has a higher efficacy in the reduction of hormonal symptoms compared to monotherapy with lithium or Valproat."</seg>
<seg id="120">"in a Placebo-controlled study on 26 weeks, followed by a long-term expansion of a long-term expansion of 74 weeks with manoeuvol during a stabilisation phase, in regard to the prevention of a bipolar return, mainly with the prevention of a return in the prevention of a return."</seg>
<seg id="121">"in Caninchs, these effects were to dosing, the expositions of the 3- and 11cent of the middle Steady State auc at the recommended clinical trial."</seg>
<seg id="122">Patients suffering from ABLE FY tablets can take the melt-tabletins to ABILIFY tablets (see Section 5.2).</seg>
<seg id="123">Late dyskinesia: in clinical trials which was a year or less, there was no reports about during treatment with Aripiprazol Dyskinesie. "</seg>
<seg id="124">"71 In a Placebo-controlled study on 6 weeks with patients with a manic or mixed choir of a bipolar-I disorder, with or without psychological features, the accompanying therapy with Aripiprazol has a higher efficacy in the reduction of hormonal symptoms compared to monotherapy with lithium or Valproat."</seg>
<seg id="125">Patients suffering from ABLE FY tablets can take the melt-tabletins to ABILIFY tablets (see Section 5.2).</seg>
<seg id="126">Late dyskinesia: in clinical trials which was a year or less, there was no reports about during treatment with Aripiprazol Dyskinesie. "</seg>
<seg id="127">"84 In a Placebo-controlled study of 6 weeks with patients with a manic or mixed choir of a bipolar-I disorder, with or without psychological features, the accompanying therapy with Aripiprazol has a higher efficacy in the reduction of hormonal symptoms compared to monotherapy with lithium or Valproat."</seg>
<seg id="128">200 mg Fructose per ml 400 mg suyl-4-hydroxybenzoat (E218) per ml 0.2 mg propyl-4-hydroxybenzoate (E216) per ml.</seg>
<seg id="129">The recommended initial dose for ABLE FY is 15 mg once daily, regardless of the meals as monotherapy or combination therapy (see section 5.1). "</seg>
<seg id="130">"for the prevention of resettlement in patients who have obtained Aripiprazol, therapy with the same dose."</seg>
<seg id="131">Late dyskinesia: in clinical trials which was a year or less, there was no reports about during treatment with Aripiprazol Dyskinesie. "</seg>
<seg id="132">"hyperglycemia, in some cases extremely and associated with Ketoazide or hyperosmolarem Compa or death, was reported in patients who were treated with atypical antipsychotic substances, including ABLE FY."</seg>
<seg id="133">There is no precise risk assessment for hyperglycemia-related events with ABLE FY and other atypical antipsychotic substances which allow direct failure.</seg>
<seg id="134">"92 In a clinical study with healthy subjects, the auc of Aripiprazol for 107%, while the Crate remained unchanged."</seg>
<seg id="135">"Diltiazem or Escaffopram) or CYP2D6, together with ABLE FY, can be found with an increase in Aripiprazol- concentrations."</seg>
<seg id="136">Reasons To Buy • This report allows you to plan future business decisions using the forecast figures given for the market.</seg>
<seg id="137">It is assumed that the efficacy of Aripiprazol in schizophrenia and Biotonin 5HT1a receptors and a antagonist effect on Serotonin 5HT2a receptors.</seg>
<seg id="138">"in a Olanzapin-controlled, multinational double blind study with Schizzol (N = 18 or 13% of the primary patient listing), under the average weight of at least 7% compared to the output value (i.e. a increase of at least 5,6 kg) at a average weight of ca."</seg>
<seg id="139">"97 In a Placebo-controlled monotherapy study of 3 weeks with high dosage for patients with a manic or mixed choir of the bipolar-I disorder, Aripiprazol were not excessive."</seg>
<seg id="140">"in a relative Biophysics study, in which the pharokinetics of 30 mg Aripiprazol as a solution to take a 30 mg Aripiprazol in tabular form, the ratio between the geometric Cmax -middle value of the solution and value of tablets at 122% (N = 30)."</seg>
<seg id="141">"as a result of the recommended clinical dose of alcohol, Metabolzol in the Galle of Monpiprazol in the Galle of Monpiprazol in the Galle of Monpiprazol in the recommended clinical dose or 16- to 81owing to the recommended maximum dose for people based on mg / m2)."</seg>
<seg id="142">"in rabbits, these effects were to dosing, which led to expositions of 3- and 11cent of the middle Steady State auc at the recommended clinical maximum dose, observed."</seg>
<seg id="143">ABLE FY injection solution is used for fast control of Agiogenesis and behavioral disorders in patients with schizophrenia or patients with mansions of the Bible-I disorder if an orale therapy is not appropriate.</seg>
<seg id="144">"as soon as it is mounted, the treatment should be completed with Aripiprazol injector solution and with the oral application of Aripiprazol."</seg>
<seg id="145">"in order to increase the resorption and the variability, a injunction is recommended in the M. deltoideus or deep in the gluttoideus or deep in the gluttoideus or deep in the glutoideus or deep in the glamorous regions."</seg>
<seg id="146">A lower dose of 5.25 mg (0.7 ml) can be given depending on the individual clinical status under consideration of the existing or akut therapy (see section 4.5).</seg>
<seg id="147">"if a special treatment with Aripiprazol indian is, see the summary of the features of the drug using ABLE FY tablets, ABLE FY melt-tabletins or ABLE FY solution."</seg>
<seg id="148">"there are no investigations to the efficacy of Aripiprazol injunction solution for patients with Agidium and behaviors, which caused differently than by schizophrenia and manic episodes of the Bible-I disorder."</seg>
<seg id="149">"if a parable therapy with benzene-benzene in addition to the Aripiprazol injector solution, the patient should be observed in terms of extreme Sealing or a blood pressure in case (see section 4.5)."</seg>
<seg id="150">Investigations to safety and efficacy of Aripiprazol injector solution for patients with alcohol and drug intoxication (due to defective or illegal drugs).</seg>
<seg id="151">"Aripiprazol should be used with the treatment of patients with known kardiovasculariatric diseases, diseases that are used for hypotony fracture, hypovolution, treatment with blood pressure sensing treatment) or hypertension (including aqueous and maligne)."</seg>
<seg id="152">Late dyskinesia: in clinical trials which was a year or less, there was no reports about during treatment with Aripiprazol Dyskinesie. "</seg>
<seg id="153">"clinical manifestations of a MNS are high fever, muscle stimulation and signs autonomous instability (irregular or blood pressure, troughing, sweating and heart rhythm disorders)."</seg>
<seg id="154">"polydipans, polyphagy and weakness) are observed and patients with diabetes mellitus or with risk ofdiabetes mellitus should regularly be monitored using schimellitus or with risk factors for diabetes mellitus."</seg>
<seg id="155">"in general, patients and patients with bipolarized patients and patients with bipolar bears, the application of antipsychotics, the application of antipsychotics, the use of antipsychotics, which could lead to serious complications and could lead to serious complications."</seg>
<seg id="156">"nevertheless the intensity of the Sedation is greater compared with the most of Aripiprazol, in a study in which it was applied in a study in which it was applied in healthy subjects."</seg>
<seg id="157">"105 The H2-Antagonis Famotidin, a Magicic acid-blocker, reduces the Resorpchart rate of Aripiprazol, with this effect is no longer relevant."</seg>
<seg id="158">"in addition to CYP2D6 'bad' (=" "T" ") Metabolishing can be used in comparison to CYP2D6 extensible Metabolism in higher plasma concentration of Aripiprazol."</seg>
<seg id="159">Other highly effective inhibitors of CYP3A4 like Itraconazol and HIV- Proteasinhibitors have similar effects and therefore should be similar to similar Dosisreinducement.</seg>
<seg id="160">"depending on the CYP2D6- or 3A4-inhibitors, the dosage of ABLE FY is on the Dosisheight before the beginning of the accompanying therapy."</seg>
<seg id="161">"106 Lori (2 mg) infamous, the intensity of the Sedation was greater compared with the most of the gift of Aripiprazol."</seg>
<seg id="162">The following side effects were found in clinical trials in clinical trials with Aripiprazol injunctions more often than possible medical side effects (*) (see section 5.1):</seg>
<seg id="163">"the frequency of the above side effects is defined according to the following criteria: often (Acts 1 / 100, &lt; 1 / 10); occasionally (Acts 1 / 1,000, &lt; 1 / 100)."</seg>
<seg id="164">107. the following side effects were found in clinical trials with oral clinical trials in clinical trials (see section 5.1):</seg>
<seg id="165">"in a Placebo-controlled study on 26 weeks, the incidence of EPS 19% in patients under Aripiprazol- Treatment and 13.1% in patients under Placebo."</seg>
<seg id="166">In a different study about 12 weeks the incidence of EPS 26.6% in patients under Aripiprazol- Treatment and 17.6% for those under lithium-treatment.</seg>
<seg id="167">"in the long time period, over 26 weeks with a Placebo of EPS 18,2% for patients under Aripiprazol-treatment and 15,7% for patients under Aripiprazol-treatment and 15,7% for patients."</seg>
<seg id="168">"a comparison between the patient groups of the Aripiprazol and Placebo, where potential clinically significant changes of the routines, have not been a serious problem."</seg>
<seg id="169">"evidence of the CPK (Kreatinphosphokinase), in general, temporarily withdrawals were observed in 3.5% of the Aripiprazol patients, compared to 2.0% of the surgical treatment patients."</seg>
<seg id="170">"on the side effects that occur in connection with Aripiprazol, the maligne neuroleptic syndrome, late dyskinesie and cramphetamine in older dementia patients, hyperglycemia and diabetes mellitus (see section 4.4)."</seg>
<seg id="171">110 and behavioral disorders were the Aripiprazol injunction solution with statistical results in a significant improvement of agglomeration / behaviors and was similar to Haloperials.</seg>
<seg id="172">"in a Placebo-controlled short time study (24 h) with 291 patients with bipolar disorder and behavioral disorders, the Aripiprazol injections, was the Aripiprazol injunction and behavioral disorders in comparison to Placebo and similar to the Lorentam- Reference Low."</seg>
<seg id="173">"during the PANSS results of the initial value on the PANSS exceptions, the Component Score was 5.8 for Placebo, 9.6 for Lorpiprazol."</seg>
<seg id="174">"in analyses of subgroups in patients with mixed fans or patients with severe diaphragms, a similar efficacy should be observed in relation to the total population, but a statistical Signifidentiz could be determined due to a reduced patient."</seg>
<seg id="175">"in three Placebo-controlled short time studies (4 to 6 weeks), Aripiprazol (oral) in comparison to Placebo a statistical analysis was significantly significant improvement of the psychotic symptoms."</seg>
<seg id="176">"in a Haloperidium-controlled study was 52 of the proportion of the individual patients who were similar to the study mediator, in both groups (Aripiprazol 77% (oral) and Haloperiosis 73%)."</seg>
<seg id="177">"current values from measured values, which were defined as secondary research goals, including PANSS and the Montgomery-asberg-depressions-scale, showed significantly significant improvement as in Haloperials."</seg>
<seg id="178">"in a Placebo-controlled study on 26 weeks of stabilized patients with chronic schizophrenia, a significantly higher reduction of return rate which is at 34% in the Aripiprazol- (oral) -group and at 57% under Placebo."</seg>
<seg id="179">"in a Olanzapin-controlled, multinational double blind study with Schizzol (N = 18 or 13% of the primary patient listing), at least 7% compared to the output value (i.e. a increase of at least 5,6 kg) at a average weight of ca."</seg>
<seg id="180">"111 In a Placebo-controlled study of 6 weeks with patients with a manic or mixed choir of a bipolar-I disorder, with or without psychological features, the accompanying therapy with Aripiprazol has a higher efficacy in the reduction of hormonal symptoms compared to monotherapy with lithium or Valproat."</seg>
<seg id="181">"in a Placebo-controlled study on 26 weeks, followed by a 74-wristband in a stabilisation phase, using Aripiprazol during a stabilisation phase, in regard to the prevention of a bipolar return, mainly with the prevention of a return in the mania."</seg>
<seg id="182">The Aripiprazol auc is bigger the auc after a gift of the same dose as tobacco; the systematic exposition was similar between the two formulations.</seg>
<seg id="183">"in 2 studies with healthy subjects, the medium time to reaching the maximum plasma cutting range at 1 to 3 hours."</seg>
<seg id="184">"the gift of Aripiprazol injectionsolution was tolerated by rats and monkeys well tolerated, resulting in no direct toxicity in a systematic exposition (auc), the 15- or 5 times over the maximum human body position of 30 mg."</seg>
<seg id="185">"in studies for the reproduction of intravenous application for intravenous application, the 15- (rats) and 29 times (canine) over the maximum human body position of 30 mg."</seg>
<seg id="186">"based on conventional studies with Aripiprazol (oral) for security spicology, toxicity with repeated gift, reproduction of reproduction, genotoxicity and the channel potential have no particular dangers for people."</seg>
<seg id="187">"ecologically significant effects were observed in dosing or expositions, which have been significantly exceeded for the maximum dosage or exposition in humans. thus they have not limited to the clinical application only or no importance."</seg>
<seg id="188">The effects include a variety of severe side effects (Lipofuscin-pigment-accumulation and / or paratrophy) at the recommended maximum dose (auc) at the recommended maximum dose of 60 weeks to 60 mg / kg / day (the 10-times of the middle-state-position (auc) at the recommended maximum dose on people).</seg>
<seg id="189">"in addition, a Choleliac has been found as a result of the failure of the hydroxy- Metabolite from Aripiprazol in the Galle of Monpiprazol in the recommended clinical dose or 16- to 81 tons of the recommended maximum dose for people based on mg / m2)."</seg>
<seg id="190">"in Caninchen, these effects were to dosing, which led to expositions of 3- and 11-nine of the middle-elauc in the recommended clinical trial period, observed."</seg>
<seg id="191">Firm of the Year for Compliance Audits and Investigations Gibson Dunn & Crutcher Firm of the Year for Private Construction Luther</seg>
<seg id="192">"in accordance with the" "CHMP leader on Risk Management Systems for Hong Kong" "must be submitted to the updated risk management plan at the same time with the next periodic Safety Update Report (PSUR)."</seg>
<seg id="193">"in addition, a updated risk management plan must be submitted if new information is known to the current safety data, denomers or the measures for risk inimbalances, within 60 days after a more important milestone of the pharmaceutical market is achieved."</seg>
<seg id="194">14 x 1 tablets 28 x 1 tablets 49 x 1 tablets 56 x 1 tablets 98 x 1 tablets</seg>
<seg id="195">EU / 1 / 04 / 276 14 x 1 tablets EU / 1 / 04 / 11549 x 1 tablets EU / 1 / 04 / 276 56 x 1 tablets EU / 1 / 04 / 276 56 x 1 tablets EU / 1 / 04 / 1098 x 1 tablets</seg>
<seg id="196">EU / 1 / 04 / 276 14 x 1 tablets EU / 1 / 04 / 276 28 x 1 tablets EU / 1 / 04 / 276 28 x 1 tablets EU / 1 / 04 / 276 56 x 1 tablets EU / 1 / 04 / 010 98 x 1 tablets</seg>
<seg id="197">EU / 1 / 04 / 276 / 011 14 x 1 tablets EU / 1 / 04 / 276 / 014 56 x 1 tablets EU / 1 / 04 / 276 / 014 56 x 1 tablets</seg>
<seg id="198">EU / 1 / 04 / 276 / 016 14 x 1 tablets EU / 1 / 04 / 276 / 019 56 x 1 tablets EU / 1 / 04 / 276 / 020 98 x 1 tablets</seg>
<seg id="199">"if one of the linked side effects will be considerably lower or if you notice any side effects that are not specified in this product information, please inform your doctor or pharmacist."</seg>
<seg id="200">"it will be applied for the treatment of adults who suffer from a disease, which is characterized by symptoms such as hearing, in sight or sight of things that are not present, enlightening, creative ideas, unrelated, own behavior and a flat tuning situation."</seg>
<seg id="201">"ABLE FY is applied to adults to treat an extra-feeling, the feeling of excessive energy, much less sleep than usually, very fast spinning with fast changing ideas and sometimes strong friction."</seg>
<seg id="202">"high blood sugar or cases of diabetes (sugardisease) in the family, insignificant muscle movements, especially in the face of heart or vascular disease or cases of heart disease (transitory attack) / TIA), normal blood pressure."</seg>
<seg id="203">"if you suffer as a healthy patient of dementia (loss of memory, or other spiritual abilities), you should have a certificate of your doctor if you have ever dreamed a stroke or temporary blood flow of the brain."</seg>
<seg id="204">Inform your doctor if you suffer from muscle stiffness or rigidity.</seg>
<seg id="205">Children and young people ABLE FY does not apply to children and adolescents because it was not examined in patients under 18 years.</seg>
<seg id="206">"when taking care of ABLE FY with other medicines, please inform your doctor or pharmacist if you have to use other medicines."</seg>
<seg id="207">Medicines for treating heart rhythm disorders Antioxidsiva or herbal medicine prescribed for treatment of depressions and anxiety medication. medicines for treatment of epilepsy diseases are used for treating epilepsy diseases.</seg>
<seg id="208">Pregnancy and lactation you should not take care if you are pregnant, unless you are pregnant, you have discussed this with your doctor. "</seg>
<seg id="209">You should not take your car or use machines or use machines until you know how ABLE FY will work with you.</seg>
<seg id="210">Please take this medication only after return with your doctor if you suffer from a disregard to certain sugar.</seg>
<seg id="211">Please talk with your doctor or pharmacist if you have the impression that the effect of ABLE FY is too strong or weak.</seg>
<seg id="212">"even if you feel better, change or set the daily dose of ABLE FY, without your doctor before."</seg>
<seg id="213">"if you have taken a bigger amount of ABILIFY tablets, when you recommended that you prefer more ABLE FY tablets than by your doctor recommended (or if someone else has some of your ABFY tablets), please contact your doctor."</seg>
<seg id="214">"if you forgotten your dose of ABLE FY If you have forgotten a dose, take the forgotten dose, take it not to one day the double dose."</seg>
<seg id="215">"frequent side effects (with more than 1 of 100, less than 1 of 10, less than 1 of 10 patients) of uncontrollable sugar movements, headache, hypocrisy, sleep problems, sleep problems, ruffness, malignant, citrus, citrus, malignant, citrus, malignant, citrus, malignant, citrus, swelling"</seg>
<seg id="216">"the side effects (for more than 1 of 1,000, less than 1 of 100 patients) Some persons can feel comfortable, especially when they stand out of one or sitting position, or they can find an accelerated pace."</seg>
<seg id="217">Please inform your doctor or pharmacist if one of the adverse side effects or side effects that are not specified in this form information.</seg>
<seg id="218">"like ABLE FY looks and content of ABLE FY 5 mg tablets are rectangular and blue, with embossing of A-007 and 5 on one side."</seg>
<seg id="219">Inform your doctor if you suffer from muscle stiffness or rigidity.</seg>
<seg id="220">"even if you feel better, change or set the daily dose of ABLE FY, without your doctor before."</seg>
<seg id="221">"like ABLE FY looks and content of the package ABSOFY 10 mg tablets are rectangular and rosafinks, with embossing of A-008 and 10 on one side."</seg>
<seg id="222">Inform your doctor if you suffer from muscle stiffness or rigidity.</seg>
<seg id="223">"even if you feel better, change or set the daily dose of ABLE FY, without your doctor before."</seg>
<seg id="224">"like ABLE FY looks and content of the package ABSOFY 15 mg tablets are around and yellow, with embossing from A-009 and 15 on one side."</seg>
<seg id="225">Inform your doctor if you suffer from muscle stiffness or rigidity.</seg>
<seg id="226">"even if you feel better, change or set the daily dose of ABLE FY, without your doctor before."</seg>
<seg id="227">"as ABILIFY looks and content of the package ABSOFY 30 mg tablets are round and rosafers, with embossing of A-011 and 30 on one side."</seg>
<seg id="228">"171 If you suffer as a healthy patient of dementia (loss of memory, or other spiritual abilities), you should have a certificate of your doctor if you have ever dreamed a stroke or temporary blood flow of the brain."</seg>
<seg id="229">Inform your doctor if you suffer from muscle stiffness or rigidity.</seg>
<seg id="230">"important information about certain other components of ABLE FY patients, which may not be phenylalanine, should note that ABLE FY melt-tabletins are included as source for phenylalanine."</seg>
<seg id="231">"on the opening of the Blisterboards, the tablet with dry hands and put the melt in the whole at the tongue."</seg>
<seg id="232">"even if you feel better, change or set the daily dose of ABLE FY, without your doctor before."</seg>
<seg id="233">"if you have taken a bigger amount of ABLE FY taken when you should find more ABLE FY melt-tabletins, or if someone else is recommended to your doctor if you need some of your ABSOFY melt-tabletins), please contact your doctor."</seg>
<seg id="234">"Calciumtrimetasitic, Crombulfam-Kalium, Crombulfam-Kalium, Pariulfam-Kalium, Vanilla - aroma artificial (contains vanilla and ethylvanes), wine-acid, magnesium (III) - dioxide (E172)."</seg>
<seg id="235">"like ABLE FY looks and content of the package The ABLE FY 10 mg melting tabletins are round and rosafers, with embossing of" "640" on one side and "" 10 "on the other."</seg>
<seg id="236">"177 If you suffer as a healthy patient of dementia (loss of memory, or other spiritual abilities), you should have a certificate of your doctor if you have ever dreamed a stroke or temporary mancipation of the brain."</seg>
<seg id="237">Inform your doctor if you suffer from muscle stiffness or rigidity.</seg>
<seg id="238">"calciumtrimetric, Crombulfam-Kalium, Crombulfam-Kalium, Pariulfam-Kalium, Vanilla-oxide (contains vanilla and ethylvanes), wine-acid, magnesium (III) - hydroxid-oxide x H2O (E172)."</seg>
<seg id="239">"like ABLE FY looks and content of the package The ABLE FY 15 mg melting tabletins are around and yellow, with embossing of" A "over" 641 "on one side and" 15 "on the other."</seg>
<seg id="240">"183 If you suffer as a healthy patient of dementia (loss of memory, or other spiritual abilities), you should have a certificate of your doctor if you have ever dreamed a stroke or temporary mancipation of the brain."</seg>
<seg id="241">Inform your doctor if you suffer from muscle stiffness or rigidity.</seg>
<seg id="242">"like ABLE FY looks and content of the package The ABLE FY 30 mg melting tabletins are round and rosafers, with embossing of" A "over" 643 "on one side and" 30 "on the other."</seg>
<seg id="243">Inform your doctor if you suffer from muscle stiffness or rigidity.</seg>
<seg id="244">You should not take your car or use machines or use machines until you know how ABLE FY will work with you.</seg>
<seg id="245">190 Important information on certain other components of ABLE FY any ml ABILIFY solution to take up 200 mg Fructose and 400 mg Sucrose.</seg>
<seg id="246">"if your doctor is sent to you, you can suffer from an Intolerance to certain sugar levels, please contact your doctor before you take this medicine."</seg>
<seg id="247">The dose of ABLE FY solution has to be measured with the gearing measuring cups or the gearing 2 ml tie pipette that are included in the package.</seg>
<seg id="248">Please talk with your doctor or pharmacist if you have the impression that the effect of ABLE FY is too strong or weak.</seg>
<seg id="249">If you prefer a larger amount of ABILIFY solution as you should find more ABLE FY solution to be taken as from your doctor (or if any other ABUSE FY solution to be taken), please contact your doctor. "</seg>
<seg id="250">"Dinucci umedate, fructose, glyceric acid, methyl-4-hydroxyloat (E216), sodium hydroxid, Sucrose, platin-4-hydroxybenzoat (E216), sodium hydroxylozoat (E216), sodium hydroxylozoat (E216), sodium hydroxylozoat (E216), sodium hydroxylozoat (E216), sodium hydroxylozoat (E216), sodium hydroxylozoat (E216), sodium hydroxylozoat (E216), sodium hydroxylozoat (E216), sodium hydroxylozoat (E216), sodium hydroxylozoat (E216), sodium hydroxylozoat (E216), sodium hydroxylozoat (E216), sodium hydroxylozoat (E216), sodium hydroxylozoat (E216), sodium hydroxylozoat (E216), sodium hydroxylozoat (E216), sodium hydroxylozoat (E216), sodium hydroxylozoat (E216),</seg>
<seg id="251">"like ABLE FY looks and content of the package ABSOFY 1 mg / ml solution to take a clear, color-resistant to light yellow liquid in bottles with a child safe polypropylene cap and to 50 ml, 150 ml or 480 ml"</seg>
<seg id="252">"ABILIFY injection solution is applied for the rapid treatment of increased unrest and desperate behavior, which is characterized by symptoms such as: the hearing, sight or sight of things that are not present, unrelated, friendly behavior, and flawling mood."</seg>
<seg id="253">"people with this illness can also be depressed, feel guilty or afraid. overweight, the feeling of excessive energy, much less sleep than usually, very rapid trace with changing ideas and sometimes strong friction."</seg>
<seg id="254">Inform your doctor if you suffer from muscle stiffness or rigidity.</seg>
<seg id="255">"use ABLE FY with other medicines, please inform your doctor or pharmacist if you use other medicines or use in other drugs, even if it is not non-prescription drugs."</seg>
<seg id="256">Medicines for treating heart rhythm disorders Antioxidsiva or herbal medicine prescribed for treatment of depressions and anxiety medication. medicines for treatment of epilepsy treatments for treatment of epilepsy diseases are used for treating epilepsy.</seg>
<seg id="257">"196 pregnancy and lactation you should not use ABLE FY if you are pregnant, unless you are pregnant, you have discussed this with your doctor."</seg>
<seg id="258">"you should not use the car or use machines if you do not use vehicles or machines, if you feel right after application of ABLE FY injection solution."</seg>
<seg id="259">"if you have concerns that you need more ABACFY injection solution, please contact your doctor or care."</seg>
<seg id="260">"frequent side effects (with more than 1 of 100, less than 1 of 10, less than 1 of 10 patients) of ABLE FY injection solution, fatigue, headache, headache and vomiting."</seg>
<seg id="261">"the side effects (for more than 1 of 1,000, less than 1 of 100 patients) Some individuals can feel a change of blood pressure, especially when setting out of the lights or sitting, or a fast pulse, a drying-feeling in mouth or have beaten out."</seg>
<seg id="262">"frequent side effects (with more than 1 of 100, less than 1 of 10, less than 1 of 10 patients) uncontrollable sugar movements, headache, anomination, sleep problems, ruffness, sleep problems, rums, citrus, citrus, citrus, malignant, citrus, citrus, lemon."</seg>
<seg id="263">"if you need further information about your illness or treatment, please read the parcel service (also part of the EPAR), or contact your doctor or pharmacist."</seg>
<seg id="264">Abrasion should only be applied under the supervision of a qualified Oncoologist on the application of cytostatika (elimination of cells) specialized departments.</seg>
<seg id="265">Patients with patients when certain side effects on the blood or the nervous system can reduce the dose or treatment.</seg>
<seg id="266">"if you want to send us a question about this product, simply complete all the fields marked * and click" "Send". ""</seg>
<seg id="267">The efficacy of oxane was examined in a major study at the 460 women with metastatic breast cancer annually.</seg>
<seg id="268">The effect of abraxane (in allways or monotherapy) was compared with the conventional Paclitaxel in combination with other medicines to reduce the side effects).</seg>
<seg id="269">"in the main study 72 (31%) of the treatment of patients at the treatment of 37 (16%) of 225 patients who received conventional Paclitaxel patients."</seg>
<seg id="270">"in addition to metastatic breast cancer, the patients were treated for the first time due to metastatic breast cancer, there were no difference between drugs and survival."</seg>
<seg id="271">Patients were obtained from patients who had previously received other treatment of their metastatic breast cancer in relation to these indicators that the xane is effective as conventional Paclitaxel.</seg>
<seg id="272">It must not be applied to patients who have been treated or before the treatment of low methylactic cells in the blood.</seg>
<seg id="273">"in contrast to other Paclitaxel the drug, it was to be effective as conventional Paclitaxel and that it must be given to other Paclitaxel in contrast to other Paclitaxel."</seg>
<seg id="274">"in January 2008, the European Commission reported the European Commission on the company's own bioscience Limited."</seg>
<seg id="275">Oral therapy in patients with patients with patients for metastatic disease associated with patients with chronic inflammatory disease is not shown in patients with the standard anthracyclin therapy (see also section 4.4).</seg>
<seg id="276">"in patients with chronic inflammatory conditions &lt; 0,50 x 109 / l over a period of a week or longer) or severe neuroneuropathy, the dose should be reduced to 220 mg / m2."</seg>
<seg id="277">"in sensory neuropathy 3 is the treatment to break up to degrees 1 or 2, and with all the following cycles, the dose must be reduced."</seg>
<seg id="278">There is currently no adequate data for the recommendation of Dosiser adapters in patients with easier to increase the liver function (see section 4.4 and 5.2).</seg>
<seg id="279">No studies were carried out with the impact of kidney function and there is no adequate data for the recommendation of Dosisometric parameters in patients with impairment of kidney function (see Section 5.2).</seg>
<seg id="280">Abrasion is not recommended for use in children under 18 years because of not sufficient data for accidents and effectiveness.</seg>
<seg id="281">Xane is a Albumin-born nanoparsis of Paclitaxel which could have much other pharmacological characteristics as other formulations of Paclitaxel (see section 5.1 and 5.2).</seg>
<seg id="282">"if an allergic reaction should be removed immediately, the medicine should immediately set immediately and a symptomatic treatment, and the patient may not be treated with Paclitaxel."</seg>
<seg id="283">"during the patient, there should not be a member of the patient's treatment to &gt; 1.5 x 109 / l-tizing, and the thrombocytes returned to &gt; 100 x 109 / l."</seg>
<seg id="284">Patients with severe liver disorders (bilirubin &gt; 5 x ULN or ASL / ALT &gt; 10 x ULN) should not be treated with abraxane.</seg>
<seg id="285">"during a clearly concertxane in connection, kardiotoxicity was not certified, particularly in patients with previous anthracyclin treatment or chronic heart disease or lung disease."</seg>
<seg id="286">"if the patient is treated after the gift of abraxane nausea, vomiting and penetration, this may be treated with the usual antiques and constipative means."</seg>
<seg id="287">"it should not be used for pregnant women in pregnant or in pregnant women, the treatment of the mother with Paclitaxel is unsuitable for the treatment of mother with Paclitaxel."</seg>
<seg id="288">During and until 1 month after treatment with abraxane a reliable verification method.</seg>
<seg id="289">Male patient who can be treated with abraxane is to be used during and up to six months after treatment no child.</seg>
<seg id="290">Male patient should be advised to advise against the treatment of the treatment of the treatment with abraxane the possibility of a missounding infertility.</seg>
<seg id="291">Roxane can cause side effects such as fatigue (very often) and Schwinn (frequently) that can be associated with traffic and the ability to serve machines.</seg>
<seg id="292">"the following are the most common and most important cases of side effects in the pivotal phase III study, which were treated in the pivotal phase III study once all three weeks with 260 mg / m2 abrasion were treated."</seg>
<seg id="293">Neutrular morphology was the most important essential to toxicological toxicity (at 79% of patients) and was quickly resealed and sealed; the leukopenie was increased at 71% of the patients.</seg>
<seg id="294">Anaemia (Hb &lt; 10 g / dl) was observed in 46% of the patients treated in three cases (Hb &lt; 8 g / dl).</seg>
<seg id="295">In the table 1 are the side effects listed in combination with the gift of abraxane as monotherapy for each dose and indication of studies (N = 789).</seg>
<seg id="296">"very often (Acts 1 / 10); frequently (Acts 1 / 100, &lt; 1 / 100); rare (Acts 1 / 10,000, &lt; 1 / 100); very rare (&lt; 1 / 10,000); very rare (&lt; 1 / 10,000)."</seg>
<seg id="297">"occasionally, increased blood pressure, weight gain, increased metabolism in blood, increased blood sugar, increased blood sugar, increased blood sugar, increased blood sugar, increased blood sugar, increased blood glucose in blood, reduced blood sugar, increased blood sugar to blood vessels."</seg>
<seg id="298">"lime spheres, bubbles, dry mouth, mucophagitis, pain in the mouth, orphophagitis, pain in the mouth, orphophagitis, pain in the mouth, orale pain, pain in the kidneys and urinary tract:"</seg>
<seg id="299">"pain in the breast cancer, weakness of muscle muscles, pain pain, pain in the skeletal musculature, flanges and muscular musculine."</seg>
<seg id="300">Ruhelogens 1 The frequency of oversensitive actions will be calculated based on a definitions in a population of 789 patients.</seg>
<seg id="301">"since these events on a voluntary basis during clinical practice, there are no estimates of the actual frequency and it has been proven to be established with these events."</seg>
<seg id="302">Paclitaxel is a antimikrotubuli-active substance that promotes the assembly of the microtubules of the tube indices and the microtubules by inhibitors of their deportation.</seg>
<seg id="303">"this stabilization leads to an inhibition of the normal dynamic reproduction of the mikrotubularly network, which is essential for vitale interphase and the mites of cell functions."</seg>
<seg id="304">It is known that Albumin the Transcytsis of plasma components in the endothelium cells and in-vitro tests were demonstrated that the present presence of Paclitaxel cells promotes the endothelial cells by the endothelial cells.</seg>
<seg id="305">It is assumed that this improved transendothelial transportation by the gp-60-nightstand or conveys a Paclitaxel-accumulation in cysteine) a Paclitaxel accumulation in the field of tumors.</seg>
<seg id="306">The application of oxane for metastatic micromazinom is supported by data from 106 patients in two single-dimensional studies and of 454 patients who were treated in a prospective study phase III-comparison study.</seg>
<seg id="307">"in a study, 43 patients were treated with metastatic matism, which was given in the form of an infusion over 30 minutes with a dose of 175 mg / m2."</seg>
<seg id="308">"in the second study, a dose of 300 mg / m2 were used as Infusion over 30 minutes to 63 patients with metastatic mmazinom."</seg>
<seg id="309">This multidisciplinary study was carried out in patients with metastatic maclitaxel which had been made in form of soluble paclitaxel 175 mg / m2 as a 3-hour Infusion with premeditative reaction (N = 225) or in the form of abraxane 260 mg / m2 as 30-minute Infusion (N = 229).</seg>
<seg id="310">"in the study, 64% of the patients had a impact on general conditions (ECOG 1 or 2), 79% of visceral metastases and 76% had more than 3 metastases."</seg>
<seg id="311">"14% of patients had not received any chemotherapy, 27% had only a fat chemotherapy, 40% due to metastatic and 19% due to metastatic and 25%."</seg>
<seg id="312">"9 The results for the general range and time to the progression of the disease as well as progressive survival and survival for patients, the first-line therapy are listed below."</seg>
<seg id="313">Neurotoxicity compared to Paclitaxel was produced by the improvement around a degree of patients who were at a time during the treatment of peripheral neuropathy 3.</seg>
<seg id="314">The natural course of peripheral neuropathy at Baseline on Baseline due to cumulative toxicity of indixane to &gt; 6 Treatment was not investigated and is still unknown.</seg>
<seg id="315">The Pharmacokinetics of the total-Paclitaxel to 30- and 180-minute infusions of abraxane with a dose of 80 to 375 mg / m2 was measured in clinical trials.</seg>
<seg id="316">The active substance (auc) increased by 2653 to 16736 n.h / ml of a dose of 80 to 300 mg / m2.</seg>
<seg id="317">"10 And intravenous gift of orxane in the recommended clinical dose of 260 mg / m2, the Paclitaxel plasma concentration of multiphasers."</seg>
<seg id="318">The medium volume of distribution amounted to 632 l / m2; the high distribution volume is based on an extensive extract of Paclitaxel and / or Weights by Paclitaxel.</seg>
<seg id="319">In a study with advanced sound absorption properties of Paclitaxel the pharmacokinequalities of Paclitaxel after intravenous 30-minute injectors were compared with the values after a 3 hour injections by 175 mg / m2 soluble paclitaxel.</seg>
<seg id="320">The Clearance of Paclitaxel was higher (43%) than after a soluble paclitaxel injection and the distribution volume was higher (53%).</seg>
<seg id="321">"in the published literature on in-vitro tests the humanoid microxypaxel and to two smaller metabolites (3" "p-Hydroxypaclitaxel and 6α -3" -p-Dihydroxypaclitaxel). "</seg>
<seg id="322">"after a 30-minute Infusion of 260 mg / m2 with metastatic treatment of the intoxication of 4% of the metabolites 6α -Hydroxypaclitaxel and 3" "p-Hydroxypaclitaxel and 3" -p-Hydroxypaclitaxel "</seg>
<seg id="323">"in the age of over 75 years, the age of over 75 years are only few data, since only 3 patients have been involved in the pharmacokinetics analysis."</seg>
<seg id="324">The chemical and physical stability was established at 2 ° C - 8 ° C in original box and above light light protected by 8 hours.</seg>
<seg id="325">"Paclitaxel is a cytotoxidized medicine and as well as other potential toxic substances, should be relied in handling."</seg>
<seg id="326">"under use of sterile syringe, slow down over a period of at least 1 minute 20 ml of a 9 mg / ml (0.9%) sodium chloride solution."</seg>
<seg id="327">"according to complete body of the solution, the penetration bottle should be at least 5 minutes to ensure a good use of solid material."</seg>
<seg id="328">"for at least 2 minutes, then the penetration bottle is carried out for at least 2 minutes and be careful and / or throws, until a complete Reseller-board of the Pulvers is done."</seg>
<seg id="329">"in case of dispersing or saucers, the penetration bottle has to be removed too gently to achieve a complete resusability to achieve a complete resusboard."</seg>
<seg id="330">The 5-mg / ml Suspension is calculated and the corresponding quantity of the refractions are calculated and the corresponding quantity of the reluctxane in an empty, sterile PVC- or non-PVC-infuelling bag injectors. "</seg>
<seg id="331">Firm of the Year for Compliance Audits and Investigations Gibson Dunn & Crutcher Firm of the Year for Private Construction Luther</seg>
<seg id="332">Risk management plan The owner of the permit is described in the pharmaceutical company (RMP) and in the module 1.8.2 of the approval process (RMP) and in the module 1.8.2 of the authorisation procedure, as well as all subsequent updates of the RMP that are agreed with the CHMP. "</seg>
<seg id="333">"according to the CHMP Directive, risk management systems for medicines used to use the updated RMP simultaneously with the next periodic Safety Update Report (PSUR)."</seg>
<seg id="334">"in addition, a updated RMP evalues • If new information refer to the current safety specification, pharmaceutical kovigilding or the risk inimpairment of 60 days after reaching a major millimeter (pharmaceutical grade or risk inding) • On request of the customer service"</seg>
<seg id="335">"8 hours in the fridge in the penetration bottle, if it is stored in the box, to protect the content before light."</seg>
<seg id="336">"after treatment of Mammakarzinom, the treatment of Mammakarzinom, however, were not successful, and if you were not successful for anthracyclin-therapies in question."</seg>
<seg id="337">"if you are allergic to Paclitaxel or one of the other components of oxane, if you are allergic to Paclitaxel or one of the other components of oxane, the initial values for neutralisation of &lt; 1.5 x 109 / l - your doctor will inform you about it)"</seg>
<seg id="338">"special caution on the application of abraxane is necessary: • If you have an impact of kidney function, if you suffer from the feeling of feeling, contact-sensitive or muscle weakening • if you have heart problems, if you have heart problems?"</seg>
<seg id="339">"if you use other medicines, please inform the doctor if you could use other medicines or more recently, even if it could not cause any prescription drugs, since these may cause an interchangeable effect with abraxane."</seg>
<seg id="340">During and until 1 month after treatment with abraxane a reliable verification method.</seg>
<seg id="341">"in addition, they should be advised to advise against the treatment of a sperm cell, because of the abraxane treatment, the possibility of any remaining infertility is possible."</seg>
<seg id="342">"there is no side effects such as fatigue (very often) and scalability (frequently) that can be associated with traffic and the ability to serve machines."</seg>
<seg id="343">"if you will receive other medicines in your treatment, you should advise on the driving or use of machines from your doctor."</seg>
<seg id="344">"22 • impact on the peripheral nerves (pain and divers) • pain in one or more joints • pain in one or more joints • pain in the muscles • nausea, penetration and fatigue and fatigue"</seg>
<seg id="345">"the lack of adverse side effects (at least 1 of 100 patients reported: • Hautes, pain, skin disorders • bone disorders, reduced muscle coordination or difficulty for reading • change in the heart rate or in heart rhythm • swelling of the mucous or pasture tongue, mouth-mouth or waking tongue, mousoor • sleep disorders."</seg>
<seg id="346">The rare side effects of the rare side effects (at least 1 of 10.000 patients reported): • lung-infection • skin-action</seg>
<seg id="347">Please inform your doctor or pharmacist if one of the adverse side effects or side effects that are not specified in this form information.</seg>
<seg id="348">"if they are not used immediately, it can be stored in the penetration bottle of up to 8 hours in the fridge (2 ° C - 8 ° C) if these are stored in the box to protect the contents before light."</seg>
<seg id="349">"each piece of bottle contains 100 mg of Paclitaxel. • The other component is running in the middle of the body (contains sodium, sodium caprylate and N Acetyltryptophan (Ph.D.)."</seg>
<seg id="350">Preventive measures for preparing and use Paclitaxel is a cytotoxidized medicine and as well as in other potential toxic substances.</seg>
<seg id="351">"under use of a sterile spraying should slow down over a period of 1 minute 20 ml of a 9 mg / ml (0,9%) sodium chloride solution."</seg>
<seg id="352">"afterwards the penetration bottle for at least 2 minutes slowly and careful, and / or inlay, until a complete Reseller-board of the Pulvers is done."</seg>
<seg id="353">"for the patient, exact power volume of the 5 mg / ml Suspension and the appropriate amount of refractions are in an empty, sterile PVC infusioning type IV injectors."</seg>
<seg id="354">"in the case of parenteral medicine, it should be used before use on any particle testing and discolation, whenever the solution or the containers are used."</seg>
<seg id="355">The stability of the date is stable even when the penetration of the date is stable when the penetration of the box is stored in the box to protect the contents before light.</seg>
<seg id="356">Firm of the Year for Private Construction Luther Firm of the Year for Pharmaceuticals and Healthcare Hogan Lovells</seg>
<seg id="357">"the member states have to ensure that the owner of the permit will take place in dialysis centres and individuals in dialysis centres and retailers, with the following information and materials:"</seg>
<seg id="358">"• Packaging brochure • summary of the characteristics of the product (subject information), labelling and packing facilities. • With clear picture of the correct application of the product, cooling boxes for transport through the patient."</seg>
<seg id="359">This means that Abuse of a biological medicine can be found in the European Union (EU) approved and the same active substance (also "reference of patients").</seg>
<seg id="360">It will occur in patients with normal blood cells which may occur in connection with a blood transfusion complications if prior to the procedure a blood loss of 900 to 1 800 ml is expected.</seg>
<seg id="361">Treatment with sampling must be made under the supervision of a doctor which is being shown in the treatment of patients with diseases for which the drugs is shown.</seg>
<seg id="362">Patients with kidney problems and patients with kidney problems and patients who want to make a heart failure to injected into a vene.</seg>
<seg id="363">"the injunction can also be made by the patient or of its staff members, if they have a appropriate guide."</seg>
<seg id="364">Patients with chronic kidney disease or patients who receive a chemotherapy in the recommended area (between 10 and 12 grams per deciliter in adults or between 9.5 and 11 g / dl in children).</seg>
<seg id="365">"the iron values of all patients are given before treatment to ensure that there is no iron deficiency, and the iron deficiency should be included during the treatment."</seg>
<seg id="366">"in patients who receive chemotherapy, or patients with kidney problems can be caused by a erythropoitic deficiency or that the body is not sufficient to the body's own erythropoietin."</seg>
<seg id="367">Erythropoietin is used to increase the number of red blood cells and to increase the consequences of a blood loss.</seg>
<seg id="368">It is produced by a cell in which a gene (DNA) was brought to the formation of epetin.</seg>
<seg id="369">"as a injunction as a injunction in a vene in the frame of a major study with 479 patients, which is compared to a kidney problems caused by kidney problems caused by kidney problems."</seg>
<seg id="370">"at least eight weeks, Eprex / Erypo was arrested in a vene injector before they were placed on abamed or continue Eprex / Erypo."</seg>
<seg id="371">Main indices for the effectiveness was the change of the hemmop values between the beginning of the study and the payment period in the weeks 25 to 29.</seg>
<seg id="372">The company laid out the results of a study in which the effects of using Eprex / Erypo at 114 cancers were examined with chemotherapy.</seg>
<seg id="373">"in the study with patients that caused by kidney problems caused by kidney problems caused by kidney problems caused by kidney problems caused by kidney problems, in the same extent as with those patients that continue to Eprex / Erypo."</seg>
<seg id="374">"in comparison to the patients that continue to Eprex / Erypo, an increase of 0,063 g / dl of the output value of 12,0 g / dl."</seg>
<seg id="375">"the most common side effects of Abseamed is an increase in blood pressure, the symptoms of symptoms of endoshalopathy (brain problems) such as sudden, staging headache and contasies."</seg>
<seg id="376">"may not be used in patients that may be sensitive (allergic) against epetin, or one of the other components."</seg>
<seg id="377">Abseamed as injtion under the skin is not recommended to treat kidney problems because further studies are required to ensure that this is no allergic reactions.</seg>
<seg id="378">"the Committee for Humanities (CHMP) corresponds to the conclusion that the provisions of the European Union of detection has been approved in accordance with the provisions of the European Union, the medicine was a comparable quality, safety and efficacy like Eprex / Erypo."</seg>
<seg id="379">Firm of the Year for Compliance Audits and Investigations Gibson Dunn & Crutcher Firm of the Year for Private Construction Luther</seg>
<seg id="380">"in August 2007, the European Commission published the media media Pectter GmbH & Co KG, a permit for the insured by Abseamed in the whole European Union."</seg>
<seg id="381">"treatment of anaemia and reduction of the Transaction requirements for adults with solid tumors, maligor lymatitis or multiplem myelom, which is to obtain a chemotherapy at the beginning of chemotherapy."</seg>
<seg id="382">"the treatment should not be used for patients with medium capacity (hemmoglobin [Hb] 10 - 13 g / dl [6.2 - 8.1 mmol / l], no iron deficiency or inadequate measures (4 or more units blood in women; 5 or more units blood in men)."</seg>
<seg id="383">"the reduction of foreign blut can be used in adults without iron deficiency in adults without iron deficiency, where a high risk of transfusioning applications is expected."</seg>
<seg id="384">HB 10-13 g / dl) and a expected blood loss of 900-1800 ml are applied to participate in an autologists of blood vessels.</seg>
<seg id="385">"as a result, the hermoglobin objective concentration is between 10 and 12 g / dl (6,2 - 7,5 mmol / l), except for luggage diatonic patients, with which the hemmop concentration between 9.5 and 11 g / dl (5,9 - 6,8 mmol / l)."</seg>
<seg id="386">"according to age, gender and overall disease may be different; therefore, the evaluation of individual clinical study and disease is required by the physician."</seg>
<seg id="387">An increase in hermoglobin to more than 2 g / dl (1.25 mmol / l) over a period of four weeks should be avoided.</seg>
<seg id="388">"due to the variability between patients, occasionally patients can be observed in patients with a patients individual hemmomobindings via or under the hemoferbinder - targets are observed."</seg>
<seg id="389">"in view of this hemmop management, it should be tried to achieve an appropriate dosensin concentration concentration of 10 g / dl (6,2 mmol / l) to 12 g / dl (7,5 mmol / l) to reach 12 g / l (7,5 mmol / l)."</seg>
<seg id="390">"if the hemisphere value for more than 2 g / dl (1.25 mmol / l) per month, the epetin-alfa dose is reduced by 25%."</seg>
<seg id="391">Patients should be monitored to ensure that epetin is necessary to ensure that epetin is necessary in the lower dose that is necessary for control of anaemia and the anaesthesia symptoms.</seg>
<seg id="392">"results appear ordered" "by relevance" "or" "by date" "(publication date),"</seg>
<seg id="393">"results appear ordered" "by relevance" "or" "by date" "(publication date),"</seg>
<seg id="394">Initial sdosis 50 I.E. / kg three times per week by intravenous application if necessary with a Dosy increase of 25 I.E. / kg (three times per week) until the desired target is reached (this should be made in steps of at least 4 weeks).</seg>
<seg id="395">"according to age, gender and overall disease may be different; therefore, the evaluation of the individual clinical study and disease is required by the physician."</seg>
<seg id="396">"in view of this hemmop management, it should be tried to achieve an appropriate dosensin concentration concentration of 10 g / dl (6,2 mmol / l) to 12 g / dl (7,5 mmol / l) to reach 12 g / l (7,5 mmol / l)."</seg>
<seg id="397">Patients should be monitored to ensure that epetin is necessary to ensure that epetin is necessary to ensure that epetin is necessary for control of infection processes.</seg>
<seg id="398">"if after 4 treatment weeks of the bungee rated to at least 1 g / kg (0.62 mmol / l) or the Reticulocytotic acid, the dose of 150 mg / kg three times per week or 450 I.E. / kg once per week."</seg>
<seg id="399">"if the hemisphere, &lt; 1 g / l (&lt; 0.62 mmol / l) and the Reticulocytotals &lt; 40,000 cells / µl compared to the output value, the dose to 300 I.E. / kg three times a week."</seg>
<seg id="400">"if after another 4 treatment weeks with 300 I.E. / kg / kg / kg, the dose of a 1 g / kg / l) or the Reticulocytotic acid has been retained for the dose of 300 mg / kg in three times per week."</seg>
<seg id="401">"if you have any queries, please contact us on Tel.: + 49 5764 318 444. or contact us per email. if you want to send us a question about this product, simply complete all the fields marked * and click" "Send". ""</seg>
<seg id="402">Patients with light anaemia (hematocrine 33 - 39%) in which the precipitation of vessels should be required in a dose of 600 mg / kg body weight twice a weekly for 3 weeks before the operating procedure.</seg>
<seg id="403">"with the iron-degree programme should be as early as possible - e.g. some weeks before the beginning of the autologists blood spies, which will be at the beginning of the Abroad-treatment of large iron reserves."</seg>
<seg id="404">"6 The recommended dosage is 600 mg / kg epetin, which should be given on three weeks (day 21, 14 and 7) before the operating procedure and on the day of the surgery (day 0)."</seg>
<seg id="405">"in this case, the epoxy of 300 I.E. / kg are subject to a minimum of 10 days before, on the day of the trial, as well as 4 days."</seg>
<seg id="406">"alternatively, the injunction at the end of the dialysis on the hose of a Fistelnadel, followed by 10 ml isotononcooking solution to ensure the hose and a sufficient injector of the medicines through the circulation."</seg>
<seg id="407">Patients treated under the treatment with any Erythropotin at an Erythroblatin (Pure Red Cell Aplasia, PRCA) should be obtained (see section 4.4 - Erythroblafenie). "</seg>
<seg id="408">"heart attack or stroke within one month before the treatment, instabile Angina pectoris, increased risk of depth of Venanromboli (e.g. anamnestically known venous thrombooths)."</seg>
<seg id="409">"in patients that are provided for a larger electrical conductive programme, the use of epoxy disease, the use of epoxy disease, peripheral arterial disease, peripheral arterial disease, peripheral arterial disease, peripheral arterial disease, peripheral arterial disease or cerebrovascular disease."</seg>
<seg id="410">Erythroblahenie (PRCA) Very rare was reported on the appearance of an anchorpering of PRCA to monthly to years of years with subcutaneous Erythropotin.</seg>
<seg id="411">"in patients with sudden drug loss, the Reticulocyte value is determined and the usual causes for a non-use (ice cream, Followers re- or vitamin B12 deficiency, radial toxication, infections, or infections, blood loss and hammers)."</seg>
<seg id="412">"if the Reticulocytes value, under consideration of the anemia (i.e. the Reticulocyte" Index "), the anti-Erythropods or &lt; 0,5%), the anti-Erythropotin sitin is determined and a investigation of the bone figure should be found in the diagnosis of a PRCA."</seg>
<seg id="413">The data to immunogenesis is not sufficient for patients with a risk to patients with a risk to patients with a risk to patients with renal anaemia).</seg>
<seg id="414">8 patients with chronic kidney disease should not be exceeded under section 4.2.</seg>
<seg id="415">"clinical trials were observed in clinical trials when erythropoese stimulates, if erythropoese-stimulating substances (ESA) with a hemostrong stimuli - objective concentration of over 12 g / dl (7.5 mmol / l)."</seg>
<seg id="416">"controlled clinical trials have not shown significant benefits that is due to the administration of epetines, if the hemmop concentration above the control of the symptoms and the avoidance of blood transfusions."</seg>
<seg id="417">"if you want to send us a question about this product, simply complete all the fields marked * and click" "Send". ""</seg>
<seg id="418">"in patients with chronic kidney infiltration and clinically evidular coronary heart disease, or reservoir intoxication should not be exceeded under section 4.2. the lower limit of the hermoglobin objective concentration should not be exceeded."</seg>
<seg id="419">"due to the treatment of anemia with epoxetalfa at adults with kidney failure, the progression of kidney disease is not accelerating."</seg>
<seg id="420">"in tumour patients, chemotherapy should be taken into account for the assessment of the therapeutic treatment of epetin-alfa-gift and the Erythropotin-response (patients who might be transacted)."</seg>
<seg id="421">"if the Hb increase is greater than 2 g / dl (1.25 mmol / l) per month or a Hb value of 13 g / dl (8,1 mmol / l), must be adjusted to the risk of possible thrombotic events."</seg>
<seg id="422">The decision for the application recombined conythropoetine should take on a benefit risk of participation in the respective patients that should consider the specific clinical context.</seg>
<seg id="423">Patients treated for a larger electrical conductive surgery should be obtained if possible at the beginning of the epetin-alfa therapy the cause of anemia and accordingly be treated accordingly.</seg>
<seg id="424">Patients who receive an increased risk for thrombotic and vascular diseases should have a increased risk for thrombotic and vascular diseases.</seg>
<seg id="425">"in addition, it can not be excluded that in treatment with epeetalfa, for patients with epealkaline value of &gt; 13 g / dl a increased risk of postoperative postoperative thrombotic / vascular events."</seg>
<seg id="426">"in several controlled trials, it has been proven to improve patients with symptomatic anemia treatment with symptomatic anaemia treatment."</seg>
<seg id="427">4 months in patients with metastatic breast cancer in patients with metastatic breast cancer when a Hämoglobin-goal concentration of 12 - 14 g / dl (7.5 - 8.7 mmol / l) was created</seg>
<seg id="428">"as a result, epictin can be controlled by Ciclosporin with Ciclosporin, should check the blood level of Ciclosporin and the ciclosslindosis can be adjusted."</seg>
<seg id="429">"in vitro tests, there is no evidence on an interaction between epetin and G-CSF or GM-CSF."</seg>
<seg id="430">"utf-8 (Unicode, worldwide) utf-16 (Unicode, worldwide) utf-16 (Unicode, worldwide) utf-16 (Unicode, worldwide) utf-16 (Unicode, worldwide) utf-16 (Unicode, worldwide) utf-16 (Unicode, worldwide) utf-16 (Unicode, worldwide) utf-16 (Unicode, worldwide)"</seg>
<seg id="431">The most common side effects during treatment with epetin is an increase in the blood pressure or deterioration of an existing hypertension.</seg>
<seg id="432">An increased incidence thrombovascular events (see Section 4.4 and Section 4.8 - General) was observed in patients with Erythropoetines.</seg>
<seg id="433">"regardless of the Erythropotin treatment, it can occur in surgical patients with carcinovasculariums after repeated blood vessels and vascular diseases."</seg>
<seg id="434">It is identical with the endothelial cells and the carbohydrates that are identical with the endoidal neythropotin that was isolated from the urine due to the urine patient.</seg>
<seg id="435">"it could be shown with the help of cultures human bone tissue, that epetin is stimulating the erythropoese stimulates the erythropoese stimuli."</seg>
<seg id="436">"389 patients with hemisphere (221 multiple myelome, 144 Non-Hodgkinase) and 332 patients with solid tumors (172 Mammakarzinome, 22 gastrointestinal carcinoma, 21 gastrointestinal carcinome, and 30 more)."</seg>
<seg id="437">"1895 patients with solid tumors (683 Mammakarzinome, 260 bronchia tumors, 300 gastrointestinal tumors, 300 gastrointestinal tumors and 478 others) and 802 patients with hemisphere."</seg>
<seg id="438">In five large patients with a total of 2833 patients were investigated with a total of 2833 patients; four of these studies were double blind placeboots with a total of 2833 patients.</seg>
<seg id="439">"in the open study, there is no difference in the overall survival between the patients with recombinant humanities, patients and control procedures."</seg>
<seg id="440">"in these studies showed the patients with recombinant humanoid macythropotin patients with a anemia due to different common malignome, statistical analysis particularly significant amounts of mortality as with the controls."</seg>
<seg id="441">The overall survival in the studies could not be explained by differences in the inscription of thrombals and related complications associated with recombinant Erythropotin patients and may be satisfactory.</seg>
<seg id="442">"there is a increased risk of thrombovine, which can be treated with recombinant Erythropotin, and a negative impact on the overall survival may not be excluded."</seg>
<seg id="443">"it is not valid, as far as these results have been treated to the application of recombinant Erythropotin with tumours which were treated with chemotherapy, to be transferred to a hermop value under 13 g / dl, since a few patients were included with these characteristics."</seg>
<seg id="444">Epoxy-alfa regulations according to repeated intravenous application showed a half hours of about 4 hours at healthy subjects and a little extended half hours of about 5 hours in patients with kidney disease.</seg>
<seg id="445">"after subcutaneous injections, the Serum mirror of epetin is much lower than the serum levels which are reached after intravenous injection."</seg>
<seg id="446">"there are no Kumulation, regardless of whether they are 24 hours after the first gift or 24 hours after the last gift."</seg>
<seg id="447">(bone markfibrosis is an unknown complications associated with chronic kidney disease in humans and could be due to a secondary hyperparathyreoidism or unknown factors.</seg>
<seg id="448">"patients were treated with epoxetate patients who were treated with epetin, which were not increased with epictin, which were not increased with epetin."</seg>
<seg id="449">"14 In its experimental studies with approximately the 204,000 of the application to the use in humans recommended Woetin alfa to reduced body weight, to a delay of the Ossification and an increase in the fötal mortality."</seg>
<seg id="450">These reports are based on in vitro diagnostics with cells from human tumours which are for the clinical situation but by unsafe Signifikanz.</seg>
<seg id="451">"in the framework of the interdisciplinary application, the patient can lead to a period of maximum 3 days outside of the cooling water and not over 25 ° C."</seg>
<seg id="452">"the syringes are fitted with inspection plates and the filling volume is displayed by a sealed label, so that if necessary, the measurement of partial load is possible."</seg>
<seg id="453">Treatment with sampling must be made under supervision of doctors who have received the experience in the treatment of patients with the above indications.</seg>
<seg id="454">"21 The recommended dosage is 600 mg / kg epetin, which should be given on three weeks (day 21, 14 and 7) before the operating procedure and on the day of the surgery (day 0)."</seg>
<seg id="455">23. patients with chronic kidney disease should not be exceeded under section 4.2.</seg>
<seg id="456">"if you want to send us a question about this product, simply complete all the fields marked * and click" "Send". ""</seg>
<seg id="457">"utf-8 (Unicode, worldwide) utf-16 (Unicode, worldwide) utf-16 (Unicode, worldwide) utf-16 (Unicode, worldwide) utf-16 (Unicode, worldwide) utf-16 (Unicode, worldwide) utf-16 (Unicode, worldwide) utf-16 (Unicode, worldwide) utf-16 (Unicode, worldwide)"</seg>
<seg id="458">An increased incidence thrombovascular events (see Section 4.4 and Section 4.8 - General) was observed in patients with Erythropoetines.</seg>
<seg id="459">"389 patients with hemisphere (221 multiple myelome, 144 Non-Hodgkinase) and 332 patients with solid tumors (172 Mammakarzinome, 22 gastrointestinal carcinoma, 21 gastrointestinal carcinome, and 30 more)."</seg>
<seg id="460">"29 In its experimental studies with approximately the 204,000 of the application to the use in humans recommended Woetin alfa to reduced body weight, to a delay of the Ossification and an increase in the fötal mortality."</seg>
<seg id="461">"in the framework of the interdisciplinary application, the patient can lead to a period of maximum 3 days outside of the cooling water and not over 25 ° C."</seg>
<seg id="462">"36 The recommended dosage is 600 mg / kg epetin, which should be given on three weeks (day 21, 14 and 7) before the operating procedure and on the day of the surgery (day 0)."</seg>
<seg id="463">38. patients with chronic kidney disease should not be exceeded under section 4.2.</seg>
<seg id="464">"if you want to send us a question about this product, simply complete all the fields marked * and click" "Send". ""</seg>
<seg id="465">"utf-8 (Unicode, worldwide) utf-16 (Unicode, worldwide) utf-16 (Unicode, worldwide) utf-16 (Unicode, worldwide) utf-16 (Unicode, worldwide) utf-16 (Unicode, worldwide) utf-16 (Unicode, worldwide) utf-16 (Unicode, worldwide) utf-16 (Unicode, worldwide)"</seg>
<seg id="466">An increased incidence thrombovascular events (see Section 4.4 and Section 4.8 - General) was observed in patients with Erythropoetines.</seg>
<seg id="467">"389 patients with hemisphere (221 multiple myelome, 144 Non-Hodgkinase) and 332 patients with solid tumors (172 Mammakarzinome, 22 gastrointestinal carcinoma, 21 gastrointestinal carcinome, and 30 more)."</seg>
<seg id="468">Spatial Dependence and Heterogeneity in Empirical Analyses of Regional Labour Market Dynamics 23 June 2015</seg>
<seg id="469">"in the framework of the interdisciplinary application, the patient can lead to a period of maximum 3 days outside of the cooling water and not over 25 ° C."</seg>
<seg id="470">"51 The recommended dosage is 600 mg / kg epetin, which should be given on three weeks (day 21, 14 and 7) before the operating procedure and on the day of the surgery (day 0)."</seg>
<seg id="471">53. patients with chronic kidney disease should not be exceeded under section 4.2.</seg>
<seg id="472">"if you want to send us a question about this product, simply complete all the fields marked * and click" "Send". ""</seg>
<seg id="473">"utf-8 (Unicode, worldwide) utf-16 (Unicode, worldwide) utf-16 (Unicode, worldwide) utf-16 (Unicode, worldwide) utf-16 (Unicode, worldwide) utf-16 (Unicode, worldwide) utf-16 (Unicode, worldwide) utf-16 (Unicode, worldwide) utf-16 (Unicode, worldwide)"</seg>
<seg id="474">An increased incidence thrombovascular events (see Section 4.4 and Section 4.8 - General) was observed in patients with Erythropoetines.</seg>
<seg id="475">"389 patients with hemisphere (221 multiple myelome, 144 Non-Hodgkinase) and 332 patients with solid tumors (172 Mammakarzinome, 22 gastrointestinal carcinoma, 21 gastrointestinal carcinome, and 30 more)."</seg>
<seg id="476">"in its experimental studies with approximately the 204,000 of the application to the use in the person recommended Wooltin, epoxic body weight, to a delay of the Ossification and an increase in the fötal mortality."</seg>
<seg id="477">"in the framework of the interdisciplinary application, the patient can lead to a period of maximum 3 days outside of the cooling water and not over 25 ° C."</seg>
<seg id="478">"66 The recommended dosage is 600 mg / kg epetin, which should be given on three weeks (day 21, 14 and 7) before the operating procedure and on the day of the surgery (day 0)."</seg>
<seg id="479">68. patients with chronic kidney disease should not be exceeded under section 4.2.</seg>
<seg id="480">"if you want to send us a question about this product, simply complete all the fields marked * and click" "Send". ""</seg>
<seg id="481">"utf-8 (Unicode, worldwide) utf-16 (Unicode, worldwide) utf-16 (Unicode, worldwide) utf-16 (Unicode, worldwide) utf-16 (Unicode, worldwide) utf-16 (Unicode, worldwide) utf-16 (Unicode, worldwide) utf-16 (Unicode, worldwide) utf-16 (Unicode, worldwide)"</seg>
<seg id="482">An increased incidence thrombovascular events (see Section 4.4 and Section 4.8 - General) was observed in patients with Erythropoetines.</seg>
<seg id="483">"389 patients with hemisphere (221 multiple myelome, 144 Non-Hodgkinase) and 332 patients with solid tumors (172 Mammakarzinome, 22 gastrointestinal carcinoma, 21 gastrointestinal carcinome, and 30 more)."</seg>
<seg id="484">"74 In this experimental studies with approximately the 204,000 of the application to the use in humans recommended Woetin alfa to reduced body weight, to a delay of the Ossification and an increase in the fötal mortality."</seg>
<seg id="485">"in the framework of the interdisciplinary application, the patient can lead to a period of maximum 3 days outside of the cooling water and not over 25 ° C."</seg>
<seg id="486">"81 The recommended dosage is 600 mg / kg epetin, which should be given on three weeks (day 21, 14 and 7) before the operating procedure and on the day of the surgery (day 0)."</seg>
<seg id="487">83 patients with chronic kidney disease should not be exceeded under section 4.2.</seg>
<seg id="488">"if you want to send us a question about this product, simply complete all the fields marked * and click" "Send". ""</seg>
<seg id="489">"utf-8 (Unicode, worldwide) utf-16 (Unicode, worldwide) utf-16 (Unicode, worldwide) utf-16 (Unicode, worldwide) utf-16 (Unicode, worldwide) utf-16 (Unicode, worldwide) utf-16 (Unicode, worldwide) utf-16 (Unicode, worldwide) utf-16 (Unicode, worldwide)"</seg>
<seg id="490">An increased incidence thrombovascular events (see Section 4.4 and Section 4.8 - General) was observed in patients with Erythropoetines.</seg>
<seg id="491">"389 patients with hemisphere (221 multiple myelome, 144 Non-Hodgkinase) and 332 patients with solid tumors (172 Mammakarzinome, 22 gastrointestinal carcinoma, 21 gastrointestinal carcinome, and 30 more)."</seg>
<seg id="492">"89 In its experimental studies with approximately the 204,000 of the application to the use in humans recommended Woetin alfa to reduced body weight, to a delay of the Ossification and an increase in the fötal mortality."</seg>
<seg id="493">"in the framework of the interdisciplinary application, the patient can lead to a period of maximum 3 days outside of the cooling water and not over 25 ° C."</seg>
<seg id="494">"96 The recommended dosage is 600 mg / kg epetin, which should be given on three weeks (day 21, 14 and 7) before the operating procedure and on the day of the surgery (day 0)."</seg>
<seg id="495">98 In patients with chronic kidney disease should not be exceeded under section 4.2.</seg>
<seg id="496">"if you want to send us a question about this product, simply complete all the fields marked * and click" "Send". ""</seg>
<seg id="497">"anti-inflammatory diseases such as myocardiale, arattorical events such as myocarardinfants, cyokardinfants, pulsmetic and 101 blood caffluous in artificial kidneys in patients with erythropotin treatments, so also to patients under epoxicalfa."</seg>
<seg id="498">An increased incidence thrombovascular events (see Section 4.4 and Section 4.8 - General) was observed in patients with Erythropoetines.</seg>
<seg id="499">"389 patients with hemisphere (221 multiple myelome, 144 Non-Hodgkinase) and 332 patients with solid tumors (172 Mammakarzinome, 22 gastrointestinal carcinoma, 21 gastrointestinal carcinome, and 30 more)."</seg>
<seg id="500">"104 In its experimental studies with approximately the 204,000 of the application in the area of recommended vodka, epoxic body weight, on a delay of the Ossification and an increase in the fötal mortality."</seg>
<seg id="501">"in the framework of the interdisciplinary application, the patient can lead to a period of maximum 3 days outside of the cooling water and not over 25 ° C."</seg>
<seg id="502">"recommend this product to friends and acquaintances via e-mail. to do so, simply complete all the fields marked * and click" "Send". ""</seg>
<seg id="503">2. patients with chronic kidney disease should not be exceeded under section 4.2.</seg>
<seg id="504">"if you want to send us a question about this product, simply complete all the fields marked * and click" "Send". ""</seg>
<seg id="505">"utf-8 (Unicode, worldwide) utf-16 (Unicode, worldwide) utf-16 (Unicode, worldwide) utf-16 (Unicode, worldwide) utf-16 (Unicode, worldwide) utf-16 (Unicode, worldwide) utf-16 (Unicode, worldwide) utf-16 (Unicode, worldwide) utf-16 (Unicode, worldwide)"</seg>
<seg id="506">An increased incidence thrombovascular events (see Section 4.4 and Section 4.8 - General) was observed in patients with Erythropoetines.</seg>
<seg id="507">"389 patients with hemisphere (221 multiple myelome, 144 Non-Hodgkinase) and 332 patients with solid tumors (172 Mammakarzinome, 22 gastrointestinal carcinoma, 21 gastrointestinal carcinome, and 30 more)."</seg>
<seg id="508">"119 In animal trials with approximately the 204,000 of the application to the use in the person recommended Woetin alfa to reduced body weight, to a delay of the Ossification and an increase in the fötal mortality."</seg>
<seg id="509">"in the framework of the interdisciplinary application, the patient can lead to a period of maximum 3 days outside of the cooling water and not over 25 ° C."</seg>
<seg id="510">"126 The recommended dosage is 600 mg / kg epetin, which should be given on three weeks (day 21, 14 and 7) before the operating procedure and on the day of the surgery (day 0)."</seg>
<seg id="511">128 for patients with chronic kidney disease should not be exceeded under section 4.2.</seg>
<seg id="512">"if you want to send us a question about this product, simply complete all the fields marked * and click" "Send". ""</seg>
<seg id="513">"anti-inflammatory diseases such as myocardiale, arattorical events such as myocardiums, cyokardinfants, cyokardsticks, lung cancer, refractive and 131 blood caffeine in artificial kidneys in patients with erythropofa treatment, so also to patients under epoxicalfa."</seg>
<seg id="514">An increased incidence thrombovascular events (see Section 4.4 and Section 4.8 - General) was observed in patients with Erythropoetines.</seg>
<seg id="515">"389 patients with hemisphere (221 multiple myelome, 144 Non-Hodgkinase) and 332 patients with solid tumors (172 Mammakarzinome, 22 gastrointestinal carcinoma, 21 gastrointestinal carcinome, and 30 more)."</seg>
<seg id="516">"134 In its experimental studies with approximately the 204,000 of the application to the use in the person recommended Woetin alfa to reduced body weight, to a delay of the Ossification and an increase in the fötal mortality."</seg>
<seg id="517">"in the framework of the interdisciplinary application, the patient can lead to a period of maximum 3 days outside of the cooling water and not over 25 ° C."</seg>
<seg id="518">"141 The recommended dosage is 600 mg / kg epetin, which should be given on three weeks (day 21, 14 and 7) before the operating procedure and on the day of the surgery (day 0)."</seg>
<seg id="519">143. patients with chronic kidney disease should not be exceeded under section 4.2.</seg>
<seg id="520">"if you want to send us a question about this product, simply complete all the fields marked * and click" "Send". ""</seg>
<seg id="521">"utf-8 (Unicode, worldwide) utf-16 (Unicode, worldwide) utf-16 (Unicode, worldwide) utf-16 (Unicode, worldwide) utf-16 (Unicode, worldwide) utf-16 (Unicode, worldwide) utf-16 (Unicode, worldwide) utf-16 (Unicode, worldwide) utf-16 (Unicode, worldwide)"</seg>
<seg id="522">An increased incidence thrombovascular events (see Section 4.4 and Section 4.8 - General) was observed in patients with Erythropoetines.</seg>
<seg id="523">"389 patients with hemisphere (221 multiple myelome, 144 Non-Hodgkinase) and 332 patients with solid tumors (172 Mammakarzinome, 22 gastrointestinal carcinoma, 21 gastrointestinal carcinome, and 30 more)."</seg>
<seg id="524">"in this experimental studies with approximately the 204,000 of the use for the use in the person recommended Wooltin, epoxic body weight, on a delay of the Ossification and an increase in the fötal mortality."</seg>
<seg id="525">"in the framework of the interdisciplinary application, the patient can lead to a period of maximum 3 days outside of the cooling water and not over 25 ° C."</seg>
<seg id="526">"the owner of the owner of the law, on the market and according to agreement with the responsible authorities of the member states of the European Union of member states the medical professionals in Dialysis centres and individuals with the following information and materials. • With clear picture presentation of the product, cooling boxes for transport through the patient."</seg>
<seg id="527">The owner of the approval for the Induction has been set up in version 1.8.1 of the approval process to be applied in version 1.8.1 of the approval process to be applied in version 1.8.1 of the authorisation procedure before the medicine is applied in the traffic and as long as the medicine is used in the traffic.</seg>
<seg id="528">The owner of the permit is committed to the pharmaceutical industry as in version 5 of the Risk Management plan (RMP) as well as in version 5 of the Risk Management plan (RMP) as well as in accordance with each following by the CHMP certification of Risk Management plan.</seg>
<seg id="529">A updated RMP should be provided in accordance with the "CHMP Interdeline on Risk Management Systems for Hong Kong" s "at the same time with the next updated report about the disadvantes of the drugs using (Periodic Safety Update Report, PSUR)."</seg>
<seg id="530">"in addition, a updated RMP should be submitted: • with regard to the current safety regulations (Safety Specification), the pharmaceutical kovigilding or the measures for risk reduction."</seg>
<seg id="531">• within a month before your treatment a heart attack or stroke have a heart failure (the first or reinforced breast pain).</seg>
<seg id="532">"you suffer from severe pain disorders of heart (coronare heart disease), the arteries of legs or arms (peripheral arterial disease) or the brain (cerebrovascular disease), you suffer a heart attack or stroke."</seg>
<seg id="533">"during treatment with sampling may occur within the normal range of the blood, which will come back in the normal treatment."</seg>
<seg id="534">Your doctor will carry on regular blood tests to control the number of bloodshed during the first 8 weeks of treatment.</seg>
<seg id="535">"iron deficiency, resolution of red blood cells (hammers), blood loss, vitamin B12- or torture, should be taken into account before the treatment of therapy."</seg>
<seg id="536">"very rare, due to the appearance of an anaesthesithroblaenie to monthly to years of years of treatment with subcutted (under the skin) Erythropotin."</seg>
<seg id="537">"if you suffer under Erythrobe conenie, he will be treated your treatment with abuses and how your anemia is best."</seg>
<seg id="538">Therefore the injections must be treated by injtion in a vene (intravenous) if you are treated due to a kidney disease due to a kidney disease.</seg>
<seg id="539">A high kermop value the risk for problems with the heart or the blood vessels and the sterilization can be increased.</seg>
<seg id="540">"at elevated or, your doctor may result in an interruption of treatment with the treatment of the treatment, until the Caliph values are again in the normative area."</seg>
<seg id="541">"if you suffer under chronic kidney disease and clinically obvious coronary heart disease or reservoir sign by insufficient heart rate, your doctor ensure that your hemmop mirror is not overestimated."</seg>
<seg id="542">"due to the treatment of blood vessels, the treatment of blood circulation with chronic kidney disease (kidney disease), which is not even dialysis, the progression of kidney disease is not accelerating."</seg>
<seg id="543">A 2-3 delay delay between epetin-alfa-gift and the desired effect should be taken into account for the evaluation of the effectiveness of Abseamed.</seg>
<seg id="544">"200 your doctor will regularly determine your values of red blood-color (hemmoglobin), to determine the risk of a blood flow formation (thrombotic event)."</seg>
<seg id="545">"this risk should be carefully selected from the treatment with epetin, especially if you have a higher risk of thrombotic events, for example if you have a higher risk of thrombotic events, e.g. if you have a low risk of thrombotic events, e.g. in the past already thrombotic events (e.g. a depth of Vena romblosis or lung damage)."</seg>
<seg id="546">"if you are interested in cancer patients, please note that abamed as a growth factor for blood cells and certain circumstances can affect the tumor."</seg>
<seg id="547">"if you have a larger orthopedic surgery, the treatment should be examined in the treatment of treatment with the cause of your anemia and accordingly."</seg>
<seg id="548">"if your values of red blood-color (hemmoglobin) are too high, you should not receive a risk of blood circulation after surgery."</seg>
<seg id="549">"please inform your doctor or pharmacist if you use other medicines to use or have recently taken care, even if it is not non-prescription drugs."</seg>
<seg id="550">"if you take Ciclosporin (means to the suppression of the immune system) while your therapy is able to apply specific blood tests, to measure the blood level of Ciclosporin."</seg>
<seg id="551">Laboratory tests have no interaction between epeetalfa and G-CSF (G-CSF and GM-CSF are means for installation of the immune system, for example with cancer - chemotherapy or in HIV). "</seg>
<seg id="552">"depending on how your blood arrays (anaemia) will be adjusted to the treatment, the dose is about all four weeks, until your condition is under control."</seg>
<seg id="553">"if your doctor is required to check the treatment results in order to check the treatment success, and make sure that the medicine is correct and your hemmop value is not reduced to a certain value."</seg>
<seg id="554">"as soon as you are well positioned, you will get regular doses of Abseamed between 25 and 50 I.E. / kg twice a week, distributed on two simultaneously large injections."</seg>
<seg id="555">Your doctor will be able to check the treatment results in order to check the treatment success in order to check the treatment success and ensure that your hamop value does not have a specific value.</seg>
<seg id="556">"depending on the treatment, the dose can be adjusted to all four weeks, until the state is under control."</seg>
<seg id="557">"in order to ensure this and ensure that the hermop value does not have a specific value, the prescribed doctor will perform regular blood tests."</seg>
<seg id="558">"if it is necessary to shorten the treatment time before surgery, a dose of 300 mg / kg can be given up to 10 days before surgery, on the day of the input and further 4 days after the operation."</seg>
<seg id="559">"however, you can also learn when your doctor is appropriate for you, as you can learn how to remove the skin even under the skin."</seg>
<seg id="560">"heart of heart disease, heart attack, heart failure, temporary blood circulation of the brain, deep venous thrombence, lung disease, arteries of the retina and blood cortation in artificial kidneys were reported in patients under Erythropotin treatment."</seg>
<seg id="561">"the eye of the lips and the lips of the lips and the lips are allergic reactions with symptoms such as Kribbles, redness, heat-feeling and accelerated pace in rare cases."</seg>
<seg id="562">Erythroblafenie means that there is no longer enough red blood cells in bone marines (see section "special caution on the application of Abuse is required).</seg>
<seg id="563">"after repeated blood, it may occur - regardless of the treatment with cut - to a blood circulation formation (thrombotic events)."</seg>
<seg id="564">Treatment with treatment can be associated with an increased risk of blood props according to the surgery (postoperative postoperative thrombotic events) if your starting age is too high</seg>
<seg id="565">Inform your doctor or pharmacist if one of the adverse side effects will be considerably reduced or if you notice any side effects that are not specified in this form information.</seg>
<seg id="566">"if a splash from the fridge has been removed and room temperature reached (up to 25 ° C), it must be used either within 3 days or not."</seg>
<seg id="567">"Aclasta is used to treat the following diseases: • Osteoporosis (a disease, the bone sprinkled) both for women after the exchange of years than in men."</seg>
<seg id="568">"it will be applied to patients with a high level of disease (bone), including patients who recently recently changed a minimal bite like when they have recently changed. • Morbus Paget of the bone, a disease, which changes the normal course of bone growth."</seg>
<seg id="569">Patients with Morbus can get at least 500 mg calcium twice daily for minimum 10 days after treatment; patients with hip fracture should be obtained before the first Infusion (50 000 to 125 000 IE) oral or by injtion in a muscle.</seg>
<seg id="570">"the administration of Paracetamol or Ibuprost (means of inflammation) short after the application of acetlasta, in the three days after the Infusion symptoms, such as fever, muscle pain, grippesimilar symptoms, joint pain and headache."</seg>
<seg id="571">Treatment of the Morbus Paget can only be prescribed by doctors who have prescribed the experience in the treatment of these disease.</seg>
<seg id="572">"since the active substance in Aclasta is the same as in Zometa, a part of the data material for Zometa's evaluation of Aclasta."</seg>
<seg id="573">"during the first study, almost 8 000 older women with osteoporosis, and it was examined the number of vertebultural and hip fractures about a period of three years."</seg>
<seg id="574">The second study included 2 127 men and women with osteoporosis over 50 years.</seg>
<seg id="575">"by Morbus Paget, Aclasta was tested in two studies at a total of 357 patients and six months with Risedronat (one of other Biscuits)."</seg>
<seg id="576">"the main indikator for the effectiveness was, whether the content of the alkaline phosphatase in Serum (a enzymes, bone sublime) in the blood is again normal or at least 75% compared to the output value."</seg>
<seg id="577">"in the study with older women, the risk of vertorials are reduced by Aclasta (without any other osteoporosemedification) over a period of three years in comparison to the patients under Placebo by 70%."</seg>
<seg id="578">"in comparison of all patients under Aclasta (with or without any other osteoporosemedification), which reduces the risk of hip fractures around 41%."</seg>
<seg id="579">In the study with men and women with hip fracture had 9% of patients under Aclasta (92 of 1 065) compared to 13% of patients under Placebo (139 of 1 062).</seg>
<seg id="580">Most of the side effects of acetlasta within the first three days after the infusion and are less frequent.</seg>
<seg id="581">"Aclasta may not be used in patients that may be sensitive (allergic) against Zoledronic acid or other Biscuits, or one of the other components."</seg>
<seg id="582">"as with all the biscuits, patients are subject to patients with Aclasta's risk of kidney disease, reaction to the infusionist and osteotonectious disease (die by bone tissue) in pine trees."</seg>
<seg id="583">"the manufacturer of Aclasta provides an explanatory material for doctors, the Aclasta to treatment of osteoporosis, the evidence contains such as the medicine, as well as similar material for patients, in which the side effects of the drugs should be explained."</seg>
<seg id="584">"in April 2005, the European Commission published the European Commission to the company Novartis Europharm Limited: a permit for the Instruction of Aclasta in the whole European Union."</seg>
<seg id="585">Conditions ODER restrictions on a safe and effective application of THE COD • BEDINGITIONS OF THE WORKING OF THE WORKING OF THE WORKING OF THE WORKING OF THE WORKING OF THE WORKING OF THE WORKING OF THE WORKING OF THE WORKING OF THE WORKING OF THE WORKING OF THE WORKING OF THE WORKING OF THE WORKING OF THE WORKING OF THE DRUG POLICATION</seg>
<seg id="586">"treatment of osteoporosis at postmenopausal women and men with an increased risk for war, including patients with a recently discovered low-traumatic hip fracture."</seg>
<seg id="587">"the patient information is provided, and the following core competences include: • The packet of calcium and vitamin D, appropriate physical activity, non-smoking and a healthy diet • Important effects of calcium and vitamin D, appropriate signs and symptoms for serious side effects • Wann on medicines or nursing aid."</seg>
<seg id="588">Treatment of osteoporosis • in case of postmenopausal women</seg>
<seg id="589">For treatment of postmenopausal osteoporosis and osteoporosis in men is recommended a intravenous Infusion of 5 mg Aclasta once annually.</seg>
<seg id="590">"in patients with a low-traumatic hip fracture, the adoption of the Infusion of Aclasta two or more weeks after the operational supply of the hip fracture (see section 5.1)."</seg>
<seg id="591">Aclasta should only be prescribed for treatment of the Morbus Paget only from doctors who have experience in the treatment of Morbus.</seg>
<seg id="592">"after a treatment of the Morbus Paget with Aclasta has been observed with Aclasta, a long replenary period with patients who have found on therapy (see section 5.1)."</seg>
<seg id="593">"in addition, it is very advisable to ensure that patients with Morbus Paget a sufficient criterion of calcium, according to twice a minimum of 500 mg of calcium, for at least 10 days after the gift of Aclasta (see section 4.4)."</seg>
<seg id="594">"in patients with a recently discovered low-traumatic hip fracture, an initialdosis of 50,000 to 125.000 I.E. or intro-Infusion is recommended for the first Aclasta Infusion."</seg>
<seg id="595">"the frequency of symptoms which occur within the first three days after the administration of Aclasta, can be reduced by a gift of parachamol or Ibuprof shortly after the application of acetlasta."</seg>
<seg id="596">Patients with kidney function (see Section 4.4) of patients with an Kreatinin-Clearance &lt; 35 ml / min will be recommended as limited clinical experience for these patients.</seg>
<seg id="597">"older patients (R65 years) A Dosisement is not necessary, since the bipharmability, distribution and Elimination in older patients is similar to younger patients."</seg>
<seg id="598">Children and adolescents Aclasta is not recommended for use in children and adolescents under 18 years since the data are missing and effective.</seg>
<seg id="599">"Aclasta is not recommended for patients with severe kidney disease (Kreatinin-Clearance &lt; 35 ml / min), because it is not recommended for this patient population only limited clinical experience."</seg>
<seg id="600">A pre-existing hypokalemia treatment occurs before the treatment of calcium and vitamin D to treat calcium and vitamin D (see section 4.3).</seg>
<seg id="601">"due to the quick release of the effect of Zoledron acid to bone fracture can develop a temporary, sometimes symptomatic Hypokalemia function, whose maximum usually within the first 10 days after the Infusion of Aclasta (see section 4.8)."</seg>
<seg id="602">"in addition, it is very advisable to ensure that patients with Morbus Paget a sufficient criterion of calcium, according to twice a minimum of 500 mg of calcium, for at least 10 days after the gift of Aclasta (see section 4.2)."</seg>
<seg id="603">"cancer immunotherapy, chemotherapy, treatment with corticoids, bad mouth hygiene, should be used to treat breast cancer treatment with appropriate preventive dental treatment."</seg>
<seg id="604">"for patients, patients need no data to be available, whether the interruption of treatment with biscuits are reduced in the jaw area."</seg>
<seg id="605">Clinical evaluation by the attending physician should be based on the treatment plan of each patient and are based on an individual benefit-risk assessment.</seg>
<seg id="606">"the frequency of symptoms which occur within the first three days after adoption of Aclasta, can be reduced by a gift of parachamol or Ibuprof shortly after the application of Aclasta (see Section 4.2)."</seg>
<seg id="607">Luther Firm of the Year for Pharmaceuticals and Healthcare Hogan Lovells</seg>
<seg id="608">"in the osteoporosis studies (PFT, HORIZON - recurrent Fracture Trial [RFT]) was comparable to the total amount of prevalence between Aclasta (2.6%) and Placebo (2,1%)."</seg>
<seg id="609">"very frequent (Acts 1 / 10), frequent (Acts 1 / 100, &lt; 1 / 10), rare (Acts 1 / 1,000, &lt; 1 / 100), rare (Acts 1 / 10,000, &lt; 1 / 1,000)"</seg>
<seg id="610">Kidney function of cardioledronic acid with kidney function as a decrease in kidney function (i.e. a increase of Serum-Kreatinins) and rare cases in rare cases as acute kidney disease.</seg>
<seg id="611">The change of creatinin-Clearance (annually before the adoption) and the appearance of kidney function in a clinical study with osteoporosis was comparable to osteoporosis over three years between the Aclastasis and the Placebo Group.</seg>
<seg id="612">A temporary increase in the Serum-Kreatinins within 10 days of the gift was observed in 8% of the patients with acetylene in 0.8% of the treated patients.</seg>
<seg id="613">"based on the evaluation of laboratory tests, the temporary disease values which were under the normal vibration range (less than 2.10 mmol / l), with acetlasta in a large clinical study of patients with acetlasta in a large clinical study of patients with Aclasta in the Morbus-Paget patients."</seg>
<seg id="614">"in the study, all patients received sufficient amounts of vitamin D and calcium in the study for postmenopausal osteoporosis, in the study to avoid clinical disease according to a hip fracture and in the Morbus-Paget studies (see Section 4.2)."</seg>
<seg id="615">"in the study to avoid clinical disease, the vitamin D-D-mirror were not measured, however, the majority of patients have a initialdosis vitamin D before the administration of Aclasta (see section 4.2)."</seg>
<seg id="616">"local reactions to the administration of Zoledron acid in a large clinical study was about local reactions to the infusionist, such as valve, swelling and / or pain, reports (0.7%)."</seg>
<seg id="617">"Osteonecrosen in the jaw area, especially for cancers, about Osteonekrosen (primarily in the jaw area) that were treated with biscuits, including Zoledron acid."</seg>
<seg id="618">"many of these patients had signs for local infections including osteomyelia, and the majority of the reports refers to cancer patients or other diligence."</seg>
<seg id="619">"7 study with 7.736 patients, Osteonecond in orthodontic treatment area with acetlasta and in one with Placebo, patients and patients."</seg>
<seg id="620">"in the event of an overdose, which leads to a clinically relevant hypokalzophrenia, can be achieved by a gift of org. calcium and / or intravenous infusion of calcium."</seg>
<seg id="621">"clinical treatment in the treatment of postmenopausal osteoporosis (PFT) The effectiveness and security of Aclasta 5 mg once annually for three consecutive years in postmenopausal women (7.736 women in age between 65 and 89 years) with either a bone gradient or a BMD-T-score for the Schenkelhas ≤ -2.5, or without signs of an existing vertebral body."</seg>
<seg id="622">"effects on morphometric boards of Aclasta infantigens are significantly significant over a period of three years, as well as for one year the frequency of one or more new eddy bodies (see table 2)."</seg>
<seg id="623">Aclasta-treated patients were compared to 60 years and older than 60% reduced risk of eddy patients (p &lt; 0.00001).</seg>
<seg id="624">"effects on hip fractures Aclasta joined a consistent effect of three years, which result in a around 41% (95% CI, 17% to 58%) reduced risk for hip fractures."</seg>
<seg id="625">"effect on bone density (BMD) Aclasta increased bone density at the Lectangular acid, hip and on distal radius compared to all time points (6, 12, 24 and 36 months)."</seg>
<seg id="626">"9 increase the bone density of the Lectins of 6,7%, the total surface of 6,0%, of the shrinkage of 5,1%, and the distal radius to 3.2%."</seg>
<seg id="627">Bone histology at 152 postmenopausal patients were treated with Aclasta (N = 82) or Placebo (N = 70).</seg>
<seg id="628">"in comparison with Aclasta patients, patients showed an increase of two patients in comparison with acetlasta patients in comparison with acetlasta patient and maintaining the extra virgin bone architecture."</seg>
<seg id="629">"bone-specific phosphatase (BPNP) in Serum and the beta-C-Telopeptid (P1NP) in Serum and the beta-C-Telopeptid (b-CTx) in Serum and the beta-C-Telopeptid (b-CTx) in the Serum and the beta-C-Telopeptid (b-CTx) in the Serum, and the beta-C-Telopeptid (b-CTx)."</seg>
<seg id="630">"the treatment with an annual 5-mg dose Aclasta is reduced by 30% compared to the initial value and was held at 28% below the output volume of up to 36 months."</seg>
<seg id="631">P1NP was significantly reduced by 61% below the output voltage after 12 months and was held at 52% below the output level up to 36 months.</seg>
<seg id="632">B-CTx was significantly reduced by 61% below the initial value for 12 months and was held at 55% below the output level up to 36 months.</seg>
<seg id="633">The vitamin D-D mirror were not measured but the majority of patients received a initial topdose vitamin D (50,000 to 125.000 I.E. oral or intro) 2 weeks before the Infusion.</seg>
<seg id="634">The total difference between 10% (101 patients) is compared with acetlasta group, compared with 13% (141 patients) in the Placebo Group. "</seg>
<seg id="635">Effect on bone mineral-density (BMD) In the HORIZON-RFT Study increased the Aclasta treatment in comparison to the Placebo treatment and shrinkage.</seg>
<seg id="636">"the Aclasta treatment led over 24 months in comparison to the Placebo treatment, the BMD um 5,4% of the total amount and around 4,3% on Schenkelhas."</seg>
<seg id="637">"clinical efficacy of men in the HORIZON-RFT-RFT-study were randomised and replaced by 185 patients, the BMD was added to 24 months."</seg>
<seg id="638">The study was not designed to show a reduction of clinical disease in men; the frequency of clinical study was 7.5% at Aclasta-treated men in comparison to 8.8% in Placebo.</seg>
<seg id="639">"in a different study in men (study CZOL446M2308), once the annual administration of Aclasta has to be accepted by an old gift from Alendronate to 24 months in comparison to the output value."</seg>
<seg id="640">"clinical efficacy of the treatment at Morbus Paget in patients with radiologically unrelated to patients and patients at the age of 30 years with radiology, especially suitable for patients at the age of 30 years. (medium Serum-mirror of the alkaline phosphatase accordingly, in the study)."</seg>
<seg id="641">11 The effectiveness of an Infusion of 5 mg Zoledron acid compared to taking over 30 mg of Risedronate once daily during 2 months was tested in two six-month comparison studies.</seg>
<seg id="642">After 6 months a similar acceptance of pain and pain impairment compared to the initial value of Actusta and Risedronate.</seg>
<seg id="643">Patients who were treated at the end of the six smonatite main study (in therapy) could be included in a follow-up phase.</seg>
<seg id="644">"from the 143 with Aclasta and the 107 with Risedronate patients, the therapeutic bond was compared with acetlasta, compared to 71 of the patients with Risedronate patients, in an average duration of follow-up time after the application period of 18 months after application."</seg>
<seg id="645">"a unique and multiple 5-15 minutes, infusions of 2, 4, 8 and 16 mg Zoledronic acid in 64 patients, the following pharmacokinetic data that has proven to be independent."</seg>
<seg id="646">"after four h and &lt; 1% of the maximum value according to 4 h and &lt; 1% after 24 h, followed by a long-lasting phase of very low concentration, not more than 0.1% of the maximum value."</seg>
<seg id="647">"if you have any queries, please contact us on Tel.: + 49 5764 318 444. or contact us per email."</seg>
<seg id="648">"in the early stage phases (α and, with the above-mentioned ½ -values) represent the fast resorption in the bone and the extermination of the kidneys."</seg>
<seg id="649">"in the first 24 h, 39 ± 16% of the dose is bound in the urine while the rest of bone tissue is bound to bone tissue."</seg>
<seg id="650">The total body temperature is independent from the dose 5.04 ± 2.5 l / h and remains uninfluenced by gender, age, breed or body weight. "</seg>
<seg id="651">"one extension of the infusion period of 5 to 15 minutes they led to the acceptance of the Zoledrones - concentration around 30% at the end of the Infusion, but no impact on the surface under the curve (plasma concentration against time)."</seg>
<seg id="652">"reduced Clearance from Cytochile-P450-Enzymic acid treatment is not likely because Zoledronic acid in humans is unlikely because Zoledronic acid in humans is unlikely because Zoledronic acid in humans is unlikely because they are a weak or even more direct and / or missealed, material-sensitive inhibitor of the P4501."</seg>
<seg id="653">Firm of the Year for Restructuring and Corporate Rescue Freshfields Bruckhaus Deringer Firm of the Year for Insolvency Administration Schneider Geiwitz & Partner</seg>
<seg id="654">It is that a light (Clcr = 50- 80 ml / min) and a moderate kidney function to a Kreatinin-Clearance up to 35 ml / min.</seg>
<seg id="655">"as for heavy kidney function (Kreatinseparance &lt; 30 ml / min) only limited data, are not possible for this population."</seg>
<seg id="656">"toxicity is the highest non-acting intravenous single species in mice 10 mg / kg body weight and with rats 0.mg / kg body weight."</seg>
<seg id="657">"for studies at Hacks, single-wing of 1.0 mg / kg (based on the auc the 624 of the recommended car body position), fits over a period of 15 minutes, good and without a renal flow flow."</seg>
<seg id="658">"in studies with intravenous infection with intravenous use of intravenous use in patients with intravenous use in 3-day intervals, the amount of 6 times (an accumulation dose, which corresponds to the 74,000 of the son-therapeutic exposition, relative to the auc, corresponds to the auc, corresponds to the auc, corresponds to the auc."</seg>
<seg id="659">"in long-term studies with repeated use in cumulated expositions, the maximum of the intended human-position sufficiently exceeded the maximum of the intended human position in other organs, including the Gastrointestinal tract and the liver, as well as the intravenous injectors."</seg>
<seg id="660">"the most common examination and studies with repeated application was an increase of primary Spongiosa in the metaphyse of the long bone at animals in the growth phase with almost all dosing, an attempt and the influence of the pharmacological, antiresorical effect of substance."</seg>
<seg id="661">The rats showed a teratogenic in dosing systems from 0.2 mg / kg as outer and inner (visceral) misconceptions and such of the skeleton.</seg>
<seg id="662">"on rabbits have no teratoid effects or embryo-fetal effects, although the maternal toxicity is observed in 0.1 mg / kg due to the lower Serum-calcium mirror."</seg>
<seg id="663">"if the medicine is not used immediately, the user is responsible for the storage time after preparation and conditions before application; usually 24 h at 2 ° C to 8 ° C."</seg>
<seg id="664">Aclasta is supplied as a package with a bottle of packaging unit or as bundling packers consisting of 5 items that contain a bottle of bottle.</seg>
<seg id="665">"treatment of osteoporosis at postmenopausal women and men with an increased risk for war, including patients with a recently discovered low-traumatic hip fracture."</seg>
<seg id="666">"the patient information is provided, and the following core competences include: • The packet of calcium and vitamin D, appropriate physical activity, non-smoking and a healthy diet 17 • Important signs and symptoms for serious side effects • Wann on medicines or nursing aid."</seg>
<seg id="667">Firm of the Year for Insolvency Administration Schneider Geiwitz & Partner Firm of the Year for Tax Gleiss Lutz</seg>
<seg id="668">Risko-management plan The owner of the permit is obliged to perform the studies and the additional activities for pharmaceutical kovigilance which are approved in the pharmaceutical company plan (RMP) in a module 1.8.2 of the approval process and all the following versions of the RMP approved versions of the RMP.</seg>
<seg id="669">"according to the CHMP Directive for the risk management systems for Humanities, the revised RMP should be submitted with the next" Periodic Safety Update Report (PSUR). "</seg>
<seg id="670">"• The second-half of 60 days should be submitted • If new information is known, the current statements are submitted to safety, pharmaceutical kovigilance or activities to minimise the risk of risk. • Vhalf of 60 days if an important milestone (for pharmaceutical kovigilance or risk inimbalances) was achieved."</seg>
<seg id="671">"Zoledronic acid is a representative of a Substanzer class, which is used by the osteoporosis in postmenopausal women, osteoporosis in men and the Morbus Paget of the bone."</seg>
<seg id="672">"blood levels of sexually shormonen, above all oils, which are made of andropy, play a role in the physical loss of bone mass, which is observed in men."</seg>
<seg id="673">"after Morbus Paget started the bone structure too fast, and new bone material is unmoved, which makes the bone material as normal."</seg>
<seg id="674">Aclasta works by using bone fracture to normalize a normal bone formation and thus helps the bones again.</seg>
<seg id="675">"if you need to remove your medical treatment or a dental surgery, inform your doctor if you will be treated with Aclasta."</seg>
<seg id="676">"using Aclasta with other medicines, please inform your doctor, pharmacer or nursing staff if you use other drugs, even if you have other drugs, even if it is not non-prescription drugs."</seg>
<seg id="677">"for your doctor, it is especially important to know if you use drugs, of which it is known that they are the kidneys."</seg>
<seg id="678">"using Aclasta together with food supplements and drinks, you can take care of your doctor in accordance with the instructions of your doctor before and after treatment with Aclasta."</seg>
<seg id="679">Osteoporosis The usual dose is 5 mg once per year that will help you from your doctor or nursing staff as infusion in a vene.</seg>
<seg id="680">"if you have recently added the hip is broken, it is recommended to use Aclasta two or more weeks after the operating supply of the hip fractures."</seg>
<seg id="681">Morbus Paget the usual dose is 5 mg that will help you from your doctor or nursing staff as infusion in a vene.</seg>
<seg id="682">"because Aclasta for a long time, you will be able to make a further dose for a year or longer."</seg>
<seg id="683">It is important to follow these instructions so that the calcium-mirror in your blood will not be too low.</seg>
<seg id="684">"after Morbus Paget can help Aclasta longer than a year, and your doctor will inform you if you need a renewed treatment."</seg>
<seg id="685">"if the administration of Aclasta should be missed, please contact your doctor or hospital in conjunction with a new appointment."</seg>
<seg id="686">"before the end of treatment with Aclasta, you will take the end of treatment with acetlasta, please take your next doctor's doctor and discuss this with your doctor."</seg>
<seg id="687">Side effects in connection with the first Infusion occurs very often (with more than 30% of patients) that are less frequent.</seg>
<seg id="688">"if you want to send us a question about this product, simply complete all the fields marked * and click" "Send". ""</seg>
<seg id="689">"currently it is unclear whether Aclasta has caused this unpleasant heart failure, but you should notice your doctor if you notice such symptoms if you have Aclasta."</seg>
<seg id="690">"physical pain due to low calzies - concentration in blood, like muscle stimulating or dovellous or dobes, especially in the area around the mouth."</seg>
<seg id="691">"pain, pain, diarrhoeal, pain, diarrhoeal, pain, pain, pain, pain, diarrhoeal, stomach ache, pain, redness, stomach, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, redness, pain, redness,</seg>
<seg id="692">Persistent pain and / or not healing wounds in the mouth or at the pine were reported above all patients who were treated with the biscuits of other diseases.</seg>
<seg id="693">"about allergic reactions, including rare cases of respiratory problems, nuts and Angioids (as for example swelling in the face, tongue or in Rains)."</seg>
<seg id="694">"please inform your doctor, pharmacer or Nursing staff if one of the side effects will be considerably reduced or you notice that not in this use information."</seg>
<seg id="695">"if the medicine is not used immediately, the user is not used for the warehouse time and conditions for use; usually 24 h at 2 ° C to 8 ° C will not be exceeded."</seg>
<seg id="696">"in patients with a recently discovered low-traumatic hip fracture is recommended, the Infusion of Aclasta two or more weeks after the operating supply of the hip fracture."</seg>
<seg id="697">"before and after the administration of Aclasta, patients need to be sufficient with liquid; this is especially important in patients who receive an diuretic therapy."</seg>
<seg id="698">"due to the quick release of the effect of Zoledron acid to bone fracture can develop a temporary, sometimes symptomatic and hypokalemia function, whose maximum usually within the first 10 days after the Infusion of Aclasta."</seg>
<seg id="699">"in addition, it is very advisable to ensure a sufficient criterion of calcium, according to at least twice a day of 500 mg of calcium, for at least 10 days after the gift of Aclasta."</seg>
<seg id="700">"in patients with a recently recently, low-traumatic hip fracture will be recommended for the initial sample of 50,000 to 125.000 I.E. or infusion (vitamin D before the Infusion of Aclasta)."</seg>
<seg id="701">"if you need further information about your illness or treatment, please read the parcel service (also part of the EPAR) or contact your doctor or pharmacist."</seg>
<seg id="702">"ACOMPLIA is applied to a diet and movement for the treatment of adult patients, which are applied to obesity - (BMI of 27 kg / m ² or above), and beyond."</seg>
<seg id="703">"in addition, four studies were carried out over 7 000 patients, in which ACOMPLIA was used in comparison to a Placebo as a support for the setting of the smoker."</seg>
<seg id="704">"studies on the attitude of the smokers were no uniform results, so that the effect of ACOMPLIA field was difficult to estimate the effect of ACOMPLIA to this application area."</seg>
<seg id="705">"which risk is associated with ACOMPLIA? it is the most common side effects of ACOMPLIA, which were observed during the studies (observed in more than 1 of 10 patients), the sea (nausea) and infections of the upper respiratory infections."</seg>
<seg id="706">"it may also be treated with patients who suffer from chronic depression or antidepressants, since there may be the risk of depression, and among others in a small minority of patients."</seg>
<seg id="707">"caution is provided with simultaneous use of ACOMPLIA with medicines such as Ketoconazol or Ispconazol, drugs against fungal cavir (a means for use in HIV- infection), Telonavir (antibiotics)."</seg>
<seg id="708">The Committee for Humanities (CHMP) corresponds to the conclusion that the effectiveness of ACOMPLIA results in regard to the weight reduction in patients with obesity or excessive</seg>
<seg id="709">It is applied to patients who are treated by health and non-toxic reasons (by providing qualified patients for patients and doctors) and to prepare the Arz</seg>
<seg id="710">Additional patients (BMI &gt; 27 kg / m ²) or more important patients (BMI &gt; 27 kg / m ²) that provides a or several risk factors such as type-2 diabetes or Dyslipidemia (see section 5.1).</seg>
<seg id="711">"ACOMPLIA is not recommended for the use of children and adolescents under 18 years, because of the lack of data for the effectiveness and discomfort."</seg>
<seg id="712">"La depressive diseases or voice changes with depressive symptoms were reported to 1%, Suitable to 1% of the patients who received the Rimonabant (see section 4.8)."</seg>
<seg id="713">"(see section 4.3 and 4.8), the risk of treatment in the individual case is the risk (see section 4.3 and 4.8)."</seg>
<seg id="714">"in patients, patients treated with obesity - no risks associated with obesity, depressive reactions may occur."</seg>
<seg id="715">"in other words, it is necessary to ensure that it is necessary to monitor the curiosity of such symptoms and immediately take care of medical advice if these symptoms occur."</seg>
<seg id="716">• The effectiveness and discomfort of Rimonabant in the treatment of patients over 75 years have not been shown in the treatment of patients over 75 years.</seg>
<seg id="717">Patients with a karmic event (Myokardinfantry or stroke loss etc.) before less than 6 months were produced by trials with Rimonabant.</seg>
<seg id="718">"* Understand the competitive environment, the market's major players and leading brands; * Use five-year forecasts to assess how the market is predicted to develop."</seg>
<seg id="719">Patients and patients with obesity and patients with obesity and patients were investigated at 3800 patients in additional indications.</seg>
<seg id="720">"the following table (table 1) shows that the following table (table 1) shows the treatment of unrelated effects in placeboarding, which were treated for weight reduction and due to inadequate metabolic disease."</seg>
<seg id="721">"if the incidence of statistical analysis was significantly higher than the cortical Placebrates (for unwanted effects &lt; 1%) or if it was clinically relevant (for unwanted effects &lt; 1%) or if it was clinically relevant (for unwanted effects &lt; 1%)."</seg>
<seg id="722">"very often (Acts 10%); often (Acts 1, &lt; 10%); occasionally (S1, &lt; 1%); rare (Acts 0,01, &lt; 0.1%); very t lä"</seg>
<seg id="723">"in a subsequent study study, in which a limited number of persons were found from up to 300 mg, were found only slight symptoms."</seg>
<seg id="724">The patients had a BMI of 30 kg / m ² and BMI &gt; 27 kg / m ² and at the same time existing hypertension and / or Dyslipidules.</seg>
<seg id="725">"for a year for the ACOMPLIA 20 mg of 6.5 kg, the output value, compared to 1.6 kg and CI95% -5.8; -4,4, p &lt; 0.001)."</seg>
<seg id="726">"the patients who were treated with ACOMPLIA 20 mg, and 1.2 kg in the Placeboggroup (difference -3.8 kg; CI95% -4.4, -3.3; p &lt; 0.001)."</seg>
<seg id="727">"after 2 years the difference in the whole weight reduction in the total weight reduction between ACOMPLIA and Placebo -4,2 kg (CI95% -5.0%; -3,4, p &lt; 0.001)."</seg>
<seg id="728">Firm of the Year for Compliance Audits and Investigations Gibson Dunn & Crutcher Firm of the Year for Tax Gleiss Lutz</seg>
<seg id="729">"under Rimonabant 20 mg, a working waste of Triglyceride from 6,9% (output value triglyceride 1,62 mmol / l) compared to a increase of 5.8%"</seg>
<seg id="730">"in a second study with obesity, the absolute change of the HbA1c value (Serenade) was the absolute change of the HbA1c value (with a output value of 7,9% for both groups) after 6 months -0.8 for Rimonabant 20 mg and -0.3."</seg>
<seg id="731">The percentage of patients who reached a hbAv - value of &lt; 7% reached at 51% in the Rimonabant Group and 35% in the Placebo Group.</seg>
<seg id="732">"the difference of the middle weight change between the 20 mg- and the Placebo Group was 3,8 kg (CI95% -5.0, -2.6 p &lt; 0.001)."</seg>
<seg id="733">"improvement of the HbA1c value in patients, the Rimonabant 20 mg, were about 50% by direct effects of Rimonabant and about 50% by the weight reduction."</seg>
<seg id="734">"2 hours, the Steady State Plasmaspberries were reached after 13 days (Cmax = 196 ± 28.1 ng / ml; Ctrough = 91.6 ± 14.1 ng / ml; CC0-24 = 2960 ± 268."</seg>
<seg id="735">"influence of food: he received treatment, the Rimonabant should be either in the nest-state or after a hot meal in case of food supply by 67%, increased by 67%, increased by 67%."</seg>
<seg id="736">Patients with black skin colour can be reduced by up to 31% lower Cmax and a 43% lower auc.</seg>
<seg id="737">Firm of the Year for Insolvency Administration Schneider Geiwitz & Partner Firm of the Year for Tax Gleiss Lutz</seg>
<seg id="738">"5.3, clinical data for security in clinical trials were observed which were evaluated by animals after exposition in human therapeutic area, as may be relevant for clinical application:"</seg>
<seg id="739">"in some cases, however, in some cases, however, in all cases, the beginning of the convulsion is to be connected with a state-of-the-art stress as dealing with the animals."</seg>
<seg id="740">"in Rimonabant about a longer period before the Paintment (9 weeks) which allowed an recovery from the initiation effects of Rimonabant, so no unwanted effects on the fertilation or cyclussive disorders are observed."</seg>
<seg id="741">"results appear ordered" "by relevance" "or" "by date" "(publication date),"</seg>
<seg id="742">"in a study of counsel for preventive and postnatal development, an exposition of Rimonabant in Utero and with lactation does not cause changes in learning behavior or in memory."</seg>
<seg id="743">Detailed information about this medicine can be found on the website of the European Trade Agency (EMEA) http: / / www.boschpackag.eu / item</seg>
<seg id="744">"La In the packaging of the packaging, the name and address of the manufacturer, which is responsible for the release of the data."</seg>
<seg id="745">"26 Weightlifting psychiatric events such as depression, or voice changes were reported in patients who received the ACOMPLIA (see paragraph" "WELT side effects)"</seg>
<seg id="746">"if symptoms of depression (see below) during the treatment with ACOMPLIA occur, contact your doctor and break the treatment."</seg>
<seg id="747">"if you have any queries, please contact us on Tel.: + 49 5764 318 444. or contact us per email. if you want to send us a question about this product, simply complete all the fields marked * and click" "Send". ""</seg>
<seg id="748">"please use your doctor or pharmacist if one of the adverse side effects will be considerably lower or if you notice any side effects that are not specified in this form information."</seg>
<seg id="749">Abstract of the Order of 24 September 2015</seg>
<seg id="750">Actos will be applied to treatment of type-2 diabetes (also known as non-dependent diabetes).</seg>
<seg id="751">"it can also be applied to metformin in patients (especially excessive patients), which can not be adjusted in the highest possible dose."</seg>
<seg id="752">"in combination with an sulfonylornated or insulin in the beginning of the Actos treatment, except for patients with hypoglycemia (low blood sugar)."</seg>
<seg id="753">"this means that the body's own insulin can be better distributed and the blood sugar levels, thus reducing type-2 diabetes better."</seg>
<seg id="754">"in more than 1 400 patients, the efficacy of Actos in Triplesis, patients received a combination of metformin with an sulfonylated, in addition to 3.5 years long."</seg>
<seg id="755">"in the studies, the concentration of a substance in the blood (glycosyliemblamoglobin, HbA1c) was measured as well as good of the blood sugar."</seg>
<seg id="756">"Actos led to a decrease of HbA1c value, which leaves the blood sugar values at the use of dosing of 15 mg, 30 mg and 45 mg."</seg>
<seg id="757">"at the end of the tripletion study, the effect of an additional gift of Actos to the existing treatment with metformin and an sulfonylated in a decrease of HbA1c values for 0.94%, while the extra gift of Placebo has led to 0.35%."</seg>
<seg id="758">"in a small study in the combination of Actos and insulin in 289 patients, patients, Actos were investigated for insulin, a decrease of HbA1c values of 0.69% after 6 months."</seg>
<seg id="759">"the most common side effects in connection with Actos, tendons, infections of the upper respiratory tract (cold water), weight gain and hypokerie (reduced sensitivity compared to friction)."</seg>
<seg id="760">"Actos may not be used for patients that may be sensitive (allergic) to Pioglitazon or one of the other components, nor in patients with liver problems, heart disease or diabetics."</seg>
<seg id="761">"it was decided that Actos in the frame of a monotherapy (in case of some use) as an alternative to the standard treatment with metformin patients, where metformis not displayed."</seg>
<seg id="762">"October 2000, the European Commission on the company Takeda Europe R & D Centre Limited offers a permit for the Instruction of Actos in the whole European Union."</seg>
<seg id="763">"the tablets are white to welded, round, curved and wear on one side the marking" 15 "and on the other side the wording" ACTOS. "</seg>
<seg id="764">"Pioglitazon is also shown for the combination with insulin in patients with type 2 diabetes mellitus, their blood sugar with insulin in inadequate and incompatibility. (see section 4.4)."</seg>
<seg id="765">"for the use of Pioglitazon in patients under 18 years, the application is not recommended in this age group."</seg>
<seg id="766">"in patients treated by the presence of at least one risk factor (e.g. vitamins, heart attack or symptomatic coronare heart disease), the physician should begin with the lowest possible dose and increase the dose."</seg>
<seg id="767">Patients should be observed on signs and symptoms of heart failure.</seg>
<seg id="768">Patients should be observed on signs and symptoms of a heart failure if Pioglitazon is applied in combination with insulin.</seg>
<seg id="769">A karmic Outcome study with Pioglitazon in patients under 75 years with type 2 diabetes mellitus and pre-advanced mavascular disease.</seg>
<seg id="770">"in this study, an increase of reports about Herziness, however, does not lead to a increase in the mortality in the study."</seg>
<seg id="771">Patients with increased risk reduction (ALT &gt; 2.5 x upper limit of the standard) or with other signs of liver disease may not be used.</seg>
<seg id="772">"when the ALT-mirrors are increased up to 3 speed of the standard limits, the liver has been increased as soon as possible."</seg>
<seg id="773">"in case of a patient symptoms that have been developed on a couple of erectile dysfunction, such as unconditional love, ertibles, toretitlessness, and / or dark Harn, are the liver."</seg>
<seg id="774">"the decision, whether the treatment of treatment with Pioglitazon, should be the laboratory parameters of the clinical evaluation."</seg>
<seg id="775">Clinical trials with Pioglitazon has been demonstrated in clinical trials with pioglitazon.</seg>
<seg id="776">"as a consequence of a hemisphere, under therapy with Pioglitazon a slightly lower reduction of the middle hemmop values (relative to 4%) and the hematocrits (relative to 4.9%)."</seg>
<seg id="777">Similar changes were observed with Pioglitazon at 3-4% and hematocrits at 3-4% and hematocrits at 1-2% and hematocrits at 1-2% and hematocrits at 1-2%).</seg>
<seg id="778">"as a consequence of the increased insulin sensitivity in patients, Pioglitazon as orale double or triple-combination therapy with an sulfonylated or twin-combination therapy with insulin-related hypoglycemia."</seg>
<seg id="779">"after the market was reported under the treatment with Thiazoligarine, including Pioglitazon, an appearance or deterioration of a diabetic agent with a reduction of visual acuity."</seg>
<seg id="780">It is unclear whether it should be aware between taking care of Pioglitazon and the appearance of Makulaödems.</seg>
<seg id="781">"in a summary analysis of the latest events regarding bone transplantation, controlled, double-blind clinical trials over a period of up to 3.5 years with more than 8.100 patients who were treated with Pioglitazon."</seg>
<seg id="782">"at the end of the last few years, the group reported a few patients with Pioglitazon in patients with Pioglitazon treated women and 1.1 leader per 100 patient years of women who were treated with a comparison."</seg>
<seg id="783">"in the proactive study, a study on 3.5 / 870 (5,1%; 1.0 group per 100 patients) of the patients were treated with Pioglitazon patients, compared with 23 / 905 (2.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%;</seg>
<seg id="784">Patients should be aware of the possibility of a pregnancy and if a patient wants to wish or maintain the treatment (see section 4.6).</seg>
<seg id="785">"studies on the study of interactions have shown that Pioglitazon have no relevant effects on the pharokinetics or pharmaceutical industries of Digoxin, Wargames in, Phenomousels and metformin."</seg>
<seg id="786">"interactions with medicines created by these enzymes, e.g. orale contrast and HMGCoA-Reinducer and HMGCoA-Reinducer are not expected."</seg>
<seg id="787">The simultaneous application of Pioglitazon with mixtures P450 2C8- Incinor) results in an increase in the auc of Pioglitazon to increase the 3 times.</seg>
<seg id="788">The simultaneous application of Pioglitazon with Rifampicin (a Cytochma P450 2C8-Inductor) resulting in a decrease of the auc of Pioglitazon at 54%.</seg>
<seg id="789">This is due to due to treatment with Pioglitazon the breast cancer patients and increased insulin resistance of the parent's disease and thereby reduce the availability of metabolic Substrate for the flue growth.</seg>
<seg id="790">"very often &gt; 1 / 10; frequently &gt; 1 / 100, &lt; 1 / 10; occasionally &gt; 1 / 1000, &lt; 1 / 1000, &lt; 1 / 1000; very rare &lt; 1 / 10000, individual cases: unknown (made of this data does not exist)."</seg>
<seg id="791">This lead to a temporary change of the turbine and the bending of the lens to be observed in other hypoglycemia.</seg>
<seg id="792">"clinical trials with Pioglitazon came in clinical trials with Pioglitazon, as well as in comparison with the upper limit of the standard. however, less than in comparison with metformin or sulfonylated."</seg>
<seg id="793">"in a Outcome study, the frequency of a severe hereditary disease was the frequency of a severe hereditary disease under Pioglitazon."</seg>
<seg id="794">"since the market launch, rarely has been reported by Pioglitazon, more common when Pioglitazon has been used in combination with insulin or in patients with heart failure."</seg>
<seg id="795">"a combined analysis of significant events related to bone transplantation, controlled, double-blind clinical trials over a period of up to 3.5 years with more than 8.100 patients at Pioglitazon treated groups and over 7.400 patients in patients with comparison of patients."</seg>
<seg id="796">"in over a period of 3.5 years of ongoing proactive study, group leader at 44 / 870 (5,1%) of the patients were treated with Pioglitazon patients, compared with 23 / 905 (2.5%) of patients who were treated with a comparison."</seg>
<seg id="797">"when taking the maximum dose of 120 mg / day over four days, then 180 mg / day over seven days are no symptoms."</seg>
<seg id="798">"at the same time, Pioglitazon seems to be an activation of specific core receptor in the animal model, which leads to elevated insulin sensitivity of liver, fat and skeleton cells."</seg>
<seg id="799">It could be shown that Pioglitazon is reduced to glucose production in the liver and the peripheral glucosamine in the case of insulin resistance.</seg>
<seg id="800">Clinical study with Pioglitazon versus Gliclazid as monotherapy was taken over two years to investigate the therapeutic effect (defined as HbA1c) 8.0% after the first 6 treatment months).</seg>
<seg id="801">"after two years after the beginning of the treatment, a blood sugar control (defined as HbA1c &lt; 8,0%) by Pioglitazon at 69% of the patients (compared to 50% of patients under Gliclazid)."</seg>
<seg id="802">"in a placeboy study about 12 months, patients, their blood sugar despite three monatists of optimizing processes with insulin in inadequate, at Pioglitazon or Placebo."</seg>
<seg id="803">Patients under Pioglitazon reduced the medium HbA1c - value around 0.45% compared with patients that continue only insulin; a reduction of insulin used in the Pioglitazine group has been observed.</seg>
<seg id="804">"in clinical studies at Pioglitazon, there was a significant significant decrease in the Albumin / Kreatinin-Quotiations compared to the initial values."</seg>
<seg id="805">"the effect of Pioglitazon (monotherapy with 45 mg of Plazda) was tested in a small, on 18 weeks of investigation on type-2 Diabetics."</seg>
<seg id="806">"in most clinical trials were observed in comparison to Placebo, a reduction of the total hardness-triglyzeride and the free fatty acids and an increase of HDL- cholesterol, but not significantly increased LDL- cholesterol."</seg>
<seg id="807">"clinical trials over a period of up to two years of Pioglitazon compared to placebo, metformin or Gliclazid the total plasticizers and the free fatty acids and increased the HDL cholesterol."</seg>
<seg id="808">"in comparison to Plazlitazon, there was no statistics at Pioglitazon at Pioglitazon at Pioglitazon, while metformin and Gliclazid reduced values were observed."</seg>
<seg id="809">"in a study about 20 weeks, Pioglitazon is not just the nuts-triglyceride but also improved the posture of Triglyceridmirror, this is also an effect on the Triglyzeride absorbing, as well as on the traditional Triglyzerid synthesis."</seg>
<seg id="810">"in the proactive study, a karovascularized Outcome study, 5238 patients were randomised with type 2 diabetes mellitus and pressurised therapy in groups that were found over a period of up to 3.5 years."</seg>
<seg id="811">"according to the application of Pioglitazon, the top concentration of Pioglitazon can be reached in the plasma in the plasma, usually 2 hours after application."</seg>
<seg id="812">"on this basis, the contribution of M-IV to the effectiveness of Pioglitazon, whereas the relative effectiveness of M-II is minimal."</seg>
<seg id="813">Firm of the Year for Compliance Audits and Investigations Gibson Dunn & Crutcher Firm of the Year for Private Construction Luther</seg>
<seg id="814">The simultaneous application of Pioglitazon with mixtures P450 2C8- Inducor) or with Rifampicin (a Cytochma P450 2C8-Inductor) or reduces the plasma concentration of Pioglitazon (see section 4.5).</seg>
<seg id="815">"after orderly application of radioactive Pioglitazon, the market was mainly found in the barrels (55%) and to a lesser extent in Harn (45%)."</seg>
<seg id="816">Delivery time: 1-2 days * size XXXL (7) | Delivery time: 1-3 days *</seg>
<seg id="817">The plasma concentration of Pioglitazon and its metabolite are lower than in patients with reduced kidney function.</seg>
<seg id="818">"in toxicological studies in mice, rats, hubs and monkeys in accordance with repetitions, anaemia and resealed exchanger for recurrent, anemia and resealed exchanger."</seg>
<seg id="819">"this is due to due to treatment with Pioglitazon which reduces the hypertension and increased insulin resistance of the parent, thereby reducing the availability of metabolic Substrate for the fillergrowth."</seg>
<seg id="820">"in long-term studies (up to 2 years) have been increased incidence of hyperplasia (for male and female rats) and tumors (with male enhancement), and tumors (with male rats) of the urinary tract of the urine epithelium."</seg>
<seg id="821">"in a animal model of the family-owned polymers Polypositive (FAP), the treatment with two other Thiazoligaris to increased frequency of colontumors."</seg>
<seg id="822">"the tablets are white to welded, round, flat and wear on one side the marking" 30 "and on the other side the wording" ACTOS. "</seg>
<seg id="823">"at the end of the last few years, the group reported a few patients with Pioglitazon in patients with Pioglitazon treated women and 1.1 leader per 100 patient years of women who were treated with a comparison."</seg>
<seg id="824">"in the proactive study, a study on 3.5 / 870 (5,1%; 1.0 group per 100 patients) of the patients were treated with Pioglitazon patients, compared with 23 / 905 (2.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%;</seg>
<seg id="825">"in a further study over two years, the effects of a combination therapy can be studied with Pioglitazon or Gliclazid."</seg>
<seg id="826">"in clinical trials of 1 year, Pioglitazon has a significant significant decrease in the Albumin / Kreatinin-Quotiations compared to the initial values."</seg>
<seg id="827">"in a study about 20 weeks, Pioglitazon is not just the nuts-triglyceride, but also improved the posture of triglyceridmirror, this is an effect on the Tryglyzerid absorption characteristics as well as on the character of Tryglizerid synthesis."</seg>
<seg id="828">"although the study focuses on their primary endpoint, which corresponds to their primary endpoint, which corresponds to a combination of the total iron, coronarisation of coronarisation and Revascularization of the leg, coronarisation and Revascularization of the leg arteries."</seg>
<seg id="829">"the tablets are white to welded, round, flat and wear on one side the marking" 45 "and on the other side the wording" ACTOS. "</seg>
<seg id="830">"in a summary analysis of the latest events regarding bone transplantation, controlled, double-blind clinical trials have been treated with more than 8.100 patients who were treated with Pioglitazon and from over 7.400 patients, increased incidence of bone species in women."</seg>
<seg id="831">"in the proactive study, a study on 3.5 / 870 (5,1%; 1.0 group per 100 patients) of the patients were treated with Pioglitazon patients, compared with 23 / 905 (2.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%; 0.5%;</seg>
<seg id="832">"in a study about 20 weeks, Pioglitazon is not just the nuts-triglyceride but also improved the posture of Triglyceridmirror, this has an effect on the Triglyzeride absorbing, as well as on the traditional Triglyzerid synthesis."</seg>
<seg id="833">"in addition to the packaging of the packaging, the name and address of the manufacturer that is responsible for the release of the data is specified."</seg>
<seg id="834">Firm of the Year for Compliance Audits and Investigations Gibson Dunn & Crutcher Firm of the Year for Private Construction Luther</seg>
<seg id="835">It must be a updated risk management plan according to CHMP-guideline on Risk Management Systems for Medicinal Products for Human Use.</seg>
<seg id="836">"if you are interested in type 2 diabetes, Actos 15 mg tablets control the control of your blood sugar levels using a better risk of physical insulin."</seg>
<seg id="837">"if you are known for you, please contact using Actos 15mg tablets your doctor."</seg>
<seg id="838">"please inform your doctor or pharmacist if you take other drugs or until recently, even if it is non-prescription drugs."</seg>
<seg id="839">"if you are Actos 15 mg tablets in combination with other medicines for treatment of diabetes (such as insulin, chlorine clutamide, Gliclazid, Tolbutamide), your doctor will help you to reduce the dose of your medicine."</seg>
<seg id="840">"in some patients with long-term type 2 diabetes mellitus and heart disease, which have been treated with Actos and insulin in treated with acetylene."</seg>
<seg id="841">In clinical trials in clinical trials in which Pioglitazon has been compared to women (but not in men) that were found in women (but not in men) that are higher number of bone transplants.</seg>
<seg id="842">"if you have accidentally worry about many tablets or if a child or child, your medicine must be taken immediately with a doctor or pharmacist in conjunction with a doctor or pharmacist."</seg>
<seg id="843">"like Actos looks and content of the package of Actos 15 mg tablets are white to welded, round, velled tablets with the marking" 15 "on one side and the wording" ACTOS "on the other side."</seg>
<seg id="844">"if you are interested in type 2 diabetes, Actos 30 mg tablets control the control of your blood sugar levels using a better risk of physical insulin."</seg>
<seg id="845">"if you are known for you, please contact using Actos 30mg tablets your doctor."</seg>
<seg id="846">"if you are Actos 30 mg tablets in combination with other medicines for treatment of diabetes (such as insulin, chlorine clutamide, Gliclazid, Tolbutamide), your doctor will help you to reduce the dose of your medicine."</seg>
<seg id="847">"61 Informing you soon as possible as possible your doctor if you have signs of a heart failure, such as unusual short zip or rapid weight compensation or local swings (Ödeme)."</seg>
<seg id="848">In clinical trials in clinical trials in which Pioglitazon has been compared to women (but not in men) that were found in women (but not in men) that are higher number of bone transplants.</seg>
<seg id="849">"as Actos looks and content of the package of Actos 30 mg tablets are white to welded, round, flat tablets with the marking" 30 "on one side and the wording" ACTOS "on the other side."</seg>
<seg id="850">"if you are interested in type 2 diabetes, Actos 45 mg tablets control of your blood sugar level by making a better understanding of the body's own insulin."</seg>
<seg id="851">"if you are known for you, please contact using Actos 45mg tablets your doctor."</seg>
<seg id="852">"if you are Actos 45 mg tablets in combination with other medicines for treatment of diabetes (such as insulin, chlorine clutamide, Gliclazid, Tolbutamide), your doctor will help you to reduce the dose of your medicine."</seg>
<seg id="853">"66 on some patients with long-term type 2 diabetes mellitus and heart disease, which have been treated with Actos and insulin in treated with acetylene."</seg>
<seg id="854">"inform you as soon as possible your doctor if you have signs of a heart failure, such as an unusual muscle or rapid weight compensation or local swings (Ödeme)."</seg>
<seg id="855">In clinical trials in clinical trials in which Pioglitazon has been compared to women (but not in men) that were found in women (but not in men) that are higher number of bone transplants.</seg>
<seg id="856">67 If one of the linked side effects depend on the side effects or side effects that are not specified in this product information please inform your doctor or pharmacist.</seg>
<seg id="857">"like Actos looks and content of the package of Actos 45 mg tablets are white to welded, round, flat tablets with the marking" 45 "on one side and the wording" ACTOS "on the other side."</seg>
<seg id="858">This document is a summary of the European Union's application report (EPAR) which will be explained as the Committee for Humanities (CHMP).</seg>
<seg id="859">"if you need further information about your medical state or treatment of your illness, please read the package delivery (also part of the EPAR) or contact a doctor or pharmacist."</seg>
<seg id="860">"if you wish for further information on the basis of the recommendations of the CHMP, please read the scientific discussion (also part of the EPAR)."</seg>
<seg id="861">Acrophane 10: solitary insulin in 10% and Isophan-insulin in 90% Actraphane 40: soluble insulin in 40% and Isophan-insulin in 40% Actraphane 50: soluble insulin in 50% and Isophan-insulin in 50% and Isra for insulin in 50% and Isra for insulin in 50%</seg>
<seg id="862">Acrophane is usually applied once or twice a day as a rapid initiating effect together with a longer lasting effect.</seg>
<seg id="863">Firm of the Year for Restructuring and Corporate Rescue Freshfields Bruckhaus Deringer Firm of the Year for Insolvency Administration Schneider Geiwitz & Partner</seg>
<seg id="864">Actphane has a total of 294 patients with type 1 diabetes in which the pancreas can not produce insulin and type 2 diabetes while the body is not able to use insulin in effectively.</seg>
<seg id="865">"in the study, after 12 weeks the concentration of a substance (glycosylitis hemmoglobin (HbA1c) was measured as well as the blood sugar."</seg>
<seg id="866">"Acrophane led to a decrease in the HbA1c Spiegels, which caused the blood sugar levels similar to another humanities."</seg>
<seg id="867">Acrophane should not be applied to patients that may be excessive (allergic) to humanoid (rDNA) or one of the other components.</seg>
<seg id="868">"in addition, the cans need to be adapted depending on the blood sugar (the complete list is of the package sheet)."</seg>
<seg id="869">The Committee for Humanities (CHMP) corresponds to the conclusion that the benefits of Actraphane in treatment of diabetes compared to the risks associated with diabetes.</seg>
<seg id="870">"October 2002, the European Commission published the European Commission Novo Nordisk A / S a permit for the Instruction of Actraphane in the whole European Union."</seg>
<seg id="871">"used insulin products are usually applied once or twice daily, if a rapid initiating effect is required with a longer lasting effect."</seg>
<seg id="872">The injections must be at least 6 seconds in the skin to ensure that the entire dose is injected.</seg>
<seg id="873">"patients, their blood sugar settings are significantly improved, the hypoglycemia is significantly improved, the hypoglycemia treatment can be changed and should be advised."</seg>
<seg id="874">"each change in terms of strength, brand (manufacturer), insulin type (fast-effective, biphans, long term insulin in insulin), type of insulin (animal insulin, insulin or insulin in animal origin) can cause that a change of dosage is required."</seg>
<seg id="875">"if you need a Dosisometric parameters, this can be necessary to be necessary in the first dosage or in the first weeks or months after the changeover."</seg>
<seg id="876">Some patients treated with hypoglycemic reactions after a change of animal patterns in human insulin reported that the early warning symptoms of a Hypoglycemia is less pronounced or different than with their previous insulin.</seg>
<seg id="877">"before traveling to take over several times zones, the patient should be aware of the advice of his doctor, as such travels can lead to insulin and meals to other times."</seg>
<seg id="878">"the doctor must be able to take place to take place in the treatment of therapy, and their patients always have to ask them to others from them by them."</seg>
<seg id="879">4 Soviet Hypoglycemia as well as hyperglycemia as well as hyperglycemia with a non-controlled digestion therapy can increase the risk of abnormalities and fruit tod in Utero.</seg>
<seg id="880">"heavy metals may lead to consciousness and / or crampings, and with temporary disturbances of the brain function and even death."</seg>
<seg id="881">"the diseases of the nervous system is a rapid improvement of neuropathy means a rapid increase in blood sugar control, which can be used as acute painful neuropathy and normally resealed."</seg>
<seg id="882">"5 A Intensification of insulin therapy with an abruptive improvement of the blood sugar setting, however, may be associated with a temporary deterioration of diabetic retinopathy."</seg>
<seg id="883">"- Liliystrophie to the injection point, a liacystrophie to the injection point can occur a liacystrophie to switch within the injection area."</seg>
<seg id="884">"physical diseases and dissemination of the use case - Local ersensitive action to the injuncation therapy, local hypersensitivity actions (Romans, swelling, Juckish, pain, and hematom at the injector office)."</seg>
<seg id="885">"- Urutaria, exantageous - anaphylaktic reactions symptoms generated from high-sensitivity, gastrointestinal, gastrointestinal, gastrointestinal, gastrointestinal, gastrointestinal, gastrointestinal, low blood pressure and osteoporosis / consciousness."</seg>
<seg id="886">"however, a hypoglycemia can be set up with a long-term hypoglycemia, can be treated by glucose and sugar or sugar foods."</seg>
<seg id="887">"• This report provides you with valuable data on the actual market situation, trends and future outlook for furniture in the country in question, 2015-2019 (US dollars)"</seg>
<seg id="888">The effect begins within a half hour which is reached within 2-8 hours and the entire operation time is up to 24 hours.</seg>
<seg id="889">Resorption of Resorption profile lies in it to ensure that it is a mixture of insulin with faster or delayed resorption.</seg>
<seg id="890">"a series of column (hydrolysis) places on the humanoid molecular molecule have been moved to the humanoid molecular biology; none of the unspecified metabolite is active."</seg>
<seg id="891">"based on conventional studies on safety spicology, toxicity with repeated gift, genotoxicity, for carcinogenous potential and to reproductive data, the preventive data does not require special dangers for people."</seg>
<seg id="892">It is recommended - after the Accountphane bottle out of the fridge the temperature of the insulin ends at room temperature (not via 25 ° C) before it is used in operation for the first use for the first use.</seg>
<seg id="893">Some patients treated with hypoglycemic reactions after a change of animal patterns in human insulin reported that the early warning symptoms of a Hypoglycemia is less pronounced or different than with their previous insulin.</seg>
<seg id="894">"the doctor must be able to take place to take place in the treatment of therapy, and their patients always have to ask them to others from them by them."</seg>
<seg id="895">12 Soviet Hypoglycemia as well as hyperglycemia as well as hyperglycemia with a non-controlled Diabide therapy can increase the risk of misuse and fruit tod in Utero.</seg>
<seg id="896">"13 A Intensification of insulin therapy with an abruptive improvement of the blood sugar setting, however, may be associated with a temporary deterioration of diabetic retinopathy."</seg>
<seg id="897">The terminated semi-dose time (t ½) is rather a measure of the resorption than a measure of Elimination by the insulin from the plasma (insulin in the blood circulation (a ½ minutes of only a few minutes).</seg>
<seg id="898">It is recommended - after the Accountphane bottle out of the fridge the temperature of the insulin ends at room temperature (not via 25 ° C) before it is used in operation for the first use for the first use.</seg>
<seg id="899">Some patients treated with hypoglycemic reactions after a change of animal patterns in human insulin reported that the early warning symptoms of a Hypoglycemia is less pronounced or different than with their previous insulin.</seg>
<seg id="900">20 Soviet Hypoglycemia as well as hyperglycemia as well as hyperglycemia with a non-controlled Diabide therapy can increase the risk of misuse and fruit tod in Utero.</seg>
<seg id="901">21 A Intensification of insulin therapy with an abruptive improvement of the blood sugar setting may be associated with a temporary deterioration of diabetic retinopathy.</seg>
<seg id="902">"- Urutaria, exantageous - anaphylaktic reactions symptoms generated from high-sensitivity, gastrointestinal, gastrointestinal, gastrointestinal, gastrointestinal, gastrointestinal, gastrointestinal, low blood pressure and osteoporosis / consciousness."</seg>
<seg id="903">Cartridges are used only together with products that are compatible with them and ensure safe and effective function of the cartridge.</seg>
<seg id="904">It is recommended - after Acrophane Pensions from the fridge the temperature of the insulin ends at room temperature (not via 25 ° C) before it is used in operation for the first use for the first use.</seg>
<seg id="905">Some patients treated with hypoglycemic reactions after a change of animal patterns in human insulin reported that the early warning symptoms of a Hypoglycemia is less pronounced or different than with their previous insulin.</seg>
<seg id="906">28 Soviet Hypoglycemia as well as hyperglycemia as well as hyperglycemia with a non-controlled Diabide therapy can increase the risk of misuse and fruit tod in Utero.</seg>
<seg id="907">29 A Intensification of insulin therapy with an abruptive improvement of the blood sugar setting may be associated with a temporary deterioration of diabetic retinopathy.</seg>
<seg id="908">Some patients treated with hypoglycemic reactions after a change of animal patterns in human insulin reported that the early warning symptoms of a Hypoglycemia is less pronounced or different than with their previous insulin.</seg>
<seg id="909">"36 Nohl Hypoglycemia as well as hyperglycemia, which occur in a non-controlled digestion therapy, increase the risk of misunderstanding and fruit tod in Utero."</seg>
<seg id="910">"37 A Intensification of insulin therapy with an abruptive improvement of the blood sugar setting, however, may be associated with a temporary deterioration of diabetic retinopathy."</seg>
<seg id="911">44 Soviet Hypoglycemia as well as hyperglycemia as well as hyperglycemia with a non-controlled testing therapy can increase the risk of abnormalities and fruit tod in Utero.</seg>
<seg id="912">45 A Intensification of insulin therapy with an abruptive improvement of the blood sugar setting may be associated with a temporary deterioration of diabetic retinopathy.</seg>
<seg id="913">Some patients treated with hypoglycemic reactions after a change of animal patterns in human insulin reported that the early warning symptoms of a Hypoglycemia is less pronounced or different than with their previous insulin.</seg>
<seg id="914">52 Nohl Hypoglycemia as well as hyperglycemia as well as hyperglycemia with a non-controlled digestion therapy can increase the risk of abnormalities and fruit tod in Utero.</seg>
<seg id="915">"53 A Intensification of insulin therapy with an abruptive improvement of the blood sugar setting, however, may be associated with a temporary deterioration of diabetic retinopathy."</seg>
<seg id="916">"the injection hoods must be prepared before the injectors so that the Dosiser controller is being prepared to zero, and an insulin resistance to the top of the injector nadel appears."</seg>
<seg id="917">"for example, the hypoglycemia treatment can significantly improves the hypoglycemia treatment."</seg>
<seg id="918">"as well as hyperglycemia as well as hyperglycemia, the risk of miseration therapy can increase the risk of misuse and fruit tod in Utero."</seg>
<seg id="919">Stimulating insulin therapy with an abruptive improvement of the blood sugar setting may be associated with a temporary deterioration of diabetic retinopathy.</seg>
<seg id="920">"- Urutaria, exantageous - anaphylaktic reactions symptoms generated from high-sensitivity, gastrointestinal, gastrointestinal, gastrointestinal, gastrointestinal, gastrointestinal, gastrointestinal, low blood pressure and osteoporosis / consciousness."</seg>
<seg id="921">"these manufacturing shoes may only be used together with products that are compatible with them, and ensure safe and effective function of the finished tape."</seg>
<seg id="922">It is recommended - after Acrophane Novocks from the fridge the temperature of the insulin ends at room temperature (not via 25 ° C) before it will be used in operation for the first use for the first use.</seg>
<seg id="923">"for example, the hypoglycemia treatment can significantly improves the hypoglycemia treatment."</seg>
<seg id="924">"75 patients, whose blood sugar settings are significantly improved, the hypoglycemia is significantly improved, the hypoglycemia treatment can be changed and should be advised."</seg>
<seg id="925">"83 patients, their blood sugar settings are significantly improved, the hypoglycemia is significantly improved, the hypoglycemia treatment can be changed and should be advised."</seg>
<seg id="926">"in 91 patients, their blood sugar settings are significantly improved, the hypoglycemia is significantly improved, the hypoglycemia treatment can be changed and should be advised."</seg>
<seg id="927">"for example, the hypoglycemia treatment can significantly improves the hypoglycemia treatment."</seg>
<seg id="928">"each change to strength, brand (manufacturer), insulin type (fast-acting insulin, insulin insulin, insulin) and / or manufacturing method (due to recombinant melanoma) and / or production method (by recombinant DNS against insulin in animal origin) can cause a change of dosage."</seg>
<seg id="929">It is recommended - after Acrophane Innov from the fridge the temperature of the insulin ends at room temperature (not via 25 ° C) before it is used in operation for the first use for the first use.</seg>
<seg id="930">It is recommended - after Acrophane Flexi from the fridge the temperature of the insulin ends at room temperature (not via 25 ° C) before it is used in operation for the first use for the first use.</seg>
<seg id="931">"in addition to the packaging of the packaging, the name and address of the manufacturer that is responsible for the release of the data is specified."</seg>
<seg id="932">"in the fridge, the refrigerator (2 × C - 8 ˚ C) Not available in the box to protect the content from light to protect the content of light, not in the fridge or over 25 ° C."</seg>
<seg id="933">Subcutaneous application of capillary cartridges are used for the application with insulin devices of Novo Nordisk mixtures. Actraphane 10 Pensions may only be used only by one person</seg>
<seg id="934">"in the refrigerator store (2 × C - 8 ˚ C) Not available on the box to protect the content from light to protect the content of light, not in the fridge or over 30 ° C."</seg>
<seg id="935">Subcutaneous application of capillary cartridges are used for the application with insulin devices of Novo Nordisk mixers. Actraphane 20 Penalty may only be used only by one person</seg>
<seg id="936">Subcutaneous application of capillary cartridges are used for the application with insulin devices of Novo Nordisk mixtures. Actraphane 30 Penalty may only be used only by one person</seg>
<seg id="937">Subcutaneous application of capillary cartridges are used for the application with insulin devices of Novo Nordisk mixtures. Actraphane 40 Penalty may only be used only by one person</seg>
<seg id="938">Subcutaneous application of capillary cartridges are used for the application with insulin devices of Novo Nordisk mixtures. Actraphane 50 Penalty may only be used only by one person</seg>
<seg id="939">Subcutaneous application for the use of Acrophane 10 Novosts are intended to be used by Acrophane 10 Novosts.</seg>
<seg id="940">"in the refrigerator store (2 × C - 8 ˚ C) Not available for light on light, not in refrigerator or over 30 ° C."</seg>
<seg id="941">Subcutaneous application for the use of Acrophane 20 Novosts are intended to be used by Acrophane 20 Novocks.</seg>
<seg id="942">"subcutaneous application for use with Acrophane 30 Novocks, Novostrong injectors are provided by Actrapane 30 Novocks, may only be used only by one person."</seg>
<seg id="943">"subcutaneous application for use with Acrophane 40 Novocks, Novody injectors are intended to be used by Acrophane 40 Novovic, may only be used only by one person."</seg>
<seg id="944">Subcutaneous application for the use of Acrophane 50 Novosts are intended to be used by Acrophane 50 Novosts. Acquphane 50 Novosts may only be used only by one person</seg>
<seg id="945">"subcutaneous application for use with Acrophane 30 Innography, NovoFine S injectors are provided by Acrophane 30 Innography may only be used only by one person."</seg>
<seg id="946">This means that about half an hour after you have applied it to sink your blood sugar and that the effect is about 24 hours.</seg>
<seg id="947">"if you allergic to allergic (oversensitive) to this insulin, Metacresol or one of the other components (see section 7 Show other information)."</seg>
<seg id="948">Watch on the 5 Which side effects are possible? the symptoms of allergy suffices if you feel the first signs of a Hypoglycemia treatment (Symptoms).</seg>
<seg id="949">"if your doctor has a change of insulin or brand, you must be adapted to your doctor if your doctor needs to be adapted to your doctor."</seg>
<seg id="950">"check out the label, whether it is the correct insulin type ► Describe your rubber buffer with a medical Tub."</seg>
<seg id="951">"if this is not completely unnecessary, if you have not been stored correctly, the penetration bottle of your pharmacy is not properly stored or einrors (see 6 How is Acquphane?) ► if it is not properly stored, it is not evenly."</seg>
<seg id="952">Use the injection technology that allows you to your doctor or pharmacology treatment in your skin to ensure that the complete dose injected.</seg>
<seg id="953">"the warning signs of a submering may suddenly occur, and can be seen: kage sweat, cold blet skin, headaches, heart rascal, nausea, large hunger, pain, and weakness, nerves or citrus, confusion, concentration."</seg>
<seg id="954">"tell your relatives, friends and tight work, that they need to bring you in the case of consciousness into the stable side situation and immediately take a doctor."</seg>
<seg id="955">"in order to eat nothing to eat or drink, since you may take care of your doctor. ► If a heavy underpation is not treated, it can lead to (temporary or lasting) brain damage or even for death."</seg>
<seg id="956">"you can create awareness faster, if you have a hormone glucagon of one person who is familiar with its gift."</seg>
<seg id="957">This can happen: • If you can eat much insulin when you eat little or a meal. • If you can eat more than otherwise physically.</seg>
<seg id="958">"reinforced film, thirst, appiclessness, nausea or vomiting, Benommenity or fatigue, dry skin, mouth, and fruity (according to Aceton) ribs."</seg>
<seg id="959">• You have forgotten your insulin levels • repeated injections of less insulin than you need a infection or fever • more food than usual • less physical exercise than usual.</seg>
<seg id="960">"if you have to give a injunction on the same place, can the lower fat tissue damage (Lipatrophie) or increase (Lipohypertrophie)."</seg>
<seg id="961">"if you notice, drag or thicknesses of your skin at the injection point, notice your doctor or pharmacologist if you influence your doctor if you influence in such a place."</seg>
<seg id="962">"if you are looking for a doctor if the symptoms of an allergy to other parts of the body, or • If you suddenly suddenly feel comfortable and you feel comfortable and you feel relaxed, breathing, heart rasen, you can do, or you have the impression."</seg>
<seg id="963">You may have a very rare severe allergic reaction to Acrophane or one of its components (a so-called systemic reaction).</seg>
<seg id="964">"if one of the linked side effects will be considerably lower or if you notice any side effects that are not specified in this product information, please inform your doctor if your doctor or pharmacist."</seg>
<seg id="965">What Actuphane 30 contains - The active substance is due to recombinant DNS technology for insulin (30% as a soluble insulin and 70% as a solophan insulin insulin).</seg>
<seg id="966">"as Acquphane looks and content of the package suspension is distributed as a cloudy, white, wary suspension in packing with 1 or 5 watering bottles with 1 or 5 watering bottles with 5 litre bottles per 10 ml."</seg>
<seg id="967">Use the injection technology that allows you to your doctor or pharmacology treatment in your skin to ensure that the complete dose injected.</seg>
<seg id="968">It is recommended - after they leave out from the fridge - the temperature of the penetration bottle on room temperature before they are used for the first use for the first use.</seg>
<seg id="969">"as Acquphane looks and content of the package suspension is distributed as a cloudy, white, wary suspension in packing with 1 or 5 watering bottles with 1 or 5 watering bottles with 5 litre bottles per 10 ml."</seg>
<seg id="970">"check out the label, whether it is the correct insulin type ►"</seg>
<seg id="971">Do not use them if any damage is seen or a gap between the rubber band and the white band of the label.</seg>
<seg id="972">"more information can be found on the operating instructions of your insulin equipment. ► Desinquire, you always provide a new injectors to prevent contamination of contamination."</seg>
<seg id="973">"in each case it is not properly stored, it is damaged or broken. (see 6 How is Acrophane's risk?) ► if it is not properly stored, it is not possible to keep the risk of failure."</seg>
<seg id="974">"if you are treated with Acrophane 10 Pensions and another insulin in Penalty cartridges, you should use two insulin injection systems, depending on each insulin type."</seg>
<seg id="975">"before you use the cartridge in the insulin system, you move at least 20 times between the positions a and b (see figure), so that the glass is from one end of the cartridge to the other."</seg>
<seg id="976">Use the injection technology that allows you to remove your doctor or your diligence System in order to ensure that the complete dose of injectors was found.</seg>
<seg id="977">"183 Saver your relatives, friends and tight work, that they have to bring you in the case of consciousness into the stable side situation and immediately."</seg>
<seg id="978">• You have forgotten your insulin levels • repeated injections of less insulin than you need a infection or fever • more food than usual • less physical exercise than usual.</seg>
<seg id="979">"if one of the linked side effects will be considerably lower or if you notice any side effects that are not specified in this product information, please inform your doctor if your doctor or pharmacist."</seg>
<seg id="980">It is recommended - after they leave out from the fridge - the temperature of the Pencil Patrol was removed at room temperature before they are used for the first use for the first use for the first use.</seg>
<seg id="981">185 requests can always be used in the carton if you don't use it to protect them before light.</seg>
<seg id="982">What Accuphane 10 contains - The active substance is due to recombinant DNS technology for insulin (10% as a soluble insulin and 90% as a solophan insulin insulin).</seg>
<seg id="983">"as Acquphane looks and content of the package suspension is distributed as a cloudy, white, wary suspension in packing with 1, 5 or 10 cartridges."</seg>
<seg id="984">"more information can be found on the operating instructions of your insulin equipment. ► Desinquire, you always provide a new injectors to prevent contamination of contamination."</seg>
<seg id="985">"if you use Acrophane 20 Penile and another insulin in Penalty cartridges, you should use two insulin injection systems, depending on each insulin type."</seg>
<seg id="986">"189 Saws your relatives, friends and tight work, that they have to bring you in the case of consciousness into the stable side situation and immediately."</seg>
<seg id="987">"if one of the linked side effects will be considerably lower or if you notice any side effects that are not specified in this product information, please inform your doctor if your doctor or pharmacist."</seg>
<seg id="988">191 Choose your cartridges in the carton if you don't use it to protect them before light.</seg>
<seg id="989">What Actuphane 20 contains - The active substance is due to recombinant DNS technology for insulin (20% as a soluble insulin and 80% as a solophan insulin insulin).</seg>
<seg id="990">"as Acquphane looks and content of the package suspension is distributed as a cloudy, white, wary suspension in packing with 1, 5 or 10 cartridges."</seg>
<seg id="991">"more information can be found on the operating instructions of your insulin equipment. ► Desinquire, you always provide a new injectors to prevent contamination of contamination."</seg>
<seg id="992">"if you use Acrophane 30 Penile and another insulin in Penalty cartridges, you should use two insulin injection systems, depending on each insulin type."</seg>
<seg id="993">195 Saws your relatives, friends and tight work, that they have to bring you in the case of consciousness into the stable side situation and immediately. "</seg>
<seg id="994">"if one of the linked side effects will be considerably lower or if you notice any side effects that are not specified in this product information, please inform your doctor if your doctor or pharmacist."</seg>
<seg id="995">Here you can always use the cartridges in the carton if you don't use it to protect them before light.</seg>
<seg id="996">Manufacturers and manufacturers can be identified using the charter type that can be identified on the cardboard box and on the label.</seg>
<seg id="997">"in case of the second and third place the character combination W5, S6, P5, K7, K7, K7, K7, K7, K7, K7, K7, K7, K7, K7, K7, K7, K7 and ZF."</seg>
<seg id="998">"in case of the second and third position of the character name H7 or T6, the manufacturer Novo Nordisk Production SAS, 45, Avenue d'Orléans, F-28002 Chartres, France."</seg>
<seg id="999">"more information can be found on the operating instructions of your Instruction system. ► Desinquire, you always specify a new injectors to prevent an contamination."</seg>
<seg id="1000">"if you are treated with Acrophane 40 Pensions and another insulin in Penalty cartridges, you should use two insulin injection systems, depending on each insulin type."</seg>
<seg id="1001">"201 Saver you your relatives, friends and tight work, that they have to bring you in the case of consciousness into the stable side situation and immediately."</seg>
<seg id="1002">"if one of the linked side effects will be considerably lower or if you notice any side effects that are not specified in this product information, please inform your doctor if your doctor or pharmacist."</seg>
<seg id="1003">203 reviews Remove the cartridges in the carton if you don't use it to protect them before light.</seg>
<seg id="1004">What Accuphane 40 contains - The active substance is due to recombinant DNS technology that has 40% as a solitary insulin in and 60% as a solophan insulin for insulin.</seg>
<seg id="1005">"more information can be found on the operating instructions of your Instruction system. ► Desinquire, you always specify a new injectors to prevent an contamination."</seg>
<seg id="1006">"if you use Acrophane 50 Pensions and another insulin in Penalty cartridges, you should use two insulin injection systems, depending on each insulin type."</seg>
<seg id="1007">"before you use the Penguin Patrol into the insulin system, you move at least 20 times between the positions a and b (see figure), so that the glass is from one end of the cartridge to the other."</seg>
<seg id="1008">"207 Saints your relatives, friends and tight work, that they have to bring you in the case of consciousness into the stable side situation and immediately take a doctor."</seg>
<seg id="1009">"if one of the linked side effects will be considerably lower or if you notice any side effects that are not specified in this product information, please inform your doctor if your doctor or pharmacist."</seg>
<seg id="1010">209 requests the cartridges always in the carton if you don't use it to protect them before light.</seg>
<seg id="1011">What Actuphane 50 contains - The active substance is due to recombinant DNS technology for insulin (50% as a soluble insulin and 50% as a solophan insulin insulin).</seg>
<seg id="1012">"antioxidant antidiabetics (for use), Monochromium, Acetyl salicylic acid, thyophonic acid, thyroid hormone, endocotid, calazol, Octagotid or Lanreotid."</seg>
<seg id="1013">"check out the label, whether it is a new injector type ► Bench you always have a new injectors to prevent contamination from contamination."</seg>
<seg id="1014">"in insulin when the Novoirs were damaged, it is damaged or broken (see 6 How is Acquphane's risk?) ► if it is not properly stored, it is not evenly."</seg>
<seg id="1015">"the warning signs of a submering may suddenly occur, and can be seen: kage sweat, cold blet skin, headaches, heart rascal, nausea, large hunger, pain, and weakness, nerves or citrus, confusion, concentration."</seg>
<seg id="1016">214 when one of the side effects will be considerably lower or if you notice any side effects that are not specified in this product information please inform your doctor if your doctor or pharmacist.</seg>
<seg id="1017">"if you are ready for use in the fridge, you will be able to keep it in the refrigerator for use in the fridge."</seg>
<seg id="1018">It is recommended - after starting out of the fridge - the temperature of the Novolets will take place on room temperature before they are used for the first use for the first use for the first use.</seg>
<seg id="1019">Let the clamping force of your Novolets will always be placed when Novoeing does not use in use to protect insulin in front of light.</seg>
<seg id="1020">"as Acquphane looks and content of the package suspension is distributed as a cloudy, white, waking suspension in packing with 5 or 10 ready meals."</seg>
<seg id="1021">"before each injtion • check, whether to stay at least 12 units insulin in the patterns. so that a uniform mixture is ensured."</seg>
<seg id="1022">"to avoid the injunction of air to avoid and to ensure a correct dosage: • Hide you Actphane 10 Novocks with the injection nadel after above, you can easily find a few times with fingers to the cartridge."</seg>
<seg id="1023">"if air bubbles are present in the Patras, you will continue to keep up a click in the direction of the path (Figure C) • During you keep the injector nadel after above, press the push button in the direction of the injector needle (figure D) • Now, then press the push button in the direction of the injector needle."</seg>
<seg id="1024">• Supports the connection flap again on the precondition that the digit 0 compared to the metering unit (figure E) • account you can set whether the pressure button is completely removed.</seg>
<seg id="1025">"if not, turn the lock flap, up to the printer-button, • Hook your Accuphane 10 Novocks."</seg>
<seg id="1026">"if the push button does not move freely according to the outside, e.g. insulin in the injector pin • The scale on the lock flap shows 0, 2, 4, 6, 10, 12, 14, 16 and 18 units."</seg>
<seg id="1027">"the push button moves upwards, while you turn the arrow flap • The scale under the push button displays 20, 40 and 60 units."</seg>
<seg id="1028">"if you have to set a wrong dose, you can get the highest number that you can set to the printed dose • if you have a wrong dose, turn the clamping force or backward, until you have the right number to units."</seg>
<seg id="1029">Otherwise the dose is not correctly correctly and the dose will not be correctly correctly. if you have any dose you have to set a dose of more than 78 units you will take the following steps through:</seg>
<seg id="1030">Then take the adjustment flap and set it so again that the 0 of the metering unit is located.</seg>
<seg id="1031">Make sure to press only during the injection button on the push button. • Hook the push button after the injector up to the injection nadel from the skin.</seg>
<seg id="1032">"if not, turn the clamping flap, until the pressure button, then you will then continue as in the use of the printing button."</seg>
<seg id="1033">It is possibly unjust • You can set up a dose that is higher than the number of the previous units • you can use the residual amounts of amounts to estimate how much insulin are still left.</seg>
<seg id="1034">"antioxidant antidiabetics (for use), Monochromium, Acetyl salicylic acid, thyophonic acid, thyroid hormone, endocotid, calazol, Octagotid or Lanreotid."</seg>
<seg id="1035">"224 If one of the linked side effects will be considerably lower or if you notice any side effects that are not specified in this shop information, please inform your doctor if your doctor or pharmacist."</seg>
<seg id="1036">"before each injector • Overdrive, check whether or at least 12 units insulin in the patterns. so that a uniform mixture is ensured."</seg>
<seg id="1037">"to avoid the injunction of air to avoid and to ensure a correct dosage: • Hide you Accuphane 20 Novocks with the injection nadel after above • clocking a few times with the fingers slightly against the cartridge."</seg>
<seg id="1038">"if air bubbles are present, this makes it possible to keep up a click in direction of the drop (Figure C) • During you keep the injector topping in the direction of the path (Figure D) • Now, push the push button in the direction of the injector needle (figure D) • Now, then turn the push button in the direction of the injector needle."</seg>
<seg id="1039">"if not, turn the lock flap, up to the printer-button, • Hook your Accuphane 20 Novocks."</seg>
<seg id="1040">"antioxidant antidiabetics (for use), Monochromium, Acetyl salicylic acid, thyophonic acid, thyroid hormone, endocotid, calazol, Octagotid or Lanreotid."</seg>
<seg id="1041">"234 If one of the linked side effects depend on the side effects or side effects that are not specified in this product information, please inform your doctor if your doctor or pharmacist."</seg>
<seg id="1042">236 of each injtion • check whether or at least 12 units insulin in the patterns. so that a uniform mixture is ensured.</seg>
<seg id="1043">"you are as follows to avoid the injector of air to avoid and to ensure a correct dosage: • Hide you Actphane 30 Novocks with the injection nadel after above, you can easily find a few times with fingers to the cartridge."</seg>
<seg id="1044">"if air bubbles are present, this makes it possible to keep up a click in the drop down (Figure C) • During you keep the injector topping in the direction of the path (Figure D) • Now, push the push button in the direction of the injector needle (figure D) • Now, then turn the push button in the direction of the injector needle."</seg>
<seg id="1045">"if not, turn the lock flap, up to the printer-button, • Hook your Accuphane 30 Novocks."</seg>
<seg id="1046">"antioxidant antidiabetics (for use), Monochromium, Acetyl salicylic acid, thyophonic acid, thyroid hormone, endocotid, calazol, Octagotid or Lanreotid."</seg>
<seg id="1047">"244 If one of the adverse side effects depend on the side effects or side effects that are not specified in this product information, please inform your doctor if your doctor or pharmacist."</seg>
<seg id="1048">"after each injtion • help to check whether or at least 12 units insulin in the patrol, so that a uniform mixture is ensured."</seg>
<seg id="1049">"to avoid the injunction of air to avoid and to ensure a correct dosage: • Hide you Actphane 40 Novocks with the injector nadel after above, you can easily find a few times with fingers to the cartridge."</seg>
<seg id="1050">"if air bubbles are present, this makes it possible to keep up a click in direction of the drop (Figure C) • During you keep the injector topping in the direction of the path (Figure D) • Now, push the push button in the direction of the injector needle (figure D) • Now, then turn the push button in the direction of the injector needle."</seg>
<seg id="1051">"if not, turn the lock flap, up to the printer-button, • Hook your Accuphane 40 Novocks."</seg>
<seg id="1052">"antioxidant antidiabetics (for use), Monochromium, Acetyl salicylic acid, thyophonic acid, thyroid hormone, endocotid, calazol, Octagotid or Lanreotid."</seg>
<seg id="1053">"254 If one of the linked side effects will be considerably reduced or if you notice any side effects that are not specified in this product information, please inform your doctor if your doctor or pharmacist."</seg>
<seg id="1054">It is recommended - after starting out of the fridge - the temperature of the Novolets will take place on room temperature before they are used for the first use for the first use for the first use.</seg>
<seg id="1055">"after each injunction • check, whether to stay at least 12 units insulin in the patterns. so that a uniform mixture is ensured."</seg>
<seg id="1056">"to avoid the injunction of air to avoid and to ensure a correct dosage: • Hide you Accuphane 50 Novocks with the injector nadel after above, you can easily find a few times with fingers to the cartridge."</seg>
<seg id="1057">"if air bubbles are present, this makes it possible to keep up a click in direction of the drop (Figure C) • During you keep the injector nadel after above, press the push button in the direction of the injector (Figure D) • Now, then press the push button in direction (Figure D) • Now, then turn the push button in the direction of the injector needle."</seg>
<seg id="1058">"if not, turn the lock flap, up to the printer-button, • Hook your Accuphane 50 Novocks."</seg>
<seg id="1059">"antioxidant antidiabetics (for use), Monochromium, Acetyl salicylic acid, thyophonic acid, thyroid hormone, endocotid, calazol, Octagotid or Lanreotid."</seg>
<seg id="1060">"as a result, the risk of failure (see 6 How is Acrophane's risk?) it is not possible to keep the risk of failure (see 6 How is Actraphane?) ►"</seg>
<seg id="1061">"the warning signs of a submering may suddenly occur, and can be seen: kage sweat, cold blet skin, headaches, heart rascal, nausea, large hunger, pain, and weakness, nerves or citrus, confusion, concentration."</seg>
<seg id="1062">"264 If one of the linked side effects will be considerably reduced or if you notice any side effects that are not specified in this product information, please inform your doctor if your doctor or pharmacist."</seg>
<seg id="1063">"in use of use in use of insensitive induction systems, such as a substitute can be used to be used in the fridge, not in the fridge."</seg>
<seg id="1064">"it is recommended - after starting out of the fridge, the temperature of the Innoons finished on room temperature before they are used for the first use of operation for the first use for the first use."</seg>
<seg id="1065">Let the clamping force of your innolets will always be placed when Innock doesn't use in use to protect insulin in front of light.</seg>
<seg id="1066">"as Acquphane looks and content of the package suspension is distributed as a cloudy, white, wary suspension in packing with 1, 5 or 10 finished goods."</seg>
<seg id="1067">"the movement must be repeated, until the liquid is evenly. and it looks like the resusation, you will use all the following steps of the injector without delay."</seg>
<seg id="1068">• Descrify your rubber buffer with a medical Tub • Bench you always for any injections to prevent an contamination of contamination • remove the protective lashing of a NovoFine S Innodel (Figure 1B) • Zipper the large outer injection needle and the inner injector pin connector.</seg>
<seg id="1069">• Enhances you always adjust the pressure button and the Dosisregulator to zero stands for the number of units that you need to injector by using the Dosisregulator in watchmaking process (Figure 2).</seg>
<seg id="1070">Do not use the residual hardness - scale to measure your insulin levels • You hear for each individually set unit.</seg>
<seg id="1071">Perform the injection technology that you have shown your doctor from your doctor if you want to press the push button (figure 3).</seg>
<seg id="1072">"the injector controller is not block to zero, and you listen to the injector • The injection nadel must remain under the skin to ensure that the complete insulin controller must not block the injection valve after the injector. • remove the injector needle depending on the injector."</seg>
<seg id="1073">Medical staff and family members as well as other engineers have to avoid general knowledge measures for removal and disposal of the injections to prevent unintended use of the injectors.</seg>
<seg id="1074">"antioxidant antidiabetics (for use), Monochromium, Acetyl salicylic acid, thyophonic acid, thyroid hormone, endocotid, calazol, Octagotid or Lanreotid."</seg>
<seg id="1075">"in insulin when the FlexPen was damaged, it is damaged or broken. (see 6 How is Acquphane's risk?) ► if it is not properly stored, it is not necessary."</seg>
<seg id="1076">"if you notice, drag or thicknesses of your skin at the injection point, notice your doctor or pharmacologist if you influence your doctor if you influence in such a place."</seg>
<seg id="1077">"274 If one of the linked side effects will be considerably reduced or if you notice any side effects that are not specified in this product information, please inform your doctor if your doctor or pharmacist."</seg>
<seg id="1078">"in use with the Flexi ready-to-use FlexPen ready meals and such that will be used in the refrigerator, not in the fridge."</seg>
<seg id="1079">It is recommended - after starting out of the fridge - the temperature of the FlexPen production comes on room temperature before they are used for the first use for the first use for the first use.</seg>
<seg id="1080">Allow the clamping force of your FlexPen ready to ensure that it is not in use to protect insulin in front of light.</seg>
<seg id="1081">"as Acquphane looks and content of the package suspension is distributed as a cloudy, white, wary suspension in packing with 1, 5 or 10 finished goods."</seg>
<seg id="1082">Manufacturers and manufacturers can be identified using the charter type that can be identified on the cardboard box and on the label.</seg>
<seg id="1083">"in case of the second and third place the character combination W5, S6, P5, K7, K7, K7, K7, K7, K7, K7, K7 or ZF, is the manufacturer of Novo Nordisk Production SAS, 45, Avenue d'Orléans, F- 28002 Chartres, France."</seg>
<seg id="1084">"B Beaches the production line between the positions 1 and 2 times, so that the glass of the glass is moved from one end of the cartridge to the other."</seg>
<seg id="1085">"at least 10 times between the positions 1 and 2, between the positions 1 and 2, until the liquid is white and red."</seg>
<seg id="1086">"• To reduce the risk of unintended needle valve, you never have the inner ring again on the injection nadel after you have taken once again."</seg>
<seg id="1087">"279 G Hexagon the FlexPen with the injection nadel after above and knocking out a few times with fingers to the cartridge, thus reducing air bubbles in the cartridge."</seg>
<seg id="1088">"the dose can be corrected both according to the above, by using the Doseliac button in the appropriate direction, until the correct dose is opposite to the markings."</seg>
<seg id="1089">This document is a summary of the European Union's application report (EPAR) which will be explained as the Committee for Humanities (CHMP) to enter recommendations regarding the application of the medicines.</seg>
<seg id="1090">"an effective part in Acropid, insulin in Africa (rDNA), is made with the procedure of the so-called" recombinable technology ":"</seg>
<seg id="1091">"* Pinpoint growth sectors and identify factors driving change; * Understand the competitive environment, the market's major players and leading brands; * Use five-year forecasts to assess how the market is predicted to develop."</seg>
<seg id="1092">Actpid may not be used in patients that may be sensitive to insulin (rDNA) or one of the other components.</seg>
<seg id="1093">"in addition, the cans need to be adapted depending on the blood sugar."</seg>
<seg id="1094">"October 2002, the European Commission published the European Commission Novo Nordisk A / S a permit for the Instruction of Actrapid in the whole European Union."</seg>
<seg id="1095">"if two types of insulin are mixed in mixed, first the amount of need for insulin must be opened to the quantity of long term insulin."</seg>
<seg id="1096">"3) If you need a Dosisometric parameters, it is necessary to be required in the first dosage or in the first weeks or months after the changeover."</seg>
<seg id="1097">"before traveling to take over several times zones, the patient should be aware of the advice of his doctor, as such travels can lead to insulin and meals to other times."</seg>
<seg id="1098">"5 General diseases and dissemination of the use of the web site, take a look at the injection point of the injection point in the injuring therapy (Romans, swelling, Juckery, pain, and hematom at the injector office)."</seg>
<seg id="1099">"• This report provides you with valuable data on the actual market situation, trends and future outlook for furniture in the country in question, 2015-2019 (US dollars)"</seg>
<seg id="1100">A clinically attempt to treat hyperglycemia (blood sugar via 10 mmol / l) with 204 diabetic and 1344 non-diabetic patients who showed greater surgical surgery caused by intravenous acetate patients (blood sugar 4.4 - 6.1 mmol / l) into a 42% reduced (8% compared to 4.6%).</seg>
<seg id="1101">The effect begins within a half hour which is reached within 1.5 to 3.5 hours and the entire operation time is about 7 to 8 hours.</seg>
<seg id="1102">Children and teenagers are investigated at a smaller number (n = 18) diabetic children (aged between 6 and 12 years) and youth (in age between 13 and 17 years).</seg>
<seg id="1103">"the data are limited, however, the assumption that the pharmacokinetics profile for children and adolescents are similar to adults."</seg>
<seg id="1104">Infusionsystems with acetates 0.05 I.E. / ml - 1.0 I.E. / ml insulin with 40 mmol / l Kaliumchloride are stable at room temperature 24 hours long.</seg>
<seg id="1105">"11 If you need a Dosisometric parameters, this can be necessary to be necessary in the first dosage or in the first weeks or months after the changeover."</seg>
<seg id="1106">"before traveling to take over several times zones, the patient should be aware of the advice of his doctor, as such travels can lead to insulin and meals to other times."</seg>
<seg id="1107">"13 general conditions and dissemination of the contact form, take a look at the injection point of the injection point in the injuring therapy (Romans, swelling, Juckery, pain, and hematom at the injector office)."</seg>
<seg id="1108">"• This report provides you with valuable data on the actual market situation, trends and future outlook for furniture in the country in question, 2015-2019 (US dollars)"</seg>
<seg id="1109">Children and teenagers are investigated at a smaller number (n = 18) diabetic children (aged between 6 and 12 years) and youth (in age between 13 and 17 years).</seg>
<seg id="1110">"the intravenous use of acetpid made of recycled polyester, or cartridges should be subject to a exception and only in situations where no penetration is available."</seg>
<seg id="1111">"if you need to be used in the first dosage, this can be necessary for the first dosage or in the first weeks or months after the changeover."</seg>
<seg id="1112">"21 diseases of the skin and the undersides of the skin - Livonystrophie to the injection point, a lithuystrophie is to change in the injections within the injection unit."</seg>
<seg id="1113">Children and teenagers are investigated at a smaller number (n = 18) diabetic children (aged between 6 and 12 years) and youth (in age between 13 and 17 years).</seg>
<seg id="1114">29 diseases of the skin and the lower linkage system - Livonystrophie to the injection point can be a liposystrophie to switch a liacystrophie.</seg>
<seg id="1115">"- Urutaria, exantageous - anaphylaktic reactions symptoms generated from high-sensitivity, gastrointestinal, gastrointestinal, gastrointestinal, gastrointestinal, gastrointestinal, gastrointestinal, low blood pressure and osteoporosis / consciousness."</seg>
<seg id="1116">Children and teenagers are investigated at a smaller number (n = 18) diabetic children (aged between 6 and 12 years) and youth (in age between 13 and 17 years).</seg>
<seg id="1117">"- Urutaria, exantageous - anaphylaktic reactions symptoms generated from high-sensitivity, gastrointestinal, gastrointestinal, gastrointestinal, gastrointestinal, gastrointestinal, gastrointestinal, low blood pressure and osteoporosis / consciousness."</seg>
<seg id="1118">"38 A clinically attempt to treat hyperglycemia (blood sugar via 10 mmol / l) with 204 diabetic and 1344 non-diabetic patients who showed greater surgical surgery, which has been reduced to 42% (8% compared to 4.8%)."</seg>
<seg id="1119">"- Urutaria, exantageous - anaphylaktic reactions symptoms generated from high-sensitivity, gastrointestinal, gastrointestinal, gastrointestinal, gastrointestinal, gastrointestinal, gastrointestinal, low blood pressure and osteoporosis / consciousness."</seg>
<seg id="1120">"46 A clinically attempt to treat hyperglycemia (blood sugar via 10 mmol / l) with 204 diabetic and 1344 non-diabetic patients who showed greater surgical surgery, which has been reduced to 42% (8% compared to 4.8%)."</seg>
<seg id="1121">"in the refrigerator store (2 ° C - 8 ° C) Not available in the box to protect the content from light to protect the content of light, not in the fridge or over 25 ° C."</seg>
<seg id="1122">Subcutaneous application of capillary cartridges are used for use with Novo Nordisk insulin-fill systems for use with Novo Nordisk insulin and can be used only by one person</seg>
<seg id="1123">In the fridge (2 ° C - 8 ° C) Not available The cartridge in the box to protect the content from light to the light: not in the fridge or over 30 ° C.</seg>
<seg id="1124">Subcutaneous application for the use of Acropid Novosts are used to be used by Actrapid Novosts. Actpid Novofangame may only be used only by one person</seg>
<seg id="1125">"in the refrigerator store (2 ° C - 8 ° C) Not suitable for light, protect the light: not in refrigerator or over 30 ° C."</seg>
<seg id="1126">Subcutaneous application for use by Actrapid Innov are used to be used by Actrapid Innov. Actpid Innov may only be used by one person</seg>
<seg id="1127">This means that about half an hour after you have applied it to sink your blood sugar and that the effect is about 8 hours.</seg>
<seg id="1128">"in order to check the label, whether it is the correct insulin type. ► Desinquire, choose the rubber buffer with a medical Tub."</seg>
<seg id="1129">"if this is not completely unnecessary, if you have not been stored correctly, you can store the penetration bottle of your pharmacy or use it (see 6 How is Actrapid-store?) it is not clear like water and color looks."</seg>
<seg id="1130">Use the injection technology that allows you to your doctor or pharmacology treatment in your skin to ensure that the complete dose injected.</seg>
<seg id="1131">"83 Saws your relatives, friends and tight work, that they must bring you in the case of consciousness into the stable side situation and immediately."</seg>
<seg id="1132">"you may have a very rare severe allergic reaction to Actrapid, or one of its components (a so-called systemic reaction)."</seg>
<seg id="1133">"the injunction solution will be as clear, colourless, waking solution in packing with 1 or 5 watering bottles with 5 ml or a bundles of 5 litre bottles with 5 litre bottles per 10 ml."</seg>
<seg id="1134">"89 Saws your relatives, friends and tight work, that they have to bring you in the case of consciousness into the stable side situation and immediately."</seg>
<seg id="1135">"check out the label, whether it is a proper insulin type, please check the cartridge including rubber cap (plug)."</seg>
<seg id="1136">"each of them has been stored in insulin or the device that has been removed, damaged or broken. (see 6 How is Actrapid-store?) it is not clear like water and color looks."</seg>
<seg id="1137">"if you are treated with Actrapid Pensions and another insulin in Penalty cartridges, you should use two insulin injection systems, depending on each insulin type."</seg>
<seg id="1138">Use the injection technology that allows you to remove your doctor or your diligence System in order to ensure that the complete dose of injectors was found.</seg>
<seg id="1139">"• If the second and third place of charter name W5, S6, P5, K7, K7, K7, K7, K7, K7, K7, K7, K7, K7, K7 or ZF, is the manufacturer Novo Nordisk A / S, Novo allé, DK-2880 Bagsvnloca, Denmark"</seg>
<seg id="1140">"• If the second and third place the character name H7 or T6 appears, the manufacturer Novo Nordisk Production SAS, 45, Avenue d" Orléans, F- 28002 Chartres, France. "</seg>
<seg id="1141">"antioxidant antidiabetics (for use), Monochromium, Acetyl salicylic acid, thyophonic acid, thyroid hormone, endocotid, calazol, Octagotid or Lanreotid."</seg>
<seg id="1142">► use through the label if it is in order to avoid the correct insulin type. ► Bench you always for any injtion to prevent an contamination of contamination.</seg>
<seg id="1143">"as a result, the danger of the failure was damaged or broken. (see 6 How is Actrapid-store?) it is not clear like water and color looks."</seg>
<seg id="1144">This can happen: • If you can eat much insulin when you eat little or a meal.</seg>
<seg id="1145">Let the clamping force of your Novolets will always be placed when it is not in use to protect him before light.</seg>
<seg id="1146">• Retinxing the rubber buffer with a medical Tub • Bench you always be able to prevent contamination from a NovoFine injection nadel to prevent contamination of contamination. • Supporting the protective lashing of a NovoFine injection nadel and the internal cap of the injection nadel and the inner head of the injection nadel.</seg>
<seg id="1147">"you are as follows to avoid the injector of air to avoid and to ensure a correct dosage: • Hide you Accupid Novocks with the injection nadel after above • clocking a few times with fingers to the cartridge."</seg>
<seg id="1148">"if air bubbles are present, it will continue to keep in the cartridge (figure B) • During the injection nadel continue to follow a click in the direction of the path (Figure C) • Now, push the push button in the direction of the injector needle (Figure C) • Now, then press the push button in the direction of the injector needle."</seg>
<seg id="1149">• Supports the connection flap again on the precondition that the digit 0 compared to the dosing brand stands (Figure D) • account of the pressure button.</seg>
<seg id="1150">"if the push button does not move freely, insulin from the injector pin • The scale on the lock flap shows 0, 2, 4, 6, 10, 12, 14, 16, 16 and 18 units."</seg>
<seg id="1151">The push button moves upwards to the outside while you turn the arrow flap • The scale under the push button (Druckansicht) displays 20, 40 and 60 units. "</seg>
<seg id="1152">107 • Notary you can see the highest number you have to get to the printed dose • If you have a wrong dose you have to set a wrong dose if you have a wrong dose if you have a wrong dose or turn the right number to units.</seg>
<seg id="1153">Turn it until the pressure knob is completely below and you will feel the adjustment flap and set it so again that the 0 of the dosing unit is over.</seg>
<seg id="1154">Make sure to press only during the injection button on the push button</seg>
<seg id="1155">It is possibly inaccurate • you can use any dose that is higher than the number of the previous units • you can use the residual value of the previous units • you can not use the residual value of the previous units. you can not use them to set your dose or select.</seg>
<seg id="1156">"antioxidant antidiabetics (for use), Monochromium, Acetyl salicylic acid, thyophonic acid, thyroid hormone, endocotid, calazol, Octagotid or Lanreotid."</seg>
<seg id="1157">"as a result, the risk of failure (see 6 How is Actrapid's treatment?) if it is not properly stored, it is not clear like water and colourless."</seg>
<seg id="1158">Let the clamping force of your innolets will always be placed when it is not in use to protect him before light.</seg>
<seg id="1159">• Descrify your rubber buffer with a medical Tub • Bench you always for any injectors to prevent contamination. • remove the protective lashing of a NovoFine S injectors • screw the large outer cap of the injection nadel and the inner head of the injection nadel.</seg>
<seg id="1160">"• Avoid it is not block to zero, and you hear the injection moulding • The injections must remain under the skin to ensure that the complete insulin controller must not block the injection valve after the injector. • Aging your injectors • remove the injection needle after each injector."</seg>
<seg id="1161">"antioxidant antidiabetics (for use), Monochromium, Acetyl salicylic acid, thyophonic acid, thyroid hormone, endocotid, calazol, Octagotid or Lanreotid."</seg>
<seg id="1162">"121 ► If it is not properly stored or frozen, (see 6 How is Actrapid?) ► if it is not clear like water and color looks."</seg>
<seg id="1163">"if one of the linked side effects will be considerably lower or if you notice any side effects that are not specified in this product information, please inform your doctor if your doctor or pharmacist."</seg>
<seg id="1164">Allow the clamping force of your FlexPen ready to ensure that it is not in use to protect him before light.</seg>
<seg id="1165">F Hold you see the FlexPen with the injection nadel after above and knocking out a few times with the fingers for the cartridge to collect existing air bubbles in the cartridge.</seg>
<seg id="1166">"the dose can be corrected both according to the above, by using the Dosisbar button in the corresponding direction, until the correct dose is calculated."</seg>
<seg id="1167">Adenuric is applied to patients who have already used signs of crystal deposits including arthritis (pain and inflammation in the joints) or greases of the joints that can lead to joint and bone damage.</seg>
<seg id="1168">"when the urinary change of a two to four weeks, even more than 6 mg per deciliter, the dose can be increased to a daily 120 mg."</seg>
<seg id="1169">"during the first treatment of treatment, the patients may occur at least during the first six months under treatment with Adenuric even more medicines for preventing plaster."</seg>
<seg id="1170">The medicine is not recommended for children and patients who had a organ transplantation since it was not investigated for these groups.</seg>
<seg id="1171">"in the first study, at the 1 072 patients, the effectiveness of three of the Adenuric dosing (once daily 80, 120 and 240 mg) is compared to the treatment of hyperbicians."</seg>
<seg id="1172">"in the second study, two dosing stations of Adenuric (once daily 80 and 120 mg) is compared to 762 patients with Allopurinol."</seg>
<seg id="1173">"in both studies, Allopurinol is applied to a dose of once daily 300 mg; patients with kidney problems are only 100 mg per day."</seg>
<seg id="1174">The main indikator for the effectiveness was the number of patients that clean the urinary tract in the blood with the last three measurements under 6 mg / dl.</seg>
<seg id="1175">"in the first study, 48% (126 of 262) of the patients who followed the Adenuric in a dose of once daily 80 mg, and 65% (175 of 269) of patients who have once daily 120 mg, and 65% (175 of 269)."</seg>
<seg id="1176">"in comparison, this was 22% (60 of 268) of patients under Allopurinol and in no one of the 134 patients under Placebo."</seg>
<seg id="1177">"the most common side effects of Adenuric (observed in 1 to 10 of 100 patients), headache, nausea (nausea), skin irritation and normal liver."</seg>
<seg id="1178">"in particular in patients with heart failure, there may also be a higher risk of certain side effects that affect the heart and blood vessels."</seg>
<seg id="1179">"the Committee for Humanities (CHMP) was raised to the conclusion that Adenuric in the blood of the urinary tract in the blood-efficient was more effective than Allopurinol, but also a higher risk of side effects in connection with the heart and the blood vessels."</seg>
<seg id="1180">Treatment of chronic allergic reactions with diseases which have already led to urine deposits (including one from the nursing history of well known or currently being tested).</seg>
<seg id="1181">"for 2-4 weeks, there is still more than 6 mg / dl (357 µl / l), a Dosenincrease at ADENURIC 120 mg 1 x daily."</seg>
<seg id="1182">"for patients with severe kidney function, the effectiveness and security are not fully examined (Kreatinised Clearance &lt; 30 ml / min, see section 5.2)."</seg>
<seg id="1183">"children and adolescents: children and adolescents, there are no experiences with children and adolescents, which are not recommended."</seg>
<seg id="1184">"this patient has no experiences yet, the application is not recommended (see section 5.1)."</seg>
<seg id="1185">"the treatment is not recommended (see section 4.8), which is not recommended (see section 4.8)."</seg>
<seg id="1186">"as with other hard drugs, it can occur during treatment periods during treatment period because due to the formation of the Serumharnate metabolism in the tissues."</seg>
<seg id="1187">"in rare cases, reading and treatment, Lesch- Nyhan syndrome) the absolute concentration of Xanthin in rare cases in rare cases, it comes to a waste in the urinary tract."</seg>
<seg id="1188">Liver disease - clinical trials of phase 3 were observed in the clinical trials of the liver function of the liver disease (3.5%).</seg>
<seg id="1189">"therefore, it is recommended to perform at the beginning of the womensor treatment and in the further course according to clinical and a liver function (see section 5.1)."</seg>
<seg id="1190">"Theophyllo was carried out in Zaragoza, but it is known that the XO Hemisphere could lead to an increase in the Theophysalinde (an inhibiting of the metastase of Theophyllo was also reported to other XO Hemmer)."</seg>
<seg id="1191">"for subjects, the simultaneous gift of the cap and Napols 250 mg 2 x daily with an increase in the cap (Cmax 28%, auc 41% and t1 / 2 26%)."</seg>
<seg id="1192">"in clinical trials, the application of Napols or other NSAR / Cox-2-Hemophilia cannot be associated with a clinically significant increase in unwanted events."</seg>
<seg id="1193">"Colchicin / Indometacin / Indometacin / Hydrochlorine, or Indometacin, can be applied together with Colchicin or Indometacin, without having a Dosistically adjustable, or at the same time the other active substance is required."</seg>
<seg id="1194">"in a study with subjects, 120 mg ADENURIC 1 x daily a medium 22% increase the auc of Desipramin, a CYP2D6-substrat, a CYP2D6-enzyme in vivo."</seg>
<seg id="1195">"Antazida has been shown that the simultaneous usage of antazims, the Magnesiumhydroxid and aluminium hydroxid, which causes a drop of 32%, but no significant change of auc causes."</seg>
<seg id="1196">"pregnancy Data about a very limited number of similar pregnant women, not on side effects of the health or health of the foetus / Neuborn child."</seg>
<seg id="1197">Animal studies not allow direct or indirect harmful effects on pregnancy, embryonic development or birth (see section 5.3). "</seg>
<seg id="1198">Patients should be careful with respect of a vehicle or serve to be careful of machines or in the exercise of the activities until they can be sure that ADENURIC will not affect their performance.</seg>
<seg id="1199">"in comparison to Allopurinol group, in comparison to Allopurinol group, in comparison to Allopurinol group, was observed in the overall feboxoic group."</seg>
<seg id="1200">"due to this patient, risk factors were a arteriosclerratic disease and / or a Myokardinfecom, or a depreciation of heart failure."</seg>
<seg id="1201">"frequent (Acts 1 / 100 up to &lt; 1 / 10), automatic (Acts 1 / 1,000 to &lt; 1 / 100) and rare (apply) in connection with 80 mg / 120 mg / 1,000) and rare (Test results) in connection with the medicines and in all-t-treatment groups, were listed in the treatment of patients with 80 mg / 120 mg."</seg>
<seg id="1202">Genetic studies were observed in patients who were treated with colchicin treated. * * In the clinical trials were observed in clinical trials.</seg>
<seg id="1203">"7-long-term extension studies in the open-long-term extension studies in the open-time extension studies, 9 patients have long for 3 years long, 57 patients up to 3 years long, 57 patients to 3 years, and 53 mg / 120 mg / 120 mg / 120 mg / 120 mg."</seg>
<seg id="1204">"during the long-term, extension studies showed that similar events were similar to the studies of phase 3 reports (see table 1)."</seg>
<seg id="1205">"the following-related events were reported in all these categories, including: 1 mg / 120 mg / 120 mg in long-time extension studies (up to 4 years of age)."</seg>
<seg id="1206">The following treatment methods were found in the Pivotal studies of the phase 3 for these doses either not reports or with a lower frequency of frequency:</seg>
<seg id="1207">"diabetes, hyperlipidemia, slandic, congenital mucation, kidney disease, kidney disease, kidney disease, kidney disease, kidney disease, kidney disease, kidney disease, kidney disease, kidney disease, kidney disease, kidney disease, kidney disease, kidney disease, kidney disease, kidney disease, kidney disease, kidney disease, kidney disease, kidney disease, kidney disease, kidney disease, kidney disease, kidney disease, kidney disease, kidney disease, kidney disease, kidney disease, kidney disease, kidney disease, kidney disease, kidney disease, kidney disease, kidney disease, kidney disease, kidney disease, kidney disease, kidney disease, kidney disease, kidney disease, kidney disease, kidney disease, kidney disease, kidney disease, kidney disease, kidney disease, kidney disease, kidney disease, kidney disease, kidney disease, kidney disease, kidney disease, kidney disease, kidney disease, kidney disease, kidney disease, kidney disease, kidney disease, kidney disease, kidney disease, kidney disease, kidney disease, kidney disease, kidney disease, kidney disease, kidney disease, kidney disease, kidney disease, kidney disease, kidney disease, kidney disease, kidney disease, kidney disease, kidney disease, kidney disease, kidney disease, kidney disease, kidney disease, kidney disease, kidney disease, kidney disease, kidney disease, kidney disease, kidney disease, kidney disease, kidney disease, kidney disease, kidney disease, kidney disease, kidney disease, kidney disease</seg>
<seg id="1208">Active mechanism of uronic acid is used in humans the end product of Purinopathy and is used in the framework of the refractal Hypoxanthin → Xanthin → uronic acid.</seg>
<seg id="1209">"if you are already our customer, please log in using your e-mail address and your password.: + 49 5764 318 444. or contact us per email."</seg>
<seg id="1210">"clinical study results The effectiveness of ADENURIC was described in two Pivotal studies of the Phase 3 (APEX study and Fact Study as described below), which were shown with 1,832 patients with hyperurine emia and gives were shown."</seg>
<seg id="1211">"the primary suspicion point was in every study of the proportion of patients, with which the last three month in particular serumharnate (357 µl / l) were."</seg>
<seg id="1212">"if you want to send us a question about this product, simply complete all the fields marked * and click" "Send". ""</seg>
<seg id="1213">The APEX-study showed significant reduction of complications under 6 mg / dl (357 µl / l) (see table 2 and figure 1) the statistical evaluation of the treatment with ADENURIC 80 mg 1 x daily (n = 258) / 100 mg / 100 mg (n = 10).</seg>
<seg id="1214">"the Fact study showed that multiple mg / dl (357 µl / l) determine the statistical results in the treatment with ADENURIC 80 mg 1 x daily, each of the treatment with the conventional dose of Allopurinol 300 mg."</seg>
<seg id="1215">Patients with infection values &gt; 1.5 and ≤ 2.0 mg / dl) or 300 mg 1 x daily (n = 509) were used for analyses. * p &lt; 0.0001 versus Allopurinol</seg>
<seg id="1216">"the reduction of the Serumharnate respiration of the &lt; 6.0 mg / dl (357 µl / l) was observed in the doctor's visit in week 2, and permanently protects the entire treatment."</seg>
<seg id="1217">"509 patients received Allopurinol 300 mg 1 x daily; 10 patients with seruman values &gt; 1.5 and &lt; 2.0 mg / dl, 100 mg 1 x daily."</seg>
<seg id="1218">The primary endpoint in the sub-group of patients with kidney function of the APEX-study showed the effectiveness at 40 patients with kidney function.</seg>
<seg id="1219">"with ADENURIC, the primary measurement point at 44% (80 mg 1 x daily), 45% (120 mg 1 x daily) and 60% (240 mg 1 x daily)."</seg>
<seg id="1220">"there were no clinically significant differences in the process of the Serum harnacid concentration in subjects, regardless of their kidney function (58% in the group with normal kidney function and 55% in the group with severe kidney problems)."</seg>
<seg id="1221">Pricelist endpoint in the sub group of patients with serumharnacid reformation of the patients (APEX- and Fact study) were taken to study (baseline) a serumharnacid concentration of Pro10 mg / dl.</seg>
<seg id="1222">"in two years the data of the open extension of the open extension of the phase 3 showed that the permanent disruptions in the phase 3 showed that less than 3% of the patients treated in the months 16-24, the patients required no treatment against a giver in the months 16-24."</seg>
<seg id="1223">This was associated with a reduction of Giving size. what is 54% of the patients a complete disappearance of the gibility to month 24 to the result.</seg>
<seg id="1224">Increased TSH- values (&gt; 5.5 µIE / ml) were observed in patients who received a long-long-term treatment with dilation (5.0%) in the open-long-term extension studies (see section 4.4).</seg>
<seg id="1225">"in healthy proportions, the maximum plasma concentration (Cmax) and the area under the plasma concentration period (auc), by means of ± 10 mg up to 120 mg."</seg>
<seg id="1226">"for cans between 120 mg and 300 mg, there is a rise at the auc, the greater than the surplus value is observed."</seg>
<seg id="1227">After taking care or multiple sclerosis of 80 and 120 mg 1 x daily is the Cmax approx. 2.8-3.2 µg / ml and 5.0-5,3 µg / ml. "</seg>
<seg id="1228">"however, no clinically significant change in the process is observed in the process of serumharnacid concentration, if this was checked (multiple cans of 80 mg)."</seg>
<seg id="1229">"distribution of steady steady in volume distribution volume (VSS / F), from 29 to 75 l after taking doses of €10-300 mg."</seg>
<seg id="1230">"the plasma range is approx. 99,2% (primary binding on Albumin) and is reached across the concentration width, which is constant with cans from 80 and 120 mg."</seg>
<seg id="1231">"in vitro, CYP2C8, CYP2C8, CYP2C8, CYP2C8, CYP2C8, CYP2C8, CYP2C8 and CYP2C9 can be made mainly through UGT 1A1, 1A8 and 1A9."</seg>
<seg id="1232">"after taking a 80 mg dose of 14C, the dose is about 49% of the dose in the urine and its conjugate (13%), Acylglued Metabolites and their conjugate (13%), as well as other unknown metabolites (3%)."</seg>
<seg id="1233">"in addition to the expropriation of the urine, about 45% of the dose in the chair can be found in the chair as unilted, and their conjugate (25%), as well as other unknown metabolites (7%)."</seg>
<seg id="1234">"special patient groups of cardienclerosis after taking multiple sclerosis from 80 mg ADENURIC at patients with light, medium-severe or severe kidney disease."</seg>
<seg id="1235">"in the group with normal kidney function, the average total of 7.5 grams of 7.5 grams / ml in the group with normal kidney function on 13.2 μ g / ml in the group with severe kidney function."</seg>
<seg id="1236">"if you have any queries, please contact us on Tel.: + 49 5764 318 444. or contact us via e-mail. to do so, simply complete all the fields marked * and click" "Send". ""</seg>
<seg id="1237">Age There has been no significant changes in terms of the auc of Achievat or its metabolite after taking multiple sclerosis from ADENURIC in comparison to younger subjects.</seg>
<seg id="1238">"carcinogenesis, mutlar, impairment of the fertilting of uranium and carcinoma (transition cell proliferative and carcinoma) only in connection with Xanthin stones in the highly sensitive group, with about 11-7 of the Exposition in humans."</seg>
<seg id="1239">"these findings are seen as a result of special Purinopathy and Urinary tract, and for clinical application as non-relevant application."</seg>
<seg id="1240">"it was found that the kite was found in orphaned cans from up to 48 mg / kg / day no effect on the fertile and reproduction power of male and female rats."</seg>
<seg id="1241">"at high doses, which were about 4.3- to the human therapeutic position, the maternal toxicity was associated with a decrease of impact and a development delay in the descendants of rats."</seg>
<seg id="1242">Teratological studies with expositions that are about 4.3 times and with expositions that are about the 13 times higher and with expositions that are about 13 times higher the human body position.</seg>
<seg id="1243">"Colchicin / Indometacin / Indometacin / Hydrochlorine, or Indometacin, can be applied together with Colchicin or Indometacin, without having a Dosistically adjustable, or at the same time the other active substance is required."</seg>
<seg id="1244">Genetic studies were observed in patients who were treated with colchicin treated. * * In the clinical trials were observed in clinical trials.</seg>
<seg id="1245">"21 patients were treated to 1 year long, 322 patients up to 3 years long, 57 patients up to 3 years long, 57 patients up to 3 years."</seg>
<seg id="1246">"the primary suspicion point was in every study of the proportion of patients, with which the last three month in particular serumharnate (357 µl / l) were."</seg>
<seg id="1247">"in two years the data of the open extension of the open extension of the phase 3 showed that the permanent disruptions in the phase 3 showed that less than 3% of the patients treated in the months 16-24, the patients required no treatment against a giver in the months 16-24."</seg>
<seg id="1248">"26 as an unsigned, ecolate (3%), Acylglutide of the active substance (30%), its known oxidative metabolites and their conjugate (13%), as well as other unknown metabolites (3%)."</seg>
<seg id="1249">"if you have any queries, please contact us on Tel.: + 49 5764 318 444. or contact us via e-mail. to do so, simply complete all the fields marked * and click" "Send". ""</seg>
<seg id="1250">"carcinogenesis, mutlar, impairment of the fertilting of uranium and carcinoma (transition cell proliferative and carcinoma) only in connection with Xanthin stones in the highly sensitive group, with about 11-7 of the Exposition in humans."</seg>
<seg id="1251">The owner of the permission for the Instruction have to be sure that a pharmaceutical firm system like in version 2.0 module 1.8.1 of the approval process is available before the medicine is available in the traffic and so long as the medicine is brought into intercourse.</seg>
<seg id="1252">A updated RMP is set to the risk management systems for humanities with the next periodic Safety Update Report (PSUR).</seg>
<seg id="1253">"in addition, one update of the RMP is required for the new information, which have a influence on the security data, pharmaceutical kovigilding or activities for risk inimpairment."</seg>
<seg id="1254">"in some cases the ureic acid in blood and can reach concentrations, so high are the uric acid is insoluble."</seg>
<seg id="1255">"when you reduce the urinary tract by the 1 x daily intake of ADENURIC, the crystalline density and thus achieved a reduction of discomfort."</seg>
<seg id="1256">"ADENURIC may not be taken if you are sensitive (allergic) against the active substance, or one of the other components of ADENURIC."</seg>
<seg id="1257">Inform your doctor before taking this medication before taking this medication if you have a heart rate or had a heart rate or the read-Nyhan-syndroms (a rare congenital disease that can be treated too much uric acid in the blood.</seg>
<seg id="1258">"if you have a giveaway (sudden occurrence of severe pain, pressure sensitive, redness, heat, and joint pain), wait until you begin with the treatment with ADENURIC."</seg>
<seg id="1259">"this does not have to be in any way, but also with you, especially during the first treatment weeks or - monate, if you use ADENURIC."</seg>
<seg id="1260">"in order to treat your doctor, you will be able to treat another medicine in order to treat a plaster case or to treat the associated symptoms (such as pain and joint)."</seg>
<seg id="1261">"please inform your doctor or pharmacist if you use other medicines to use or have recently taken care, even if it is not non-prescription drugs."</seg>
<seg id="1262">"• Azathioprin (for treatment of cancer) • Azathioprin (for treatment of cancer) • Thecaptine (for treatment of cancer) • Theodine (for treatment of asthma) • Theodor in (for treatment of asthma) • Theodor in (for treatment of asthma) • Theotopine (for treatment of asthma) • Theotopine (for treatment of asthma) • Theotopine (for treatment of asthma) • Theotopine (for treatment of asthma) • Theotopine (for treatment of asthma) • Theotopine (for treatment of asthma) • Theotopine (for treatment of asthma) • Theotopine (for treatment of asthma) • Theotopine (for treatment of asthma) • Theotopine (for treatment of asthma) • Theotopine (for treatment of asthma) • Theotopine (for treatment of asthma) • Theotopine (for treatment of asthma) • Theotopine (for treatment of asthma) • Theotopine (for treatment of asthma) • Theotopine (for treatment of asthma) • Theotopine (for treatment of asthma) • Theotopine (for treatment of asthma) • Theotopine (for treatment of asthma) • Theodor in (for treatment of asthma) • Theodor in (for treatment</seg>
<seg id="1263">No studies have been carried out on the effects of ADENURIC to traffic and the ability to serve machines.</seg>
<seg id="1264">Please contact ADENURIC only if you are known to your doctor if you suffer from a disregard to certain sugar.</seg>
<seg id="1265">• The tablets must be registered and can be taken with or without food.</seg>
<seg id="1266">"if you have an overdose, please contact your doctor or at the Notebooks of the nearest hospital."</seg>
<seg id="1267">"if you have forgotten the taking of ADENURIC, check out this faster, unless the next dose is shortly before."</seg>
<seg id="1268">"when you try to avoid taking care of ADENURIC, your uretics can cause your urinary tract, and your discomfort can do so, because new Uratcavities are in your joints and kidneys, as well as their surroundings."</seg>
<seg id="1269">Frequent adverse side effects (more than 1 of 100 patients)</seg>
<seg id="1270">"rare side effects (more than 1 of 10.000 patients, but less than 1 of 1,000 patients): • weakness • Nervosity • heart-feeling"</seg>
<seg id="1271">Please inform your doctor or pharmacist if one of the adverse side effects or side effects that are not specified in this form information.</seg>
<seg id="1272">ADENURIC is available in 2 Blister packings with 14 tablets (pack of 28 tablets) or in 6 Blister packings with 14 tablets (package with 84 tablets).</seg>
<seg id="1273">My account has been added to our catalog on Thursday 14 March, 2006. "</seg>
<seg id="1274">"if you want to send us a question about this product, simply complete all the fields marked * and click" "Send". ""</seg>
<seg id="1275">"ADROVANCE is used for treatment of osteoporosis (a disease, in which the bone are used) of women after the menopause, when a risk of low vitamin D-D mirror is used for a low vitamin D-D mirror."</seg>
<seg id="1276">"the patio has a full glass of water (no mineral water) at least 30 minutes before eating, drinking or take other medicines (including antazida, Calcium- and vitamins)."</seg>
<seg id="1277">"in order to avoid the food intake, the patient can be carried out to the first food intake of the day, which should not be carried out after taking the tablet."</seg>
<seg id="1278">"since Alendronate and vitamin D3 already be used separately in the European Union, the company laid the company data from previous studies and published literature."</seg>
<seg id="1279">The company also led to a study with 35 men and 682 postmenopausal women with osteoporosis due to increase the effectiveness of ADROVANCE to increase the effectiveness of ADROVANCE.</seg>
<seg id="1280">"after a 15-walled treatment, the proportion of patients with low vitamin D-D mirror were treated with ADROVANCE, low (11%) than those that were only alendronate (32%)."</seg>
<seg id="1281">The company also included data before that that the ADROVANCE are exactly the dose which is required for the use of a bone loss.</seg>
<seg id="1282">"the most common side effects (observed in 1 to 10 of 100 patients) are headaches, pain of the musculature (muscles, bone or joints) and the symptoms of the diaphragms, diarrhoe (diarrhoeal), sarrhoe (diarrhoeal), reclassification (canals)."</seg>
<seg id="1283">"in patients with adequate sensitivity (allergy) against alendronate, vitamin D3 or one of the other components may not be applied to ADROVANCE."</seg>
<seg id="1284">"it may not be applied to diseases of the food safety, for patients with hypocalcemia (low calumbing mirror) or in patients who can stand at least 30 minutes."</seg>
<seg id="1285">"January 20, 2007, the European Commission President Merck Sharp & Dohme Ltd. is a permit for the Instruction of ADROVANCE in the whole of the European Union."</seg>
<seg id="1286">"caped-shaped, white to broken white tablets, marked with the edge of a bone on one side and" 710 "on the other side."</seg>
<seg id="1287">"ADROVANCE is only with water (not with mineral water) at least 30 minutes before the first meal, drink or take care of medicines (including antazida, Calcium- and vitamins) for the day."</seg>
<seg id="1288">The following notes are precisely to follow the risk of malophageal friction and associated side effects (see section 4.4):</seg>
<seg id="1289">"• ADROVANCE will be made according to the day only with a full glass of water (at least 200 ml). • The patient should not be broken or tobacco in the mouth, since there is no risk for oropharyngeal Ulzera."</seg>
<seg id="1290">"B. Cropy, active gastrointestinal, active gastrointestinal, active blood vessels or surgical operations in the top of the upper Valais (see section 4.3)."</seg>
<seg id="1291">"Özophagal reactions, such as Ösophagitis, ösophageal Ulzera and ösophageal strokes, rarely followed by ösophageal strokes, were added to patients under the taking of Alendronate (partly were these heavy and required)."</seg>
<seg id="1292">"the physician is therefore attentive to all signs and symptoms that should be carried out on possible malophageal reactions, and the patient should be aware of the occurrence of symptoms such as dyspheres, pain at the occurrence of symptoms or new or even worse sodburn."</seg>
<seg id="1293">3 The risk of severe pain side effects seems to be increased to patients who is not correctly correctly and / or after the occurrence of symptoms that can be found on a malophavale Irritation.</seg>
<seg id="1294">It is very important that all dosing instructions on patients are understood and understood by patients (see Section 4.2).</seg>
<seg id="1295">"during the large-clinical trials with Alendronate no increased risk was found, rarely (according to market) Magician and Duodenalulzera, including some serious and complications, reports (see section 4.8)."</seg>
<seg id="1296">"Osteonecclerosis of the kiefers, usually in connection with dental implant and / or a local infection (including osteomyelitis), with cancer patients with intravenous intravenous phosphoronate."</seg>
<seg id="1297">"there are no data available to give evidence, whether the removal of a biscuits therapy in patients who need a surgical procedure, the risk of a osteoporosis of the pine shafts."</seg>
<seg id="1298">The clinical assessment by the attending physician is a decisive factor for therapy planning in each patient based on an individual benefit-risk assessment.</seg>
<seg id="1299">Patients should be aware that they should be able to take a dose of any dose ADROVANCE the tablet on the next morning after they have noticed.</seg>
<seg id="1300">"they should not take two tablets at the same day, but taking care of a tablet per week as originally planned on the planned date."</seg>
<seg id="1301">Other diseases related to the minerals (such as vitamin D deficiency and hypoparathyreoidism) should be treated before the beginning of therapy with ADROVANCE.</seg>
<seg id="1302">"Alendronate food and drinks (including mineral water), calcium supplements, antazida and some orale medicines can be taken into consideration when they are taken at the same time."</seg>
<seg id="1303">Therefore the patients need to wait at least 30 minutes before they take other medicines (see sections 4.2 and 5.2).</seg>
<seg id="1304">"although specific application studies were not carried out, Alendronate was taken into clinical trials with a variety of usually used drugs, without the clinically relevant exchange effects."</seg>
<seg id="1305">ADROVANCE is intended only for the application in postmenopausal women and is therefore not responsible for pregnant women.</seg>
<seg id="1306">Animal studies with alendronate no reference to the necessities of pregnancy, embryonic stem cells or postnatal development. "</seg>
<seg id="1307">"Osteonecsis of the Kiefers was reported in patients with biscuits, but most reports from cancer patients were reported in osteoporosepatite."</seg>
<seg id="1308">"nevertheless, the Serum-Calcier up to &lt; 8,0 mg / dl (2.0 mmol / l) and the Serum - phosphats up to ≤ 2.0 mg / l (0,65 mmol / l) in both treatment groups with similar frequency."</seg>
<seg id="1309">"Alendronate Insequence of an oral overdose may be hypocalcemia, Hypophosphatemia and side effects in the upper Gastrointestinal tract, sodophagitis, geocophagitis, Gastritis or Ulzera."</seg>
<seg id="1310">Colecalciferol (vitamin D3) vitamin D3 is produced in the skin through UV light through the transformation of 7-Dehydrokes to vitamin D3.</seg>
<seg id="1311">"the main effect of 1,25-DihydroxyxyD3 is increased by the intestinal Resorption of Calcium and phosphate as well as the regulation of Serum-Calcium, the bone formation and bone tissue."</seg>
<seg id="1312">"in severe cases, a lack of secondary hyperparathyreoidism, hypophosphatemia, weakness of the membrane muscles and osteomalazie, and so on the increased risk of stress and bone."</seg>
<seg id="1313">Treatment: untreated clarity: opaque 1 piece 14x10 mm EUR14.40 &lt; &lt; BACK TO CATEGORY tourmaline (rubellite)</seg>
<seg id="1314">Patients received ADROVANCE in lower strength (70 mg / 2.800 I.E.) (n = 350) or fosamax (n = 332); further vitamin D-D supplement were prohibited.</seg>
<seg id="1315">"after 15-weekly treatment, the middle Serum levels of 25-hydroxyvitamin D significantly higher (26%) in the group among ADROVANCE (70 nmol / l [23 ng / l [23 ng / l [18.2 ng / ml])."</seg>
<seg id="1316">ADROVANCE (70 mg / 2.800 I.E.) significantly increased after 15 weeks after the proportion of patients with vitamin D intraocular vitamin D &lt; 335 nmol / l [&lt; 15 ng / l [&lt; 15 ng / l [&lt; 15 ng / l [&lt; 15 ng / l [&lt; 15 ng / l [&lt; 15 ng / l [&lt; 15 ng / l [&lt; 15 ng / l [&lt; 15 ng / l [&lt; 15 ng / l [&lt; 15 ng / ml]) um 62.5% compared to Alendronat alone (12% vs).</seg>
<seg id="1317">Studies with Alendronate The therapeutic effect of Alendronat once a weekly 70 mg (n = 3mg) and Alendronat 10 mg daily (n = 370) has been demonstrated in an A-year Multicular study to postmenopausal women with osteoporosis.</seg>
<seg id="1318">The effects of Alendronate at bone mass and fractured women were examined in two phase III trials of identical design (n = 944) as well as in the group-interventional design (FIT: n = 6.459).</seg>
<seg id="1319">"in the phase III studies, the middle limit of the BMD with Alendronat 10 mg / day in the relationship between placebo according to 3 years of 8.8% of the spinal cord, 5.9% of Femurhas and 7,8% on the drum."</seg>
<seg id="1320">"compared with Alendronate group, the group has a reduction of 48% (Alendronat 3.2%) in the proportion of patients that reaches one or more slanders."</seg>
<seg id="1321">"in the two-year-renewal of these studies, the BMD of Femurhalses and the entire body was stopped; the BMD of Femurhalses and the entire body was stopped."</seg>
<seg id="1322">Test results from two plazeboat daily (5 mg daily via 2 years and then 10 mg daily) was taken over over 1 or 2 years.</seg>
<seg id="1323">"Euromonitor International has over 40 years' experience of publishing market research reports, business reference books and online information systems."</seg>
<seg id="1324">Resorption may have a intravenous reference dose of alendronat at women 0.64% for cans between 5 and 70 mg according to the night and two hours before recording a standardized breakfast.</seg>
<seg id="1325">"the biometric pressure increased according to about 0,46% and 0,39%, when Alendronate one or half an hour before a standardized breakfast."</seg>
<seg id="1326">"in osteoporosestuestuestucia, Alendronat was effective when it was taken at least 30 minutes before the first meal."</seg>
<seg id="1327">"in healthy subjects, the gift of orship Prednison (20 mg three times daily via five days) does not contain any clinically significant change of orphrongate (increase in the area of 20% to 44%)."</seg>
<seg id="1328">"9 distribution studies on rats have shown that alendronate after intravenous gift of 1 mg / kg is temporarily removed, but then spread out into the bone of the bone or with the urine."</seg>
<seg id="1329">The separation of a single dose of 14C-Alendronat were about 50% of radioactive substance within 72 hours using the urine and little or radioactivity was found in the barrels.</seg>
<seg id="1330">"after intravenous gift of a single dose of 10 mg, the renale Clearance of Alendronat 71 ml / min and the systemic Clearance does not exceed 200 ml / min."</seg>
<seg id="1331">"Alendronate is not considered about the suction or basal transport system of the kidneys and therefore, therefore, it is not assumed that it is influenced by the extermination of other medicines through these transport systems."</seg>
<seg id="1332">"Resorption on healthy adult subjects (women and men), according to the gift of ADROVANCE according to the gift of ADROVANCE, and two hours before recording a meal time (AUC0-120 h) for vitamin D3 296,4 ng • h / ml (without consideration endogenous vitamin-D3-mirror)."</seg>
<seg id="1333">The medium maximum concentration in the Serum (Cmax) of vitamin D3 was 5.9 ng / ml and the media time to reaching the maximum serum concentration (TMax) 12 hours.</seg>
<seg id="1334">"vitamin D3 is produced in the liver rapidly to 25-hydroxyvitamin D3 for hydroxyy and then in the nest to 1,25-DihydroxyxyD3, the bioactive shape, metabolized."</seg>
<seg id="1335">"expropriation on the gift of radioactive vitamin D3 to healthy proportions, the medium concentration of radioactivity in the urine after 48 hours 2.4%, in the barrels after 4 days 4.8%."</seg>
<seg id="1336">Firm of the Year for Compliance Audits and Investigations Gibson Dunn & Crutcher Firm of the Year for Private Construction Luther</seg>
<seg id="1337">"although no clinical data has been received, the renal Elimination of Alendronate as in the animal will also be reduced in patients with reduced kidney function."</seg>
<seg id="1338">"therefore, in patients with reduced kidney function is a slightly higher Kumulation of alendronate in the bone (see Section 4.2)."</seg>
<seg id="1339">"Alendronate non-clinical data on the basis of conventional studies for the security spicology, chronic toxicity, to chronic toxicity and to dehydrated potential, no particular dangers for people."</seg>
<seg id="1340">"studies on rats showed that the gift of Alendronate is due to the occurrence of Dystokie in the womb, which was due to a Hypocalcemia."</seg>
<seg id="1341">Microcrystalline cellulose (E 460) Lactose intolerable polyglyceride Gelatine (Physiological) (E 572) Butylhydroxytoluol (GR)</seg>
<seg id="1342">"Etui with sealed aluminium / aluminium tunings in cartons to 2 (1 Etui with 2 tablets), 4 (3 Etuis with 4 tablets), 12 (3 Etuis with 4 tablets) or 40 (10 Etuis with 4 tablets) tablets."</seg>
<seg id="1343">EU / 1 / 06 / 364 / 001 - 2 tablets EU / 1 / 06 / 364 / 002 - 12 tablets EU / 1 / 06 / 364 / 004 - 12 tablets EU / 1 / 06 / 364 / 005 - 40 tablets</seg>
<seg id="1344">"right on the other hand, white to white tablets, marked with the top of a bone on the one side and" 270 "on the other side."</seg>
<seg id="1345">"13 • The patient should not go after taking advantage of ADROVANCE at least 30 minutes. • ADROVANCE will not be taken before the sleep, or before the first release of the day."</seg>
<seg id="1346">The risk of severe pain side effects seems to be increased to patients who is not correctly - and / or after the occurrence of symptoms that take care of ophageale Irritation.</seg>
<seg id="1347">"during the large-clinical trials with Alendronate no increased risk was found, rarely (according to market) Magician and Duodenalulzera, including some serious and complications, reports (see section 4.8)."</seg>
<seg id="1348">18 Colecalciferol (vitamin D3) vitamin D3 is produced in the skin through UV light through the transformation of 7-Dehydrokes to vitamin D3.</seg>
<seg id="1349">Patients received ADROVANCE in lower strength (70 mg / 2.800 I.E.) (n = 350) or fosamax (n = 332); further vitamin D-D supplement were prohibited.</seg>
<seg id="1350">Vitamin D3 (the amount of vitamin D3 in the higher dose of ADROVANCE) once a week was shown in a 24-wristband study with 619 postmenopausal women with osteoporosis.</seg>
<seg id="1351">"after 24-weekly treatment, the middle Serum levels of 25-hydroxyvitamin D significantly higher in the 5.600-I.E.-vitamin D3 group (64 nmol / l [27.6 ng / l [25,5 ng / ml])."</seg>
<seg id="1352">There were no statistics between the treatment of patients with hypercalciurie at the end of the 24-winged extension.</seg>
<seg id="1353">3.1% of the entire hip in the group with 70 mg once a week or in with 10 mg daily.</seg>
<seg id="1354">"Euromonitor International has over 40 years' experience of publishing market research reports, business reference books and online information systems."</seg>
<seg id="1355">"the bipheability took up to about 0,46% and 0,39%, when Alendronate one or half an hour before a standardized breakfast."</seg>
<seg id="1356">"distribution studies on rats have shown that alendronate after intravenous gift of 1 mg / kg is temporarily removed, but then spread out into the bone of the bone or with the urine."</seg>
<seg id="1357">"Resorption on healthy adult subjects (women and men), according to the gift of ADROVANCE (70 mg / 5.600 I.E.) after the price of a meal time (AUC0-80 h) for a meal time (AUC0-80 h) for a meal time (AUC0-80 h) for a meal time (AUC0-80 h) for a meal time (AUC0-80 h) for a meal time (AUC0-80 h) for a meal time (AUC0-80 h) for a meal time."</seg>
<seg id="1358">The medium maximum concentration in the Serum (Cmax) of vitamin D3 was 12,2 ng / ml and the media time to reaching the maximum serum concentration (TMax) 10,6 hours. "</seg>
<seg id="1359">Smaller quantities are stored in fat and muscle tissue and are stored as a vitamin D3 to be stored in the circulation.</seg>
<seg id="1360">"21 vitamin D3 is generated in the liver rapidly to 25-hydroxyvitamin D3 for hydroxyy and then in the nest to 1,25-DihydroxyxyD3, the bioactive shape, metabolized."</seg>
<seg id="1361">"however, there were no evidence on one saturation of the recording of the garlic for long-term intravenous intravenous intravenous doses up to 35 mg / kg in animals."</seg>
<seg id="1362">"Etui with sealed aluminium / aluminium tunings in cartons with 2 tablets), 4 (1 Etui with 4 tablets), 12 (3 Etuis with 4 tablets) or 40 (10 Etuis with 4 tablets) tablets."</seg>
<seg id="1363">Firm of the Year for Compliance Audits and Investigations Gibson Dunn & Crutcher Firm of the Year for Private Construction Luther</seg>
<seg id="1364">Firm of the Year for Compliance Audits and Investigations Gibson Dunn & Crutcher Firm of the Year for Pharmaceuticals and Healthcare</seg>
<seg id="1365">A updated RMP is in accordance with the CHMP's risk management systems for humanities with the next periodic Saftey update Report (PSUR).</seg>
<seg id="1366">"in addition, one update of the RMP is required to include new information, which have a influence on the security data, pharmaceutical kovigilding or activities for risk inimpairments within 60 days."</seg>
<seg id="1367">"you will receive a ADROVANCE tablet, as well as before the first meal and drink at any other medicines by pressing the tablet with a full glass of water (not with mineral water)."</seg>
<seg id="1368">Perhaps you would like to read these later again. • If you have any questions please contact your doctor or pharmacist. • This medicine has been registered you personally.</seg>
<seg id="1369">"in the exchange of years, the eggs are not female hormones, oils, more that help to help the skeleton of women."</seg>
<seg id="1370">"the breaches are usually used at the hip, the vertebral column or the wrist and can not only cause pain, but also significant problems like gestures" "Witness" ") and a loss of flexibility."</seg>
<seg id="1371">"ADROVANCE prevents the loss of bone mass, but also contributes to the bone loss and the risk for eddy and hip fractures."</seg>
<seg id="1372">"(3) If your doctor is found to sit at least 30 minutes to sit or stand, (4) if your doctor has found that your calciumcontent in the blood."</seg>
<seg id="1373">"40 • If you have any problems when you have problems when you have cancer, • If you have cancer, • If you have cancer, • If you have cancer, • If you have cancer, • If you have cancer treatment or radiation treatment, • if you don't have cancer treatment."</seg>
<seg id="1374">"these complaints may occur in particular if the patients will take the ADROVANCE tablet, not with a full glass of water, and / or for up to 30 minutes after taking over 30 minutes."</seg>
<seg id="1375">"when taking advantage of ADROVANCE with other medicines, Antazida and some other medicines needed to take the effectiveness of ADROVANCE with other medicines."</seg>
<seg id="1376">"certain medicines or food additives can be impaired with vitamin D in the body, including artificial fragrances, mineral oils, Orlistat and collusion."</seg>
<seg id="1377">Please inform your doctor or pharmacist if you have to use other medications at the same time.</seg>
<seg id="1378">Please take this medication only after return with your doctor if you suffer from a disregard to certain sugar.</seg>
<seg id="1379">"please follow the instructions 2), 3), 4) and 5) to facilitate the transport of the ADROVANCE tablet."</seg>
<seg id="1380">(2) If you take the ADROVANCE tablet tablet as well as taking any other medicines only with a full glass (at least 200 ml) water (not with mineral water). • Not with coffee or tea. • Not with juice or milk.</seg>
<seg id="1381">"(3) If you do not go - remain completely made (in sitting, standing or go) - at least 30 minutes after taking the tablet."</seg>
<seg id="1382">"(5) If you have difficulties or pain at the body, the pain behind the breast is to burn pain behind the breast, please contact ADROVANCE, and seek your doctor."</seg>
<seg id="1383">"(6) Apply to the gorge of your ADROVANCE tablet, at least 30 minutes before you get your first food, drinks or other medicines such as antazida (maize drugs), Calcium- or vitamins."</seg>
<seg id="1384">"should you have accidentally taken too many tablets, drink a full glass of milk and contact us immediately to your doctor."</seg>
<seg id="1385">"if you have a tablet, then take a tablet on the next morning, after you noticed your credit card."</seg>
<seg id="1386">"often: • suction or disrupture, pain in breast milk, and pain in breast milk, sodburn and pain or joint pain, the pain in breast milk, sodburn and pain or joint pain, the pain in breast milk, for pain and / or joint pain, for pain, pain, and / or joint pain."</seg>
<seg id="1387">"occasionally: • nausea; and break, • friction and inflammation of the food intake (Ösophagus - the tube that connects your mouth with your stomach) or the stomach ache,"</seg>
<seg id="1388">"the following side effects were found (frequency not known): • (turn-) Schwindel, • dampening, • fatigue, • hair loss, • fatigue problems (Osteonecsis) in connection with delay and infections, often after pulling out of teeth, • swings on hands or legs."</seg>
<seg id="1389">43 Dabei is helpful if you were noting what circumstances they had started and how long they kept it.</seg>
<seg id="1390">"the other components are based on crystal-crystalline cellulose (E 460), Lactose, medium-plated triglyceride, gelatin, high disperse silicon nituol. (E 72), strength, modified (corn), and aluminum natriumsilicat (E 554)."</seg>
<seg id="1391">• 2 tablets (1 Etui with 2 tablets in aluminium-Blisterpackings) • 3 tablets (3 Etuis with 4 tablets in aluminium-Blisterpackings) • 40 tablets (10 Etuis with 4 tablets in aluminium-Blisterpackings) • 40 tablets (10 Etuis with 4 tablets in aluminium-Blisterpackings) • 40 tablets (10 Etuis with 4 tablets in aluminium-Blisterpackings) • 40 tablets (10 Etuis with 4 tablets in aluminium-Blisterpackings) • 40 tablets (10 Etuis with 4 tablets in aluminium-Blisterpackings) • 40 tablets (10 Etuis with 4 tablets in aluminium-Blisterpackings) • 40 tablets (10 Etuis with 4 tablets in aluminium-Blisterpackings) • 40 tablets (10 Etuis with 4 tablets in aluminium-Blisterpackings) • 40 tablets (10 Etuis with 4 tablets in aluminium-Blisterpackings) • 40 tablets (10 Etuis with 4 tablets in aluminium-Blisterpackings) • 40 tablets (10 Etuis with 4 tablets in aluminium-Blisterpackings) • 3 tablets (10 Etuis with 4 tablets in aluminium-Blisterpackings) • 40 tablets (10 Etuis with 4 tablets in aluminium-Blisterpackings) • 40 tablets (10 Etuis with 4 tablets in aluminium-Blisterpackings) • 40 tablets (10 Etuis with 4 tablets in aluminium-Blisterpackings) • 40 tablets (10 Etuis with 4 tablets in aluminium-Blisterpackings) • 40 tablets (10 Etuis with 4 tablets in aluminium-Blisterpackings) • 40 tablets (10 Etuis with 4 tablets in aluminium-Blisterpackings) • 40 tablets (10 Etuis with 4 tablets in aluminium-Blister</seg>
<seg id="1392">"in the exchange of years, the eggs are not female hormones, oils, more that help to help the skeleton of women."</seg>
<seg id="1393">"48 • If you have allergies, • If you have any problems when you have cancer, • If you have cancer, • If you have cancer, • If you have cancer, • If you have cancer, • If you have cancer, • If you have cancer treatment or radiation treatment, • if you don't have cancer treatment."</seg>
<seg id="1394">"when taking advantage of ADROVANCE with other medicines, Antazida and some other medicines needed to take the effectiveness of ADROVANCE with other medicines."</seg>
<seg id="1395">"2) If you take the ADROVANCE tablet, including any other medicines only with a full glass (at least 200 ml) water (not with mineral water). • Not with coffee or tea. • Not with juice or milk."</seg>
<seg id="1396">"3) If you don't go - remain silent (in sitting, standing or go) - at least 30 minutes after taking the tablet."</seg>
<seg id="1397">"5) If you have difficulties or pain at the body, the pain behind the breast is to burn pain behind the breast, please contact ADROVANCE, and seek your doctor."</seg>
<seg id="1398">"6) And waiting for the gorge of your ADROVANCE tablet, at least 30 minutes before you get your first food, drinks or other medicines such as antazida (maize drugs), Calcium- or vitamins."</seg>
<seg id="1399">"• (turn-) Schwindel, • Needed drainage, • fatigue, • hair loss, • tooth problems (Osteonecsis) in connection with delay and infections, often after pulling out of teeth, • swings on hands or legs."</seg>
<seg id="1400">"tablets are available as a rectangular, white up to white tablets, marked with the edge of a bone on the one side and" 270 "on the other side."</seg>
<seg id="1401">"in general cases, adult patients receive a kidney or liver transplantation, in order to prevent the immune system by the immune system."</seg>
<seg id="1402">"since the Tacrolimus and Prograf / Prograft were already used in the EU, the company has been submitted to the results from previously completed studies with Prograf / Prograft as well as data from the published literature."</seg>
<seg id="1403">"furthermore, the results of a clinical study of 668 patients with kidney transplantation must be compared with Prograf / Prograft / Prograft."</seg>
<seg id="1404">"the result was the number of patients in which the transplantation was carried out after a treatment period of one year (by example, such as often a renewed organ transplantation or a re-recording of dialysis)."</seg>
<seg id="1405">"in addition, there were longer shorter studies on 119 patients with kidney transplantation and 129 patients with liver transplantation and studied, as described in Prograf / Prograft from the body."</seg>
<seg id="1406">"diabetes, kidney problems, severe blood sugar levels (hyperglycemia), kidney problems, increased blood sugar levels (Hyperglycemia), diabetes, multiplicity of blood sugar levels (hypertheremia), blood pressure (hypertension), and stroke (Insomnie)."</seg>
<seg id="1407">"in patients with adequate sensitivity (allergy) against Tacrolimus, macro antibacterial infections (such as Erythromycin) or one of the other components must not be applied."</seg>
<seg id="1408">Patients and doctors must be careful when others (in particular some herbal) medicine at the same time they must be taken into consideration when the Advancement of the dose or the dose of the same time must be adapted accordingly.</seg>
<seg id="1409">"in red ink, yellow-orange gels, printed in red ink on the light yellow capsule part with" "647" "; they contain white powder."</seg>
<seg id="1410">"only doctors who are familiar with the immunity therapy and treatment of transplanting patients, this medicine should take place or changes in immunity therapy."</seg>
<seg id="1411">"due to clinically relevant differences of the systemic position of Tacrolimus, this can lead to transplantation or increased incidence of side effects, including sub- or overimmunotherapy."</seg>
<seg id="1412">Patients should always be made by the same Tacrolimus formulation and the corresponding daily dosage; transfer of the formulation or the regime should only be made under the engined control of one in transplant-transplantation (see sections 4.4 and 4.8).</seg>
<seg id="1413">"in a sequence of an alternative formulation, a therapeutic drug must be carried out in order to ensure that the systematic exposition of Tacrolimus remains to ensure that the systematic exposition of Tacrolimus remains to ensure that the systemic position of Tacrolimus remains."</seg>
<seg id="1414">The dosage of Advancement should be primarily associated with clinical assessment of rejection and compensation in the case and on blood level regulations (see below).</seg>
<seg id="1415">"according to the implementation of Prograf on Advancement f, the Tacrolimus-Provence is to be controlled before the changeover and over two weeks to be controlled."</seg>
<seg id="1416">"in the day 4, the systematic exposition, measured as the mirror, with both formulations, both at nibbing and graberces, were comparable to patients."</seg>
<seg id="1417">"careful and repeated checks of the Tacrolimus-la levels are recommended during the first two weeks after transplantation, in order to ensure appropriate substance results in the direct dial."</seg>
<seg id="1418">The Tacrolimus a substance with low Clearance can take a adjustment of the prof-Dosisticas several days until the Steady State is reached.</seg>
<seg id="1419">"if the condition of the patient in the first postoperative phase does not allow drugs, the Tacrolimus treatment intravenous (Prograf 5 mg / ml concentrate on the production of an infusion solution), with a dose of ca."</seg>
<seg id="1420">"in the case of application for the suppression of transplantation, the immunotherapy must not be specified; therefore a maximum duration of the oral treatment can not be specified."</seg>
<seg id="1421">Dosisition - kidney transplantation: prevention of transplantation with 0.20 - 0.030 mg / kg / day as a daily gift on the morning.</seg>
<seg id="1422">Other Dosisines may be necessary as the pharokinetics of Tacrolimus in the course of stabilization of the patient after transplantation.</seg>
<seg id="1423">Dosisén - liver transplantation - liver transplantation with 0.10 - 0.20 mg / kg / day as a daily gift on the morning.</seg>
<seg id="1424">"recommended by Prograf recommended a transplantation by Prograf capsules on a daily intake of Prograf capsules on one day, this change in relation to 1: 1 (mg: mg), can be done on the entire day dosis."</seg>
<seg id="1425">Kidney and liver transplantation after a conversion of other immune diseases the treatment with kidney and liver transplantation must begin the treatment with kidney and liver transplantation of transplantation of transplantation.</seg>
<seg id="1426">Heart transplantation with adult patients that are to be carried on in vain is an orale initialdosis of 0.15 mg / kg / day every day.</seg>
<seg id="1427">Other transplantation shortcomings of 0.2 mg / kg / day for patients in a oral initialdosis of 0.2 mg / kg / day and at the intestinal initialdosis of 0.2 mg / kg / day and at the intestinal initialdosis of 0.2 mg / kg / day.</seg>
<seg id="1428">Dosiser adapters in special patients with reduced liver function for maintaining blood-shaped disease in patients with severe liver function in patients with severe liver disorders.</seg>
<seg id="1429">"patients with reduced kidney function, the kidney function may not affect the pharokinetics of Tacrolimus, which is not necessary, that a Dosiscope is not necessary."</seg>
<seg id="1430">"due to the nephonic potentials as of Tacrolimus, however, a careful monitoring of kidney function (including a regular determination of the kidney function, a calculation of the creatinincance and monitoring of the urinary volume)."</seg>
<seg id="1431">The Ciclosporous to a Tacrolimus-based treatment is required (see sections 4.4 and 4.5).</seg>
<seg id="1432">"recommendations to the Talmirror in the full blut The dose should be in first line on the clinical evaluation of rejection and compensation of full blueprints of full blut-Tacrolimus-Talmud checks."</seg>
<seg id="1433">It is recommended frequent checks of the Tacrolimus valley mirror while the first two weeks after transplantation, followed by periodic checks during the maintenance therapy. "</seg>
<seg id="1434">"blood circulation of Tacrolimus should also be set to change of Prograf, Dosisement, alteration of immunity therapy or use of substances that could be controlled (see section 4.5)."</seg>
<seg id="1435">"there is a medicine with a low Clearance, the dose may require several days until the Steady State."</seg>
<seg id="1436">The information in clinical studies showed that a successful treatment in most cases is possible if the Talbot is not exceed in the blood of 20 ng / ml.</seg>
<seg id="1437">"in clinical practice, the Talbot of Tacrolimus in the first time after liver transplantation is usually in the area of 5 - 20 ng / ml and with the heart-grained patient at 10 - 20 ng / ml."</seg>
<seg id="1438">"during the search therapy of liver, kidney and heart transplantation were usually used in blood concentration in the area of 5 - 15 ng / ml."</seg>
<seg id="1439">"this has led to serious adverse events, including transplantation or other side effects, which can occur in a result of Tacrolimus sub- or overthrown."</seg>
<seg id="1440">Patients should always be made by the same Tacrolimus formulation and the corresponding daily dosage; transfer of the formulation or the regime should only be made under the engined control of one in transplant-transplantation (see sections 4.2 and 4.8).</seg>
<seg id="1441">"5 For the treatment of adult patients with transplantation, which were no clinical data for the retractive formulation."</seg>
<seg id="1442">"for prophylaxis of transplantation in adult heart transplantation and transplantation in the child, nor does not contain clinical data for the retarding formulation."</seg>
<seg id="1443">"due to potential interactions that can lead to a herding of the Tacrolimus mirror in the blood and a weakening of the clinical effect of Tacrolimus, is to avoid reproductive preparation for patients (see section 4.5)."</seg>
<seg id="1444">"in patients with diarrhö, a particularly careful monitoring of the Tacrolimus concentration levels in blood vessels, since the Tacrolimus blood levels under such circumstances can be considerable variations under such circumstances."</seg>
<seg id="1445">"in rare cases, under Prograf is known as Kardiomyopathy, who can be treated as Kardiomyopathy."</seg>
<seg id="1446">"other factors affecting the risk of such clinical disturbances are already existing heart disease, a treatment with corticoids, blood pressure, kidney or liver function, infections, liquid, kidney or liver disorders."</seg>
<seg id="1447">"as with other immunoressiva, the penetration of sunlight or UV light because of the possible risk of malnutrition, alterations by suitable clothes or use of a sunlight with a high level of protection."</seg>
<seg id="1448">"if patients who use Tacrolimus, Symptoms for PRES as headache, alterations for PRES as headache, alterations and tendons should show a radiological investigation."</seg>
<seg id="1449">"in general, there is no translation for this news-article."</seg>
<seg id="1450">"the simultaneous use of medicines or herbal remedy that are known as Hemmer or Inductors of CYP3A4, the metabolism of Tacrolimus can increase the metabolism of Tacrolimus or reduce the blood flow of Tacrolimus or reduce the blood flow of Tacrolimus."</seg>
<seg id="1451">It is recommended to change the Tacrolimus- blood level of simultaneous usage of substances that can change the CYP3A metabolic dose to maintain equal concentrations (see sections 4.2 and 4.4).</seg>
<seg id="1452">Firm of the Year for Compliance Audits and Investigations Gibson Dunn & Crutcher Firm of the Year for Private Construction Luther</seg>
<seg id="1453">Pharmacokinetics studies showed that the increase in blood levels mainly caused by the elevated biodiversity of Tacrolimus due to the inhibition of the gastrointestinal refinement, resulting in the inhibition of the gastrointestinal tract. "</seg>
<seg id="1454">"high-term Prednisolon or Methylprednisolon, as it can increase concentration of Tacrolimus, or reduce the concentration of Tacrolimus in the blood."</seg>
<seg id="1455">Effect of Tacrolimus to the metabolism of other drugs Tacrolimus is known as CYP3A4-Hemmer.</seg>
<seg id="1456">"since the Tacrolimus, the Clearance of Steriliary contrast, and thus the hormones can increase the hormonal measures."</seg>
<seg id="1457">The results of veterans have shown that Tacrolimus potentials can reduce the Clearance of Pentobstructive and phenazon and their half-value.</seg>
<seg id="1458">"results appear ordered" "by relevance" "or" "by date" "(publication date),"</seg>
<seg id="1459">"in Utero Exposition, a monitoring of the curiosity to any harmful effects of Tacrolimus (especially in terms of its effect on the kidneys)."</seg>
<seg id="1460">"there is the risk of a spring-birth (&lt; week 37) and a hyperkalieinemia of Neuborn (Inzieu 8 of 111 Neuborn, i.e.:"</seg>
<seg id="1461">The low-effective profile of immunoressiva can often be seen because of the patients and the simultaneous treatment with a multitude of other medicines.</seg>
<seg id="1462">"below the side effects are listed according to their frequency in descending order: very often (Acts 1 / 10, ≤ 1 / 1,000, ≤ 1 / 1,000, ≤ 1 / 1,000, ≤ 1 / 1,000, ≤ 1 / 1,000, ≤ 1 / 1,000, ≤ 1 / 1,000, ≤ 1 / 1,000, ≤ 1 / 1,000, ≤ 1 / 1,000, ≤ 1 / 1,000, ≤ 1 / 1,000, ≤ 1 / 1,000, ≤ 1 / 1,000, ≤ 1 / 1,000, ≤ 1 / 1,000, ≤ 1 / 10,000, ≤ 1 / 10,000, ≤ 1 / 10,000, ≤ 1 / 10,000, ≤ 1 / 10,000, ≤ 1 / 10,000, ≤ 1 / 10,000, ≤ 1 / 10,000, ≤ 1 / 10,000, ≤ 1 / 10,000, ≤ 1 / 10,000, ≤ 1 / 10,000, ≤ 1 / 10,000, ≤ 1 / 10,000, ≤ 1 / 10,000, ≤ 1 / 10,000, ≤ 1 / 10,000, ≤ 1 / 10,000, ≤ 1 / 10,000, ≤ 1 / 10,000, ≤ 1 / 10,000, ≤ 1 / 10,000, ≤ 1 / 10,000, ≤ 1 / 10,000, ≤ 1 / 10,000, ≤ 1 / 10,000, ≤ 1 / 10,000, ≤ 1 / 10,000, ≤ 1 / 10,000, ≤ 1 / 10,000, ≤ 1</seg>
<seg id="1463">"cardiovascular diseases of the heart attack, tyocarcinogenesis, myyokardiopathy, chamber hypertension, scarianism, palomatic, palomatic, palate, heart rate, heart rate, heart rate, heart rate, heart rate, heart rate, heart rate, heart rate, heart rate, heart rate, heart rate, heart rate, heart rate, heart rate, heart rate, heart rate, heart rate, heart rate, heart rate, heart rate, heart rate, heart rate, heart rate, heart rate, heart rate, heart rate, heart rate, heart rate, heart rate, heart rate, heart rate, heart rate, heart rate, heart rate, heart rate, heart rate, heart rate, heart rate, heart rate, heart rate, heart rate, heart rate, heart rate, heart rate, heart rate, heart rate, heart rate, heart rate, heart rate, heart rate, heart rate, heart rate, heart rate, heart rate, heart rate, heart rate, heart rate, heart rate, heart rate</seg>
<seg id="1464">"penetration, nausea-intestinal tract, asthma, pain in the stomach-intestinal range and deforation, asthma, pain in the stomach-intestine area and Abdomen, dye, rain and wording, lockerly, sign and symptoms in the stomach-intestine -"</seg>
<seg id="1465">"infections and parcasses are treated with patients who are treated with Tacrolimus, the susceptibility of infections (viral, bacterial, mycotic, mywood) often increases."</seg>
<seg id="1466">Cases of BK-virus scanning nephropathy and JC virus infected progressive multifocal opathy (PML) patients were reported in patients under immunity therapy including therapy with regard to patients.</seg>
<seg id="1467">It was reported in good or billing Neoplasms including EBV- associated lymphoeal disease and skin diseases in conjunction with Tacrolimus.</seg>
<seg id="1468">"due to its high molecular weight, its low water solubility and the high binding of Erythrocytes and plasma maples can be accepted that Tacrolimus is not dialysis."</seg>
<seg id="1469">"on the basis of the molecular level, the effects of Tacrolimus has the effects of Tacrolimus (FKBP12), which is responsible for the connection of the connection in the cell."</seg>
<seg id="1470">This leads to a calcible inhibiting of signals due to the T cell and prevents the transcriptions of a certain set of Lymphokin-Gels.</seg>
<seg id="1471">The assumption of full take-up tends to exaggerate the simulated increase in caseloads and fiscal costs of a social policy reform.</seg>
<seg id="1472">"unapproved comment on the first 24 weeks in the Advancement f Group (N = 237) 32,6% and in the Prograf group (N = 234) 29.3%."</seg>
<seg id="1473">"after 12 months after 12 months in 89,2%, in the Advocf-arm, 25 (14 women, 11 men, 11 men) and in Prograf-arm 24 (5 women, 19 men)."</seg>
<seg id="1474">Kidney transplantation The effectiveness and security of Advocalf and Prograf was included in combination with Mycophenolatmofetil (MMF) and Korfu oids at 667 de novo kidney transplantation in 667 de novo kidney transplantation.</seg>
<seg id="1475">"after 12 months after 12 months at 96,9% for Advantf and 97.5% for Prograf; in the Advf-arm, 10 (3 women, 7 men) and in Prograf-arm 8 (3 women, 5 men)."</seg>
<seg id="1476">"the effectiveness and safety of Prograf, Ciclosporin and Advantal, in combination with Basiliximab-antiperintra, MMF and Korticulture, at 638 de novo kidney transplants."</seg>
<seg id="1477">"according to 12 months (defined as death, transplantation or missing follow-up- data) was 14.0% in the Prograf group (N = 214), 15.1% in the Prograf group (N = 212) and 17.0% in the Ciclosporin group (N = 212)."</seg>
<seg id="1478">"the treatment difference was -3.0% (Advancement of Ciclosporin) (95.6%, 4,0%) for the Ciclosporin and -1.9% (Prograf-Ciclosporin) (95.6%, 5.3%]) for Prograf vs Ciclosporin."</seg>
<seg id="1479">"in the Advantf-arm, 3 (men), in Prograf-arm 10 (3 women, 7 men) and the Ciclosporin-arm 6 (3 women, 3 men)."</seg>
<seg id="1480">"results of the primary immunotherapy with Tacrolimus in form of twice daily, Prograf capsules was developed by a recognised primary immunity in the form of panksine, lung and intestinal transplantation."</seg>
<seg id="1481">Table 175 Forecast Sales of Food Preparation Appliances by Category: volume 2009-2014 Table 2 Sales of Impulse and Indulgence Products by Category:% Value Growth 2009-2014</seg>
<seg id="1482">"the safety profile of orderly Prograf in these published studies have been applied to the major studies in which Prograf in liver, kidney and heart transplantation are applied to primary immunotherapy."</seg>
<seg id="1483">"in a interim analysis of a recent analysis, multicentralized study with orphonic test was reported in the framework of a 1: 1-sealed test, either Tacrolimus or Ciclosporin."</seg>
<seg id="1484">"a chronic transplantation, the bronchiolitis, the bronchiolitis, was in the first year after transplantation (2.86% versus 8,57%)."</seg>
<seg id="1485">"the survival rate after a year was 80.8% in the Tacrolimusus and 83% in the Ciclosporin group (Treede et al., 3rd ici San Diego, USA, 2004; abstract 22)."</seg>
<seg id="1486">Patients were treated in 21.7% of the cases for the formation of a bronchiolitis in comparison to 38.0% under Ciclosporin (p = 0.025).</seg>
<seg id="1487">"(n = 2), the number of cases where ciclosporous to the Tacrolimus (n = 1) was significantly larger (p = 2), was significantly larger (p = 2) (Keenan et al., Ann Thoracic Surg 1995; 60: 580)."</seg>
<seg id="1488">"the number of cases in which it came to any kind of transplantation after 6 months (57,7%) and after 1 year (50% versus 33.3%) and after 1 year (50% versus 33.3%)."</seg>
<seg id="1489">"in a study was the frequency of the formation of a bronchiolitis, syndroms in patients with Tacrolimus patients."</seg>
<seg id="1490">"Pankreastfeeding a multidisciplinary study with orphonic test was carried out on the 205 patients who were carried out at the same time a Pankment and kidney transplant, which received after a prospective study of Tacrolimus (n = 103) or Ciclosporin (n = 102)."</seg>
<seg id="1491">The orale initialdosis (per protocol) of Tacrolimus was 0.2 mg / kg / day and was then passed to reaching the desired height of 8 to 15 ng / ml on 5.</seg>
<seg id="1492">"the published results of a periodical study with orphres, 75 patients and 25 multivisceral transplantation of 75% after 1 year, 5% after 5 years and 42% after 10 years."</seg>
<seg id="1493">"methods for early detection of Epstein-Barr (EBV) - and CMV infections, bone tissue, additional gift of the interleukin-2-Antenna Daclizumab, lower initial initial position of the interleukin-2-Antarctic Daclizumab., Ann Surg 2001; 234: 404)."</seg>
<seg id="1494">Factors such as a lower hemmatocritation and low protein concentration, which should lead to increase the loss of unapproved health of the Metabolism, or treatment with corticosis should be responsible for the transplantation of higher Clearance. "</seg>
<seg id="1495">"this makes it possible to close the Tacrolimus prior to the extermination, whereby the expropriation is mainly used over the fermentation."</seg>
<seg id="1496">"for stable patients suffering from prograf (twice daily) in the ratio of 1: 1 (mg: mg), the systematic exposition of Tacrolimus (AUC0-24) can be less than 10% lower than under Prograf."</seg>
<seg id="1497">It is recommended frequent checks of the Tacrolimus valley mirror while the first two weeks after transplantation, followed by periodic checks during the maintenance therapy. "</seg>
<seg id="1498">"21 For the treatment of adult patients with transplantation, which were no clinical data for the retractive formulation."</seg>
<seg id="1499">"other factors affecting the risk of such clinical disturbances are already existing heart disease, a treatment with corticoids, blood pressure, kidney or liver function, infections, liquid, kidney or liver disorders."</seg>
<seg id="1500">"28 unapproved examinations were within the first 24 weeks in the Advancement of Group (N = 237) 32,6% and in the Prograf group (N = 234) 29.3%."</seg>
<seg id="1501">"the effectiveness and safety of Prograf, Ciclosporin and Advantal, in combination with Basiliximab-antiperintra, MMF and Korticulture, at 638 de novo kidney transplants."</seg>
<seg id="1502">"in red ink, a red ink on the grated red capsule part with" "5 mg" "and the whole capsule part with" "687", "they contain white powder."</seg>
<seg id="1503">It is recommended frequent checks of the Tacrolimus valley mirror while the first two weeks after transplantation, followed by periodic checks during the maintenance therapy. "</seg>
<seg id="1504">"37 For the treatment of adult patients with transplantation, which were no clinical data for the retractive formulation."</seg>
<seg id="1505">"other factors affecting the risk of such clinical disturbances are already existing heart disease, a treatment with corticoids, blood pressure, kidney or liver function, infections, liquid, kidney or liver disorders."</seg>
<seg id="1506">"44 approved deliveries were within the first 24 weeks in the Advancement of Group (N = 237) 32,6% and in the Prograf group (N = 234) 29.3%."</seg>
<seg id="1507">"the effectiveness and safety of Prograf, Ciclosporin and Advantal, in combination with Basiliximab-antiperintra, MMF and Korticulture, at 638 de novo kidney transplants."</seg>
<seg id="1508">"a total of 34 patients were provided by Ciclosporus in Tacrolimus, while only 6 Tacrolimus patients a other treatment required (forstein et al., transplantation 2004; 77: 1221)."</seg>
<seg id="1509">"the published results of a periodical study with orphres, 75 patients and 25 multivisceral transplantation of 75% after 1 year, 5% after 5 years and 42% after 10 years."</seg>
<seg id="1510">"this makes it possible to close the Tacrolimus prior to the extermination, whereby the expropriation is mainly used over the fermentation."</seg>
<seg id="1511">Risk management plan The owner of the permit is described in Version 3.2 of the risk management plan (RMP) and in the module 1.8.2 of the approval process (RMP) are described and all further updates of the RMP that are approved by CHMP.</seg>
<seg id="1512">"according to the CHMP Committee on the risk management systems for medicines to use on people, the updated RMP can be submitted to the next periodic security report (Periodic Safety Update Report, PSUR)."</seg>
<seg id="1513">"perhaps you will receive the treatment of your liver, kidney or heart transplantats or other transplantation of your body or because the immune response of your body can not be experienced by a expected treatment."</seg>
<seg id="1514">"with other medicines, please inform your doctor or pharmacist if you have other medicines or pharmacist if you have other medicines or pharmacist, even if it is non-prescription drugs or medicinal plants."</seg>
<seg id="1515">"Amilorid, triamous or Spironolacton), certain pain (so non-steroidal antiphlogics), antioagulators or medicines to take care of diabetes mellitus."</seg>
<seg id="1516">Pregnancy and lactation If a pregnancy is planned or already exists for taking care of all drugs or pharmacist for advice.</seg>
<seg id="1517">"you may not be able to use the control of a vehicle or machines or machines if you feel safe, or feel free to feel or destroy."</seg>
<seg id="1518">"important information about certain other components of different kinds of subjects, please take place only after return with your doctor if you suffer from a disregard to certain sugar."</seg>
<seg id="1519">"make sure that you will always receive the same Tacrolimus medication if you want to solve your recipe, unless your specialist has expressly explicitly approved a change of the Tacrolimus preparation."</seg>
<seg id="1520">"if you receive a medicine, it is necessary to do so quickly as possible with your treatment doctor or pharmacist, so that you can get the right drugs."</seg>
<seg id="1521">This allows your doctor to identify the correct dose and set up time to time when he needs to carry out blood tests.</seg>
<seg id="1522">"if you have taken a greater amount of time taken when you should have taken a larger amount of time, you will find your doctor or the emergency department of the nearest hospital."</seg>
<seg id="1523">"if you have forgotten your password, If you have forgotten the capsules you pay, take this to the same day as soon as possible."</seg>
<seg id="1524">If you don't want to increase the risk of time to fall in the treatment of the treatment you can increase the risk of a transplant of your transplant.</seg>
<seg id="1525">"" "0.5 mg" "and their oranges lower part with" "0.5 mg" "and their oranges lower part with" "647" "and their oranges lower part with" "647" "and their oranges lower part with" "647" "and their oranges lower part with" "647" "and their oranges lower part with" "647" "and their oranges lower part with" "647" "and their oranges lower part with" "647". ""</seg>
<seg id="1526">"the" "677" "and its oranges lower part with" "677" "and its oranges subdivided with" "677" "and its oranges subdivided with" "677" "and their oranges subdivided with" "677" "and their oranges lower part with" "677" "and its oranges subdivided with" "677" "and its oranges subdivided into a white powder."</seg>
<seg id="1527">"if you are already our customer, please log in using your e-mail address and your password.: + 49 5764 318 444. or contact us per email."</seg>
<seg id="1528">"if you want to send us a question about this product, simply complete all the fields marked * and click" "Send". ""</seg>
<seg id="1529">Slovenian tolka Astellas Pharma s.r.o., itač ná zlova ka Galániho 15 / C SK- 821 04 Bratislava 2 Tel: + 421 2 4444 2157</seg>
<seg id="1530">Strate is used for treatment and prevention of blood vessels in patients with Hessibillie A (one through the lack of factor related to chronic blood clauses).</seg>
<seg id="1531">The dosage and frequency of application can then be applied to the treatment of blood vessels or for prevention of blood vessels.</seg>
<seg id="1532">Patients with glaucoma is suffering from a factor which is caused by blood cells into the joints, muscles or internal organs. "</seg>
<seg id="1533">"Octocog alfa is not made of human plasma, but after a method that is called" recombinant DNA technology ":"</seg>
<seg id="1534">It is produced by a cell in which a gene (DNA) was brought to the formation of the human odours.</seg>
<seg id="1535">"Advate is a different in the European Union approved drugs called Recombinate, similar, but it is different, so that the medicine is no proteins of human or animal origin."</seg>
<seg id="1536">"in three additional studies in patients with severe damage caused by 53 children under six years, the use of medicines was examined by the prevention of blood vessels and surgery."</seg>
<seg id="1537">"in the main study, the effectiveness of Advancement in 86% of 510% of 510% of 510% of 510% from 510% from 510% from 510% from 510% from 510% from 510% from 510% from 510% from 510% from 510% from 510% from 510%."</seg>
<seg id="1538">The most common side effects of Regina (observed in 1 to 10 of 100 patients) are Schwindel, headaches, pyrexie (fever) and the formation of antibodies against factor VIII. "</seg>
<seg id="1539">"may not be used in patients that may be sensitive (allergic) against the human odours factor VIII, mouse or hamsterers or one of the other components."</seg>
<seg id="1540">"Swiss Hemp Initiative, collecting signatures at Paleo-Festival Nyon 2005"</seg>
<seg id="1541">"dosage, dosage and duration of the subproject therapy, according to the heavy-wheel of the factor VIII, according to the location and the extent of blood circulation and the clinical state of the patient."</seg>
<seg id="1542">"during the following period of the period of the period, the amount of activity in the corresponding period is not under the specified plasma treatment (in% of standard or in I.E. / dl)."</seg>
<seg id="1543">Injtion all 12-24 hours (8-24 hours in patients under 6 years) for 3-4 days or longer repeat until the pain and the stress damage.</seg>
<seg id="1544">Injtion all 8-24 hours (6-12 hours in patients under 6 years) repeat until the risk for patients.</seg>
<seg id="1545">During treatment of treatment it will be used to control the dose and frequency of injections to appropriate determination of factor VIII plasmrasping.</seg>
<seg id="1546">Individual patients can achieve different patients in vivo Recovery and different semi-value-value.</seg>
<seg id="1547">3 prophylaxis of the long-term prophylaxis of blood vessels in patients with severe asthmatic lie A must be given in doses between 20 and 40 I.E. by factor VIII per kg body weight in the distance of 2-3 days.</seg>
<seg id="1548">"if the expected factor VIII plasmasts cannot be reached or if the blood flow with an adequate dose, must be carried out, a test must be carried out if required."</seg>
<seg id="1549">In patients with high inductive values it is possible that the factor of non-therapy is not effective so that other therapeutic measures have to be used.</seg>
<seg id="1550">"the adoption of the patient is to judge the position of the patient, whereby a maximum injector rate of 10 ml / min should not be exceeded."</seg>
<seg id="1551">The formation of neutral antibodies (inhibitors) against factor VIII is a well-known complications in the treatment of patients with Hammers lie A.</seg>
<seg id="1552">"these inhibitors are always performed against prokoagultism activity of factor VIII, IgG Immunglobuline, which can be quantified in Bethesda units (B.E.) per ml plasma by modified Bethesda Assay."</seg>
<seg id="1553">"the risk of inhibitors, correlate with the extent of its position in the first 20 years, with the risk within the first 20 expositions at the greatest and of genetic and other factors."</seg>
<seg id="1554">"in the treated cases (PTPs) with more than 100 expositions and anamnestically known inhibitors, according to the conversion of a recombinant factor VIII-product is observed."</seg>
<seg id="1555">"due to the rare development of the Hammers lie A with women lie about the application of factor VIII during pregnancy and breastfeeding time."</seg>
<seg id="1556">Patients (5 patients) that were previously treated against factor VIII (5 patients) that have been higher risk to formation of inhibitors and headaches (5 patients) and fever and infiltration (3 patients).</seg>
<seg id="1557">"very often (Acts 1 / 10), often (Acts 1 / 100 to &lt; 1 / 10), very rare &lt; 1 / 10,000), very rare &lt; 1 / 10,000), very rare &lt; 1 / 10,000), very rare &lt; 1 / 10,000), very rare (frequency based on available information)."</seg>
<seg id="1558">"a) The percentage of patients had been calculated based on the sum of the individual patients (234) calculation (10 - 14 postoperable day) in one patient under continuous ADVATE-Infusion."</seg>
<seg id="1559">Blood circulation was measured during the whole period and both the factor VIII- mirrors in plasma as well as the Clearance Rate showed sufficient values at the 15 postoperative day.</seg>
<seg id="1560">"in clinical trials with ADVATE to 145 children and adults 2 with diagnosed optic nerve cells (Pro150 days), only a patient after 26 Expresses with ADVATE with ADVATE or low intoxication (2.4 B.E. in the modified Bethesda approach)."</seg>
<seg id="1561">In no case of the 53 Bagdiatonic patients with a age of 6 years and diagnosed patients with a age of 6 years and diagnosed with a age of 6 years and diagnosed patients with a age of 6 years.</seg>
<seg id="1562">"in case of non-treated patients an ongoing clinical study were 5 out of 25 (20%) with ADVATE, patients were diagnosed against factor VIII."</seg>
<seg id="1563">The immunotherapy of the patients were analysed by the investigation of anti-proliferation proteins against these proteins, laboratory parameters and above side effects. "</seg>
<seg id="1564">"a patient showed a significant reduction in the anti-CHO cell function, otherwise the signs or symptoms occur in an allergic reaction or oversensitivity."</seg>
<seg id="1565">"in four patients the occurrence of urine, Pruritus, skin irritation and increased number of eosinophiles pomulocytes at several repeated product expositions in the context of the study."</seg>
<seg id="1566">"7 As in other intravenous products, the manufacturer of allergic type, including anaphylaktic / anaphylaktosis (frequency was not known)."</seg>
<seg id="1567">- What is the market potential compared to other countries? - How are the overall market and different product segments growing? - How is the market predicted to develop in the future?</seg>
<seg id="1568">All Pharmacokinetics studies with ADVATE were carried out in pre-treated patients with severe or medium fluorescence A (base value of factor VIII-activity ≤ 2%).</seg>
<seg id="1569">The pharmacokinetic parameters are originating from a cross-Over study with ADVATE in 100 previously treated cases or &gt; 10 years and are listed in the next table 3.</seg>
<seg id="1570">"table 3: French Particle Board Existing Stock (US $Million) by Category, 2009-2013"</seg>
<seg id="1571">"not clinical data, based on the studies at security spology, repeated and local toxicity and genotoxicity, show no special risk for people."</seg>
<seg id="1572">Each individual packet is made of a penetration bottle with 5 ml solvents (both glass type I with chlorobutyl rubber rubber) and one device for the conglomeration (BAXJECT II).</seg>
<seg id="1573">"if the product is stored in the fridge, both diameters of the fridge and solvents from the fridge and on room temperature (between 15 and 25 ° C)."</seg>
<seg id="1574">"a significant increase of pulse frequency can be reduced by means of slow, time-saving the injector usually once again (see sections 4.4 and 4.8)."</seg>
<seg id="1575">14 prophylaxis of the long-term prophylaxis of blood vessels in patients with severe asthmatic lie A should be given to a weight between 20 and 40 I.E. from factor VIII per kg body weight in the distance of 2-3 days.</seg>
<seg id="1576">"due to the rare development of the Hammers lie A with women lie about the application of factor VIII during pregnancy and breastfeeding time."</seg>
<seg id="1577">"children (aged 0-1 month), small children (aged 1 month - 2 years), children (aged 12-12 years), children (aged 12-16 years), adults (aged 16-16 years), adults (over 16 years)"</seg>
<seg id="1578">"in clinical trials with ADVATE to 145 children and adults 4 with diagnosed optic nerve cells (Pro150 days), just a patient after 26 Expresses with ADVATE with ADVATE or low infiltration (2.4 B.E. in the modified Bethesda approach)."</seg>
<seg id="1579">"18 As in other intravenous products, the manufacturer of allergic type, including anaphylaktic / anaphylaktosis (frequency was not known)."</seg>
<seg id="1580">"table 3: French Particle Board Existing Stock (US $Million) by Category, 2009-2013"</seg>
<seg id="1581">"not clinical data, based on the studies at security spology, repeated and local toxicity and genotoxicity, show no special risk for people."</seg>
<seg id="1582">25 prophylaxis of the long-term prophylaxis of blood vessels in patients with severe asthmatic lie A should be given to a weight between 20 and 40 I.E. from factor VIII per kg body weight in the distance of 2-3 days.</seg>
<seg id="1583">"children (aged 0-1 month), small children (aged 1 month - 2 years), children (aged 2-12 years), children (aged 12-16 years), adults (aged 16-16 years), adults (over 16 years)"</seg>
<seg id="1584">"in clinical trials with ADVATE to 145 children and adults 6 with diagnosed optic nerve cells (Pro150 days), just a patient after 26 Expresses with ADVATE with ADVATE or low-inhibitorised (2.4 B.E. in the modified Bethesda approach)."</seg>
<seg id="1585">"29 As in other intravenous products, it has been reported in ADVATE with oversensitive actions of allergic type, including anaphylaktic / anaphylaktosis (frequency non-known)."</seg>
<seg id="1586">"not clinical data, based on the studies at security spology, repeated and local toxicity and genotoxicity, show no special risk for people."</seg>
<seg id="1587">36 prophylaxis of a long-term prophylaxis of blood vessels in patients with severe asthmatic lie A should be given to a weight between 20 and 40 I.E. from factor VIII per kg body weight in the distance of 2-3 days.</seg>
<seg id="1588">"7 reborn (aged 0-1 month), small children (aged 1 month - 2 years), children (aged 2-12 years), children (aged 12-16 years), adults (aged 16-16 years), adults (over 16 years)"</seg>
<seg id="1589">"in clinical trials with ADVATE to 145 children and adults 8 with diagnosed optic nerve cells (Pro150 days), just a patient after 26 Expresses with ADVATE with ADVATE or low infiltration (2.4 B.E. in the modified Bethesda approach)."</seg>
<seg id="1590">"40 As for other intravenous products, the manufacturer of allergic type, including anaphylaktic / anaphylaktosis (frequency was not known)."</seg>
<seg id="1591">"not clinical data, based on the studies at security spology, repeated and local toxicity and genotoxicity, show no special risk for people."</seg>
<seg id="1592">47 prophylaxis of the long-term prophylaxis of blood vessels in patients with severe asthmatic lie A should be given to a weight between 20 and 40 I.E. from factor VIII per kg body weight in the distance of 2-3 days.</seg>
<seg id="1593">"9 new born (aged 0-1 month), small children (aged 1 month - 2 years), children (aged 2-12 years), children (aged 12-16 years), adults (aged 16-16 years), adults (over 16 years)"</seg>
<seg id="1594">"in clinical trials with ADVATE to 145 children and adults 10 with diagnosed optic nerve cells A (FVIII ≤ 2%) and previous exposition compared to 26 exogenous (AK150 days), only a patient after 26 Exterior (2.4 B.E. in the modified Bethesda approach)."</seg>
<seg id="1595">"51 As for other intravenous products, the manufacturer of allergic type, including anaphylaktic / anaphylaktosis (frequency was not known)."</seg>
<seg id="1596">"not clinical data, based on the studies at security spology, repeated and local toxicity and genotoxicity, show no special risk for people."</seg>
<seg id="1597">58 prophylaxis of the long-term prophylaxis of blood vessels in patients with severe asthmatic lie A should be given to a weight between 20 and 40 I.E. from factor VIII per kg body weight in the distance of 2-3 days.</seg>
<seg id="1598">"11 new born (aged 0-1 month), small children (aged 1 month - 2 years), children (aged 2-12 years), children (aged 12-16 years), adults (aged 16-16 years), adults (over 16 years)"</seg>
<seg id="1599">"in clinical trials with ADVATE to 145 children and adults 12 with diagnosed optic nerve cells A (FVIII ≤ 2%) and previous exposition compared to 26 exogenous (AK150 days), only a patient after 26 exogenous (2.4 B.E. in the modified Bethesda approach)."</seg>
<seg id="1600">"62 As in other intravenous products, ADVATE has been added to an allergic reaction from allergic type, including anaphylaktic / anaphylaktosis (frequency non-known)."</seg>
<seg id="1601">"not clinical data, based on the studies at security spology, repeated and local toxicity and genotoxicity, show no special risk for people."</seg>
<seg id="1602">Firm of the Year for Compliance Audits and Investigations Gibson Dunn & Crutcher Firm of the Year for Private Construction Luther</seg>
<seg id="1603">"as in the CHMP directive on the risk of Managment Plan for Human Resources, these updates are submitted to the next periodic Safety Update Report (PSUR)."</seg>
<seg id="1604">"• If new information have been received, the influence on the valid safety requirements, the pharmaceutical kovigilance or the measures for risk reduction • within 60 days after an important event (with regard to the risk reduction)"</seg>
<seg id="1605">"this product is compatible too (for example):" "how to" "and" "Tools, Internet Options, Security" "and" "Tools, Internet Options, Privacy". ""</seg>
<seg id="1606">"this product is compatible too (for example):" "how to" "and" "Tools, Internet Options, Security" "and" "Tools, Internet Options, Privacy". ""</seg>
<seg id="1607">"special caution in the application of ADVERATE you should inform your doctor if you have recently been treated with factor VIII products, especially if you have research."</seg>
<seg id="1608">These symptoms can be found in early signs of an anaphylaktic shock which can be found in the following symptoms: extreme scopes, consciousness and extreme breathing. "</seg>
<seg id="1609">"with other medicines, please inform your doctor if you take other medicines or later, even if it is not non-prescription drugs."</seg>
<seg id="1610">Your doctor will calculate your dose ADVATE (in international units or I.E.).</seg>
<seg id="1611">"in addition, the expected factoral mirrors in your plasma could not be achieved or the blood circulation may not be achieved, this could be achieved at the development of factor VIII-"</seg>
<seg id="1612">"in conjunction with operations catheter infectomy, lower number of red blood cells, Anschwine of Gliedonian and joints, extended blood pressure according to the distance of a drainage, reduced factor-VIII mirror and postoperative hemmatome."</seg>
<seg id="1613">"very rare side effects on the market, a large and potential life-threatening reactions (Anaphylaxie) and other allergic reactions (see above)."</seg>
<seg id="1614">Inform your doctor if one of the adverse side effects will be considerably reduced or if you notice any side effects that are not listed in this package site.</seg>
<seg id="1615">Portugal Baxter Médico FRA Sintra Business Park Zona Industrial Park Zona Industrial Park Zona Industrial Park Zona Industrial Park Zona Industrial Park Zona Industrial Park Zona Industrial Park Zona Industrial Park Zona Industrial Park Zona Industrial Park Zona Industrial Park Zona Industrial Park Zona Industrial Park Zona Industrial Park Zona Industrial Park Zona Industrial Park Zona Industrial Park Zona Industrial Park Zona Industrial Park Zona Industrial Park Zona Industrial Park Zona Industrial Park</seg>
<seg id="1616">"• The BAXJECT II doesn't use if its sterile barrier is damaged, its packaging is damaged or signs of a manipulation, as in the symbol."</seg>
<seg id="1617">You can check the product on Schiereteille or discerning.</seg>
<seg id="1618">"the solution should be slow with an Infudiversion speed, which is being protected from 10 ml per minute."</seg>
<seg id="1619">106 In case of blood vessels should not be determined within the appropriate time period (in% or in I.E. / ml).</seg>
<seg id="1620">These symptoms can be found in early signs of an anaphylaktic shock which can be found in the following symptoms: extreme scopes, consciousness and extreme breathing. "</seg>
<seg id="1621">"in addition, the expected factoral mirrors in your plasma could not be achieved or the blood circulation may not be achieved, this could be achieved at the development of factor VIII-"</seg>
<seg id="1622">"the side effects of liquorice, reinforced sweating, unusual taste, fenders, migration, bulk, digestive, digestive, digestive, skin, inflammation, skin irritating, skin irritating, skin irritated, extreme cheeks, extreme cheeks, extreme cheeks, extreme cheeks, extreme cheek"</seg>
<seg id="1623">"116 In the case of blood vessels, the factor specified in the corresponding time period (in% or in I.E. / ml)."</seg>
<seg id="1624">These symptoms can be found in early signs of an anaphylaktic shock which can be found in the following symptoms: extreme scopes, consciousness and extreme breathing. "</seg>
<seg id="1625">"in addition, the expected factoral mirrors in your plasma could not be achieved or the blood circulation may not be achieved, this could be achieved at the development of factor VIII-"</seg>
<seg id="1626">"126 In the case of blood vessels, the factor specified in the appropriate time period (in% or in I.E. / ml) will fall under the specified conditions (in% or in I.E. / ml)."</seg>
<seg id="1627">These symptoms can be found in early signs of an anaphylaktic shock which can be found in the following symptoms: extreme scopes, consciousness and extreme breathing. "</seg>
<seg id="1628">"in addition, the expected factoral mirrors in your plasma could not be achieved or the blood circulation may not be achieved, this could be achieved at the development of factor VIII-"</seg>
<seg id="1629">136 In case of bleeding in the appropriate time period (in% or in I.E. / ml).</seg>
<seg id="1630">These symptoms can be found in early signs of an anaphylaktic shock which can be found in the following symptoms: extreme scopes, consciousness and extreme breathing. "</seg>
<seg id="1631">"in addition, the expected factoral mirrors in your plasma could not be achieved or the blood circulation may not be achieved, this could be achieved at the development of factor VIII-"</seg>
<seg id="1632">"146 In the case of blood vessels, the factor specified in the corresponding period not under the specified conditions (in% or in I.E. / ml)."</seg>
<seg id="1633">These symptoms can be found in early signs of an anaphylaktic shock which can be found in the following symptoms: extreme scopes, consciousness and extreme breathing. "</seg>
<seg id="1634">"in addition, the expected factoral mirrors in your plasma could not be achieved or the blood circulation may not be achieved, this could be achieved at the development of factor VIII-"</seg>
<seg id="1635">"the side effects of liquorice, reinforced sweating, unusual taste, fenders, migration, bulk, digestive, digestive, digestive, skin, inflammation, skin irritating, skin irritating, skin irritated, extreme cheeks, extreme cheeks, extreme cheeks, extreme cheeks, extreme cheek"</seg>
<seg id="1636">"very rare side effects on the market, a large and potential life-threatening reactions (Anaphylaxie) and other allergic reactions (see above)."</seg>
<seg id="1637">156 In case of bleeding in the appropriate time period (in% or in I.E. / ml).</seg>
<seg id="1638">"based on the first approval of your data, the CHMP the benefit risk reduction continues to be positively evaluated, but consider the safety profile of the following reasons."</seg>
<seg id="1639">"therefore, the CHMP is required for the basis of the security filing of ADVATE, which is necessary to apply for the approval of PSURs all 6 months."</seg>
<seg id="1640">"in December 2008 Gendux Molecular Limited presented to the Committee for Humanities (CHMP), that the company can be reactive in the treatment of Li-women's treatment for the treatment of Li-women's treatment."</seg>
<seg id="1641">"however, the breast, the brain, the bone, or the wheat (tissue, the other structures in the body, and supports) of it."</seg>
<seg id="1642">"it is a kind of virus, the genetic table, that it is a gene in the cells of the body."</seg>
<seg id="1643">"in the virus in Advexin, it is a" A302 virus "," so that there was no copies of themselves, and therefore no infections in humans. "</seg>
<seg id="1644">"" "if you are looking for the tumour, we will be able to develop the normal p53 protein to form the normal p53 protein."</seg>
<seg id="1645">"the p53 protein, which is not defective in the human body using existing p53 gene is usually used to restore damaged DNA and kill the cells when the DNA can not be remanufactured."</seg>
<seg id="1646">"at Li-womb cancer, the p53-gene is not correct, the p53 protein is not correct, and the cancer cells can continue to grow and share."</seg>
<seg id="1647">"data coverage: market sizes (historic and forecasts), company shares, brand shares and distribution data. why buy this report?"</seg>
<seg id="1648">"after the CHMP the answers of the company, there were still some questions."</seg>
<seg id="1649">"based on the testing of the initial documents created by the CHMP, a list of questions which will be sent to the company."</seg>
<seg id="1650">"after view of the CHMP there was not sufficient that the injunction of Advexin Li-Fraumeni tumors benefits for patients.</seg>
<seg id="1651">"the Committee had further concerns about the processing of medicines in the body, the type of administration and security of medicines."</seg>
<seg id="1652">"in addition, the company does not have adequate to be manufactured in a reliable way that the company can not be manufactured in a reliable way and that it is neither the environment nor the environment for people who come into contact with the patient."</seg>
<seg id="1653">Firm of the Year for Compliance Audits and Investigations Gibson Dunn & Crutcher Firm of the Year for Private Construction Luther</seg>
<seg id="1654">"this means that the tablets can be set up so that the tablets are placed so that one of the most effective ingredient immediately and the other slowly spread over a few hours."</seg>
<seg id="1655">Aerinaze is used for the treatment of the seasonal rhinitis (hay infections) in patients with nasal infections (copause nose).</seg>
<seg id="1656">"for adults and young people from 12 years, the recommended dose of aerinaze twice a tablet, which should be taken with a glass of water with or without food."</seg>
<seg id="1657">"the length of the treatment should be as short as possible, as soon as the symptoms, especially the swelling of the nose of the nasal nose."</seg>
<seg id="1658">Treatment duration of more than 10 days is not recommended because the effects of the medicines can be found in the constipation of the nose.</seg>
<seg id="1659">The main objective dimensions were the changes of the cause of the hypoglary symptoms that were reported from patients before the start of treatment and during the 15-day treatment.</seg>
<seg id="1660">During the study carried out the patients all 12 hours into a diary and rated with a standard skala as difficult to have symptoms in the last 12 hours.</seg>
<seg id="1661">"in the case of all hypoglary symptoms of the nose of the nose reported the patients who reported aerinaze, over a decrease of symptoms of 46,0%, compared with 35,9% in patients that pseudoephedrin alone."</seg>
<seg id="1662">"when only the swelling of the nasal loop, the patient showed a lens of the symptoms of 37.4% compared to 26,7% of the patients, the Despadin alone."</seg>
<seg id="1663">"the most common side effects of aerinaze (observed in 1 to 10 of 100 patients), tulcertis, dehydration, headache, headache, headache, insomnia (urgency), sleep disorders and nerves."</seg>
<seg id="1664">"aerinaze may not be sensitive to patients that may be sensitive (allergic) against Desloratadin, pseudoephedrin or one of the other components against allergies, or Loratadin (another medicine prescribed for the treatment of allergies)."</seg>
<seg id="1665">"aerinaze may also be used in patients who are treated with hypertension (increased eye pressure), cardiovascular disease (overflow pressure), hyperthyophile (overfunction of the thyroid)."</seg>
<seg id="1666">"on 30 July 2007, the European Commission published the European Commission to the company SP Europe, the European Commission adopted by Aerinaze in the whole European Union."</seg>
<seg id="1667">"the tablet can be taken with a glass of water, however, in the whole."</seg>
<seg id="1668">Aerinaze should be applied to the lack of data for inaccuracies and effectiveness (see section 5.1) not for children under 12 years.</seg>
<seg id="1669">The duration of application is as short as possible and should not be continued.</seg>
<seg id="1670">It is recommended to limit the application period to 10 days since they can reduce the activity of pseudoephedrin with time.</seg>
<seg id="1671">"after a decline in the swelling of the mucous membranes in the top breathing, the treatment can be carried out with Deseratadin as a monotherapy."</seg>
<seg id="1672">The medicine may also be used in patients with chronic oxidase (Mao) inhibitors or can be treated within 2 weeks after the end of such treatment.</seg>
<seg id="1673">"this is based on the notamimetic activity in combined application of pseudoephedrin, Pergoid, Cabergo, Cabergo, Cabinet, Dihydrootent or other decrimination (phenylpropantooteric), phenylefié, oxymetazine, Naphazard, etc.)."</seg>
<seg id="1674">The safety and effectiveness of this combination therapy were not tested and the data are not tested for the patient treatment.</seg>
<seg id="1675">The safety and the effectiveness of aerinaze were not tested with kidney or liver function in patients with kidney or liver function.</seg>
<seg id="1676">Patients need to be informed that the treatment in relation to hypertension or a troughor by palatal disorders such as headache or any other neurological symptoms (like headache or a reinforcement of headache).</seg>
<seg id="1677">Patients with hypertension • patients with heart rhythmic disorders • patients with hypertension • patients with hypertension • Patients with a Myokardinfin in Anamnese, bladder cancer or bronchospassions in Anamnese. "</seg>
<seg id="1678">"aerinaze is at least 48 hours before the implementation of the matological tests, since Antihistamine often occurs positive reactions on indicators for skin actions or in their income."</seg>
<seg id="1679">"in the framework of clinical trials with Despatadin, where erythromycin or Ketoconazol were observed, however, there were no clinically relevant exchange effects or changes of the plasma concentration."</seg>
<seg id="1680">"due to the results of the psychomotomy tests, there were no significant differences between associated with Despatadin and with the Placebo patients, regardless of whether Desloratadin alone or alcohol was taken."</seg>
<seg id="1681">The metaphors of Desloratadin enzymes was not identified so that interactions with other medicines can not be excluded.</seg>
<seg id="1682">"in vivo CYP3A4, in vivo CYP3A4 not, and in-vitro studies have shown that the medicine CYP2D6 is non-inhibiting and neither a substrate nor a inhibitor of the P-glycocks."</seg>
<seg id="1683">"during pregnancy, the infertility of aerinaze during pregnancy is not secured, experiences from a large number of affected families, however, not increase the frequency of abnormalities compared to the frequency during normal population."</seg>
<seg id="1684">"however, reproduction studies on animals are not always transferred to humans and on the reason of the vasoconical properties of pseudoephedrin should not be applied in pregnancy."</seg>
<seg id="1685">"however, patients should be sure that there may be very rare cases that can be used in very rare cases that can lead to a supply of traffic or the ability to serve machines."</seg>
<seg id="1686">"the symptoms may vary between a ZNS depression (Sealing, Apnoe, reduced mental attention, cya, cardiovascular disease) and a ZNS stimulation."</seg>
<seg id="1687">"headaches, fear, smilations, museal and increased muscle tension, Euphemia, transpiration, pain, transpiration, nautical pain, tinnitus, pinnitus, pinnitus, anxiety disorders, hypertension or hypotony or hypotony."</seg>
<seg id="1688">"a ZNS stimulation is particularly likely for children, as well as Atropin-typical Symptoms, Pupillaret and - dilatation, skin skin and gastrointestinal symptoms."</seg>
<seg id="1689">"these include both inhibition of proinflammatory cytokines such as IL-4, IL-6, IL-8, IL-8 and IL-13 from human Mastal cells / Basophiles, as well as the inhibition of the expression of the expression of the expression of the expression of endothelial cells."</seg>
<seg id="1690">"in case of a single dose study with adults, Despatadin 5 mg no influence on standard measurement sizes of the river, including the reinforcement of subjective resistance or the tasks which are connected with the airplane."</seg>
<seg id="1691">In controlled clinical trials was found in the recommended dosage of 5 mg daily.</seg>
<seg id="1692">"the orale application of pseudoephedrin in the recommended dosage may result in the recommended dosage, such as a increase of blood pressure, tachyate or manifestation of a ZNS arousal."</seg>
<seg id="1693">"there were 1,248 patients at the age of 12 and 78 years with seasonal allergic to the part, whereby 414 patients were aerinaze tablets."</seg>
<seg id="1694">"in both studies, the histories of aerinaze tablets, determined by the total control for the symptoms (except nose grinding), significantly higher than under a monotherapy with pseudoephedrin over the 2-winged treatment period."</seg>
<seg id="1695">The efficacy of aerinaze tablets in regard to the abductive effect which was significantly higher than under a monotherapy with Desloratadin over the 2-winged treatment period.</seg>
<seg id="1696">"the effectiveness of aerinaze tablets showed no significant differences in relation to gender, age or ethnic minority groups, no significant differences."</seg>
<seg id="1697">A Culinary Tour through the Alps. read on Biwak # 17: wild Food</seg>
<seg id="1698">"according to the pertinal application of aerinaze at healthy subjects, the flow-weight of Desloratadin, 3-hydroxydun and pseudoephedrin to day 10."</seg>
<seg id="1699">Firm of the Year for Restructuring and Corporate Rescue Freshfields Bruckhaus Deringer Firm of the Year for Insolvency Administration Schneider Geiwitz & Partner Firm of the Year for Tax Gleiss Lutz</seg>
<seg id="1700">A component interacting study shows that the Exposition (Cmax and auc) of pseudoephedrin after the allest gift of pseudoephedrin biosis.</seg>
<seg id="1701">"based on conventional studies on safety spicology, toxicity with repetition of repetition of repetition, for Genotoxides and reproductive data, the preventive data with Desloratadin, however no particular dangers for people."</seg>
<seg id="1702">The combination had no more toxicity than their individual components and the observed effects were in general in connection with the content of pseudoephedrin.</seg>
<seg id="1703">In reproductive studies the combination of Loratadin / pseudoephedrin in a dosage of up to 150 mg / kg / day and for canine in a dosage of up to 120 mg / kg / day.</seg>
<seg id="1704">"Swiss Hemp Initiative, collecting signatures at Paleo-Festival Nyon 2005"</seg>
<seg id="1705">Antihistamine can be used to protect the allergic reactions when they prevent histamine as a body's own substance.</seg>
<seg id="1706">"aerinaze tablets implant symptoms that occur in connection with seasonal toxication (hay, ongoing or juckling nose, or juices, or juicy eyes with simultaneous constipation of the nose."</seg>
<seg id="1707">"20 Under certain circumstances, you can be particularly sensitive to the veil of the mucous medication pseudoephedrin, which is included in this medicine."</seg>
<seg id="1708">"(sugar diseases), a stenobespoised stomach (the intestine), a string of the stomach or the diaphragms (intestinal tract), a string of stomach or problems with the liver, the kidneys, or the bladder."</seg>
<seg id="1709">Inform your doctor if the use of aerinaze the following symptoms or diseases occur or diagnosed:</seg>
<seg id="1710">"if taking advantage of aerinaze with other medicines, please inform your doctor or pharmacist if you have other medicines or pharmacist, even if it is not non-prescription drugs."</seg>
<seg id="1711">"by using machines on the recommended dosage and use of machines to use in the recommended dosage, it is not possible to reduce aerinaze of Benommenities or attention to the attention."</seg>
<seg id="1712">"if you have a bigger amount of aerinaze, when you should contact your doctor or pharmacist if you should have a bigger amount of aerinaze."</seg>
<seg id="1713">"if you have forgotten the taking of aerinaze If you have forgotten your dose on time, take the application so soon as possible and turn the next dose for the subject at time."</seg>
<seg id="1714">Please inform your doctor or pharmacist if one of the adverse side effects or side effects that are not specified in this form information.</seg>
<seg id="1715">"heart hunt, coldness with multiplied physical activity, mouth, pain, curation, sugar in the urine, increased blood sugar levels, thirst, fatigue, headaches, nerves and Benommenity."</seg>
<seg id="1716">"cardiovascular diseases, pain or difficulties in water, urinary tract, nose or difficulty in water, urinary tract, nasal pain, pain or difficulties during water, swinging, pain or difficulties during water, swinging, pain or difficulties during water, swinging, pain, anxiety, anxiety, anxiety and friction."</seg>
<seg id="1717">"after the market of Despatadin was very rare in cases of severe allergic reactions (breathing, pipes of breathing, Juckery and pigs) or skin suggestions."</seg>
<seg id="1718">"more than cases of heart failure, heart attack, abdominal pain, stomach pain, scucinations, hibits, muscle pain, pain pain, muscle pain, muscle pain, crampings, muscle pain, muscle pain, crampings, muscle pain, muscle pain, cramped and above cases of striking liver function was also very rare."</seg>
<seg id="1719">"it is available as a 5 mg tablet, 5 mg- and 5 mg-melt tabletins (tablets, which can be used in mouth), 0.5 mg / ml water and as 0.5 mg / ml solution."</seg>
<seg id="1720">"for children aged up to five years, the dose 1.25 mg once daily, the dose 1.25 mg once daily, which is used in the form of 2.5 ml Sirup."</seg>
<seg id="1721">"for children aged six to eleven years, the dose 2.mg once daily, either in the form of 5 ml syrup."</seg>
<seg id="1722">"Aerius was examined in a total of eight studies with about 4 800 adults and young people with allergic rhinitis (including four studies at seasonal rhinitis and two studies in patients who had studied Asthma)."</seg>
<seg id="1723">"the effectiveness has been measured by the change of symptoms (Juckery, number and size of squares, impairment of sleep, and the performance on days) before and after six weekly treatment."</seg>
<seg id="1724">"further studies showed that the body can take the syrup, the solution to take and take the melt-tabletins in the same way as the tablets and the application for children are unthinkable."</seg>
<seg id="1725">"with allergic rhinitis, if the results of all studies were collected, the two mg amerius have been collected at a average decrease of the symptoms (Symptoms) of 25 to 32%, compared to the decrease of 12 to 26% in comparison to the patients who received a Placebo."</seg>
<seg id="1726">"in the two studies in Urutaria, the decrease of the symptomatic decreases with Aerius 58 and 67%, compared with 40 and 33%, compared with over 40 and 33%."</seg>
<seg id="1727">"Aerius may not be used in patients that may be sensitive (allergic) against Desloratadin, Loratadin or one of the other components."</seg>
<seg id="1728">"in January 2001, the European Commission adopted the European Commission to the company SP Europe to take a permit for the Instruction of Aerius in the whole European Union."</seg>
<seg id="1729">"a tablet per day, with one or without a meal, to initiating the symptoms in allergic rhinitis (including intermitment and persist) and Urinary (see under section 5.1)."</seg>
<seg id="1730">There is restricted experience from clinical trials for the effectiveness of Despatadin in adolescents from 12 to 17 years (see sections 4.8 and 5.1).</seg>
<seg id="1731">The treatment of intermittallergic rhinitis (of the symptoms for less than 4 days per week or less than 4 weeks) should be taken accordingly accordingly.</seg>
<seg id="1732">"in the Persian Rhinitis (of the symptoms of 4 or more days per week, and more than 4 weeks) can be recommended for patients during the treatment time."</seg>
<seg id="1733">"clinical trials were not found in the framework of clinical trials with Desloratadin tablets, when Erythromycin or Ketoconazol were included (see section 5.1)."</seg>
<seg id="1734">The clinical study was not reinforced in a clinical trial study by Aerius and alcohol use the powerful effect of alcohol (see under section 5.1).</seg>
<seg id="1735">"however, patients should be sure that it can be used in very rare cases that can be used in very rare cases that can lead to use of traffic or the ability to serve machines."</seg>
<seg id="1736">"clinical trials in various indications, including allergic rhinitis and chronic idiopathic Urinary, were reported in the recommended dose of 5 mg daily."</seg>
<seg id="1737">"the most frequently selected side effects on the most common side effects were reported, fatigue (1.2%), mouth-dry (0.8%) and headaches (0.6%)."</seg>
<seg id="1738">"in a clinical study with 578 juvenile patients were treated from 12 to 17 years, the most common side effects of the patients were treated to 5.2% of patients who were treated with dissiatadin."</seg>
<seg id="1739">"in a multi-dose study, in which up to 45 mg the loratadin (Neunusually clinical dose) were observed, were observed in clinical effects."</seg>
<seg id="1740">"this includes both inhibition of provisional cytokines as IL-4, IL-6, IL-8, IL-8 and IL-13 from human mastal cells / basophiles to endothelial cells on endothelial cells."</seg>
<seg id="1741">"in the framework of a clinical study with multi-professional study, in the Despatadin in a dosage of up to 20 mg daily over 14 days, no statistics have been described or clinically significant."</seg>
<seg id="1742">"in a clinical trial study, in the Despatadin in a dosage of 45 mg daily (the Neunites of clinical dose) over ten days, showed no renewal of the QTc interval between ten days."</seg>
<seg id="1743">"- Gain an outlook of the historic development, current market situation, trends, and future outlook of the furniture in the country in question, 2015-2019 (US dollars)"</seg>
<seg id="1744">"in patients with allergic rhinitis, Aerius was effective at the lens of the symptoms such as Niesen, nasal secretion and beckness of the nose, Juckish, the flow and redness of the eyes as well as Juckery on the palate."</seg>
<seg id="1745">"in addition to the established classifications in seasonal and permissible, can be allergic to the duration of the symptoms even in intermitory Rhinitis and anarchist Rhinitis."</seg>
<seg id="1746">"for less than 4 days a week or less than 4 weeks, or less than 4 weeks."</seg>
<seg id="1747">The allergic reactions will be defined as an appearance of the symptoms of 4 or more days per week and more than 4 weeks.</seg>
<seg id="1748">"* Understand the competitive environment, the market's major players and leading brands; * Use five-year forecasts to assess how the market is predicted to develop."</seg>
<seg id="1749">The chronically idiopathic macroparia has been investigated for further forms of urine due to different forms of pathology at different forms and chronic patients with chronic patients.</seg>
<seg id="1750">"as the histaminfant of a cell factor in all urine diseases is expected, Deseratadin is expected to improve the symptoms of urine in other forms of urine. this is confirmed by the recommendations of the clinical guidelines."</seg>
<seg id="1751">"in two Placebo, studies on 6 weeks with chronic idiopathic macular urine was effective in the improvement of Pruritus and the heart rate of size and number of squares at the end of the first Dosisium."</seg>
<seg id="1752">"as in other studies with antihistamine, the minority of the patients, the minority of the patients who are not excluded in antihistamine, were excluded from the study."</seg>
<seg id="1753">A improvement of the juices for more than 50% of patients with Despatadin patients were observed in comparison to 19% of the treated patients in comparison to 19% of the patients.</seg>
<seg id="1754">Treatment with Aerius reduced the disorder of sleep and the juniper-consciousness as due to a 4-points scale to rating of this variables.</seg>
<seg id="1755">"in a Pharmacokinetics study, which were comparable to patients with general seasonal institutions, were comparable to 4% of patients a higher concentration of Desloratadin."</seg>
<seg id="1756">There are currently no items for a clinically relevant Kumulation to once daily use of Desloratadin (5- 20 mg) over 14 days.</seg>
<seg id="1757">The metaphors of Desloratadin enzymes was not identified so that interactions with other medicines are not excluded.</seg>
<seg id="1758">In vivo non-vitro tests are shown in vivo non-vitro tests that the medicine CYP2D6 is non-inhibiting and neither a substrate nor a substrate or intoxication of the P-glycocks.</seg>
<seg id="1759">In a single line study with Despatadin in a dosage of 7.5 mg. meals are not included in the availability of Desloratadin.</seg>
<seg id="1760">"the paper investigates the impact of non-take-up for two hypothetical scenarios, namely increasing and decreasing the base amount of social assistance in Germany by €100 per month. IAB-Discussion Paper 20 / 2015"</seg>
<seg id="1761">"based on conventional studies on safety spicology, toxicity with repetition of repetition, genotoxicity and the reproduction of reproduction, the preventive data with Desloratadin no particular dangers for people."</seg>
<seg id="1762">"colourless film (contains Lactose-Monohydrat, Hygol 400, indigocarmin (E 132), colourless film (contains hypromatism, Macrogol 400), Carnaun-wax, wax wax."</seg>
<seg id="1763">"Aerius can be taken independently of the meals, to initiating the symptoms of allergic rhinitis (including intermitment and persist) and Urutaria (see under section 5.1)."</seg>
<seg id="1764">The verdict doctor should be aware that most cases of Rhinitis are caused by a infection (see under section 4.4) and that no data have been received by an infectious Rhinitis with Aerius.</seg>
<seg id="1765">"in addition to the exclusion of the air-breathing, or anatomical Anomalies should play a role in diagnosis the anamnese, physical tests and appropriate laboratory tests."</seg>
<seg id="1766">"for about 6% of the adults and children between 2 and 11 years, Deseratadin is restricted and experienced a higher output load (see under section 5.2)."</seg>
<seg id="1767">"the safety of Aerius Sirup for children between 2 and 11 years, which is identical with children, the normal metabolic."</seg>
<seg id="1768">This medicine contains Saccharosis and Sorbitol; therefore patients should not take patients with chronic problems of a fructose intolerance or a Saccharase-Isomatic treatment.</seg>
<seg id="1769">"clinical studies were not found in the framework of clinical trials with Aerius tablets, when Erythromycin or Ketoconazol were included (see section 5.1)."</seg>
<seg id="1770">In a clinically-pharmacological study was not reinforced with hererius tablets and alcohol use the powerful effect of alcohol (see under section 5.1).</seg>
<seg id="1771">The total of the side effects of the side effects of children between 2 and 11 years was similar to the Aerius Sirup Group like at the Placebo Group.</seg>
<seg id="1772">"clinical trials with adults and young people in various indications, including allergic rhinitis and chronic ophthalmologic urine, were reported in patients with Aerius, as in patients who were treated with Placebo."</seg>
<seg id="1773">"in a multi-dosis study on adults and young people, with up to 45 mg the loratadin (Neunusually clinical dose) were found no clinical effects were observed."</seg>
<seg id="1774">Children aged between 1 and 11 years that were used for Antihistamine therapy in question; a daily dissiatadindosis of 1.25 mg (in age between 1 and 5 years) or 2.5 mg (in age between 6 and 11 years).</seg>
<seg id="1775">"because the course of allergic rhinitis / chronically idiopathic Urinary and the profile of Desloratadin in adults and children, the efficacy of Deseratadin at adults are similar to the children's population."</seg>
<seg id="1776">"in the framework of a clinical study with multiple professional training for adults and adolescents, in the Despatadin in a dosage of up to 20 mg. a day of up to 20 mg daily, was described."</seg>
<seg id="1777">"in a clinical trial study on adults and adolescents, in the Despatadin in a dosage of 45 mg daily (the Neunequaradin in a dosage of 45 mg daily), no renewal of the QTc interval."</seg>
<seg id="1778">In controlled clinical trials was found in the recommended dosage of 5 mg daily for adults and teenagers.</seg>
<seg id="1779">"at a single-day dosis of 7,5 mg, Aerius tablets at adults and young people in clinical trials will not affect the psychomotment."</seg>
<seg id="1780">"clinical studies on adults, there were no need for alcohol, neither too excessive the alcohol-induced performance improvement."</seg>
<seg id="1781">"in adult and juvenile patients with allergic rhinitis were effective in the lens of the symptoms such as Niesen, nasal secretion and juices of the nose, Juckish, flow and redness of the eyes as well as Juckery on the palate."</seg>
<seg id="1782">"* Understand the competitive environment, the market's major players and leading brands; * Use five-year forecasts to assess how the market is predicted to develop."</seg>
<seg id="1783">"in two Placebo, studies on 6 weeks with chronic idiopathic macular urine was effective in the improvement of Pruritus and the heart rate of size and number of squares at the end of the first Dosisium."</seg>
<seg id="1784">"it is comparable to adults (6%) and children between 2 and 11 years (6%) and in both Populations bigger at Black (18% adults, 16% children) as at Kaukasians (2% adults, 3% children)."</seg>
<seg id="1785">Similar pharmacokinetic parameters were found in a pharmacokinetics study with the siupformation of children between 2 and 11 years with allergic rhinitis that is limited to children between 2 and 11 years.</seg>
<seg id="1786">"the load (auc) through Desloratadin was about 3 to 6 hours, about 6times higher and the Cmax about 3 to 4times higher than a date half of about 120 hours."</seg>
<seg id="1787">"there are no additional costs for a clinically relevant plant-Kumar to once daily use of Desloratadin (5- 20 mg) over 14 days at adults and young people."</seg>
<seg id="1788">"12 In various individuals studies showed that AUC- and Cmax values of Desloratadin in the recommended doses were comparable to those of adults, the Despadin-Sirup in a dosage of 5 mg."</seg>
<seg id="1789">The metaphors of Desloratadin enzymes was not identified so that interactions with other medicines can not be excluded.</seg>
<seg id="1790">"Aerius Sirup is offered in type-III-Braunglasses with child-proof polypropylene cap with 30, 50, 60, 100, 120, 150, 225 and 300 ml."</seg>
<seg id="1791">"equipped with rigid, transparent polystyrene measuring spoon, kalibried with 2.5 ml and 5 ml or with an application injection for loading with scale of 2.5 ml and 5 ml (only for 150 ml bottle)."</seg>
<seg id="1792">A dose of aserius lyric acid is to take a dose of allergic rhinitis (including intermitment and persands of allergic rhinitis) and urinary (see under section 5.1).</seg>
<seg id="1793">"immediately before application needs to be carefully opened, and the dose of Lyric lisats to take you without them."</seg>
<seg id="1794">"clinical studies were not found in the framework of clinical trials with Aerius tablets, when Erythromycin or Ketoconazol were applied (see under section 5.1)."</seg>
<seg id="1795">"clinical trials in various indications, including allergic rhinitis and chronic idiopathic Urinary, were reported in the recommended dose of 5 mg daily 3% more side effects in patients with Aerius tablets, when patients were treated with Placebo."</seg>
<seg id="1796">"in a multi-dose study, in which up to 45 mg of the loratadin (Neunconventional clinical dose) were observed, were observed in clinical effects."</seg>
<seg id="1797">"in two single dose studies, Aerius lyophilisate was to take well to take well; this was documented by clinical laboratory results, medical examinations, vitamins and EKG interval data."</seg>
<seg id="1798">"in the framework of a clinical study with multiple methods, in the Despatadin in a dosage of up to 20 mg. a day of up to 20 mg daily, was described."</seg>
<seg id="1799">"in a clinical trial study, in the Despatadin in a dosage of 45 mg daily (the Neunites of clinical dose) over ten days, the extension of the QTc interval is applied to the QTc interval."</seg>
<seg id="1800">In controlled clinical trials was found in the recommended dosage of 5 mg daily.</seg>
<seg id="1801">"at a 17 single dose-study with adults, Despatadin 5 mg no influence on standard - measuring sizes of the river or the tasks which are connected with the airplane."</seg>
<seg id="1802">"in patients with allergic rhinitis, Aerius tablets were effective in the lens of symptoms such as Niesen, nasal secretion and juices of the nose, Juckish, flow and redness of the eyes as well as Juckery on the palate."</seg>
<seg id="1803">"* Understand the competitive environment, the market's major players and leading brands; * Use five-year forecasts to assess how the market is predicted to develop."</seg>
<seg id="1804">"18 In a pharokinetics study, which were comparable to patients with general seasonal institutions, were comparable to 4% of patients a higher concentration of Desloratadin."</seg>
<seg id="1805">Food has no significant influence on auc and Cmax of Aerius lyn from 2.5 to 4 hours and Tmax of 3-OH-Desloratadin from 4 to 6 hours.</seg>
<seg id="1806">Gelatin Mannitol Ache am (E 951) Polacama in-Kalium Colour - Opatint Red (E 172) and Hypromatism (E 464)</seg>
<seg id="1807">"an Aerius 2.5 mg melt each day in the mouth, to initiating the symptoms of allergic rhinitis (including intermitment and persist) and Urutaria (see under section 5.1)."</seg>
<seg id="1808">"two Aerius 2,5 mg melt tabletins once every day in the mouth, to initiating the symptoms of allergic rhinitis (including intermitment and persist) and Urinary (see under section 5.1)."</seg>
<seg id="1809">There is restricted experience from clinical trials for the effectiveness of Despatadin in adolescents from 12 to 17 years (see sections 4.8 and 5.1)</seg>
<seg id="1810">"immediately before the application needs to be carefully opened, and the dose of the melt ends without them to damaged."</seg>
<seg id="1811">The effectiveness and inaccuracies of Aerius 2.5 mg melt tabletins during treatment of children under 6 years were not been proven.</seg>
<seg id="1812">The total stiffness of the side effects between the Despatadine siup- and the Placeboggroup was the same and important for adult patients.</seg>
<seg id="1813">"during the recommended dose, Aerius melt filtration as biogenic equivalent to the Aerius 5 mg of conventional tablets, and the Aerius 5 mg lysat to inscri- formulation of Desloratadin."</seg>
<seg id="1814">"in the framework of a clinical study with multi-clinical study, in the Despatadin in a dosage of up to 20 mg daily over 14 days, was no statistics or clinically significant or clinically."</seg>
<seg id="1815">"in case of a single dose-study with adults, Despatadin 5 mg no influence on standard - measuring sizes of the river or the tasks which are connected with the airplane."</seg>
<seg id="1816">"the spread of this bad formulation of phenotyps was comparable to adult (6%), and under Black (adults 18%, children 16%), the safety profile of these patients were not contradicted by the general population."</seg>
<seg id="1817">"there are 5 mg of conventional tablets or Aerius 5 mg of conventional tablets or Aerius 5 mg lysat to take the formulations of biosis."</seg>
<seg id="1818">Aerius 2.5 mg tablets were examined in conjunction with the Dosisfines studies in conjunction with the Dosisfines studies with children which support 2.5 mg dosage for children from 6 to 11 years.</seg>
<seg id="1819">Food has no significant influence on auc and Cmax of Aerius Aerius lyn from 2.5 to 4 hours and Tmax of 3-OH- Despatadin from 4 to 6 hours.</seg>
<seg id="1820">"the total analysis of the preclinical and clinical test results for the melt filtration, that this formulation is an ineffective risk for local Irritations at clinical application."</seg>
<seg id="1821">Microcrystalline cellulose lipolymethylmethylmethylmethylmethylmethacrylate polyethylene glyphylmethacrylate polyciumdioxide iron oxide Mannitol Aperate (E951) aroma Ty Fran</seg>
<seg id="1822">The cold formatted foil is made of polyvinylchloride (PVC) polyamide (OPA) film. laminated in polyvinylchloride (PVC) film.</seg>
<seg id="1823">"an Aerius 5 mg melzette once daily in the mouth, to initiating the symptoms of allergic rhinitis (including intermitment and persist) and Urinary (see under section 5.1)."</seg>
<seg id="1824">"during the recommended dose, Aerius 5 mg melamine as biogenic equivalent to the Aerius 5 mg conventional tablets, and the Aerius 5 mg lysat to inscri- formulation of Desloratadin."</seg>
<seg id="1825">"in the framework of a clinical study with multiple methods, in the Despatadin in a dosage of up to 20 mg. a day of up to 20 mg daily, was described."</seg>
<seg id="1826">"at a 30 individual dose-study with adults, Despatadin 5 mg no influence on standard - measuring sizes of the river, including the reinforcement of subjective resistance or the tasks which are connected with the airplane."</seg>
<seg id="1827">"in patients with allergic rhinitis, Aerius tablets were effective in the lens of symptoms such as Niesen, nasal secretion and juices of the nose, Juckish, flow and redness of the eyes as well as Juckery on the palate."</seg>
<seg id="1828">In single dose of Aerius 5 mg melamine with Aerius 5 mg conventional tablets or Aerius 5 mg lyrical tablets or Aerius 5 mg lyric acid to take the formulations of biosis.</seg>
<seg id="1829">"the total analysis of the preclinical and clinical test results for the melt filtration, that this formulation is an ineffective risk for local Irritations at clinical application."</seg>
<seg id="1830">"safety of Despatadin for children between 2 and 11 years, the limited metabolic is identical with children, the normal metabolic."</seg>
<seg id="1831">This medicine contains Sorbitol; therefore patients should not take patients with chronic problems of a fructance, glucose metabolism or a Saccharase-Isomaltase inhibitors. "</seg>
<seg id="1832">The total number of side effects of the side effects of children between 2 and 11 years was similar to the Despatadin group like at the Placebo Group.</seg>
<seg id="1833">"when small children between 6 and 23 months, the most frequent adverse side effects were reported on the most common side effects on the most common side effects (3.2%), fever (2.3%) and stroke (2.3%)."</seg>
<seg id="1834">An additional study were observed in an additional study by 2.5 mg vloratadin solution to take a side effects in patients at age between 6 and 11 years.</seg>
<seg id="1835">"during the recommended cans, the plasma concentration of Desloratadin (see under section 5.2) in the children and adult population comparable."</seg>
<seg id="1836">In controlled clinical trials was found in the recommended dosage of 5 mg daily for adults and teenagers.</seg>
<seg id="1837">"in addition to the established classifications in seasonal and permissible, can be allergic to the duration of the symptoms as well as in intermitan allergic Rhinitis and"</seg>
<seg id="1838">"* Understand the competitive environment, the market's major players and leading brands; * Use five-year forecasts to assess how the market is predicted to develop."</seg>
<seg id="1839">"it is comparable to adults (6%) and children between 2 and 11 years (6%) and in both Populations bigger at Black (18% adults, 16% children) as at Kaukasians (2% adults, 3% children)."</seg>
<seg id="1840">"as Aerius solution to take the same concentration of Desloratadin, was necessary to expect a Biofeedback study and it is necessary to expect the syrup and tablets."</seg>
<seg id="1841">In various individuals studies showed that AUC- and Cmax values of Desloratadin in the recommended doses were comparable to those of adults who were Deseratadin-Sirup in a dosage of 5 mg.</seg>
<seg id="1842">"Sorbitol, propylene glycol, Sucralose E 955, Hypromeric E 2910, sodium and artificial flavours (Bubble-Gum), water-free Citron acid, sodium nitedate (Ph.D.), straight water."</seg>
<seg id="1843">"Aerius solution will take advantage of 30, 50, 60, 100, 120, 120, 120, 150, 150, 225 and 300 ml in type III Braunglasses with a multi-shaped polyethylene layer."</seg>
<seg id="1844">All packing sizes except the 150 ml packaging size are offered with a measuring spoon with markers for dosing of 2.5 ml and 5 ml.</seg>
<seg id="1845">The 150 ml packaging size is a measuring spoon or a application insert for insertion of 2.5 ml and 5 ml.</seg>
<seg id="1846">"after the extension of approval, the approval of the approval shall be updated regularly on the accidents of a drug using all two years, except it will be a bit of the CHMP."</seg>
<seg id="1847">1 movie screenings 2 film tabletins 5 film tabletins 10 film tabletins 30 film tabletins 30 film tabletins 30 film tabletins 30 film tabletins 40 film tabletins 40 film tabletins 40 film tabletins 40 film tabletins 40 film tabletins 40 film tabletins 40 film tabletins 40 film tabletins 40 film tabletins 40 film tabletins 40 film tabletins 40 film tabletins 40 film tabletins 40 film tabletins 40 film tabletins 40 film tabletins 40 film tabletins 40 film tabletins 40 film tabletins 40 film tabletins 40 film tabletins 40 film tabletins 40 film tabletins 40 film tabletins 40 film tabletins 40 film tabletins 40 film tabletins 40 film tabletins 40 film tabletins 40 film tabletins 40 film tabletins 40 film tabletins 40 film tabletins 40 film tabletins 40</seg>
<seg id="1848">1 movie screenings 2 film tabletins 5 film tabletins 10 film tabletins 30 film tabletins 30 film tabletins 30 film tabletins 30 film tabletins 40 film tabletins 40 film tabletins 40 film tabletins 40 film tabletins 40 film tabletins 40 film tabletins 40 film tabletins 40 film tabletins 40 film tabletins 40 film tabletins 40 film tabletins 40 film tabletins 40 film tabletins 40 film tabletins 40 film tabletins 40 film tabletins 40 film tabletins 40 film tabletins 40 film tabletins 40 film tabletins 40 film tabletins 40 film tabletins 40 film tabletins 40 film tabletins 40 film tabletins 40 film tabletins 40 film tabletins 40 film tabletins 40 film tabletins 40 film tabletins 40 film tabletins 40 film tabletins 40 film tabletins 40 film tabletins 40</seg>
<seg id="1849">Sirup 30 ml with 1 measurement laps 50 ml with 1 measuring spoon 150 ml with 1 measuring spoon 150 ml with 1 measuring spoon 150 ml with 1 measuring spoon 150 ml with 1 measuring spoon 300 ml with 1 measuring spoon 300 ml with 1 measuring spoon 300 ml with 1 measuring spoon 150 ml with 1 measuring spoon</seg>
<seg id="1850">30 ml with 1 measuring spoon 50 ml with 1 measuring spoon 150 ml with 1 measuring spoon 150 ml with 1 measuring spoon 150 ml with 1 measuring spoon 150 ml with 1 measuring spoon 150 ml with 1 measuring spoon 300 ml with 1 measuring spoon 300 ml with 1 measuring spoon 150 ml with 1 measuring spoon 150 ml with 1 measuring spoon</seg>
<seg id="1851">"1 dose Lyophilisate to take 3 doses Lyric lisle to take 3 cans, Lyric lisle to take 3 cans Lyric lisle to take 3 cans Lyric lisle to take 3 cans Lyric lisle to take 3 cans Lyric lisle to take 3 cans Lyric lisle to take 3 cans Lyric lisle to take 3 cans Lydia."</seg>
<seg id="1852">"5 melt-tabletins 6 melting tabletins 15 melt-tabletins, 60 melt-tabletins 60 enamel tabletins 60 enamel tabletins 60 enamel tabletins 60 enamel tabletins 60 enamel tabletins 60 enamel tabletins 60 enamel tabletins 60 enamel tabletins 60 enamel tabletins 60 enamel tabletins 60 enamel tabletins 60 enamel tabletins 60 enamel tabletins 60 enamel tabletins 60 enamel tabletins 60 enamel tabletins 60 enamel tabletins 60 enamel tabletins 60 enamel tabletins 60 enamel tabletins 60 enamel tabletins 60 enamel tabletins 60 enamel tabletins 60 enamel tabletins 60 enamel tabletins 60 enamel tabletins 60 enamel tabletins 60 enamel tabletins 60 enamel tabletins 60 enamel tabletins 60 enamel tabletins 60 enamel tabletins 60 enamel tabletins 60 enamel tabletins 60 enamel tabletins 60 enamel tabletins 60 enamel tabletins 60 enamel tabletins 60 enamel tab</seg>
<seg id="1853">"30 ml with 1 measuring spoon 50 ml with 1 measuring spoon 150 ml with 1 measuring spoon 150 ml with 1 measuring spoon 150 ml with 1 measuring spoon 150 ml with 1 measuring spoon 150 ml with 1 measuring spoon 300 ml with 1 measuring spoon 300 ml with 1 measuring spoon 150 ml with 1 measuring spoon 150 ml with 1 measuring spoon 150 ml with 1 measuring spoon 150 ml with 1 measuring spoon 150 ml with 1 measuring spoon 150 ml with 1 measuring spoon 150 ml with 1 measuring spoon 150 ml with 1 measuring spoon 150 ml with 1 measuring spoon 150 ml with 1 measuring spoon 150 ml with 1 measuring spoon 150 ml with 1 measuring spoon 150 ml with 1 measuring spoon 150 ml with 1 measuring spoon 150 ml with 1 measuring spoon 150 ml with 1 measuring spoon 150 ml with 1 measuring spoon 150 ml with 1 measuring spoon 150 ml with 1 measuring spoon 150 ml with 1 measuring spoon 150 ml with 1 measuring spoon 150 ml with 1 measuring spoon 150 ml with 1 measuring spoon 150 ml with 1 measuring spoon 150 ml with 1 measuring spoon 150 ml with 1 measuring spoon 150 ml with 1 measuring spoon 150 ml with 1 measuring spoon 150 ml with 1 measured</seg>
<seg id="1854">Pregnancy and lactation ask during pregnancy and lactation before taking any medicines or pharmacist for advice.</seg>
<seg id="1855">"by using machines on the recommended dosage and use of machines to use in the recommended dosage is not so that Aerius leads to Benommenities, or to reduce the attention."</seg>
<seg id="1856">"if you have told from your doctor you have said that you have an Intolerance against certain sugar, ask your doctor before you use this medicine."</seg>
<seg id="1857">"for the treatment period, your doctor will find the type of allergic reactions, under which you suffer and will take how long you take care of Aerius."</seg>
<seg id="1858">"if your allergic Rhinitis intermites (the symptoms of less than 4 days per week or less than 4 weeks long), your doctor will recommend you to a treatment system which is dependent on your current disease."</seg>
<seg id="1859">"if your allergic Rhinitis (the symptoms of 4 or more days per week, and more than 4 weeks long), your doctor can recommend you a longer lasting treatment."</seg>
<seg id="1860">"if you have forgotten your dose of Aerius, If you have forgotten your dose time, take it soon as possible, and follow the normal treatment plan."</seg>
<seg id="1861">"71 In the market of Aerius was very rare in cases of severe allergic reactions (difficulty in breathing, pipes of breathing, Judge, nuts and pigs) and skin."</seg>
<seg id="1862">"more than cases of heart failure, heart attack, abdominal pain, stomach pain, pain, muscle pain, urgency, muscle pain, asthucinations, pain, and unusual liver function, is also very rare."</seg>
<seg id="1863">"in the original film (contains Lactosi Monohydrat, Hygol 400, indigol 400, indigocarmin (E 132), colourless film (contains hypromatism, Macrogol 400), Carnaun-wax, light-wax wax."</seg>
<seg id="1864">"utf-8 (Unicode, worldwide) utf-16 (Unicode, worldwide) utf-16 (Unicode, worldwide) utf-16 (Unicode, worldwide) utf-16 (Unicode, worldwide) utf-16 (Unicode, worldwide)"</seg>
<seg id="1865">"Aerius Sirup is shown for children aged between 1 and 11 years, young people (12 years and older) and adults, older people included."</seg>
<seg id="1866">Important information about certain other components of Aerius you should not use Aerius syrup if you are allergic to the color of E 110.</seg>
<seg id="1867">"if you are informed your doctor, you have a disadvantage compared to some sugar types, please contact your doctor before you use this medicine."</seg>
<seg id="1868">"if the syrup can be used to use scalable to use scalding, you can use this alternatively to increase the corresponding quantity."</seg>
<seg id="1869">"for the treatment period your doctor will find the type of allergic reactions, under which you suffer and will then set how long you take care of Aerius syrup."</seg>
<seg id="1870">"however, with children under 2 years of age, fever and stroke, frequent side effects, while at adults fatigue, mouth, and headache and headache."</seg>
<seg id="1871">"after the market of Aerius, very rare in cases of severe allergic reactions (difficulties when breathing, pipes of breathing, Judge, nuts and pigs)."</seg>
<seg id="1872">"77 Aerius Sirup is available in bottles with child safe lock flap with 30, 50, 60, 100, 120, 150, 225 and 300 ml."</seg>
<seg id="1873">Aerius lyophilisate to take the symptoms of allergic rhinitis (through an allergy sufferation of the nasal or house dust particles).</seg>
<seg id="1874">When taking care of Aerius lyophilisate to take care of food and drinks Aerius lyrical lisate to take care of water or other liquid.</seg>
<seg id="1875">"for the treatment period your doctor will find the type of allergic reactions, under which you suffer and then set how long you suffer Aerius lysis."</seg>
<seg id="1876">"81 If you have forgotten your dose, you have forgotten your dose on time, take it as soon as possible, and follow the normal treatment plan."</seg>
<seg id="1877">"after the market of Aerius, very rare in cases of severe allergic reactions (difficulties when breathing, pipes of breathing, Judge, nuts and pigs)."</seg>
<seg id="1878">"Aerius Lyric lisses is individually in Blisterings with 1, 2, 3, 5, 10, 10, 15, 20, 20, 50, 50 or 100 cans of the Lyric lisats."</seg>
<seg id="1879">Aerius melt the symptoms for allergic rhinitis (through an allergy sufferation of the nasal or house dust or house dust - allergy).</seg>
<seg id="1880">When taking aberius melt together with food supplements and drinks Aerius melt filtration needs not be taken with water or other liquid.</seg>
<seg id="1881">"for the treatment period your doctor will find the type of allergic reactions, under which you suffer and then set how long you suffer Aerius melt-tabletins."</seg>
<seg id="1882">"86 If you have forgotten your dose, you have forgotten your dose on time, take it as soon as possible, and follow the normal treatment plan."</seg>
<seg id="1883">"melt filtration is individually in Blisterpackings with 5, 6, 10, 12, 15, 20, 20, 50, 60, 60, 90, and 100 cans."</seg>
<seg id="1884">When taking aberius melt together with food supplements and drinks Aerius melt filtration needs not be taken with water or other liquid.</seg>
<seg id="1885">"if you have forgotten your dose of aserius melt if you have forgotten your dose time, take it soon as possible, and follow the normal treatment plan."</seg>
<seg id="1886">"after the market of Aerius, very rare in cases of severe allergic reactions (difficulties when breathing, pipes of breathing, Judge, nuts and pigs)."</seg>
<seg id="1887">"Aerius solution for use is shown for children aged between 1 and 11 years, young people (12 years and older) and adults, older people included."</seg>
<seg id="1888">"if the solution to take a application is placed, you can use, alternatively, you can use this alternatively to take advantage of the appropriate solution."</seg>
<seg id="1889">"for the treatment period your doctor will find the type of allergic reactions, under which you suffer and will take how long you want to take care of Aerius solution."</seg>
<seg id="1890">"however, with children under 2 years of age, fever and stroke have frequent side effects during adults, mouth, dry and headache and headache."</seg>
<seg id="1891">"97 Aerius solution for use is available in bottles with child safe lock flap with 30, 50, 60, 100, 120, 150, 225 and 300 ml."</seg>
<seg id="1892">The 150 ml packaging size is a measuring spoon or a application injection moulding for insertion of 2.5 mln and 5 ml cans.</seg>
<seg id="1893">"June 2008, Novartis Vaccines and Diagnostics S.r.l. to the Committee for Humanitarian H5N1-influenza at adults and older people."</seg>
<seg id="1894">"Aflunov should be caused by adults and older people to protect against Grippe, which is caused by the tribe (type) H5N1 of the influenza virus."</seg>
<seg id="1895">"this is a special kind of vaccine, which could cause a future pandemic which could cause a future pandemic, to protect a future pandemic."</seg>
<seg id="1896">"a Grippepandemie occurs when a new tribe of Grippevirus, who can spread out slightly by man, because people still have no immunity (no protection)."</seg>
<seg id="1897">"after completion of the vaccine, the immune system can be used in the vaccine for the vaccination of the Grippevirus as a" physical art "and forms of antibodies."</seg>
<seg id="1898">This is the immune system later in a contact with a Grippevirus this pedigree.</seg>
<seg id="1899">"afterwards the membrane of the virus with the" surface treatment "(proteins on the membrane surface, the human body as a body of foreign bodies) separated, cleaned and as a component of vaccine."</seg>
<seg id="1900">A inspection of some of the study group showed that the study was not carried out according to the "good clinical practice" (GCP).</seg>
<seg id="1901">"in addition, the scope of the clinical data base for the evaluation of the vaccine is not made in order to fulfil the requirements of the guidelines of the EMEA for preventive vaccines."</seg>
<seg id="1902">Should you need to participate in a clinical trial and more information on your treatment please contact your doctor.</seg>
<seg id="1903">"if you wish for more information about the basis of the recommendations of the CHMP, please read the scientific discussion (also part of the EPAR)."</seg>
<seg id="1904">"in combination with other anti-viral medicines for treatment of adults and children over four years, which are caused by human immunogenesis of type 1 (HIV-1) which are infected with the immune system."</seg>
<seg id="1905">"for patients who can not swallow as a solution, but this can not be taken together with Ritonavir, since the safety of this combination was not investigated."</seg>
<seg id="1906">"if the physician should be checked only if the doctor has checked, the anti-viral medicines of the patient has taken the patient, and the probability that the virus has to be found on the drugs."</seg>
<seg id="1907">The recommended dose for patients over twelve years is 600 mg twice a day that will be taken together with twice daily 100 mg rionavir and other antiviral medicines.</seg>
<seg id="1908">For children between four and twelve years and in patients with a body weight of less than 50 kg the recommended dose of Ageneric ase after body weight.</seg>
<seg id="1909">In combination with other antiviral medicines the HIV-quantity in blood and keeps them on a low level.</seg>
<seg id="1910">"it is not to healing, however, the damage of the immune system and the development of AIDS related infections and diseases."</seg>
<seg id="1911">"in combination with other antiviral medicines, however without Ritonavir, in two main studies with 736 HIV-inexperienced adults, which were not treated with proteasant."</seg>
<seg id="1912">"with low sensitivity of Ritonavir, it was taken by 206 adults who were taken by 206 adults who were taken before proteasseh with other proteasites."</seg>
<seg id="1913">Main indices for the effectiveness was the share of patients with non-effective concentrations of HIV in blood (viral load) or the change of viral load according to treatment.</seg>
<seg id="1914">"in the studies with patients that had previously made no proteasant, after 48 weeks after the treatment of a virus under 400 copies / ml as under Placebo, but Ageneric is less effective than indinavir."</seg>
<seg id="1915">"for children, however, the virus may also treated the virus from the children who were treated with proteasseh, but only very few to the treatment."</seg>
<seg id="1916">"in the study with adults who had been treated with proteasites were treated, treated with Ritonavir, drugs asceral to 16-weekly treatment as effective as other proteaselmer:"</seg>
<seg id="1917">"in patients with HIV, against four other proteaselmer, it came to a more powerful waste of the virus from the virus after four weeks."</seg>
<seg id="1918">"the most common side effects of Ageneric (observed in more than 1 of 10 patients) are headaches, Diarrhö (penetration), bowls (nausea), vomiting, skin irritation and Fatigue (fatigue)."</seg>
<seg id="1919">"2 / 3 Anoase must not be applied in patients, which may be sensitive (allergic) against amateavir or one of the other components."</seg>
<seg id="1920">"ascerase may also be applied to patients who are used for treatment of depression, or medicines that are harmful to treatment of depression, or medicine that are harmful in high concentrations in blood health."</seg>
<seg id="1921">"as in other medicines against HIV, the risk of a lianaystrophie (changes in distribution of grain tissue) or an immune system (symptoms of infection that are caused by relaxing immune system)."</seg>
<seg id="1922">The Committee for Humanities (CHMP) was to the conclusion that the benefits of Ageneric drugs are used in combination with other anti-viral medicines and children over four years in combination with other antiviral medicines and children over four years to the risk.</seg>
<seg id="1923">Firm of the Year for Compliance Audits and Investigations Gibson Dunn & Crutcher Firm of the Year for Tax Gleiss Lutz</seg>
<seg id="1924">"if you have any queries, please contact us on Tel.: + 49 5764 318 444. or contact us per email. if you want to send us a question about this product, simply complete all the fields marked * and click" "Send". ""</seg>
<seg id="1925">"October 2000, the European Commission published the European Commission from Glaxo Group Limited: a permit for the Instruction of Ageneric, in the whole European Union."</seg>
<seg id="1926">Ageneric ase is used in combination with other antiviral medicines for treatment of HIV-1-, Proteaselmer (PI) -pre-treated adults and children from 4 years. "</seg>
<seg id="1927">"for usually, Ageneric capsules for the pharmacokinetics of Amphavir, together with low doses of Ritonavir (see sections 4.2 and 4.5)."</seg>
<seg id="1928">The use of Amacavir should be made under consideration of the individual viral resistance and the pretreatment of the patients (see section 5.1).</seg>
<seg id="1929">The bipheability of Amacavir is a solution to take 14% less than amicavir than capsule; therefore Ageneric capsules and solution for use on a milligram per milligram can't be exchangeable (see section 5.2).</seg>
<seg id="1930">"the recommended dose for Ageneric capsules is 600 mg amotavir twice daily, with 100 mg of Ritonavir twice daily in combination with other anti-viral medicines."</seg>
<seg id="1931">"2 If the generic capsules can be applied without the reinforced replacement of Ritonavir (booster), higher doses at Ageneric (1200 mg twice daily) are applied."</seg>
<seg id="1932">The recommended dose for Ageneric capsules amounts to 20 mg amateavir / kg body weight twice a day in combination with other anti-viral medicines until a day of the highest dose of 2400 mg amateavir which should not be exceeded (see section 5.1).</seg>
<seg id="1933">The pharokinetics, effectiveness and security of Ageneric ase in combination with low doses of Ritonavir or other proteasites were not investigated for children. "</seg>
<seg id="1934">"Ageneric ase is not recommended for the application for children under 4 years, because of the lack of data for discomfort and effectiveness (see Section 5.2)."</seg>
<seg id="1935">"based on the pharmacokinetics data, the dose of Ageneric capsules should be reduced to 450 mg twice daily and in patients with severe liver function on 300 mg twice daily."</seg>
<seg id="1936">The simultaneous application is to be used in patients with light or excessive liver function with caution when patients with severe liver function is contravenous (see section 4.3).</seg>
<seg id="1937">"Ageneric ase is not at the same time with medicines, which have a small therapeutic width and also substrate of the Cytochron P450-Isoenzyms 3A4 (CYP3A4)."</seg>
<seg id="1938">Intraocular lens concentration and a reduced therapeutic effect of Amacavir can not be applied (see section 4.5).</seg>
<seg id="1939">Patients should be aware that aphorically or any other antiviral therapy does not lead to a cure of HIV infection and that they can develop opportunistic infections or other complications of HIV infection.</seg>
<seg id="1940">The present anti-viral therapy including treatment with Ageneric ase does not prevent the risk of transfer from HIV to other by sexual contact or contamination with blood.</seg>
<seg id="1941">"(see section 4.2), (see section 4.2)."</seg>
<seg id="1942">Patients treated to chronic hepatitis B or C are treated with a antiretroviral combination therapy.</seg>
<seg id="1943">"in case of a simultaneous antiviral treatment of hepatitis B or C, please read the relevant information of this medicine."</seg>
<seg id="1944">Patients with pre-reduced risk function including a chronically active hepatitis is increased frequency of liver function under a antiretroviral combination therapy and should be monitored according to clinical practice.</seg>
<seg id="1945">The simultaneous use of Ageneric 3A4 (see section 4.5) is not recommended that the possible benefit of a treatment of systemic corrosion caused by the CYP3A4 size (see section 4.5).</seg>
<seg id="1946">"since the processing of HMG-CoA-Reinductase-Hemmer Lovastatin and Simvastatin was strongly dependent on the increased risk of myriad, including Rhabdomyolysis, is not recommended."</seg>
<seg id="1947">"4 For some medicines, the serious or life-threatening side effects, such as Carbazepin, phenytoin, phenytoin, tricyclical anti-depressive anti-inflammatory agent (under supervision of the International Standards Agency), are available for determination of the active substance concentration."</seg>
<seg id="1948">"in patients who take these medicines simultaneously, Ageneric gases can be less effective (see section 4.5)."</seg>
<seg id="1949">"due to the possibility of metabolic interactions with Amphavian can be changed, however, the information is not sufficient to estimate the type of interactions."</seg>
<seg id="1950">"if Methadon is given at the same time, the patient should be monitored at Opiatentric acid, especially if there are also low doses of Ritonavir."</seg>
<seg id="1951">"because of the potential risk of a toxicity, due to the high-propyl lycollosis of the Ageneric solution, these darts can be used for children under a age of four years, and should be applied with caution at certain other patient groups."</seg>
<seg id="1952">Abase should be set to duration 5. if a skin irritation of systemic or allergic symptoms or the mucous membranes are involved (see section 4.8).</seg>
<seg id="1953">Patients who received treatment of diabetes mellitus were reported on the appearance of diabetes mellitus, hyperglycemia or an expeening of an existing diabetes mellitus. "</seg>
<seg id="1954">Many of the patients had other diseases related to their therapy medications needed with the development of a diabetes mellitus or hyperglycemia.</seg>
<seg id="1955">"B. higher age, and with medicines - differentiated factors, such as a longer lasting anti-viral treatment and associated related macular disorders."</seg>
<seg id="1956">Patients were treated with proteasant patients (type A and B) which were treated with proteasites.</seg>
<seg id="1957">"in HIV-intra patients with severe immunotherapy, patients can develop a inflammatory reaction to the point of an anti-viral infection therapy (ART) a inflammatory reaction to chronic inflammatory conditions or deterioration of symptoms."</seg>
<seg id="1958">"although a multifactorial Etiology is accepted (including the use of corrooids, alcohol use, severe immunotherapy, particularly in patients with advanced HIV-disease and / or long-term use of a anti-viral combination therapy (ART)."</seg>
<seg id="1959">"CYP3A4 sub-strate with minimal therapeutic width of Ageneric, not at the same time with medicines that have a small therapeutic width, and also substrate of the Cytochron P450-Isoenzyms 3A4 (CYP3A4)."</seg>
<seg id="1960">"CYP2D6-substrate with small therapeutic width Ageneric methylated with Ritonavir may not be used together with medicines, whose active substances are mainly associated with CYP2D6 material and for increased plasmatism with serious and / or life-threatening side effects."</seg>
<seg id="1961">"it was shown that Rifampicin a 82% reduction in the auc of Amphavir causes, which can lead to a virological failure."</seg>
<seg id="1962">"in the attempt to increase the lower plasticity in combination with Ritonavir in combination with Ritonavir, very often unwanted effects on the liver."</seg>
<seg id="1963">Firm of the Year for Compliance Audits and Investigations Gibson Dunn & Crutcher Firm of the Year for Private Construction Luther</seg>
<seg id="1964">"if a patient already takes a patient, the Amacavian effect is possible to check the Viruslast and check the curial."</seg>
<seg id="1965">It is not necessary to use an Dosenoid for one of the medicine if they are finavir together with Amphavir. (see also Efavirenz below).</seg>
<seg id="1966">"508% increases, for Cmax, if Ritonavir (100 mg twice daily) is included in combination with Amphavir capsules (600 mg twice daily)."</seg>
<seg id="1967">Clinical trials were used in clinical trials were applied by 600 mg amateavir twice daily and Ritonavir 100 mg twice daily.</seg>
<seg id="1968">52% reduced if Amacavir (750 mg twice daily) in combination with Kaletra (400 mg BBinavir + 100 mg Ritonavir twice daily).</seg>
<seg id="1969">The Cmin values of Amphavir (600 mg twice daily) is reached approximately 40 to 50% lower than Amacavir (600 mg twice daily) in combination with 100 mg of Ritonavir twice daily.</seg>
<seg id="1970">"a docking recommendation for the simultaneous administration of Amphavir and Kaletra can not be given, however, it will not be known as the effectiveness and injustice of this combination is not known."</seg>
<seg id="1971">"there was no pharmacokineal study for use in combination with didanosin combination, however, due to the antaosin, however, due to the antaosin and abase at least one hour (see Antazida below)."</seg>
<seg id="1972">This is therefore a gift of Efavirenz in combination with Amacavir (600 mg twice daily) and Ritonavir (100 mg twice daily) and Ritonavir (100 mg twice daily).</seg>
<seg id="1973">"the treatment with Efavirenz in combination with Amacavir and Saquinavir is not recommended, because the exposition of both proteaselmer would be low."</seg>
<seg id="1974">The effect of Nevirapin on other proteaselmer and existing limited data, that Nevirapin the serum concentration of Amphavir may be lowers. "</seg>
<seg id="1975">"if these drugs should be used at the same time, caution is to be careful because Delavirdin is less effective or effective."</seg>
<seg id="1976">"if these medicines are used together, be careful; a thorough clinical and virological monitoring shall be made, as a precise predictive effect of the combination of Amacavir and Ritonavir to Delavirdin is difficult."</seg>
<seg id="1977">Firm of the Year for Private Construction Luther Firm of the Year for Employment Freshfields Bruckhaus Deringer Firm of the Year for Pharmaceuticals and Healthcare</seg>
<seg id="1978">"if it is needed for clinical reasons, Ripputin are required to take a reduction in the dosage of Ripputin on at least half of the recommended dose, although it is no clinical data."</seg>
<seg id="1979">Pharmacokinetics studies with Ageneric-ycycin combination with Erythromycin were not carried out but could be increased in the case of simultaneous administration.</seg>
<seg id="1980">The simultaneous application of twice daily 700 mg Ketoconazol once used to increase the cmax of Ketoconazol in the plasma by 25% and the auc (0-0) to the 2.7 mg Ketoconazol once a day without simultaneous use of Fosamprenavir.</seg>
<seg id="1981">"other drugs, which are listed below are listed below, including Substrate, Hemmer or Inductors of CYP3A4, if they are applied together with Ageneric 3A4."</seg>
<seg id="1982">Patients should therefore be applied to toxic reactions which are used with these medicines if they are used in combination with Ageneric ase.</seg>
<seg id="1983">"based on the data of other proteins, it is advisable that Antazida cannot be taken at the same time as Ageneric drugs."</seg>
<seg id="1984">"the simultaneous application of anti-vulsiva which are known as enzymes are known (phenytoin, phenobarbital, Carboniepin), with Amphavir can lead to a reduction of the plasmraspberries of Amphavir."</seg>
<seg id="1985">"the Serum concentration camp by Calciumigames, such as Amlodipin ,-pin ,-pin ,-pin and Verapamil can be increased by amateavir, which may increase the activity and toxicity of this medicine."</seg>
<seg id="1986">"in combination with Ageneric, the plasmaase can increase their plasma concentration and PDE5 inhibitors in combination with hypotubility, tendons and Priapism (see section 4.4)."</seg>
<seg id="1987">"in a clinical study, in the Ritonavir 100 mg capsules (4 times daily) over 7 days of subjects, the fluticasonprognosis at intranasal (4 times daily) over 7 days."</seg>
<seg id="1988">"as a result, the simultaneous gift of Ageneric methyl is not recommended, it is because that the possible benefit of a treatment for the risk of systemic corrosion test (see section 4.4)."</seg>
<seg id="1989">"in case of HMG-CoA-Reinductase inhibitors such as Lovastatin and Simvastatin, their verdict is strongly dependent on CYP3A4."</seg>
<seg id="1990">"since plasma treatment boosts the HMG CoA-Reinductase inhibitors, the combined application of this medicine is not recommended."</seg>
<seg id="1991">"it is recommended to be more frequent monitoring of therapeutic concentrations up to stabilization of the mirror, since the plasma concentration of Cycon porin, Rapamycin and Tacrolimus can be increased (see section 4.4)."</seg>
<seg id="1992">"(see section 4.3), while the use of Ageneric mizolam (see section 4.3), while the use of Ageneric midazolam are used."</seg>
<seg id="1993">Data for simultaneous use of parable Midazolam with other proteasolades have a possible increase in the plasma cutting of Midazolam.</seg>
<seg id="1994">"if methadon together with Amacavir, patients should be monitored at Opiatentric acid, especially if there are also low doses of Ritonavir."</seg>
<seg id="1995">"due to the low distortion of historical data, there is no recommendation to be given as the Amphavian - dose is to be adapted to the methylan at the same time."</seg>
<seg id="1996">"for simultaneous usage of warp or other oral anti antibodies together with Ageneric, a stronger control of the INR (International Standards Agency) is recommended for the possibility of a weakening or strengthening of anti-thrombotic effect (see section 4.4)."</seg>
<seg id="1997">The effect of an additional adoption of Ritonavir on hormonal contrast is not expected.</seg>
<seg id="1998">A careful supervision of therapeutic effects and side effects of trizyvoids antioxidants (for example Desipramin and Nortryptilin) is recommended by a gift of Ageneric (see section 4.4).</seg>
<seg id="1999">This medication may only be used during pregnancy only after careful consideration of the possible delivery for the mother compared to the potential risks for the foetus.</seg>
<seg id="2000">"in the milk, Amotavir-related substances have been demonstrated in the milk, but it is not known to know whether Amphavirus in men in the mother's milk."</seg>
<seg id="2001">"a reproduction study on weekly advice, which was included in Uterus to the end of the lactation in the Uterus until the end of the breastfeeding time, showed a reduced increase in the amount of time."</seg>
<seg id="2002">The further development of the period including fertile and reproductive capacity was not affected by the adoption of Amphavir to the womb.</seg>
<seg id="2003">"in addition to adults and children from 4 years, clinical trials was examined in combination with various other antiviral medicines."</seg>
<seg id="2004">"most with the Ageneric-treatment-related side effects were easy to germinate, early on and led to treatment."</seg>
<seg id="2005">"in many of these events, it is not valid if they are used in connection with taking care of Ageneric drugs or other at the same time in HIV treatment, or whether they are a result of the atrocities."</seg>
<seg id="2006">"most of the above side effects were taken from two clinical trials (PROAB3001, PROAB3006), in which with proteasites have not been received twice a day."</seg>
<seg id="2007">Events (degree 2 to 4) which were performed in connection with the study mediated and more than 1% of the patients were observed in connection with the treatment of laboratory alterations (degree 3 to 4).</seg>
<seg id="2008">"the antiretroviral combination therapy has been associated with a redistribution of the grains (liacystrophie) in HIV patients, including a loss of peripheral blood cells, hypertrophie of the breasts and dorsoy fat tissue, hypertrophie of the breasts and dorsot obesity."</seg>
<seg id="2009">"under 113 antiviral infection, which were treated with Amatic avir in combination with Lamivudin and Zidovudin on a medium duration of 36 weeks, was observed (&lt; 1%)."</seg>
<seg id="2010">"in the study PROAB 3006 consecutive patients under Amphavir 7 cases (11%) in comparison to 27 patients (11%) in comparison to 27 patients under Indinavir, in combination with various nuclear physis over a medium duration of 56 weeks (p &lt; 0.001)."</seg>
<seg id="2011">"the skin of skin is usually easy to grow, erythematulous or mastery of nature, with or without juices, and came across from two weeks without any treatment with Amacavir had to be broken."</seg>
<seg id="2012">"cases of osteoporosis, especially in patients with generally known risk factors, advanced HIV-disease or long-term use of anti-viral combination therapy (ART)."</seg>
<seg id="2013">"in HIV-intra patients with severe immunotherapy, patients can develop a inflammatory reaction at the point of an anti-viral infection therapy (ART)."</seg>
<seg id="2014">"with PI-treated patients, which have been observed in patients with low tolerated Ritonavir (100 mg twice daily), type and frequency of side effects (degree 3 to 4) and laboratory alterations (degree 3 to 4) and laboratory alterations (degree 3 to 4) and laboratory alterations (degree 3 to 4) and laboratory alterations (degree 3 to 4) and laboratory alterations (degree 3 to 4) and laboratory alterations (degree 3 to 4) and laboratory alterations (degree 3 to 4) and laboratory alterations (degree 3 to 4) and laboratory alterations (degree 3 to 4) and laboratory alterations (degree 3 to 4) and laboratory alterations (degree 3 to 4) and laboratory alterations (degree 3 to 4) and laboratory alterations (degree 3 to 4) and laboratory alterations (degree 3 to 4) and laboratory alterations (degree 3 to 4) and laboratory alterations (degree 3 to 4) and laboratory alterations (degree 3 to 4) and laboratory alterations (degree 3 to 4) and laboratory alterations (degree 3 to 4) and laboratory alterations (degree 3 to 4) and laboratory alterations (degree 3 to 4) and laboratory alterations (degree 3 to 4) and laboratory alterations (degree 3 to 4) and laboratory alterations (degree 3 to 4) and laboratory alterations (degree 3 to 4) and laboratory alterations (degree 3 to 4) and laboratory alterations (degree 3 to 4) and laboratory alterations (degree 3 to 4) and laboratory alterations (degree 3 to 4) and laboratory alterations (degree 3 to 4) and laboratory</seg>
<seg id="2015">"in the case of an overdose, the patient is to observe an intoxication (see section 4.8) if necessary, the necessary support measures are required."</seg>
<seg id="2016">Amacavir to the active centre of the HIV-1 protector and prevents the process of viral and Gag-polarity with the result of an education untouched, non-infectious Viruspartures. "</seg>
<seg id="2017">The antiviral activity of Amphavir in vitro against HIV-1 IIIB was examined both at akut and chronic cell cell lines (MT-4, CEM-CCRF, H9) as well as peripheral blood lymphocytes. "</seg>
<seg id="2018">The 50% inhibitory concentration (IC50) of Amacavir is located in the area of 0.012 to 0.008 µm to chronic cells and is 0.41 µm in chronically intra cells.</seg>
<seg id="2019">The connection between the activity of Amacavir against HIV-1 in vitro and inhibition of HIV-1 replication in humans is not defined.</seg>
<seg id="2020">Treatment: untreated clarity: very very small inclusions 0.71 cts á EUR 540.00 5.8x5.3 mm EUR59.60 &lt; &lt; BACK TO CATEGORY aquamarine</seg>
<seg id="2021">"in six ten of 434 anti-viral infection, the 700mg Fosamprenavir can be found daily in the study ESS100732, a virologariate was examined in the study ESS100732, with 14 isolate genotype."</seg>
<seg id="2022">"an genotypical analysis of insulates from 13 of 14 children, when a virologistic say in the 59-closed, with proteasites, the resistance of resistance, which were similar to adults."</seg>
<seg id="2023">"L10F / I / V, V11I, I13V, I50V, I50V, I50V, I62V, V82V, V82V, V8V, I85V, I85V, I85V, I85V, I85V, I85V, I85V, I85V, I85V, I85V, I85V, I85V, I85V, I85V, I85V, I85V, I85V, I85V, I85V, I85V, I85V, I85V, I85V, I85V, I85V, I85V, I85V, I85V, I85V, I85V, I85V, I85V, I85V, I85V, I85V, I85V, I85V, I85V, I85V, I85V, I85V, I85V, I85V, I85V, I85V, I85V, I85V, I85V, I85V, I85V, I85V, I85V, I85V, I85V, I85V, I85V, I85V, I85V, I85V, I85V, I85V, I85V, I85V, I85V, I85V, I85V, I85V, I85V, I85V, I85V, I85V, I</seg>
<seg id="2024">In the study APV30003 and its extension APV30005 and its extension APV30005 (700 mg / 100 mg Ritonavir twice daily: n = 107) with proteasticity of patients with virologistic say about 96 weeks.</seg>
<seg id="2025">"on genotype resistance based analyses Genotypical interpreter / Ritonavir / Ritonavir in patients with proteaselmer-resistant insulators."</seg>
<seg id="2026">"the current situation (July 2006) ANRS-AC-11-algorithm for the presence of mutations V32I + 147A / V / V / S / V / V / V / V / V, I84V and L90M, I62V, V82V, V82V and L90M, I62V, V82V and L90M, I62V, V82V and L90M, I62V, V82V, or at least 4 of the mutation of a virological resistance (resistance)."</seg>
<seg id="2027">"the conclusions in terms of certain mutations or mutation patterns can be subject to additional data, and it is recommended to draw the current interpretative systems to analyse the results of resistance tests."</seg>
<seg id="2028">In conjunction with the genotype or Foskavir / Ritonavir / Ritonavir / Ritonavir in patients with proteaselmer-resistant insulators.</seg>
<seg id="2029">"companies, the diagnostic resistance tests, have clinically clinically-photypical Cut-offs (release points) for FPV / rtv developed for interpretation of results of an resistance of resistance."</seg>
<seg id="2030">"each of these four with a reduced sensitivity to Amphavian associative genetically pattern creates a certain cross-resistance against Ritonavir, the sensitivity to Indinavir, the sensitivity to Indinavir and Saquinavir."</seg>
<seg id="2031">"there are currently data for cross-border resistance between Amphavir and other proteasites, either alone or in combination with other mutations."</seg>
<seg id="2032">"atacavir / Ritonavir (three of 25 Isolate), Indinavir / Ritonavir (three of 24 Isolate), Indinavir / Ritonavir (four of 24 Isolate), Indinavir / Ritonavir (four of 24 Isolate), Indinavir / Ritonavir (four of 24 Isolate), Indinavir / Ritonavir (four of 24 joules)."</seg>
<seg id="2033">"vice versa keeps its activity against some other proteaselmer-resistant isolate, which seems to be dependent on the number and the type of resistance mutations in the insulator."</seg>
<seg id="2034">The early removal of an excessive therapy is recommended to keep the cortation of a variety of mutations in limits that can affect the following treatment.</seg>
<seg id="2035">"in combination with Ritonavir 100 mg twice a day in combination with Ritonavir 100 mg twice daily, with Ritonavir (100 mg twice daily), with Ritonavir (NRTI) or a standard therapy (standard of care, SOC) with a PI, mainly with lower Ritonavir."</seg>
<seg id="2036">"one hundred three-sixty-sixty (n = 163) patients with subsequent virus sensitivity to Ageneric, at least one of another PI and at least one NRTI have been included in the partial study of PRO30017."</seg>
<seg id="2037">The primary analysis made the non-understatement of APV / Ritonavir in comparison to the SOC-PI Group in the plasma after 16 weeks.</seg>
<seg id="2038">"in the age of 2 to 18 years, it is based on two uncontrollable trials with a total of 288 HIV-aged children aged 2 to 18 years, of which 152 was treated with PI."</seg>
<seg id="2039">"in the studies, Ageneric solution to take-up and capsules in dosing of 15 mg / kg three times daily, 20 mg / kg times daily, 20 mg / kg twice daily, while the majority of patients 20 mg / kg twice daily."</seg>
<seg id="2040">The majority of PI patients were given at least one (78%) or two (42%) of which had been preserved at least one (78%) or two (42%).</seg>
<seg id="2041">"after 48 weeks, approximately 25% of the study carried out a plasma-1 RNA concentration &lt; 10,000 copies / ml and 9% &lt; 400 copies / ml at a meditate increase in CD4 cell number of 26 cells / mm ³ (n = 74) compared to the output value."</seg>
<seg id="2042">19 Bazarend to these data should be considered in therapy optimization with PI-treated children of the use of "untrusive" Ageneric.</seg>
<seg id="2043">"according to orisation, the average duration (Tmax) is to maximum Serum concentration of Amphavir about 1 to 2 hours for the capsule and about 0.5 to 1 hour for the solution."</seg>
<seg id="2044">"508% increased, for cmax to 30%, when Ritonavir (100 mg twice daily) together with Amphavir (600 mg twice daily)."</seg>
<seg id="2045">"the adoption of Amacavir with a meal leads to a 25% decrease in the auc, but has no effect on concentration of Amphavir 12 hours after dosage (C12)."</seg>
<seg id="2046">"therefore the minimum concentration in the steady state (Cmin, ss) of the food intake is influenced by the food intake and the rate of the Resorption."</seg>
<seg id="2047">"the higher distribution volume is approximately 430 l / kg at a weight of 70 kg (6 l / kg at a weight of 70 kg) and leaves a large distribution volume as well as a growing penetration of Amacavir from the blood circulation in the tissue."</seg>
<seg id="2048">"this change leads to a decrease in the total concentration of the active substance in plasma, with the amount of undisturbed amicavian, which is probably the active part of the active part."</seg>
<seg id="2049">"while the absolute concentration of undisturbed amplitude is constant, the percentage of the free active active part of the free active therapeutic concentration in the area of Cmax, ss up to Cmin, ss."</seg>
<seg id="2050">"therefore, it is necessary to use the CYP3A4 induced or inhibish or a substrate of CYP3A4; with caution, when they are given at the same time with Ageneric 3A4 (see sections 4.3, 4.4 and 4.5)."</seg>
<seg id="2051">"the gift of Ageneric capsules, either 20 mg / kg twice a day, leads to a similar daily Amacavir-Exposition as in adults with a dosage of 1200 mg twice daily."</seg>
<seg id="2052">Amphavir is made of the solution 14% less bipartitioning than from the capsules; therefore Ageneric solution and Ageneric capsules does not require on a milliliter basis.</seg>
<seg id="2053">It is also the renal Clearance of Ritonavir to neglect the impact of a kidney function to the Elimination of Amphavir and Ritonavir.</seg>
<seg id="2054">These treatment plants lead to Amacavir-Plastics which are comparable to healthy subjects after a dose of 1200 mg amateavir twice a day without simultaneous appointment of Ritonavir.</seg>
<seg id="2055">"in long-term studies for rabbits with Amphavian in mice and rats, with male animal cavir in mice and rats, the exposition of the Exposition on people, according to twice a daily gift of 1200 mg amateavir, said."</seg>
<seg id="2056">The 21 underlying mechanism for the formation of the hepatoid Adenome and Karzinome was not pursued and the relevance of these auditory effects for people is unclear.</seg>
<seg id="2057">"results appear ordered" "by relevance" "or" "by date" "(publication date),"</seg>
<seg id="2058">"in a standard battery from In-vivo- and in-vitro tests, the bacterial test test test test test test test test test test test test test test test test test test test test test."</seg>
<seg id="2059">This liver disease can be monitored at clinical everyday life by measurement of AST, ALT and the activity of alkaline phosphate. "</seg>
<seg id="2060">"however, clinical trials still have been observed in clinical trials, neither during the administration of Ageneric, nor after the treatment of treatment."</seg>
<seg id="2061">"studies on toxicity, which are treated from a age of 4 days, were treated both in the control and with Amphavirus animals a high degree of mortality."</seg>
<seg id="2062">"at a systemic plasmavera, the significant changes in patients were significantly higher (rats) or not significantly higher (rats) or not significantly higher (rats) or not significantly higher (rats), however, a number of slightly different changes, including thymuselongation and significant skeletal changes that were observed on a delayed development."</seg>
<seg id="2063">"24 If the generic capsules may be applied without the reinforced replacement of Ritonavir (booster), higher doses at Ageneric (1200 mg twice daily) are applied."</seg>
<seg id="2064">The recommended dose for Ageneric capsules amounts to 20 mg amateavir / kg body weight twice a day in combination with other anti-viral medicines until a day of the highest dose of 2400 mg amateavir which should not be exceeded (see section 5.1).</seg>
<seg id="2065">"the simultaneous application is used in patients with weak or light liver function with caution, when patients with severe liver function is a contravention (see section 4.3)."</seg>
<seg id="2066">"26 For some medicines, the serious or life-threatening side effects, such as Carbazepin, phenytoin, phenytoin, tricyclical anti-depressive anti-inflammatory conditions (under supervision of the International Standards Agency), are available for determination of the active substance concentration."</seg>
<seg id="2067">Abase should be set on duration 27. if a skin irritation of systemic or allergic symptoms or the mucous membranes are involved (see section 4.8).</seg>
<seg id="2068">"a higher risk of lianaystrophie has been associated with individual factors such as a higher age, and with medicines."</seg>
<seg id="2069">"it was shown that Rifampicin a 82% reduction in the auc of Amphavir causes, which can lead to a virological failure."</seg>
<seg id="2070">"508% increases, for Cmax, if Ritonavir (100 mg twice daily) is included in combination with Amphavir capsules (600 mg twice daily)."</seg>
<seg id="2071">The Cmin values of Amphavir (600 mg twice daily) is reached approximately 40 to 50% lower than Amacavir (600 mg twice daily) in combination with 100 mg of Ritonavir twice daily.</seg>
<seg id="2072">"a docking recommendation for the simultaneous administration of Amphavir and Kaletra can not be given, however, it will not be known as the effectiveness and injustice of this combination is not known."</seg>
<seg id="2073">"the treatment with Efavirenz in combination with Amacavir and Saquinavir is not recommended, because the exposition of both proteaselmer would be low."</seg>
<seg id="2074">"if these medicines are used together, be careful; a thorough clinical and virological monitoring shall be made, as a precise predictive effect of the combination of Amacavir and Ritonavir to Delavirdin is difficult."</seg>
<seg id="2075">"if it is needed for clinical reasons, Ripputin are required to take a reduction in the dosage of Riversutin on at least the half of the recommended dose of 31, although it is no clinical data."</seg>
<seg id="2076">"the Serum concentration camp by Calciumigames, such as Amlodipin, black-pin, cross-pin ,-pin and Verapamil can increase the activity and toxicity of this medicine."</seg>
<seg id="2077">"in a clinical study, in the Ritonavir 100 mg capsules (4 times daily) over 7 days of subjects, the fluticasonprognosis at intranasal (4 times daily) over 7 days."</seg>
<seg id="2078">"for simultaneous usage of warp or other oral anti antibodies together with Ageneric, a stronger control of the INR (International Standards Agency) is recommended for the possibility of a weakening or strengthening of anti-thrombotic effect (see section 4.4)."</seg>
<seg id="2079">The simultaneous administration of ortho-Novum 1 / 35 (0.035 methinylestradiol plus 1.0 mg Norethindron) led to a decrease of auc and Cmin by Amphavir at 22%.</seg>
<seg id="2080">"this medicine may only be used during pregnancy only after careful consideration of the possible user's teeth for the mother, compared to the possible risks for the Föp."</seg>
<seg id="2081">"a reproduction study on weekly advice, which was given by the establishment in Uterus to the end of the brewery in the Uterus until the end of the breastfeeding time, showed a reduced increase in the body weight at the time."</seg>
<seg id="2082">"in addition to adults and children from 4 years, clinical trials was examined in combination with various other antiviral medicines."</seg>
<seg id="2083">"in the case of an overdose, the patient is to observe an intoxication (see section 4.8) if necessary, the necessary support measures are required."</seg>
<seg id="2084">The antiviral activity of Amphavir in vitro against HIV-1 IIIB was examined both at akut and chronic cell cell lines (MT-4, CEM-CCRF, H9) as well as peripheral blood lymphocytes. "</seg>
<seg id="2085">The 50% inhibitory concentration (IC50) of Amacavir is located in the area of 0.012 to 0.008 µm in chronically intra cells and is 0.41 µm in chronically intra cells (1 µm = 0.050 µg / ml).</seg>
<seg id="2086">"vice versa keeps its activity against some other proteaselmer-resistant isolate, which seems to be dependent on the number and the type of resistance mutations in the insulator."</seg>
<seg id="2087">Why buy this report? * Get a detailed picture of the Baby and Child-specific Products market; * Pinpoint growth sectors and identify factors driving change;</seg>
<seg id="2088">"during the absolute concentration of undisturbed ambition, the percentage of the free active active part of the free active therapeutic concentration in the area of Cmax, ss up to Cmin, ss.."</seg>
<seg id="2089">"therefore, it is necessary to use the CYP3A4 induced or inhibish or a substrate of CYP3A4; with caution, when they are given at the same time with Ageneric 3A4 (see sections 4.3, 4.4 and 4.5)."</seg>
<seg id="2090">Also the renal Clearance of Ritonavir neglected to neglect the impact of a kidney function to the Elimination of Amphavir and Ritonavir.</seg>
<seg id="2091">"in long-term studies for rabbits with Amphavian in mice and rats, with male animal cavir in mice and rats."</seg>
<seg id="2092">The underlying mechanism for the formation of the hepatodes Adenome and Karzinome was not pursued and the relevance of these observed effects for people is unclear.</seg>
<seg id="2093">"results appear ordered" "by relevance" "or" "by date" "(publication date),"</seg>
<seg id="2094">"in a standard battery from In-vivo- and in-vitro tests, the bacterial test test test test test test test test test test results (Ames test), micro-Lymphom test, micro-Lymphom test, microfibre test on rats and chromosomal test test."</seg>
<seg id="2095">"studies on toxicity, which are treated from a age of 4 days, were treated both in the control and with Amphavirus animals a high degree of mortality."</seg>
<seg id="2096">These results can be extended that the metamortization paths are not fully mature so that Amacavir or other critical components of the formulation (z).</seg>
<seg id="2097">"in combination with other anti-viral medicines to treat HIV-1-intra, proteaselmer (PI) -pre-treated adults and children from 4 years."</seg>
<seg id="2098">"the use of Ritonavir" "oostercian" "Amenase solution was not liable for non-treating patients with PI-treated patients."</seg>
<seg id="2099">The bipheability of Amacavir is a solution to take 14% less than amicavir than capsule; therefore Ageneric capsules and solution for use on a milligram per milligram can't be exchangeable (see section 5.2).</seg>
<seg id="2100">Patients should stop as soon as they are able to stop the capsules with taking the solution to stop (see section 4.4).</seg>
<seg id="2101">The recommended dose for Ageneric solution is 17 mg (1.1 ml) Amphavir / kg body weight three times daily in combination with other anti-viral medicines until a day of the highest dosis of 2800 mg of Amacavir which should not be exceeded (see section 5.1).</seg>
<seg id="2102">"in addition, there must be no Dosisrecommended for the simultaneous use of Ageneric solution to take-up and low tolerated Ritonavir, this combination of these patients can be avoided."</seg>
<seg id="2103">"although a Dosisadjustments for Amphavian is not necessary for use, it is an application of Ageneric solution to patients with kidney disease (see section 4.3)."</seg>
<seg id="2104">"due to potential risk of a toxic reaction as a result of the high-propyl-lyshalts, Ageneric is a solution for small children and children under 4 years, with reduced liver function or liver disease in patients with reduced liver function or liver disease."</seg>
<seg id="2105">The simultaneous administration can lead to a competitive inhibiting of this medicine and possibly serious and / or life-threatening side effects like heart rhythm disorders (z.</seg>
<seg id="2106">Patients should be aware that aphorically or any other antiviral therapy does not lead to a cure of HIV infection and that they also continue to opportunistic infections or other complications of HIV infection.</seg>
<seg id="2107">The present anti-viral therapy including treatment with Ageneric ase does not prevent the risk 47 of transfer of HIV to other by sexual contact or contamination with blood.</seg>
<seg id="2108">"for some medicines, the serious or life-threatening side effects, such as Carbazepin, phenytoin, phenytoin, tricyclical anti-depressive anti-depressive anti-inflammatory agent (under supervision of the International Standards Agency), are available for determination of the active substance concentration."</seg>
<seg id="2109">Abase should be placed on the duration of systemic or allergic reactions or the mucous membranes (see section 4.8).</seg>
<seg id="2110">"a higher risk for a lithuystrophie has been developed with individual factors such as a higher age, and with medicines - 49-dependent factors, such as a longer lasting anti-viral treatment and associated disorders."</seg>
<seg id="2111">Patients were treated with proteasant patients (type A and B) which were treated with proteasites.</seg>
<seg id="2112">"it was shown that Rifampicin a 82% reduction in the auc of Amphavir causes, which can lead to a virological failure."</seg>
<seg id="2113">"508% increases, for Cmax, if Ritonavir (100 mg twice daily) is included in combination with Amphavir capsules (600 mg twice daily)."</seg>
<seg id="2114">"in combination with Ageneric, the plasmaase can increase its plasma concentration and PDE5 inhibitors in combination with hypotubility, tendons and Priapism (see Section 4.4)."</seg>
<seg id="2115">On the basis of the data to 54 other CYP3A4 inhibitors are expected to significantly higher plasma concentration of Midazolam expected.</seg>
<seg id="2116">The potential risk for humans is not well known. Ageneric solution for people may not be used during pregnancy (see section 4.3).</seg>
<seg id="2117">"in the milk, Amotavir-related substances have been demonstrated in the milk, but it is not known to know whether Amphavirus in men in the mother's milk."</seg>
<seg id="2118">"a reproduction study on weekly advice, which corresponds to the circulation in Uterus to the end of the lactation in the Uterus until the end of the breastfeeding time, showed a reduced increase in the 55 body weight at the time."</seg>
<seg id="2119">"in addition to adults and children from 4 years, clinical trials was examined in combination with various other antiviral medicines."</seg>
<seg id="2120">"in many of these events, it is not valid if they are used in connection with taking care of Ageneric drugs or other at the same time in HIV treatment, or whether they are a result of the atrocities."</seg>
<seg id="2121">Treatment: untreated clarity: very very small inclusions 0.71 cts á EUR 540.00 5.8x5.3 mm EUR59.60 &lt; &lt; BACK TO CATEGORY aquamarine</seg>
<seg id="2122">Early treatment of an unagull 60 therapy is recommended to keep the caffection of a variety of mutations in limits that can affect the following treatment.</seg>
<seg id="2123">62 Bazarend to these data should be considered in therapy optimization with PI-treated children of the use of "untrusive" Ageneric.</seg>
<seg id="2124">"the lower distribution volume is approximately 430 l (6 l / kg at a weight of 70 kg) and leaves a large Vetropic penetration of Amphavir from the blood circulation in the tissue."</seg>
<seg id="2125">The underlying mechanism for the formation of the hepatoid Adenome and Karzinome was not pursued and the relevance of these observed effects for people is unclear.</seg>
<seg id="2126">"at a systemic plasmavera, the significant changes in patients were significantly higher (rats) or not significantly higher (rats) or not significantly higher (rats) or not significantly higher (rats), however, a number of slightly different changes, including thymuselongation and significant skeletal changes that were observed on a delayed development."</seg>
<seg id="2127">"once you have any questions, please contact your doctor or pharmacist."</seg>
<seg id="2128">"if one of the most adverse effects like you. − If one of the linked side effects will be considerably reduced or you notice that not in this use information, please inform your doctor or pharmacist."</seg>
<seg id="2129">Your doctor will usually apply Ageneric capsules together with low doses of Ritonavir to improve the effect of Ageneric.</seg>
<seg id="2130">The use of Ageneric gases will be based on your doctor for you to handle individual viral resistance and treatment of treatment.</seg>
<seg id="2131">Inform your doctor if you suffer from above the above-mentioned disease or any of the above mentioned drugs.</seg>
<seg id="2132">"if your doctor is recommended that you use Ageneric capsules together with low doses of Ritonavir to the reinforcement of the effect (booster), ensure that you have read the use of the use information at Ritonavir."</seg>
<seg id="2133">There is no adequate information about the use of Ageneric capsules together with Ritonavir to use with Ritonavir to use with Ritonavir at age of 4 to 12 years or in general in patients with 50 kg body weight.</seg>
<seg id="2134">"therefore, it is important that you start the section"</seg>
<seg id="2135">"possibly you need to control additional factor in order to control the blood vessels, including patients that occur a antiretroviral combination therapy, a redistribution, Answer or a loss of grains occur."</seg>
<seg id="2136">"if you take certain medications that can lead to serious side effects, such as Carbazepin, pamycin, pamycin, pamycin, pamycin, pamycin, pamycin, tricyclical anti-depressive anti-depressive anti-depressive anti-depressive anti-depressive anti-depressive anti-depressive anti-depressive anti-depressive anti-depressive anti-depressive anti-depressive anti-depressive anti-depressive anti-depressive anti-depressive anti-depressive anti-depressive anti-depressive anti-depressive anti-depressive anti-depressive anti-depressive anti-depressive anti-depressive anti-depressive anti-depressive anti-depressive anti-depressive anti-depressive anti-depressive anti-depressive anti-depressive anti-depressive anti-depressive anti-depressive anti-depressive anti-depressive anti-depressive anti-depressive anti-depressive anti-depressive anti-depressive anti-depressive anti-depressive anti-depressive anti-depressive anti-depressive anti-depressive anti-depressive anti-depressive anti-depressive anti-depressive anti-depressive anti-</seg>
<seg id="2137">It is recommended that HIV-positive women have their children under no circumstances to avoid transfer of HIV.</seg>
<seg id="2138">"there were no studies on the influence of Ageneric machines, the ability to serve machines or the ability to serve machines."</seg>
<seg id="2139">Please take this medication only after return with your doctor if you suffer from a disregard to certain sugar.</seg>
<seg id="2140">"it is advisable that you take this more than one hour before or after Ageneric ase, the effects of Ageneric is reduced."</seg>
<seg id="2141">"the dose of Ageneric capsules is 600 mg twice daily, together with 100 mg rionavir twice daily in combination with other anti-viral medicines."</seg>
<seg id="2142">"if your doctor decides to take advantage of Ritonavir for you, you will need higher doses (1200 mg Amphavir twice daily)."</seg>
<seg id="2143">"85 Damit Ageneric ase is very important, it is very important that you have prescribed the entire day dose you take your doctor."</seg>
<seg id="2144">"if you have taken a greater amount of Ageneric dose, if you should have more than the correct dose of Ageneric dose, you should contact your doctor or pharmacist."</seg>
<seg id="2145">"if you have forgotten the taking of Ageneric ase If you have forgotten the taking of Ageneric ase, please take it as soon as you think about it, and then take the taking as previously."</seg>
<seg id="2146">"in the treatment of a HIV infection, it is not always possible to say whether the side effects can be taken by Ageneric, by other medicines that are taken at the same time or by the HIV disease."</seg>
<seg id="2147">"headaches, truncing feeling, disease, break, bubbles, bubbles (Romans, bladder or Juckery) - occasionally, the skin irritation of serious nature and to break this drug using force."</seg>
<seg id="2148">"depression, depression, sleep disturbances in the lips and in mouth, uncontrollable stomach, soft chairs, rise of certain liver enzymes, the transformers of the pancreas of the pancreas of amylase."</seg>
<seg id="2149">"increased blood values for sugar or cholesterol (a certain drains of a substance called Bilirubin swelling of the man, the lips and the tongue of the tongue, the lips and the tongue."</seg>
<seg id="2150">"this can cause fat loss of legs, poor, and in the face, a fat metabolism on the belly and in other internal organs, breast milk and fat burning in the neck (" perning ")."</seg>
<seg id="2151">Please inform your doctor or pharmacist if one of the adverse side effects or side effects that are not specified in this form information.</seg>
<seg id="2152">"therefore, it is important that you start the section"</seg>
<seg id="2153">"in some cases, a antiretroviral combination treatment can be obtained from bone tissue due to bone tissue due to preventing bone disease due to bone diseases."</seg>
<seg id="2154">"it is advisable that you take this more than one hour before or after Ageneric ase, the effects of Ageneric is reduced."</seg>
<seg id="2155">"94 Damit Ageneric ase is very important, it is very important that you have prescribed your doctor."</seg>
<seg id="2156">"if you have forgotten the taking of Ageneric ase If you have forgotten the taking of Ageneric ase, please take it as soon as you think about it, and then order them as previously."</seg>
<seg id="2157">"headaches, truncing feeling, disease, break, bubbles, bubbles (Romans, bladder or Juckery) - occasionally, the skin irritation of serious nature and to break this drug using force."</seg>
<seg id="2158">Please inform your doctor or pharmacist if one of the adverse side effects or side effects that are not specified in this form information.</seg>
<seg id="2159">"the dose of Ageneric capsules is 600 mg twice daily, together with 100 mg rionavir twice daily in combination with other anti-viral medicines."</seg>
<seg id="2160">"thus, Ageneric is a great benefit, it is very important that you have prescribed the entire day dose that will consult your doctor."</seg>
<seg id="2161">"if you have taken a larger quantities of abase, if you should have more than the correct dose of Ageneric dose, you should contact your doctor or pharmacist."</seg>
<seg id="2162">The use of Ritonavir's use of Ritonavir's use is not used in patients with proteasal patients with proteasant patients.</seg>
<seg id="2163">"for the application lower doses of Ritonavir (usually applied to the reinforcement of the effect of the effect [booster] of Ageneric capsules), together with Ageneric solution."</seg>
<seg id="2164">"Ritonavir solution to take part), or in addition to propylene glycol, while taking care of Ageneric solution (see also Ageneric ase)."</seg>
<seg id="2165">Your doctor will be able to take a side effects using the propylene glycol content of the Ageneric solution to be able to take in particular if you have kidney or liver disease.</seg>
<seg id="2166">"111 If you take certain medications that can lead to serious side effects, such as Carbazepin, cyytoin, cycjin, cycycin, pamycin, pamycin, cycycin, tricyclical anti-depressive anti-depressive anti-depressive anti-depressive anti-depressive anti-depressive anti-depressive anti-depressive anti-depressive anti-depressive anti-depressive anti-depressive anti-depressive anti-depressive anti-depressive anti-depressive anti-depressive anti-depressive anti-depressive anti-depressive anti-depressive anti-depressive anti-depressive anti-depressive anti-depressive anti-depressive anti-depressive anti-depressive anti-depressive anti-depressive anti-depressive anti-depressive anti-depressive anti-depressive anti-depressive anti-depressive anti-depressive anti-depressive anti-depressive anti-depressive anti-depressive anti-depressive anti-depressive anti-depressive anti-depressive anti-depressive anti-depressive anti-depressive anti-depressive anti-depressive anti-depressive anti-depressive anti-depressive anti-depressive anti-depressive</seg>
<seg id="2167">Ritonavir solution to take) or common Propylglycol (see Ageneric ase (see Ageneric ase).</seg>
<seg id="2168">Important information about certain other components of Ageneric solution to take the solution to take the solution to take the solution to take the solution to one side effects.</seg>
<seg id="2169">"propylene glycol can cause a range of side effects including crampings, Benommenities, heart rasen and the reduction of red blood cells."</seg>
<seg id="2170">"if you have forgotten the taking of Ageneric ase If you have forgotten the taking of Ageneric ase, please take it as soon as you think about it, and then take the taking as previously."</seg>
<seg id="2171">"headaches, truncing feeling, disease, break, bubbles, bubbles (Romans, bladder or Juckery) - occasionally, the skin irritation of serious nature and to break this drug using force."</seg>
<seg id="2172">"this can cause fat loss of legs, poor, and in the face, a fat metabolism on the belly and in other internal organs, breast milk and fat burning in the neck (" perning ")."</seg>
<seg id="2173">"the other components are propylenglycol (TPGS), Tocofersolan (TPGS), Acesulfam-Kalium, Saccharulfam-Kalium, polomenic acid, sodium nitrite acid, sodium nitrite acid, sodium nitrite acid, sodium nitrate."</seg>
<seg id="2174">"• In case of the treatment of treatment and the duration of treatment with Aldara, the cream has a weekly rate to a maximum of 16 weeks. • On small basal cell carcinoma, it is the cream of six weeks for a weekly rate of four weeks. • On small basal cell cycles, with four weeks break between the treatment cycles, three weeks."</seg>
<seg id="2175">"the cream is in front of the sleep on the affected skin surface, so that they will keep enough long (about eight hours) on the skin before they washed away."</seg>
<seg id="2176">"in all studies, Aldara has been compared with a Placebo (the same cream, but without the active substance). • Aldara was tested in four major studies at 923 patients with warts on 16 weeks."</seg>
<seg id="2177">"• Aldara has been studied at 724 patients with small basal cell carcinoma in two studies where patients were treated from six weeks, and all over a week or five times per week."</seg>
<seg id="2178">"• Aldara has been tested in two studies, in two studies at a total of 505 patients."</seg>
<seg id="2179">"• The results of the two studies in the Genenta patients were taken into account in all four major studies 15% to 52% compared with Aldara patients, but only 3% to 80% in terms with Aldara patients. • The results of the two studies in Basalophonic patients were taken into account of 0% to 3% in the Placebo Group."</seg>
<seg id="2180">The most common side effects of aldara (observed in more than 1 of 10 patients) are reaction to the use of the cream (pain or Jucketing).</seg>
<seg id="2181">"clinically typical, not hyperkeratorial candle (AKs) in face or on the scalp of immunity adults, if the size or the number of fractures the effectiveness and / or the acceptance of a cryotherapy limit and other topical treatment options."</seg>
<seg id="2182">"Monday, Wednesday and Friday or Tuesday, Thursday and Saturday) before the Zubettinger and 6 to 10 hours long."</seg>
<seg id="2183">"the treatment with Imiquimod-cream is so long forks, up to all the visible fetches in the genitration or periods of time, or to a maximum of 16 weeks per treatment period."</seg>
<seg id="2184">A interruptions in the above mentioned treatment should be carried out when intensive local infections occur (see section 4.4) or if the treatment area is observed.</seg>
<seg id="2185">"if at the follow-up investigation of 4 to 8 weeks after the second treatment period, any other treatment should be started (see section 4.4)."</seg>
<seg id="2186">"when a dose has been removed, solte the patient as soon as he / she will notice it and then continue with the usual therapeutic plan."</seg>
<seg id="2187">Imiquimod-cream is used in a thin layer and put into the rounded corners of the skin.</seg>
<seg id="2188">"in this patient, the benefits of a treatment can be carried out between the benefit of a treatment with Imiquimod and the associated risk of their autoimmune diseases."</seg>
<seg id="2189">"it should be carried out in these patients a loss of treatment between the benefit of a treatment with Imiquimod, and associated with a potential organs or Graft - reaction-related risk."</seg>
<seg id="2190">"in other studies, there were no daily authorizations, were observed in two cases of severe pain and a case with a circumcision."</seg>
<seg id="2191">"with an application of Imiquimod-cream in higher than the recommended cans (see section 4.2.) In rare cases, they have observed severe local skin supplements that have a treatment required and / or temporary physical health."</seg>
<seg id="2192">"in cases where such reactions on the output of the urinary tract, some women have difficulties during water to allow emergency drainage and treatment of the affected area."</seg>
<seg id="2193">For the application of Imiquimod-cream directly in the connection to the treatment of the treatment of the treatment of the treatment in the genitant and periodical area there are no clinical experience.</seg>
<seg id="2194">"the limited rate of HIV-positive patients, Imiquimod-cream has been shown in this patient group with HIV-positive patients, Imiquimod-cream."</seg>
<seg id="2195">"the treatment of basal cell carcinoma with Imiquimod within 1 cm um, the eye of the nose, the lips, or the hair loss was not investigated."</seg>
<seg id="2196">"local skin actions are often, but the intensity of these reactions takes in general during treatment or treatment of treatment with Imiquimod-cream."</seg>
<seg id="2197">"if it is necessary because of the discomfort of the patient, or due to the severity of the local skin actions, a treatment can be made of several days."</seg>
<seg id="2198">The clinical outcome of therapy can be obtained after the regeneration of the skin about 12 weeks after the end of treatment.</seg>
<seg id="2199">"at present, there is no data for long-term healing rates from over 36 months after treatment, should be drawn with superfixation of basal cell carcinoma."</seg>
<seg id="2200">"in patients with recurrence and pre-treated BCCs, no clinical experience is not recommended."</seg>
<seg id="2201">Data from an open clinical study indicates that in large tumors (&gt; 7.25 cm2) a lower probability of accumulation on Imiquimod therapy.</seg>
<seg id="2202">"however, Imiquimod was not investigated for the treatment of an eye on eye inside the nose or ears."</seg>
<seg id="2203">There are only very limited data about the application of Imiquimod to the treatment of Imiquimod to anatomical areas outside the face and head of the head.</seg>
<seg id="2204">"the available data on the subside and hands support the effectiveness in this application, therefore it is not recommended that such application is not recommended."</seg>
<seg id="2205">"local skin actions often occur, but these reactions usually usually occur during treatment of intensity or go after the treatment of therapy with Imiquimod-cream."</seg>
<seg id="2206">"if the local skin deposits of the patient can cause big discomfort or very strong, the treatment can be exposed to some days."</seg>
<seg id="2207">"from the data of an open-clinical study, patients with more than 8 AKP resulting in more than 8 AKP parameters, than in patients with less than 8 channels."</seg>
<seg id="2208">"due to the immunogenic properties, Imiquimod is applied to patients who receive a immunity treatment (see 4.4)."</seg>
<seg id="2209">"no direct or indirect effects on the pregnancy, embryonic effects of the embryonic development, the connection or postnatal development (see 5.3)."</seg>
<seg id="2210">"although neither after a unique application of quantifiable (&gt; 5ng / ml) can be reached, no recommendation to use during the downtime."</seg>
<seg id="2211">The most common and most likely or possibly with the application of Imiquimod-cream in related side effects were local reactions on the site of the treatment (33.7%) with Imiquimod patients.</seg>
<seg id="2212">The most commonly reported and possibly possibly with the application of Imiquimod-cream in connection with the side effects of the application location with a frequency of 28.1%.</seg>
<seg id="2213">Firm of the Year for Employment Freshfields Bruckhaus Deringer Firm of the Year for Insolvency Administration Schneider Geiwitz & Partner</seg>
<seg id="2214">"the most common, probably or possibly with the application of the Imiquimod-cream in the related side effects were a reaction at the application location (22% of the Imiquimod patients)."</seg>
<seg id="2215">The side effects caused by 252 to placeboy-treated clinical trials of the Phase III with Imiquimod-cream treated patients were listed below.</seg>
<seg id="2216">"according to testing methods of clinical trials, that it shows that in these placebo clinical trials with Imiquimod-cream is often used to local skin actions including by Imiquimod-cream frequently to local skin actions including by Imiquimod-cream (23%), Eating (23%), and oil (14%). (see section 4.4)."</seg>
<seg id="2217">"according to the clinical signs, these studies showed that in these studies with Imiquimod-cream with Imiquimod-cream with Imiquimod-cream with Imiquimod-cream with Imiquimod-cream with Imiquimod-cream (19%), heavy metals (19%)."</seg>
<seg id="2218">Clinical studies on clinical trials for the treatment of Imiquimod for the treatment of acute keratosis was determined by 0.4% (5 / 1214) at the treatment of treatment or in the surrounding area.</seg>
<seg id="2219">"there is a one-day trial of 200 mg × Imiquimod, which could lead to nausea, vomiting, headache, myalculine and fever."</seg>
<seg id="2220">"the clinically serious adrenal side effects, which according to several oral doses of &gt; 200 mg, in hypotony, which are attributed according to orphal or intravenous liquid."</seg>
<seg id="2221">In a pharmacokinetic investigation after the topical application of Imiquimod the increasing systemic concentrations of the Alphayod and other cytokines were demonstrated.</seg>
<seg id="2222">"in 3 reassed relevant phase 3 evaluations was shown that the effectiveness in relation to a complete adherence of the fetal treatment at a Imiquimod treatment has considerably improved at 16 weeks of a Placebo treatment."</seg>
<seg id="2223">"with 60% of the total 119% of the total 119% of Imiquimal patients, the patients were fully exploited, this was 20% of 105 with Placebo therapy in the case (95% CI)."</seg>
<seg id="2224">"in the case of 23% of 157 with Imiquimod, male patient could be achieved, compared to 5% of 161 with Placebo, male patients (95% CI):"</seg>
<seg id="2225">"the effectiveness of Imiquimar at five common application per week of 6 weeks was examined in two double blind, placebo-controlled clinical trials."</seg>
<seg id="2226">The targets were histologic. individual primary intraocular basal cell carcinoma with a minimum size of 0.5 cm2 and a maximum diameter of 2 cm.</seg>
<seg id="2227">"from an open, uncontrollable study study according to four years of data, that roughly 79.3% [95% CI (73.7%, 84.9%)] of all patients were healed and this will be 48 months long."</seg>
<seg id="2228">"the effectiveness of Imiquimod at three weeks time, in one or two treatment facilities of 4 weeks, interrupted by a four-flowering-treated period, was examined in two double blind, placebocontrolled clinical trials."</seg>
<seg id="2229">"the patients had been clinically typical, visible, discrete, not hyperkeratotic, not hyperkeratotic, not hypertulceration within a related 25 cm2 of the treatment of unhairs or in the face."</seg>
<seg id="2230">The year-year data from two combined observation studies show that patients with clinically heightened after a or two treatment facilities include a Rezidivrate of 27% (35 / 128 patients).</seg>
<seg id="2231">"in addition to the approved indications, actinic keratose and super fixation of basal cell carcinoma occur in pairs of paediatric patients with paediatric patients at paediatinate patients."</seg>
<seg id="2232">Deprecated: function ereg _ replace () is deprecated in / www / htdocs / w00cec0c / webEdition / we / include / we _ modules / object / we _ listview _ multiobject.class.php on line 296</seg>
<seg id="2233">The effectiveness of Imiquimetry could not be shown in these trials (3x / week for a period of ≤ 16 weeks).</seg>
<seg id="2234">A minimal systemic recording of 5% of Imiquimod-cream by the skin of 58 patients with acute keratosis was observed during three weeks after three weeks.</seg>
<seg id="2235">"the highest drug concentration in Serum at the end of the week 16 were observed between 9 and 12 hours after the end of the week 16, 0.2 and 1.6 ng / ml at the face (12.5 mg, 1 bag) and on the hands / arms (75 mg, 6 bags)."</seg>
<seg id="2236">The calculated half-time period was about 10times higher than the 2hourly half of the subcutaneous application in a former study; it has been extended to extended treatment of the drugs using the skin.</seg>
<seg id="2237">The data for systemic Exposition showed that the Resorption of Imiquimod has been low and comparable to patients at the age of 6 - 12 years and comparable to the patient with healthy adults and adults.</seg>
<seg id="2238">"in a four-monatite study, toxicity was significantly reduced to significantly reduce weight of 0.5 and 2.5 mg / kg KG, a four months long-guided study for the paint application have no similar effects when the mouse has no similar effects."</seg>
<seg id="2239">"a two-year-old study for carcinogenesis in mice were induced by three days per week, no tumors at the application location."</seg>
<seg id="2240">The corresponding mechanism is not known but because Imiquimod is only a low systemic absorbing from the human skin and is not mutable is a risk for people because of systemic exposition than very low.</seg>
<seg id="2241">"the tumor was treated in the group of mice that has been treated with the effective soy cream, earlier and in larger number and in the control group with low UVR."</seg>
<seg id="2242">"if one of the linked side effects will be considerably lower or if you notice any side effects that are not specified in this form information, please inform your doctor or pharmacist."</seg>
<seg id="2243">● Feigned (Condylomata acuminata) which is often used in the skin in the genitals (sexual organs) and the Anus (After) have formed ● upper surface of the skin with very low probability of the skin with very low probability of impact on other parts of the body.</seg>
<seg id="2244">"if it remains untreated, it can lead to discharge, especially in the face - therefore, a early detection and treatment is important."</seg>
<seg id="2245">Actinic maternity are rough areas of the skin that were exposed to people who were exposed during their previous life.</seg>
<seg id="2246">"Aldara should only be applied for flat surfaces in the face and on the scalp of patients with a healthy immune system, where your doctor has decided that there is best suitable treatment for you."</seg>
<seg id="2247">"Aldara cream supports your physical immune system in the production of natural substances, which help your body help to combat the surface cell carcinoma."</seg>
<seg id="2248">"if you have any problems with your doctor if you have any problems with your immune system, please inform your doctor if you have problems with your immune system."</seg>
<seg id="2249">"if you don't have more cream than your doctor, you don't apply more cream than your doctor."</seg>
<seg id="2250">"as soon as the reactions, you can continue your doctor if they have no normal blood image."</seg>
<seg id="2251">"if this daily cleaning is carried out under the occurrence, can be carried out with increased occurrence of precursor swelling, fertilizers, skin or difficulties during the occurrence of the skin."</seg>
<seg id="2252">"turn Aldara cream not in the Urethra (ureredness), in the vagina (Scheide), of Zervix (corn) or within the anus (after)."</seg>
<seg id="2253">Taking other medicines serious problems with your immune system should you use this medicine for more than a treatment cycle.</seg>
<seg id="2254">"if you have prepared during the infection of sexual intercourse, the treatment with Aldara creme after sexual intercourse (not before)."</seg>
<seg id="2255">"please inform your doctor or pharmacist if you have other drugs and more recently, even if it is non-prescription drugs."</seg>
<seg id="2256">Breastfeeding your infants during treatment with Aldara cream doesn't know if Imiquimod is overthrown into the mother's milk.</seg>
<seg id="2257">The frequency and duration of the treatment are different (see specific instructions for each application area).</seg>
<seg id="2258">"carry a thin layer of Aldara cream on the clean, dry skin spot with the fetches on the skin, until the cream is completely covered."</seg>
<seg id="2259">"men with feigned under the occurence must be returned and the skin area, including the skin (see section 2" What must you have to be used before the application of Aldara cream? ")."</seg>
<seg id="2260">Please talk with your doctor or pharmacist if you have the impression that the effect of aldara is too strong or weak.</seg>
<seg id="2261">"6 weeks for 5 days a week, a sufficient amount of aldara cream, to cover the affected area and 1 cm to cover this area."</seg>
<seg id="2262">Very frequent side effects (with less than 1 of 10 patients) provide a side effects (less than 1 of 10 patients) and rare side effects (less than 1 of 1 patients) Very rare side effects (less than 1 of 10.000 patients)</seg>
<seg id="2263">Inform your doctor / your health care or pharmacist / your appartment availability immediately if you feel in the application of Aldara cream.</seg>
<seg id="2264">"if your skin too strong to the treatment with Aldara cream, you should not use the cream of the skin area with water and a mild soap, your doctor or pharmacist."</seg>
<seg id="2265">A lower number of blood cells can take care of infections; they can make sure that you can make yourself faster a blender flame or she can call Abram.</seg>
<seg id="2266">Inform your doctor or pharmacist if one of the adverse side effects or side effects that are not specified in this form information.</seg>
<seg id="2267">"in addition, you can see Juckreiz (32% of patients), Brenta (26% of patients) or pain in the fields where you have Aldara cream (8% of patients)."</seg>
<seg id="2268">Most of them are more than 2 weeks after the treatment of the treatment again.</seg>
<seg id="2269">"some patients may notice some patients at the application location (wound secretion, inflammation, swelling, swelling, bladder, dermatitis) or friction, nausea, dry mouth, grippesimilar symptoms and fatigue."</seg>
<seg id="2270">"occasionally you suffer some patients under changes at the application location (Bluegration, inflammation, wounds or gripping), inflammation of the eye, eyepiding, eyepiphew, eyepiphew, bone, conical pain, fever, weakness, weakness or bulk."</seg>
<seg id="2271">Aldurazure is applied for the enzymes in patients with enhanced diagnosis of a Mucopolysacchariot I (MPS I; a -l-Iduronidase deficiency) to treat the not neurological manifestation of the disease (the symptoms that do not occur with brain or nerves in connection).</seg>
<seg id="2272">"this means that certain substances (glycosamine lykane, Gags) are not built and in most organs in the body."</seg>
<seg id="2273">"the following not neurological symptoms of the MPS I can occur: magnified liver, sticking joints, conductive lung volume, heart rate and eye diseases."</seg>
<seg id="2274">Treatment with Aldurazure should be monitored by a doctor in the treatment of patients with MPS I or other metabolic metabolic diseases.</seg>
<seg id="2275">"the adoption of Aldurazes should be made in a hospital or a clinic with ressources of cancer, and patients need appropriate drugs to prevent an allergic reaction."</seg>
<seg id="2276">"* Understand the competitive environment, the market's major players and leading brands; * Use five-year forecasts to assess how the market is predicted to develop."</seg>
<seg id="2277">"in the study, the safety of the medicines was examined in the study mainly due to its effect on the reduction of the GAG concentrations in Urine and in relation to the size of the liver."</seg>
<seg id="2278">"when children under five years, Aldurazate the GAG concentration camps in the Urine around around 60%, and half of the treated children reported a normal liver at the end of the study."</seg>
<seg id="2279">"the most common side effects of Aldurazure in patients aged over five years (observed in more than 1 of 10 patients) headaches, nausea, abdominal pain, pain in the Gliedonian (in hands and feet), heat-feeling, fever and reactions to the infusions (in hands and feet)."</seg>
<seg id="2280">"very frequent side effects in patients under five years of increased blood pressure, reduced oxygen saturation (a measuring size of the lung function), tulars (accelerated heart rate), taps and bulk."</seg>
<seg id="2281">Aldurazari must be used in patients that may be strong sensitive (allergic) to laronidase or one of the other components (anaphylaktic reaction).</seg>
<seg id="2282">"the European Medicines Agency (EMEA) will be able to update every year all new information, which may be known to verify and this summary required for more information."</seg>
<seg id="2283">The manufacturer of Aldurazés will be preserved in terms of the reactions to the infusion and the development of antibodies.</seg>
<seg id="2284">"June 2003, the European Commission adopted the European Commission of Genzyme Europe B.V. an approval for the Induction of Aldurazure in the whole of the European Union."</seg>
<seg id="2285">Laronidase is a recombinant form of humanen α -l-Iduronidase and is produced using recombinable DNA technology under use by CHO-acid-cell cultures (Chinese hamOvary, eggs of the Chinese hamster). "</seg>
<seg id="2286">Aldurazum is to treat the long-term enzymes in patients with enhanced diagnosis of a Mucopolysacchariot I (MPS I, α -l-Iduronidase deficiency) to treat the non-neurological manifestation of the disease (see section 5.1).</seg>
<seg id="2287">Treatment with Aldurazés should be made by a physician who is made in the treatment of patients with MPS I or other erectile dysfunction.</seg>
<seg id="2288">"the initial infusions rate of 2 E / kg / h, if the patient contributes to a maximum dose of 43 E / kg / h."</seg>
<seg id="2289">The safety and efficacy of Aldurazure at adults about 65 years have been not detected and for this patient can't be recommended for the patient treatment.</seg>
<seg id="2290">"the safety and efficacy of Aldurazum in patients with kidney or liver disease was not detected, and for these patients may be recommended for patients."</seg>
<seg id="2291">"with Alduractivism patients, patients can develop infusionable reactions which are defined as any in the secondary level, which is defined as each in the side effects of the infusion or until the end of the infusion day (see section 4.8)."</seg>
<seg id="2292">"for this reason, these patients should also continue to be monitored and the Infusion of Aldurazate should only be used in a reasonable clinical environment, in the ressources of medical emergency cases."</seg>
<seg id="2293">"due to the clinical phase 3 study, almost all patients receive IgG siRNA against laronidase, usually within 3 months of treatment."</seg>
<seg id="2294">Patients who develop antibodies or symptoms of infusion-related reaction must be treated with the use of Aldurazes with caution (see sections 4.3 and 4.8).</seg>
<seg id="2295">"as little experience regarding the realignment of the treatment after a longer interruption, due to the theoretically increased risk of a long-sensitive reaction after a break of the treatment."</seg>
<seg id="2296">60 minutes before the beginning of the Infusion with drugs (antihistamine and / or antistatic) preferential reactions to minimise potential occurrences.</seg>
<seg id="2297">"in case of light or medium-heavy-related reaction, the treatment with antihistamine and paranamol / Ibuproroerolls, and / or a reduction of infusion rate at half of the infusion rate, when the reaction occurred."</seg>
<seg id="2298">"in the case of a single, heavy infusionary reaction, the infusion must be brought to the decline in the decline, a treatment with antihistamine and paranamol / Ibuprose is weakened."</seg>
<seg id="2299">The Infusion can be used with a reduction of infusion rate at 1 / 2 - 1 / 4 of the infusionrate where the reaction occurred.</seg>
<seg id="2300">3) (anti-histamine and paranamol / Ibuprocal and / or Corticosteroids) as well as a reduction of infusioned rate at 1 / 2 - 1 / 4 of the infusioned rate in which the pre-balanced reaction occurred.</seg>
<seg id="2301">"Aldurazate should not be applied at the same time with chloroquin or procain, because there is potential risk of an interrogation with the intraocular lens of Laronidase."</seg>
<seg id="2302">"clinical studies allow not to direct or indirect harmful effects on pregnancy, embryonic development, birth and postnatal development (see section 5.3)."</seg>
<seg id="2303">"there is no data to new born, which have been removed from Laronidase on the mother's milk, is recommended to breastfeeding during treatment with Aldurazar."</seg>
<seg id="2304">"the side effects in clinical trials were mainly used as infusioned reactions, which have been observed in the phase 2-3 study (treatment time up to 4 years) and with 35% of patients in the study with participants under 5 years (treatment times up to 1 year)."</seg>
<seg id="2305">"undesirable medicines in connection with Aldurazes, which were observed during the phase of 5 years or older at a total of 45 years or older than a treatment period of 5 years, are often observed in the following table: very often (Acts 1 / 10 to &lt; 1 / 10)."</seg>
<seg id="2306">"in some patients with heavier MPS-I-unequalled participation of the upper respiratory tract, and lungs in the prehistory of the early respiratory tract, breathing, and facial hair (see section 4.4)."</seg>
<seg id="2307">"with a total of 20 patients were found in the age of 5 years, with a total of 20 patients at the age of 5 years, with mainly severe loss of treatment and a treatment period of up to 12 months, are reported in the table."</seg>
<seg id="2308">"100 E / kg intravenous once (recommended dose), 200 E / kg intravenous once per week, 200 E / kg intravenous all 2 weeks or 300 E / kg intravenous all 2 weeks."</seg>
<seg id="2309">In most cases it came within 3 months after the beginning of the treatment to a Serokonid (average to 26 days compared to the age of 5 days at the age of 5 years and older).</seg>
<seg id="2310">"at the end of the phase-3 study (or up to a premature expiry of the study), at 13 / 45 patients is not able to relieve the antiimmunology (RIP) Assay proven antibodies, among 3 patients, which had never come to Serokonid."</seg>
<seg id="2311">Patients with wording to low anti antipertory mirror spends a robust reduction of the GAG-Spiegels in Harn while patients with high antibodies have a variable reduction of GAG in Harn.</seg>
<seg id="2312">Four patients (three in the phase-3 study and one in the phase 2 study) were presented in vitro that the clinical efficacy and / or the reduction of GAG in Harn does not affect the effects of GAG in Harn.</seg>
<seg id="2313">The presence of antibodies seemed not in connection with the incidence of drug interactions with the formation of IgG anti-antibodies.</seg>
<seg id="2314">The reason for the enzyme therapy is in one of the hydrolyse of the akegulation of the akegulation and the deterioration of a further accumulation of the enzymes.</seg>
<seg id="2315">"after intravenous Infusion is removed from the circulation and from cells into the Lysosomes, on the most other about Mannose-6-phosphat- receptors."</seg>
<seg id="2316">"the safety and efficacy of Aldurazans were examined in a prospective study, double blind, placebocontrolled phase-3 study at 45 patients at the age of 6 to 43 years."</seg>
<seg id="2317">"for the study, the majority of the patients were transferred to the entire disease spectrum, the majority of the patients from the middle phenotype and only one patient described the severe phenotype."</seg>
<seg id="2318">Patients were modified when they had an intercontinental volume (FEV) of less than 80% of the expected value and they had to go to 6 minutes to stand and 5 metres.</seg>
<seg id="2319">The primary endpoints for the effectiveness were the process change of the expected FEV and the absolute path in the 6-minute drive.</seg>
<seg id="2320">"all patients were then returned to an open label extension, where they received more 3.5 years (182 weeks) each week 100 E / kg Aldurazari."</seg>
<seg id="2321">After 26 weeks after treatment with Alduractivism patients with an improvement of lung function and the inability in the following table is represented in the following table.</seg>
<seg id="2322">"during the open extension study, a improvement and / or maintain this effects of up to 208 weeks in the Aldurazure group and from 182 weeks in the Placebo / Alduraztic Group, as from the following table."</seg>
<seg id="2323">"the acceptance of this period was not significantly reduced and the absolute lung volume increased further proportionately to the body size growing."</seg>
<seg id="2324">"from the 26 patients with a hepatitis C before treatment, 22 (85%) until the end of the study a normal liver size."</seg>
<seg id="2325">"within the first 4 weeks, a significant waste of GAG mirror in Harn (µg / mg creatinin) was determined to the degree of study."</seg>
<seg id="2326">"in terms of heterogeneous disease patients, the clinically significant changes of the patient has been taken into consideration for five patients (58%), no change in 10 patients (22%), and a deteriorating with 9 patients (20%) and a deterioration of 9 patients (20%)."</seg>
<seg id="2327">It has been carried out in the first open phase-2 study in which the safety and pharokinetics of Aldurazum in 20 patients were examined in the study under 5 years (16 patients with the heavy load-form and 4 with the middle expiration form).</seg>
<seg id="2328">In four patients the dosage was increased to higher GAG- mirror in Harn in the last 26 weeks at 200 E / kg.</seg>
<seg id="2329">"in several cases, a size growth (n = 7) and a weight gain (n = 3), after the Z-score for this age group, the younger patients with severe failure shape (&lt; 2.5 years) and all 4 patients were treated with severe failure-form."</seg>
<seg id="2330">"in a phase-4 study, investigations were carried out on the GAG mirror in Harn, the liver volume and the 6-minute test test."</seg>
<seg id="2331">"100 E / kg intravenous once (recommended dose), 200 E / kg intravenous once per week, 200 E / kg intravenous all 2 weeks or 300 E / kg intravenous all 2 weeks."</seg>
<seg id="2332">"the dosing scheme with 200 E / kg intravenous, all 2 weeks can represent an official alternative; however, it is not proven that the long-term clinical efficacy of these two dodsions are equivalent."</seg>
<seg id="2333">"the European Medicines Agency (EMEA) will be used for any new information that are available, and if necessary, the summary of the features will be updated."</seg>
<seg id="2334">The pharmacokineal profile for patients aged 5 years were similar to older and less affected patients.</seg>
<seg id="2335">"based on conventional studies on safety spicology, toxicity in a unique gift, toxicity with repeated gift and reproduction of reproduction, the preventive data does not require special dangers for people."</seg>
<seg id="2336">"since no compensation studies were carried out, this medicine may not be mixed with other medicines, except with them under 6.6."</seg>
<seg id="2337">"if the used cleaning is not used immediately, it is no longer than 24 hours at 2 ° C - 8º C, unless the assimilation under controlled and validated conditions."</seg>
<seg id="2338">"5 ml concentrate on the production of a solution in penetration bottle (type I-glass) with plug (silicone - I-glass) with plug (silicone) and sealing cap (polypropylene)."</seg>
<seg id="2339">10 preparation of the Aldurazure Infusion (by aseptic technology) • Je according to body weight of the individual patients</seg>
<seg id="2340">The owner of the permission for the Increditation has been completed within the given time the following study programme has been confirmed that the basis for the annual review report to the benefit of the benefits of the annual review.</seg>
<seg id="2341">"this property is longer term safety and efficacy of patients who were treated with Aldurazum, as well as data for natural disasters of disease with patients without these treatment."</seg>
<seg id="2342">"in patients who suffer under MPS I suffer a enzyme called α -l-Iduronidase, which certain substances in the body (glycosamine lysis), either in low quantity before or this enzyme is missing."</seg>
<seg id="2343">"if you allergic to allergic (oversensitive) compared to one of the components of Aldurazine, or if you have a severe allergic reaction to Laronidase."</seg>
<seg id="2344">A infusion reaction is each side effect which occurs during the infusion or until the end of the infusion day (see section 4 "Which side effects are possible).</seg>
<seg id="2345">Please inform your doctor if you take medication if you use medicine prescribed chloroquin or procain, because there is a possible risk of a reduced effect of Aldurazine. "</seg>
<seg id="2346">"please inform your doctor or pharmacist if you have other drugs, including non-prescription drugs, including non-prescription drugs."</seg>
<seg id="2347">Notes for handling - failure and application for the production of an infusion solution must be used before the application of an infusion solution (see information for doctors or medical professionals).</seg>
<seg id="2348">"the initial infusion rate of 2 E / kg / h, if the patient contributes to a maximum dose of 43 E / kg / h."</seg>
<seg id="2349">"in some patients with heavy MPS-I- unmistakable participation of the upper respiratory tract and lungs in the prehistory, but heavy reactions on, including bronchospasmus, respiratory and facial hair."</seg>
<seg id="2350">• Reduces • Polypropylen (more than 1 of 10 patients): • headaches • Polypropylen (cardiac disease) • Reducing • Hypertonie • increased pulse • Hypertonie • low oxygen in the blood and reaction to the infusioner</seg>
<seg id="2351">"the European Medicines Agency (EMEA) will be used for any new information that are available, and if necessary, the packaging will be updated."</seg>
<seg id="2352">"if the used cleaning is not used immediately, it is no longer than 24 hours at 2 ° C - 8º C, unless the assimilation under controlled and validated conditions."</seg>
<seg id="2353">Preparation of the Aldurazure Infusion (by aseptic technology) • Je according to body weight of the individual patients</seg>
<seg id="2354">"Alimta is used together with Cisplatin (a different drugs against cancer), if the cancer has not been removed."</seg>
<seg id="2355">"Alimta is used for patients who are not treated, in combination with Cisplatin and patients who have previously received other chemotherapy as a few treatment."</seg>
<seg id="2356">In order to reduce side effects during treatment with Alimta a Corticosteroid and folic acid (a vitamin) and injections of vitamin B12.</seg>
<seg id="2357">"if Alimta, together with cisplatin, you should be given before or after the gift of Cisplatin in addition to the gift of Cisplatin in addition to a fluid deficiency."</seg>
<seg id="2358">"in patients, their blood image changes or during which certain side effects should occur, should be removed or the dose is reduced."</seg>
<seg id="2359">The active form of Pemetrees slowed down the formation of DNA and RNA and prevents the cells to share the cells.</seg>
<seg id="2360">The transformation of Pemetrees in its active form is easier to be used in cancer cells than in healthy cells which leads to higher concentrations of the active substance and a longer active effect in cancer cells.</seg>
<seg id="2361">"for the treatment of malignant Pleuramesendothelioms, Alimta was examined in a main study to 456 patients, which had not yet received chemotherapy against their disease."</seg>
<seg id="2362">"in the treatment of non-aquatic lung cancer, the effects of Alimta has been treated with local advanced or metastatic disease, which had already been treated with a chemotherapy, with the effects of Docetaxel (another drug against cancer)."</seg>
<seg id="2363">Alimta was compared with mixtures in a study with Cisplatin in a study with Cisplatin in a study on 1 725 patients who had to have no chemotherapy for lung cancer.</seg>
<seg id="2364">"patients who were treated with Alimta and Cisplatin were treated over 12,1 months, compared with 9,3 months in the allways of cisplatin."</seg>
<seg id="2365">"in patients who had previously received a chemotherapy, the average life-life time with Alimta 8,3 months, compared with 7.9 months in Docetaxel."</seg>
<seg id="2366">"in both studies, patients who are unable to prevent cancer cells from Alimta longer overlife times when compared with the comparison of Alimta."</seg>
<seg id="2367">"in September 2004, the European Commission published the Eli Lilly Nederland B.V. an permission for the Increditation of Alimta in the whole European Union."</seg>
<seg id="2368">"each penetration bottle must be replaced with 4,2 ml 0,9% of sodium chloride solution (9 mg / ml), which allows a solution of 25 mg / ml."</seg>
<seg id="2369">The corresponding volume of the necessary do- sis will be removed and with 0.9% sodium chloride solution (9 mg / ml) to 100 ml (see section 6.6).</seg>
<seg id="2370">ALIMTA is used in combination with cisplatin for first-line therapy of patients with locally advanced or metastatic bronzinom (see section 5.1).</seg>
<seg id="2371">ALIMTA in Monotherapy is shown to treat cancer patients with Lo- KAL advanced or metastatic bronzinom (see section 5.1).</seg>
<seg id="2372">The recommended dose of ALIMTA 500 mg / m ² body upper - surface (KOF) is enough than intravenous Infusion over a period of 10 minutes on the first day each 21-day treatment cycle.</seg>
<seg id="2373">The recommended dose of Cisplatin is 75 mg / m ² KOF as Infusion via a period of 2 hours.</seg>
<seg id="2374">The recommended dose of ALIMTA 500 mg / m ² KOF is recommended as intravenous Infusion over a period of 10 minutes on the first day each 21-day treatment cycle.</seg>
<seg id="2375">For reduction of frequency and severity of skin actions must be given on day before and on the day of the Pemetreum gift.</seg>
<seg id="2376">During the seven days before the first dose Pemetrees must be taken at least 5 days after the first dose.</seg>
<seg id="2377">Patients must also obtain a inhibition of vitamin B12 (1000 microgram) in the week before the first Pemetric dose.</seg>
<seg id="2378">"in patients, Pemetrees should be created before every gift of a full blood image, including a differentiation of the leukocytes and a thrombocytes."</seg>
<seg id="2379">Organic phosphatase (AP) and Alanin-Transaminase (ALT or SGPT) must be ≤ 3 times of the upper limit value.</seg>
<seg id="2380">"at the beginning of a new treatment cycle, a Dosenoid can take place during the beginning of a new treatment cycle."</seg>
<seg id="2381">"after the recovery, patients must be treated according to the notes in the tables 1, 2 and 3, which are used for ALIMTA, as a monotherapy or in combination with Cisplatin."</seg>
<seg id="2382">"these criteria meet the definition of the National Cancer Institute of Toxicity Criteria (CTC v2.0; NCI 1998), CTC degree 2 blood circulation."</seg>
<seg id="2383">Patients with ALIMTA must be interrupted by ALIMTA (except Neurotoxicity) must be interrupted by the patient's value before the treatment of treatment.</seg>
<seg id="2384">Treatment with ALIMTA must be broken when patients after 2 Dosisreinductive toxicity or non-systemic toxicity of 3 or 4 neurotoxicity.</seg>
<seg id="2385">"clinical trials have no indication that in patients at the age of 65, or in comparison to patients at age under 65 years of age."</seg>
<seg id="2386">ALIMTA is not recommended for use in children under 18 years because of not sufficient data for accidents and effectiveness.</seg>
<seg id="2387">Clinical trials were required in clinical trials with an Kreatinin-Clearance of ≥ 45 ml / min.</seg>
<seg id="2388">The data base in patients with an Kreatinin Clearance of 45 ml / min was not sufficient; therefore the application not recommended (see section 4.4).</seg>
<seg id="2389">"results appear ordered" "by relevance" "or" "by date" "(publication date),"</seg>
<seg id="2390">Patients need to be monitored with regard to the bone-level monitoring and pemetry may not be used to patients before their absolute neutrality rate once again increased a value of SAL1500 cells / mm ³ and the thrombo- a value of €100.000 cells / mm ³.</seg>
<seg id="2391">"a Dosisrereduction for further cycles is based on the Nadir of the absolute neutrality rate, Thrombocytes and maximization, as they observed in the previous treatment cycles - (see section 4.2)."</seg>
<seg id="2392">"a lower toxicity and a reduction of degree of degree 3 / 4 fracture and infection with degrees 3 / 4 neutralisie, febrile and infection with degrees 3 / 4 neutrropeny was carried out when a pre-treatment with folic acid and vitamin B12 took place."</seg>
<seg id="2393">Therefore all entriesother entries in this category Go to the top of the page Skip user information</seg>
<seg id="2394">Patients with light up to medium kidney disease (ASAIDs) as Ibuprocal and Acetylsalic acid (&gt; 1.3 g daily) for at least 2 days before treatment, on the day of therapy and miners - 2 days after therapy with pelvic bone (see section 4.5). "</seg>
<seg id="2395">"all patients, for therapy with pelvic bone is necessary, the intake of NSAIDs have to avoid at least 5 days before treatment, at least 2 days before treatment, on the day of therapy and at least 2 days before treatment, at least 2 days before therapy, at least 2 days before treatment, at least 2 days before therapy, at least 2 days before therapy, at least 2 days before treatment, at least 2 days before therapy, at least 2 days before therapy, at least 2 days before therapy, at least 2 days before therapy, at least 2 days before therapy, at least 2 days before therapy, at least 2 days before therapy, at least 2 days before therapy, at least 2 days before therapy, at least 2 days before therapy, at least 2 days before therapy, at least 2 days before therapy, at least 2 days before therapy, at least 2 days before therapy, at least 2</seg>
<seg id="2396">"many patients, in which these events were given, corresponding risk factors for the appearance of renal events, including elasticity, existing high blood pressure or diabetes."</seg>
<seg id="2397">It should therefore be used in patients with clinically significant fluid - Answers in the transcellular room a drainage of the ergonomics in front of the pelvic bone treatment.</seg>
<seg id="2398">"5 Heavy creatic events, including myokardinfantry, and shebrovascular events were found in clinical trials when these active substance are usually used in combination with another cytotoxic substance."</seg>
<seg id="2399">"in this reason, the simultaneous use of the use of upersities (except Gelbfever, this Image is a Indian -) not recommended (see section 4.3 and 4.5)."</seg>
<seg id="2400">"since the possibility of a missealed skull - the reproduction of the reproductive capacity by Pemetrees, men should be aware of the treatment of treatment and advice regarding the sperm cell."</seg>
<seg id="2401">In patients with normal kidney function (creatinin-Clearance) 80 ml / min) and Acetylsalicyloric acid in high dosage (made by 1.3 g / day) and Acetylsalicyloric acid in high dosage (Brut1.3 g / day) and Acetylsalicyloric acid.</seg>
<seg id="2402">Therefore be careful when patients with normal kidney function (Kreatinin-Clearance) 80 ml / min) high doses of NSAIDs or Accutylsalicyloric acid in high dosage.</seg>
<seg id="2403">Ibuprof) or Acetylsalicyl- acidity in high dosage for at least 2 days before treatment, on the day of therapy and miners - 2 days after therapy with pelvic bone (see section 4.4). "</seg>
<seg id="2404">"there is no information regarding the interaction potential than with NSAIDs, with a long-term half of the therapy for at least 5 days before the therapy, on the day of therapy and at least 2 days before therapy, on the day of therapy and at least 2 days after therapy."</seg>
<seg id="2405">The large intra-individual Variability of the Gerber status during the disease and the possibility of interaction between oral anti-inflammatory and antineoplastics requires a higher surveillance frequency of the INR (International Standards Agency) when the decision was made to treat the patient's oral anti-inflammatory diseases.</seg>
<seg id="2406">"there are no data for the use of pemetrees in pregnancy, but as with ande- and diarrheets are expected to be expected at an application in the pregnancy."</seg>
<seg id="2407">"in other words, Pemetrees may not be used during pregnancy except if necessary and careful treatment of the use for the mother and of the risk for the Fötus (see Section 4.4)."</seg>
<seg id="2408">"since the possibility of a missealed use of the reproductive force of the reproductive capacity, men should be aware of the treatment of treatment, advice regarding the sperm cell."</seg>
<seg id="2409">It is not known that Pemetrees can not be excluded in the mother's milk and undesired effects in the infants can not be excluded.</seg>
<seg id="2410">The following table shows the frequency and severity of adverse effects that were reported in &gt; 5% of 168 patients with mesotheliom and in 163 patients with mesotheliom that were randomized Cisplatin as monotherapy.</seg>
<seg id="2411">"side effects: very often (made 1 / 10), occasionally (Acts 1 / 100 and &lt; 1 / 10), very rare (&lt; 1 / 10,000 and &lt; 1 / 100), very rare (&lt; 1 / 10,000 and &lt; 1 / 100), very rare (&lt; 1 / 10,000 and &lt; 1 / 100), very rare (&lt; 1 / 10,000) and not known (based on the available data of Spontanreport not included)."</seg>
<seg id="2412">"* * * * moved to National Cancer Institute CTC (v2.0; NCI 1998) shall be made by the term" "kidneys" "(v2.0; NCI 1998)."</seg>
<seg id="2413">"for this table, a threshold of 5% set for the recording of all events where the reporting doctor has a connection with Pemetrees and Cisplatin for possible."</seg>
<seg id="2414">Clinically relevant CTC toxicity that were reported in &lt; 1% (occasionally) of patients who were reported by Cisplatin and Pemetrees were included in the majority of Arrhythmic and motionic neuropathy.</seg>
<seg id="2415">"the following table shows the frequency and severity of adverse effects, which were reported in &gt; 5% of 265 patients, were randomised as monotherapy of torture - re and vitamin B12, and 276 patients who were randomised Docetaxel as monotherapy."</seg>
<seg id="2416">"* On National Cancer Institute CTC version 2 for any toxicity, * * * moved to National Cancer Institute CTC (v2.0; NCI 1998), hair loss can only be found as a degree 1 or 2."</seg>
<seg id="2417">"for this table, a threshold of 5% set for the recording of all events where the reporting doctor has a connection with Pemetreactor for possible."</seg>
<seg id="2418">Clinically relevant CTC toxicity that were reported at &lt; 1% (occasionally) of patients were reported to have a comprehensive paediatrium Arrhythmic Arrhythms.</seg>
<seg id="2419">"the clinically relevant laboratory toxicity of 3 and 4 was compared with the preoperative results of three separate Pantifungal-Monuments (12,8%) and an increase in the Alanintransis (15,2%) and an increase in the Alanintransis (15,2% compared with 1.9%)."</seg>
<seg id="2420">"these submissions are likely to result in the patient population, since the Pha- se 2 studies both chemical and / or northening output levels of liver function tests."</seg>
<seg id="2421">"the following table shows the frequency and severity of adverse effects, which could be possible in connection with the study media; they were reported at &gt; 5% of 839 patients with NSCLC, which were randomised cisplatin and mixtures."</seg>
<seg id="2422">"* * * Measured at National Cancer Institute CTC (v2.0; NCI 1998) shall be found on National Cancer Institute CTC (v2.0; NCI 1998) are to be found on National Cancer Institute CTC (v2.0; NCI 1998). * * Beate on National Cancer Institute CTC (v2.0; NCI 1998) are to be found on a National Cancer Institute CTC (v2.0; NCI 1998)."</seg>
<seg id="2423">"for this table, for the recording of all events where the reporting doctor has a connection with pelvic bone and cisplatin for possible, a threshold of 5%."</seg>
<seg id="2424">"clinically relevant toxicity, which was reported in accordance with Pro1% and ≤ 5% (frequently) of patients were reported, the previous Cisplatin and Pemetrees had received the following:"</seg>
<seg id="2425">Clinical use of toxicity that were reported at &lt; 1% (occasionally) patients were reported that were reported - domicular Cisplatin and Pemetrees were included in the following:</seg>
<seg id="2426">"serious cardiovascular events, including myokardinfecom, Angina pectoris, malaria pectoris, the most often used in combination with a different cytotoxic substance."</seg>
<seg id="2427">"clinical trials were found in cases of Coli- TIS (including the intestinal and oral blood vessels, sometimes fatal, intestinal Perfo- ration, intestinal natives and Typhlitis)."</seg>
<seg id="2428">Clinical trials were found in cases of patients with publesbian treatment in cases of sometimes fatal interruptive interrogation with respect of ironic insufficiency.</seg>
<seg id="2429">It was reported in cases of akutem kidney or in combination with other chemotherapy in combination with other chemotherapy (see Section 4.4).</seg>
<seg id="2430">There were cases of radiation pneumonia in patients who are reported in patients during or after their pemetric therapy (see section 4.4).</seg>
<seg id="2431">ALIMTA (Pemetrees) is a antineated antifolate that causes its effect by weight - follicating processes which is necessary for the cell replication.</seg>
<seg id="2432">"in vitro tests, Pantifungi (DHFR) and glycinamidricultase (DHFR) and glycinamidrivetitase (GARFT), the follicular key enzymes of the de novo Biosynthesis of Thymidrange and Purinnucleans are."</seg>
<seg id="2433">"EMPHACIS, a multifunctional, single-blind, easy-blind, easy-blind and Cisplatin against Cisplatin and Cisplatin against Cisplatin and Cisplatin and Cisplatin and Cisplatin and Cisplatin in patients treated with Cisplatin and Cisplatin in patients with cisplatin."</seg>
<seg id="2434">The primary analysis of this study was carried out in the population of all patients who were carried out in the treatment of treatment and treated treatment.</seg>
<seg id="2435">A statistical evaluation of the clinically significant improvement of the clinically relevant symptoms (pain and dyspnoe) in connection with the malignant Pleuramesome-arm (212 patients) compared to the allest Cisplains-arm (218 patients).</seg>
<seg id="2436">The differences between the two treatment is due to a improvement of the lung disease in the ALIMTA / Cisplatin-arm and a deterioration of lung function in the time at the time of account.</seg>
<seg id="2437">Patients with ALIMTA in Patients with ALIMTA in Patients with ALIMTA in Patients with ALIMTA patients (Intent to the population n = 283) and from 7.9 months with Docetaxel patients (ITT n = 288).</seg>
<seg id="2438">"a analysis of the histology at the treatment of the histology at the overall survival of ALIMTA (n = 172, 6.7% CI = 0.61; 95% CI = 1,08-2.26, p = 0,018)."</seg>
<seg id="2439">"(detect automatically) utf-8 (Unicode, worldwide) utf-16 (Unicode, worldwide) utf-16 (Unicode, worldwide) utf-16 (Unicode, worldwide) utf-16 (Unicode, worldwide) utf-16 (Unicode, worldwide)"</seg>
<seg id="2440">"the analysis analyses of the PQ Population are consistent with the analyses of the ITT population, and support the non-subtraction of ALIMTA Cisplatin combination with the analysis of mixtures in Cisplatin combination."</seg>
<seg id="2441">"medium PFS was 4,8 months for the combination of ALIMTA Cisplatin to 5.7% (95% CI = 27.3 - 33.9) for the combination of ALIMTA Cisplatin from 28,6% (95% CI = 25,0 - 31.4) for the combination of mixtures in Cisplatin."</seg>
<seg id="2442">"the analysis of the NSCLC Histology at the survival, clinically developed clinically relevant sub- and according to histology, see below the table below."</seg>
<seg id="2443">"if you have any queries, please contact us on Tel.: + 49 5764 318 444. or contact us per email. if you want to send us a question about this product, simply complete all the fields marked * and click" "Send". ""</seg>
<seg id="2444">Patients who were treated with ALIMTA and Cisplatin have been treated with ALIMTA and Cisplatin (16.1% versus 27.3%; p &lt; 0.0001) and Thrombozytenses (1.8% versus 4.5%, p = 0,002). "</seg>
<seg id="2445">"in addition, the patient selects the gift of Erythropotin / Darbopoetin (10.4%, p &lt; 0.0001), G-CSF / GM-CSF (3.2%, p = 0.0001), and iron deficiency (4.9%, p = 0.021)."</seg>
<seg id="2446">The pharmacokinequalities of Pemetrees has been studied at 426 cancer patients with various solid tumors in cans from 0.2 to 838 mg / m ² in infusi- over a period of 10 minutes.</seg>
<seg id="2447">Pemetrees is mainly used in the urinary and 70% to 90% of the dose dose within 24 hours after application.</seg>
<seg id="2448">Pemetrees has a total of 91.8 ml / min and the half-value in the plasma is 3.5 hours in patients with normal kidney function (Kreatinin-Clearance 90 ml / min).</seg>
<seg id="2449">"in a study with Beagle Hacks, which had been observed for 9 months intravenous Bolt injections were observed (Degenity / Nectural of the semantics of epidemieles)."</seg>
<seg id="2450">"if not, however, however, the storage times and conditions after preparation in the responsibility of the workforce and should usually takes 24 hours at 2 to 8 ° C, unless the preparation / dilution has taken place under controlled and validated conditions."</seg>
<seg id="2451">Solve the content of 100 mg / ml) without preservatives (9 mg / ml) without preservatives, resulting in a solution with a concentration of approximately 25 mg / ml publeship. "</seg>
<seg id="2452">The sole solution is clear and the coloring ranges from color to yellow or green; without the product quality.</seg>
<seg id="2453">"each penetration bottle must be replaced with 20 ml 0,9% of sodium chloride solution (9 mg / ml), which allows a solution of 25 mg / ml."</seg>
<seg id="2454">"23 heavy metals events, including myokardinfantry, and shebrovascular events were found in clinical trials when these active substance are usually used in combination with another cytotoxic substance."</seg>
<seg id="2455">"* * * * moved to National Cancer Institute CTC (v2.0; NCI 1998) shall be made by the term" "kidneys" "(v2.0; NCI 1998)."</seg>
<seg id="2456">"for this table, a threshold of 5% may be set for the recording of all events where the contracted doctor has a connection with Pemetrees and Cisplatin for possible."</seg>
<seg id="2457">"* On National Cancer Institute CTC version 2 for any toxicity, * * * moved to National Cancer Institute CTC (v2.0; NCI 1998), hair loss can only be found as a degree 1 or 2."</seg>
<seg id="2458">"29 * P values &lt; 0,05 compared to National Cancer Institute CTC (v2.0; NCI 1998) shall be found on National Cancer Institute CTC (v2.0; NCI 1998)."</seg>
<seg id="2459">Clinical use of toxicity that were reported at &lt; 1% (occasionally) patients were reported that were reported - domicular Cisplatin and Pemetrees were included in the following:</seg>
<seg id="2460">"for patients with NSCLC for patients with NSCLC for patients with NSCLC for patients with NSCLC for patients with NSCLC, suitable HR = 1.56; 95% CI = 1.08-2.26, p = 0,018)."</seg>
<seg id="2461">Solve the content of 500 mg / ml bottle with 20 ml 0,9% sodium chloride solution (9 mg / ml) without preservatives, resulting in a solution with a concentration of approximately 25 mg / ml publeship. "</seg>
<seg id="2462">The sole solution is clear and the colouration ranges from colorless to yellow or green; without the product quality.</seg>
<seg id="2463">Firm of the Year for Compliance Audits and Investigations Gibson Dunn & Crutcher Firm of the Year for Private Construction Luther</seg>
<seg id="2464">"Risk Management Plan The owner of the permit is obliged to take place in the version 1.2 of Risk Management Plan, as agreed in the version 1.2 of Risk Management Plan (RMP), submitted in modules 1.8.2 the approval of the RMP that were signed by CHMP."</seg>
<seg id="2465">"according to" "CHMP Bideline on Risk Management Systems for Hong Kong" "must be submitted to the next" Periodic Safety Update Report "(PSUR)."</seg>
<seg id="2466">"in addition, a updated RMP is filed with new information about the current safety requirements, the pharmaceutical company's pharmaceutical specifications, or the risk inimpairment activities can be found in accordance with the current safety requirements."</seg>
<seg id="2467">ALIMTA 100 mg of powder used for production of a semi-fusionist - ALIMTA 500 mg powder for production of a concentration of an infusion -</seg>
<seg id="2468">"ALIMTA is used in patients that have no previous chemotherapy, used in patients with cisplatin, a other medicine prescribed for treatment of cancers."</seg>
<seg id="2469">"if you have a kidney disease or earlier, please discuss with your doctor or hospital or hospital if you may not receive ALIMTA."</seg>
<seg id="2470">"for you, any infusion of blood tests will be carried out, if your kidney and liver function is enough, and if you have enough blood cells to get to the ALIMTA."</seg>
<seg id="2471">"your doctor may change the dose or treatment, if your general condition requires, and if your blood is too low."</seg>
<seg id="2472">"if you will receive Cisplatin, your doctor will ensure that your body is sufficient water and you will ensure that your body is sufficient to avoid the break before and after the cisplatin gift."</seg>
<seg id="2473">"if you have received a liquid collection about the lungs, your doctor may receive your doctor - to eliminate these fluids before you receive ALIMTA."</seg>
<seg id="2474">"if you would like to send your doctor or pharmacist, please contact your doctor or pharmacist."</seg>
<seg id="2475">"interactions with other drugs, please tell your doctor if you are prescribed drugs against pain or inflammation (NSAIDs), including medicine, which are non-prescription drugs (such as Ibuprocal)."</seg>
<seg id="2476">Depending on the subject of your ALIMTA Infusion and / or the extent of your kidney function will your doctor will tell you what other medicines can take you and when.</seg>
<seg id="2477">"please inform your doctor or pharmacist if you have other medicines or pharmacist, even if there is not a prescription drugs."</seg>
<seg id="2478">"a hospital or physician, the care staff or medical doctor, the ALIMTA powder with sterile 0,9% of sodium chloride tablets (9 mg / ml), before it is applied to you."</seg>
<seg id="2479">Your doctor will write to you cortison-tablets (according to 4 mg danceth.two times daily) that you need to take on day during and on day after the application of ALIMTA.</seg>
<seg id="2480">Your doctor will take you folic acid (a vitamin) to take the acid (350 to 1000 microgram) that you need to take a time daily during the application of ALIMTA.</seg>
<seg id="2481">In the week before application of ALIMTA and about all 9 weeks (according to 3 cycles of treatment with ALIMTA) you will also receive an injection of Vi- tamin B12 (1000 microgram).</seg>
<seg id="2482">"in this use information, a side effect is described as" very often ", means that it was reported by at least 1 of 10 patients."</seg>
<seg id="2483">"it is described as a" "often", "this means that it was reported by at least 1 of 100 patients, but it was less than 1 of 10 patients."</seg>
<seg id="2484">"it is described as" "occasionally," "this means that it is described by at least 1 of 1,000 but less than 1 of 100 patients."</seg>
<seg id="2485">Fever or infection (frequently): if you have a body temperature of 38 ° C or any other signs of a infection (because you may not have less white blood cells as normal which is very often).</seg>
<seg id="2486">"if you feel tired or weak, quickly in breathing or billing (because you may possibly have less hamoglobin as normal what is very often)."</seg>
<seg id="2487">"if you have a blood of the tooth, the nose or the mouth of the mouth or the mouth of mouth, or a redder or rosafarburine urine or incomplete blood vessels (because you may have less bloodshed than normal, what very frequently is)."</seg>
<seg id="2488">"occasionally (occurs at least 1 of 1,000 patients, but less than 1 of 100 patients) increased pulse rate colitis (inflammation of the inner lining of the intestine) in the intestine and endothelm) interstitides of the respiratory tissue, which leads to the body tissue that leads to swelling."</seg>
<seg id="2489">"rare (occurs in more than 1 of 10.000 patients, but less than 1 of 1,000 patients)" Radiation Recall "(a skin irritation similar to a severe sunlight), appearance on the skin which was exposed (some days until years) of a radiation therapy."</seg>
<seg id="2490">"occasionally in patients, ALIMTA, usually used in combination with other cancers, received a stroke or stroke."</seg>
<seg id="2491">"in patients treated before, during or after their ALIMTA treatment can be obtained a radiation treatment can be caused by radiation of the lung disease, which occur with the radiation treatment."</seg>
<seg id="2492">52 Informing your doctor or pharmacist if one of the adverse side effects or if you notice any side effects that are not included in this package site.</seg>
<seg id="2493">"if applicable, the chemical and physical stability of dilution and infusion solution with storage in the fridge or at 25 ° C for a period of 24 hours."</seg>
<seg id="2494">"if you want to send us a question about this product, simply complete all the fields marked * and click" "Send". ""</seg>
<seg id="2495">Deprecated: function ereg _ replace () is deprecated in / www / htdocs / w00cec0c / webEdition / we / include / we _ modules / object / we _ listview _ multiobject.class.php on line 296</seg>
<seg id="2496">Tel: + 34-91-623-1732 France Lilly France SAS Tél: + 33- (0) 1 55 49 34 34 93sland Icepharma hf.</seg>
<seg id="2497">We are looking forward to hearing from you. we are looking forward to hearing from you. we are looking forward to hearing from you.</seg>
<seg id="2498">Tel.: + 48 (0) 22 440 33 00 Portugal Lilly Portugal - Produtos Fcêuticos, LDA Tel: + 351-21-4126600 România S.r.l. "</seg>
<seg id="2499">"if you want to send us a question about this product, simply complete all the fields marked * and click" "Send". ""</seg>
<seg id="2500">Solve the content of 100 mg / ml) without preservatives (9 mg / ml) without preservatives (9 mg / ml) without preservatives.</seg>
<seg id="2501">Solve the content of 500 mg / ml) without preservatives (9 mg / ml) without preservatives (9 mg / ml) without preservatives.</seg>
<seg id="2502">The sole solution is clear and the coloring ranges from colorless to yellow or green, without having the inductive quality. "</seg>
<seg id="2503">It is applied to excessive adults with a body-specific adult (Body Body Index - BMI) of Pro28 kg per square meter in combination with a caloriental body, low-fat diet. "</seg>
<seg id="2504">Patients who take care and after 12 weeks will have no weight reduction in their physician or pharmacist.</seg>
<seg id="2505">"furthermore, these enzymes can do not build some fats in the food, whereby a quarter of the food is untouched by the intestines."</seg>
<seg id="2506">"in a third study, Alli was compared with a BMI between 25 and 28 kg / m2 with Placebo."</seg>
<seg id="2507">"in the two studies in patients with a BMI of Kau28 kg / m2, patients who had the alli 60 mg, after a year a average weight loss of 4.8 kg has been generated compared to 2.3 kg."</seg>
<seg id="2508">"in the study with Alli in patients with a BMI between 25 and 28 kg / m2, there was no need for patients relevant weight loss."</seg>
<seg id="2509">"the most common side effects of Alli (observed in more than 1 of 10 patients) are a lot of spots on after, flatus (Winde) with Stuhlabyrinth, fetchment (Winde), Flatulence (Winde) and soft chairs."</seg>
<seg id="2510">It may not be applied to patients who are treated with Ciclosporin (for retracing the organs of transplantation) or medicines.</seg>
<seg id="2511">"furthermore, it may not be used for patients who suffer from a long-term malink syndrome (with which not enough nutrients from the digestive) or at Cholestase (an liver disease), and with pregnant women."</seg>
<seg id="2512">"July 2007, the European Commission published the European Commission of Glaxo Group Limited: approval for the Instruction of Orlistat GSK in the whole European Union."</seg>
<seg id="2513">Alli is used for weight reduction of adults with overweight (Body-measure-Index BMI Syndrome 28 kg / m2) and should be used in conjunction with a slightly hypocrisy, low-fat diet. "</seg>
<seg id="2514">"it may not be used for children and adolescents under 18, because there is no sufficient data for the effectiveness and security."</seg>
<seg id="2515">"when Orlistat is only minimal resumed, but with reduced liver and / or kidney function, no adaptation of the dosage is necessary."</seg>
<seg id="2516">• Oversensitive to the active substance or of the other components • Conolestase • pregnancy (see section 4.6) • Short treatment with Ciclosporin (see Section 4.6) • Conjunctions with Ciclosporin (see Section 4.6) • Conjunctions with ciclosporin (see Section 4.6) • Conjunctions (see section 4.6) • Equal treatment with warms or other oral antibodies (see section 4.6 and 4.8)</seg>
<seg id="2517">The probability of the balance of the astrointestinal symptoms (see section 4.8) may increase when alli is taken together with a fat-rich individual mastery or low-fat diet.</seg>
<seg id="2518">"since the weight reduction in diabetes with an improved control of diabetes should take care of diabetes, before the beginning of a treatment with alli a physician or pharmacist, because the dosage of the antidiabetic cells must be adapted."</seg>
<seg id="2519">Patients that are alli as well as medicine against high blood pressure or elevated cholesterol levels should be adapted to their physician or pharmacist if the dosage of these medicines must be adjusted.</seg>
<seg id="2520">"in the case of severe diarrhö possible deviations in the case of severe diarrhö possible deviations, (see section 4.5)."</seg>
<seg id="2521">"in several cases, the use of Orlistat and Ciclosporin was observed in several cases with the use of Orlistat and Ciclosporin in several cases."</seg>
<seg id="2522">"in combination with Orlistat or other oral anti antibodies in combination with Orlistat could be influenced by Orlistat, INR (see section 4.8)."</seg>
<seg id="2523">"for most patients that were treated in clinical trials to 4 full years, the concentration of vitamins A, D, E and K as well as the beta-carotins in the normative area."</seg>
<seg id="2524">"however, the patient should be recommended to ensure that the patient is recommended to ensure adequate level of vitamins (see section 4.4)."</seg>
<seg id="2525">"after a limited number of volunteers, the Amiodaron was observed in a limited number of volunteers who received Ormiodaron-plasma concentration."</seg>
<seg id="2526">"experimental studies showed no direct or indirect effects on pregnancy, embryonic development, birth or postnatal development (see section 5.3)."</seg>
<seg id="2527">The side effects of Orlistat are mainly gastrointestinal nature and are associated with the pharmacological effects of the medicines because the absorption of friction of the fat is prevented.</seg>
<seg id="2528">The gastrointestinal side effects were made from clinical trials with Orlistat 60 mg over a period of 18 months to 2 years and were temporarily temporarily unable to temporarily.</seg>
<seg id="2529">"they are defined as follows: very often (Acts 1 / 10), often (Acts 1 / 10, &lt; 1 / 10), rare (Acts 1 / 10,000, &lt; 1 / 100), rare (&lt; 1 / 10,000), rare (&lt; 1 / 10,000), rare (&lt; 1 / 10,000), rare (&lt; 1 / 10,000), not known (frequency based on available information)."</seg>
<seg id="2530">The frequency of the known effects of the side effects that were found after the market launch of Orlistat is not known as these events are voluntarily disclosed by a population.</seg>
<seg id="2531">† There is a sibel that can lead the treatment with alli in relation to possible or actual gastrointestinal side effects.</seg>
<seg id="2532">"for more than 400 mg Orlistat and multiple drops of up to 400 mg three times daily, over a period of 15 days."</seg>
<seg id="2533">"in the majority of the sections of Orlistat overdose, either side effects or similar side effects like during the recommended dose of Orlistat."</seg>
<seg id="2534">"based on investigations on human and animal can be due to a quick return of systemic effects, which are based on the lipassive properties of Orlistat."</seg>
<seg id="2535">The therapeutic effect is based on the lumens and the upper fertilizer due to the active Serin-Rest of the gastre and pankan Lipass.</seg>
<seg id="2536">"clinical trials was derived from 60 mg Orlistat, three times daily, the absorption of approximately 25% of the food feed."</seg>
<seg id="2537">"two double blind, prospective studies on adults with a BMI Syndrome 28 kg / m2, the effectiveness of 60 mg Orlistat, three times daily in combination with a hypocrisy, low-fat diet was taken."</seg>
<seg id="2538">"the primary parameters, the change of body weight compared to the output value (at the time of the boundary), as follows: as change in the study course (Table 1) and as a portion of the study course, which have more than 5% or more than 10% of their initial weight (table 2)."</seg>
<seg id="2539">"although in both studies the weight loss of 12 months was observed, the largest weight loss has been observed in the first 6 months."</seg>
<seg id="2540">"the average change in the total length of which 60 mg -2.4% (output value 5.20 mmol / l) and with Placebo + 2.8% (output value 5,26 mmol / l)."</seg>
<seg id="2541">The average change of the LDL cholesterol occurred with Orlistat 60 mg -3.5% (output value 3.9 mmol / l) and with Placebo + 3.8% (output value 3.41 mmol / l).</seg>
<seg id="2542">"at the waist circumference the average change -4.5 cm with Orlistat 60 mg (starting value 103.7 cm) and with Placebo -3.6 cm (output value 103.5 cm)."</seg>
<seg id="2543">Plasma concentration of non-diluted Orlistat were 8 hours after the oral gift of 360 mg Orlistat (&lt; 5 ng / ml).</seg>
<seg id="2544">"7 In general, therapeutic dosing is not metabolized in plasma only sporadic and extremely low concentrations (&lt; 10 ng / ml or 0.02 µmol) and without signs of a Kumulation."</seg>
<seg id="2545">"in a study with adipous patients, however, two main metabolite, M1 (in position 4 hydrolyyl-leucine group), was identified as a total of 42% of the total plastic concentration."</seg>
<seg id="2546">"based on conventional studies on safety spicology, toxicity with repetition of repetition, genotoxicity, declinical data are no particular danger for humans."</seg>
<seg id="2547">Firm of the Year for Compliance Audits and Investigations Gibson Dunn & Crutcher Firm of the Year for Corporate</seg>
<seg id="2548">Risk management planning The owner of the permit is described in accordance with the agreement of the Council's risk management (RMP) of October 2008 as well as in the pharmaceutical company (RMP) of October 2008. the Committee on the Committee and all other updates of the RCA which will be agreed with the Committee for Humanities (CHMP).</seg>
<seg id="2549">"according to the CHMP guidelines to risk management systems for humanities, the updated RMP must be submitted to the next PSUR (Periodic Safety Update Report)."</seg>
<seg id="2550">"it should be submitted to a updated RMP: • if new information is available, the current security policies, pharmaceutical kovigilance or risk inimpairment, will take place on request to the European Medicinal Agency (EMEA)."</seg>
<seg id="2551">"* Understand the competitive environment, the market's major players and leading brands; * Use five-year forecasts to assess how the market is predicted to develop."</seg>
<seg id="2552">"if you are pregnant or breastfeeding, • If you are pregnant or breastfeeding, • If you are pregnant or breastfeeding, • if you suffer from cholestase, • if you suffer from cholestase (disease of the liver, when you suffer problems with food intake (chronic malink syndrome)."</seg>
<seg id="2553">"• take a day in a day with each main focus, the fat contains a capsule with water. • You should not take a day before the sleep, a Multivitamintricette (with vitamins A, D, E and K). • You should not use it for longer than 6 months."</seg>
<seg id="2554">"• You should not take a day, before the sleep with water. • take a day, before the sleep with water. • You should not be able to use a Multivitamintball (with vitamins A, D, E and K). • You should not use it for longer than 6 months."</seg>
<seg id="2555">Perhaps you would like to read this later again. • ask your doctor or pharmacist if you need more information or advice. • If you have any weight reduction if you have any weight reduction in your doctor or pharmacist for advice.</seg>
<seg id="2556">"if one of the linked side effects will be considerably reduced or if you notice any side effects that are not specified in this product information, please inform your doctor or pharmacist."</seg>
<seg id="2557">"• If taking care of alli do not have to be used before taking care of alli, • For taking of alli with other medicines • For taking of alli together with food oils and beverages • treatment of alli together with foodstuffs and beverages • alcohol and breastfeeding, and the loading of machinery 3."</seg>
<seg id="2558">What is alli take? • How can you prepare your weights for your calorize and obesity • How long should I take place for your calorize and obesity • How long should I take place? O If you are alli in a large quantities you have forgotten?</seg>
<seg id="2559">What effects are possible? • Beginning side effects • Very frequent adverse side effects • effects on blood tests • How can you control your health benefits?</seg>
<seg id="2560">• How are the overall market and different product segments growing? - How are the overall market and different product segments growing? - How is the market predicted to develop in the future?</seg>
<seg id="2561">"in combination with a Body-measure index (BMI) of 28 or above. in combination with a body-measure index (BMI) of 28 or above, in combination with a low-fat and calorie diet."</seg>
<seg id="2562">The BMI helps you determine whether you have a normal weight or excessive weight or excessive.</seg>
<seg id="2563">"however, if these diseases do not mean that you should feel comfortable if you should ask your doctor if you ask a control test."</seg>
<seg id="2564">"for each 2 kg body weight, you can lose weight and lose weight."</seg>
<seg id="2565">"please inform your doctor or pharmacist if you take other drugs or more recently, even if it is not non-prescription drugs."</seg>
<seg id="2566">"Ciclosporin is used in rheumatoid arthritis, with severe rheumatoid arthritis and specific skin diseases."</seg>
<seg id="2567">The effect of oral hygiene and alli • The effect of oral hygiene (fungi) is weakened or rather than if you have strong diarrhö (penetration).</seg>
<seg id="2568">"please contact your doctor or pharmacist, if you use: • Amiodaron to treat heart rhythm disorders. • Acarbsis treatment for treatment of diabetes."</seg>
<seg id="2569">"if you take drugs against high blood pressure, the dosage must be adjusted against high blood pressure, since the dosage must be adjusted against high cholesterol."</seg>
<seg id="2570">Learn more helpful information on the blue pages in section 6.</seg>
<seg id="2571">"if you do not have a meal and a meal no fat contains, take no capsel. alli can only work when the food contains fat."</seg>
<seg id="2572">"if you take the capsule in combination with a meal that can be too much fat, please take a lot of fat content (see section 4)."</seg>
<seg id="2573">"to get your body to the new eating habits, you will start before the first capsule filling with a calorie and low-fat diet."</seg>
<seg id="2574">Dietary supplements are effective since you can eat what you eat as much you eat and it will probably be easier to change your nutrition habits.</seg>
<seg id="2575">"to achieve your target weight, you should set two daily goals: one for calories and one for fat."</seg>
<seg id="2576">• Need to reduce the probability of dietary supplements (see section 4). • Read more to move more about before you start using the capsules of capsules.</seg>
<seg id="2577">Think about taking your doctor if you don't want physical activity. • lead you while taking place and taking the taking of alli physically active.</seg>
<seg id="2578">• alli must not be taken longer than 6 months. • If you can't find a reduction of your weight you may ask your doctor or pharmacist for advice.</seg>
<seg id="2579">"under circumstances, you need to end the taking of alli. • For a successful weight loss, it is not to return to the diet and then return to the old habits."</seg>
<seg id="2580">"• If less than an hour since the last meal is passed, take the intake of the capsule after. • If more than an hour since the last meal is passed, take no capsel."</seg>
<seg id="2581">(see section 1). (see section 1).</seg>
<seg id="2582">"severe allergic reactions • Heavy-allergic reactions, you can recognise the following changes: heavy breathing, weld-outs, cutouts, juices, swings in face, heart rascal, circulation."</seg>
<seg id="2583">"29 The frequent side effects of this can take place in more than 1 of 10 people, which can take place in more than 1 of 10 people, the alli might take place. • Clear chair with and without armor chair • Weicher chair, your doctor or pharmacist, if one of this side effects or treatment."</seg>
<seg id="2584">"frequent side effects of this can take place in 1 of 10 people, the alli take it. • stomach ache, • Incontinence (chair) • waltriger / liquid chair • Enhance your doctor or pharmacist, if one of this side effects or treatment."</seg>
<seg id="2585">Effects on blood tests There is not known as often these effects occur.</seg>
<seg id="2586">Please inform your doctor or pharmacist if one of the adverse side effects or side effects that are not specified in this form information.</seg>
<seg id="2587">The most common side effects are made with the active capsules of capsules and thus makes it more fat from the body.</seg>
<seg id="2588">"this side effects occur within the first weeks after treatment of treatment, since you may not have to reduce fat content in the diet."</seg>
<seg id="2589">"• Learn more about the usual fatty acids, or better a week before the first taking of capsules with a low-fat diet. • Learn more about the usual fat content of your favorite desserts and about the size of the portions you usually need to take."</seg>
<seg id="2590">"if you want to know exactly how much you eat, the probability that you exceed your fat limit. • Make your recommended fat amount to daily meals."</seg>
<seg id="2591">"the amount of calories and fat, which have done per meal will not be able to take them in shape of a fat-admissible source or gearing up for weight reduction. • The most people in which they can be done with other programs to control their diet. • The most people in which they are to control their diet, learn to control their diet."</seg>
<seg id="2592">• Raw materials for children unaccessible. • The delivery includes two white sealed containers that serve to keep the content of moisture. • The bottle contains two white sealed containers with siliced containers that serve to keep the capsules dry.</seg>
<seg id="2593">You can do this on any case. • You can lead your daily dose in the blue transport box (Shuttle) that lies in this package.</seg>
<seg id="2594">"Famar, 190 11 Avlona, Greece Catalent UK Packaging Limited, Sapphire Close, Headway, Great Oakley, Corby, Northamptonshire NN18 8HS, United Kingdom"</seg>
<seg id="2595">Overweight has influence on your health and increases the risk for the origin of various serious diseases such as: • blood pressure • diabetes • cardiovascular diseases • Osteobuy.com offer with your doctor about your risk for these diseases.</seg>
<seg id="2596">"a permanent weight loss, for example through the improvement of nutrition and more movement, can prevent serious diseases and has a positive influence on your health."</seg>
<seg id="2597">Choose meals that contain a wide range of nutrients and learn to improve their healthy health.</seg>
<seg id="2598">"energy will also be measured in kilojoule, which you can also take advantage of the packaging of food. • The recommended calory consumption, how many calories you should take maximum per day."</seg>
<seg id="2599">Please note the below below in this section below. • The recommended fat supply in gram is the maximum amount of fat which you should take with each meal.</seg>
<seg id="2600">"if the amount of calories are suitable for you, the number of calories are essential for you."</seg>
<seg id="2601">"if you take the same amount of fat as previously, this mean that your body can not work with fat."</seg>
<seg id="2602">"due to compliance with the recommended fat supply, you can maximise the weight loss and at the same time the probability of nutrition is reduced. • You should try to continue, gradually and continuously increase."</seg>
<seg id="2603">34 These reduced calorie supply should allow you to take up to approximately 0.5 kg per week to lose weight without frustration and ends.</seg>
<seg id="2604">"• If physical activity is, the higher is your recommended calorie supply. •" "the physical activity" means that you can take a daily weight of 150 kcal, for example through 3 km Walk, 30- to 45-minute garden work or 2 km running in 15 minutes. "</seg>
<seg id="2605">"• For a permanent weight loss, it is necessary to set realistic calorize and fat content. • attempts to move more to move more than before you start using the taking of alli."</seg>
<seg id="2606">"the alli program for support of weight loss combines the capsules with a diet plan and a large number of information material that can help you to feed calorize and fetches and directives, physically active."</seg>
<seg id="2607">"in conjunction with your type-cut program to support the weight loss, you can help you to develop a healthier lifestyle and your target weight."</seg>
<seg id="2608">"Aloha is applied to chemotherapy for nausea and vomiting (like Cisplatin), as well as chemotherapy, such as cyclophosphamide, Doxorubicin or Carboplatin."</seg>
<seg id="2609">The efficacy of Aloxi can be increased by the additional gift of a Corticosteroids (a medicine that can be used as a antioxidant).</seg>
<seg id="2610">"the application for patients under 18 years is not recommended, because the effects in this age group does not have enough information."</seg>
<seg id="2611">"this means that the active substance of a chemical substance in the body, 5-hydroxytyptamin (5HT, also known as Serotonin), on the receptors in the intestines."</seg>
<seg id="2612">"Aloxi was examined in three main studies at 1 842 adults, the chemotherapy regiments, which are strong and homogenous for nausea and vomiting."</seg>
<seg id="2613">"in chemotherapy, the strong trigger for nautical and vomiting, the 59% of the patients who were treated with Aloxi were treated in the 24 hours after chemotherapy (132 of 223), compared to 57% of the patients (126 of 221)."</seg>
<seg id="2614">"in chemotherapy, the excessive trigger for nausea and vomiting, 81% of patients who were treated with Aloxi were treated (153 of 189), compared to 69% of the patients with Ondansetron patients (127 of 185)."</seg>
<seg id="2615">"in comparison with Dolasetron, these values at 63% for Aloxi (119 of 189 patients) and 53% for Dolasetron (101 of 191 patients)."</seg>
<seg id="2616">"Swiss Hemp Initiative, collecting signatures at Paleo-Festival Nyon 2005"</seg>
<seg id="2617">"Aloxi is indian: for prevention of acute nausea and vomiting at the prevention of nausea, and vomiting for the prevention of nausea and vomiting with a cancer disease."</seg>
<seg id="2618">The efficacy of Aloxi for prevention of nausea and vomiting which can be strengthened by a strongly ematic chemotherapy can be reinforced by adding one before the chemotherapy given Corticosteroids.</seg>
<seg id="2619">"since Palonosetron the colon should extend the colon, patients with anamnestial Obstipation or signs of a subtle structure."</seg>
<seg id="2620">"as with other 5HT3 antenna, however, it is advisable to extend the QT interval or for patients where the QT- interval is extended, or the extension of such an extension refers to."</seg>
<seg id="2621">"except in connection with another chemotherapeutics gift, Aloxi could not be used for the treatment of nausea and vomiting."</seg>
<seg id="2622">"in a clinical trials, Palonosetron angiogenous activity of the five-chemotherapeutics, cyclophosphamide, Cycloabin, Doxorubicin and Mitomycin C)."</seg>
<seg id="2623">"in a clinical study, no significant changes in a clinical study showed no significant changes between a unique intravenous dose of Palonosetron and a steady concentration of metoclopramines, a CYP2D6 inhibitors."</seg>
<seg id="2624">"in a population based on the population of CYP2D6-Inductors (Amiodaron, Cimomicin) as well as by CYP2D6-Inductors (Amiodaron, Cimalicin) as well as by CYP2D6-Inductors (Amiodarl, Cimomicin) as well as by CYP2D6-Inductors (Amiodarl, Seronavir, Sertrine and Terbinafin) have no significant effect on the Clearance of Palonosetron."</seg>
<seg id="2625">"experiences to application of Palonosetron at human pregnancy, therefore, Palonosetron at pregnancy are not applied, unless it is necessary if necessary."</seg>
<seg id="2626">"clinical trials were the most common in a dose of 250 micrograms (total of 633 patients), which may possibly be associated with Aloxi related to headaches (9%) and Obstipation (5%)."</seg>
<seg id="2627">"very rare cases (&lt; 1 / 10,000) of oversensitive actions and reactions to the administration of contact (Brent, Verhardening, complaints and pain) were given in post-marketing."</seg>
<seg id="2628">"in the group with the highest dosage, similar results showed similar effects of unwanted events such as in the other docking groups; there were no need for dose-operation relationships."</seg>
<seg id="2629">"however, no dialysis studies were carried out because of the large distribution volume is a dialysis, however, no effective therapy in a Aloxii overdose."</seg>
<seg id="2630">"in two months, a total of 1,132 patients treated with ≤ 50 mg / m2 Cisplatin, Carboplatin, ≤ 1,500 mg / m2 Cyclocks, ≤ 250 mg / m2 Cyclocking (half hours) or 100 mg Dolasetron (half-value 4 hours) or 100 mg Dolasetron (half-value 4 hours) or 100 mg Dolasetron (half-value 4 hours) or 100 mg Dolasetron (semi-werage 4 hours) or 100 mg Dolasetron (semi-werage 4 hours) or 100 mg Dolasetron (semi-werage 4 hours) or 100 mg Dolasetron (half-value 7.2 hours)."</seg>
<seg id="2631">"in a prospective study double-study double blind study, a total of 667 patients who were compared with patients with 60 mg / m2 Cyclophosphate and Dacarbazin as well as 250 or 750 microgram Palonosetron, which was added to the day 1 intravenous retinal detachment."</seg>
<seg id="2632">Results of studies with secondary chemotherapy and the study with strongly ematic chemotherapy are summoned in the following tables.</seg>
<seg id="2633">"clinical trials for indications of chemotherapy-induced chemotherapy and vomiting (CINV), the effects of Palonosetron on blood pressure, heart rate and EKG parameters including the corresponding effects of Ondansetron and Dolasetron."</seg>
<seg id="2634">"according to the clinical studies, Palonosetron, the ability to block the ventricular deduction and repolarisation of the Ionary channels, and the duration of action."</seg>
<seg id="2635">"* Understand the competitive environment, the market's major players and leading brands; * Use five-year forecasts to assess how the market is predicted to develop."</seg>
<seg id="2636">Resorption to intravenous complaints follows an initiation of the plasma concentration of a slow Elimination from the body with a average date of less than 40 hours.</seg>
<seg id="2637">The average maximum plasma concentration (Cmax) and the area under the concentration of time curve (AUC0-) are generally in general in the whole Dosisrange of 0.3- 90 kg / kg in particular and cancers.</seg>
<seg id="2638">"after intravenous gift of Palonosetron 0.mg every second day for a total of 3 cans were measured between day 1 and day 5 measured intervals (± SD), the Palonosetron concentration camp at 42 ± 34%."</seg>
<seg id="2639">"as a result, the intraocular inflammation of 0.75 mg palonosetron had been comparable to a single intravenous adoption of 0.75 mg measured value. however, the Cmax was higher than 0.75 mg higher."</seg>
<seg id="2640">"about 40% will be eliminated by the kidneys and about other 50%, compared to Palonosetron, compared to Palonosetron over less than 1% of the antagonist effect on 5HT3 receptor."</seg>
<seg id="2641">"in vitro tests to metamortisation have shown that CYP2D6 and, in lower measurements, the isoenzymes CYP3A4 and CYP1A2 on Metabolism by Palonosetron."</seg>
<seg id="2642">Elimination In a intravenous single dosis of 10 micrograms / kg [14C] -Palonosetron were found about 80% of the dose within 144 hours.</seg>
<seg id="2643">"after a unique intravenous bolt formation, the total body of 173 ± 73 ml / min and the renal Clearance 53 ± 29 ml / min."</seg>
<seg id="2644">"in patients with severe liver function reduces the date of the average systemic position with Palonosetron, a reduction of the dose is not justified."</seg>
<seg id="2645">"clinical trials were observed only after expositions, which revealed to be sufficient about the maximum human body position, which indicates a small amount of clinical use for clinical use."</seg>
<seg id="2646">"10 And a clinical studies showed that Palonosetron is involved in very high concentrations of Ionosetron, which can lead to the ventricular deduction and repolarisation."</seg>
<seg id="2647">"high doses Palonosetron (each dose), which were given over two years, led to an increased frequency of liver disease, endocrine, Pankreas, adsorremark and Hauttumors, but not with mice."</seg>
<seg id="2648">"the underlying mechanisms are not fully known, but due to the high dosing system and since Aloxi can be used for a unique application, the relevance of these results are not low."</seg>
<seg id="2649">The owner of this permit is to inform the European Commission on the plans to inform the Commission of the Commission on the framework of this decision.</seg>
<seg id="2650">"• If one of the linked side effects will be considerably lower or if you notice any side effects that are not specified in this product information, please inform your doctor."</seg>
<seg id="2651">• Aloxi is a clear, colourless injection solution to injector in a vene. • The active substance (Palonosetron) belongs to a group of medicines that can cause nausea and vomiting. • Aloxi is used for preventing nausea and vomiting, which occur in connection with chemotherapy. "</seg>
<seg id="2652">"21 In the application of Aloxi with other medicines, please inform your doctor if you use other medicines to use or have recently taken care, even if it is not non-prescription drugs."</seg>
<seg id="2653">"pregnancy If you are pregnant or believe, your doctor will not give you Aloxi, unless it is clear."</seg>
<seg id="2654">"if you are pregnant or pharmacist for advice, if you are pregnant or believe you are pregnant."</seg>
<seg id="2655">In some very rare cases it was allergic reactions to Aloxi or breeder or pain.</seg>
<seg id="2656">"as Aloxi looks and content of the package Aloxi injector solution is a clear, coloured solution and is available in a package with 1 penetration bottle made of glass, which contains 5 ml of the solution."</seg>
<seg id="2657">My Schedule &lt; 1 | 18 | 18 | 18 | 18 | 18 | 18 | 18 | 18 | 18 | 18 | 18 | 18 | 18 |</seg>
<seg id="2658">Latvija pharmaceutical Swiss Airlines SIA 54-5 business days of the Street Race, LV-1011 Tel: + 37167502185 Lietuva UAB pharmaceutical Swiss Š eimyniš. "</seg>
<seg id="2659">United Kingdom United States-Ltd. Chester Business Park Chester CH4 9QZ - UK Tel: + 44 1244 625 152</seg>
<seg id="2660">June 2006 approved the Committee for Humanities (CHMP) a negative opinions expressed by the approval of hepatitis C associated drugs using Alpheon 6 million IE / ml injection solution was recommended.</seg>
<seg id="2661">This means the alpheon is a biological medication called Roferon-A with the same medical treatment.</seg>
<seg id="2662">Alpheon should be used for the treatment of adult patients with chronic hepatitis C (one by a viral infection) of hepatitis C (a virus infection).</seg>
<seg id="2663">"in a microsimulation study the liver tissue damage occurs, the values of the liver disease is increased in blood-norm (ALT) in the blood-norm."</seg>
<seg id="2664">It is produced by a yeast produced in which a gene (DNA) was brought into the formation of the active substance.</seg>
<seg id="2665">"the manufacturer of Alpheon laid the data before the alpheon with Roferon-A clearly (active material structure, composition and purity of the medicines), active safety and efficacy in hepatitis C)."</seg>
<seg id="2666">"in the study to patients with hepatitis C, the efficacy of Alpheon will be compared to 455 patients."</seg>
<seg id="2667">"in the study, such as many patients after 12 of 48 treatment weeks and 6 months after setting the treatment on the medicine (i.e. no signs of the virus in the blood.)."</seg>
<seg id="2668">"* Understand the competitive environment, the market's major players and leading brands; * Use five-year forecasts to assess how the market is predicted to develop."</seg>
<seg id="2669">"furthermore, we have to show that the data for the stability of the active substance and the market is not affected."</seg>
<seg id="2670">"the number of patients with hepatitis C, which was similar to the treatment with Alpheon and Roferon-A, was similar to the clinical study."</seg>
<seg id="2671">After setting of the treatment with Alpheon flamming the disease in more patients come back to a reference contract; also Alpheon more side effects.</seg>
<seg id="2672">"apart from this in the study test, the test test for the investigation of the question, which the medicine is a immune response (i.e. the body forms antibodies - special proteins - against the medicine), not sufficiently validated."</seg>
<seg id="2673">"it can be used for treatment of Impetigo (one with crush formation) and small cavities (Rising or chives), departures and genders."</seg>
<seg id="2674">"Altargo should not be used for treatment of infections, which have been caused by methicillinic Staphylococcus aureus (MRSA) because alarm."</seg>
<seg id="2675">"Altargo can be used for patients from nine months, but at the age of 18 years, the skin surface is not more than 2% of the body surface."</seg>
<seg id="2676">"in case of the patient after two to three days, the physician should examine the physician to investigate patients and alternative treatments."</seg>
<seg id="2677">It works by block the bacterial Ribosses (the parts of bacteria in which proteins are produced) and inhibiting the growth of bacteria.</seg>
<seg id="2678">Main indices of the effectiveness was in all five trials of the proportion of patients whose infection was treated after the treatment of treatment.</seg>
<seg id="2679">119 (85.6%) of 139 patients under Altargo and 37 (52.1%) of the 71 patients under Placebo.</seg>
<seg id="2680">Altargo and Cefalexin similar means: if the results of both studies at the skin were collected about 90% of the patients of both groups of both groups.</seg>
<seg id="2681">"however, in these two studies were found that Altargo was caused by infections (eiterfilled cavities in the body tissue) or infections, which were not effective or perhaps caused by MRSA, not effective enough."</seg>
<seg id="2682">The most common side effects with Altargo (which was observed in 1 to 10 of 100 patients) is a travel to the supplier.</seg>
<seg id="2683">"the Committee for Humanities (CHMP) corresponds to the conclusion that the advantages of Altargo, the following surface treatment of the surface treatment: • Impetigo, • infected small Lazerations, departures or genres."</seg>
<seg id="2684">"in May 2007, the European Commission published the European Commission of Glaxo Group Ltd., called by Altargo in the whole of the European Union."</seg>
<seg id="2685">"in the case of two to three days, the patients shall not be examined in two to three days, even with an alternative therapy (see section 4.4)."</seg>
<seg id="2686">"in case of a sensitivity or severe local Irritation due to the application of reapamulin Salbe, the treatment is broken, the salbe carefully and an appropriate alternative treatment of infection will be started."</seg>
<seg id="2687">"for the treatment of infections, for example, MRSA is known to treat infections in which MRSA is known or referred to (see section 5.1)."</seg>
<seg id="2688">Clinical trials in clinical trials was the effectiveness of retinopathy in patients with infections that caused by a methicillin-resistant Staphylococcus aureus (MRSA) causes.</seg>
<seg id="2689">An alternative therapy should be moved if after a 2- or 3-day treatment.</seg>
<seg id="2690">The impact of simultaneous use of reapamulin and other topical means at the same skin is not examined and the simultaneous use of other topical drugs is not recommended.</seg>
<seg id="2691">"due to the low plasma concentration, which were achieved by topical use on the skin or the surface of the surface, is a clinically relevant inhibition in vivo is not expected (see Section 5.2)."</seg>
<seg id="2692">3. simultaneous gift of 2-times daily 200 mg Ketoconazol increased the middle of 1% reapamantiauc (0-24) and Cmax according to topical application of 1% reapamulin Salbe at the same skin of healthy adult men around 81%.</seg>
<seg id="2693">"due to the low-systemic preparation for patients, Dosiscans are not necessary for patients when topical reapamination during a systemic treatment with CYP3A4 inhibitors."</seg>
<seg id="2694">Animal studies have shown a reproduction based on a statement and are inadequate in relation to a statement on the birth and the feit / postnatal development (see section 5.3).</seg>
<seg id="2695">Reapamón Salbe should only be used during pregnancy only when a topical antibacterial therapy is clear and the application of retinapamón is to be preferable by a systemic antibacterial therapy.</seg>
<seg id="2696">"in the decision, whether the breast has continued / ended or the therapy with Altargo continued, is between the benefit of the breastfeeding for the infant and the benefit of the Altargo therapy for the mammals."</seg>
<seg id="2697">"clinical trials in clinical trials of 2150 patients with superficial skin infections, which was most commonly reported by Irritation on the appointment of the adoption of approximately 1% of the patients."</seg>
<seg id="2698">Treatment of retinopathy is a semi-synthetic derivatives of Pleuromutilin, a substance that caused by fermentation of Clitopilus passiserianus (previous Pleurotus passiserianus). "</seg>
<seg id="2699">The anti-bacterial protein synthesis is based on the selective inhibiting of bacterial proteins.</seg>
<seg id="2700">"data coverage: market sizes (historic and forecasts), company shares, brand shares and distribution data. why buy this report? * Get a detailed picture of the Baby Food market; * Pinpoint growth sectors and identify factors driving change; * Understand the competitive environment, the market's major players and leading brands;"</seg>
<seg id="2701">"thanks to Binding to this Binding, Pleuromutiline the Peptidylbank transfer, partially partly P-binding-interactions and prevent the normal education of meticular subunits."</seg>
<seg id="2702">"at least of the local prevalence of resistance the application of retinapamón, at least some of the risk of infection, should be a consultation through experts."</seg>
<seg id="2703">"there were no differences in the in-vitro activity of reapamulin, regardless of whether the insulates are sensitive or resistant to methicillin."</seg>
<seg id="2704">In case of a non-violent treatment to the treatment at S.aureus should be considered the presence of stems with additional viral factors (such as PVL = Panton-Valentine Leucocidin).</seg>
<seg id="2705">Resorption In a study with healthy adults was 1% reapamón Salbe daily under the occult and spread skin for up to 7 days.</seg>
<seg id="2706">"from 516 patients (adults and children), the 1% reapamón Salbe twice daily for 5 days to the topical treatment of secondary wounds, individual plasma systems were won."</seg>
<seg id="2707">The sample took place on the days 3 or 4 with the adult patients before the media and for the children between 0-12 hours after the last application.</seg>
<seg id="2708">"however, the maximum individual system recording at the people after topical application of 1% Salbe to 200 cm2, separate skin (Cmax = 22 ng / ml; auc (0-24) = 238 ng · h / ml) 660-times lower than the reapamulin IC50 for the PGP shirt."</seg>
<seg id="2709">Metabolism in vitro are primarily primarily caused by CYP3C8 and CYP2D6 (see section 4.5).</seg>
<seg id="2710">"in studies for oral toxicity on rats (50, 150 or 450 mg / kg), which were carried out over 14 days, there were signs of adapted liver and thyroid alterations."</seg>
<seg id="2711">In-vitro test on Genentation and / or chromosomal effects in the mouse lymph test or in cultures of human peripheral blood lymphocytes and in the rats-microscope test for in-vivo analysis chromosomatic effects.</seg>
<seg id="2712">"there was neither for male rats with female rats, with reduced fertile dosing from 50, 150 or 450 mg / kg / day, making a up to 5 times higher Exposition in person (topical application to 200 cm2)."</seg>
<seg id="2713">"in a embryotoxicity study, the rats were found in a embryonic dosing system (see above), development aid and maternal toxicity (see above), development aid and maternal toxicity."</seg>
<seg id="2714">The owner of the permission for the Insured must ensure that a pharmaceutical company has to be present in the module 1.8.1 of the approval process (version 6.2) and works before the product will be applied.</seg>
<seg id="2715">The owner of the permit is obliged to provide detailed studies and additional pharmaceutical kovigilding activities as it is described in the version 1 of Risk Management Plan (RMP) and in the module 1.8.2 of the authorisation procedure and all additional updates of the RMP that will be agreed with the CHMP.</seg>
<seg id="2716">"like in the CHMP" guideline on Risk Management Systems for Rwanda use ", the updated RMP can be submitted to the next periodic Safety Update Report."</seg>
<seg id="2717">Travel or other signs and symptoms may show the application of Altargo and with your doctor.</seg>
<seg id="2718">"do not turn any other salons, creams, or lottery on the surface, which has been treated with Altargo, if it is not expressly prohibited from your doctor."</seg>
<seg id="2719">"it may not be used in the eyes, on the mouth or on the lips, in the nose or in a female genital area."</seg>
<seg id="2720">"if the salbe made out of use on one of this area, wash the place with water and ask your doctor to advice, if complaints occur."</seg>
<seg id="2721">"after receipt of the salbe, you can cover the maximum surface with a sterile association or Gazebo, unless your doctor has to give you the area."</seg>
<seg id="2722">"it is available in a aluminium profile with a plastic clasp, which contains 5, 10 or 15 gram salbe contains, or in a aluminium bag, the 0.5 g salbe contains."</seg>
<seg id="2723">"Ambidextrous is used to protect against hepatitis A and hepatitis B (diseases, which are applied to the liver) of children aged between one and 15 years, which are still not impregnated against these two diseases."</seg>
<seg id="2724">"Ambidextrous is used in the frame of a two-cans of existing vaccines, whereby a protection against hepatitis B may possibly be achieved after use of the second dose."</seg>
<seg id="2725">"for this reason, Ambient should only be used when the immune system is a low risk of hepatitis B infection and ensure that the vaccine plan can be led to the end of two cans."</seg>
<seg id="2726">"if a defective dose is given against hepatitis A or B, it can be given amrix or another hepatitis C or -B vaccine."</seg>
<seg id="2727">Vaccines by preventing the immune system (the natural material of the body).</seg>
<seg id="2728">"after a child has received the vaccine, the immune system replaces the viruses and surface antigens as" "foreign" "and generates antibodies."</seg>
<seg id="2729">"Ambidexs contains the same components like that since 1996 approved vaccine Twinrix adults and the since 1997 approved vaccine Twinrix children."</seg>
<seg id="2730">"the three vaccines are used for protection against the same diseases, but are Twinrix and Twinrix children in the frame of a three-cans existing vaccines."</seg>
<seg id="2731">There are some of the data that used the use of Twinrix adults and also used as a cover for the application of Ambient.</seg>
<seg id="2732">The main indikator for the effectiveness was the share of the old children who had developed a month after the last injections.</seg>
<seg id="2733">In an additional study with 208 children the effectiveness of vaccine is compared to a six-month distance between the two injections.</seg>
<seg id="2734">"results appear ordered" "by relevance" "or" "by date" "(publication date),"</seg>
<seg id="2735">The additional study showed that the degree of protective measures are similar to a single and 12-month distance between the injections.</seg>
<seg id="2736">"the most common side effects of Ambidexs (observed in more than 1 of 10 vaccine) are headache, pain at the injection point, redness, fibers (fatigue) and friction."</seg>
<seg id="2737">"Ambidexs must respond to patients that may be sensitive (allergic) to the active substances, one of the other components or Neomycin (a research)."</seg>
<seg id="2738">"in August 2002, the European Commission published the European Commission of GlaxoSmithKline Biologics s.a. a permit for the Induction of Ambient in the entire world"</seg>
<seg id="2739">"the result is a result of two vaccines, whereby the first dose on the appointment and the second dose between six and twelve months after the first dose."</seg>
<seg id="2740">"if a risky limit is desired for hepatitis A as well as for hepatitis B, can be applied to the corresponding monovalous vaccines or combined with a combination of combination."</seg>
<seg id="2741">The anti-hepatitis C-virus (anti-HABsAg) and anti-hepatitis A virus (anti-HAV) and anti-hepatitis A virus (anti-HAV) -anti-hepatitis A-virus (anti-HAV) -anti-hepatitis A-virus (anti-HAV) -anti-hepatitis C virus (anti-HAV) - anti-hepatitis C virus (anti-HAV) and anti-hepatitis A virus (anti-HAV) and anti-hepatitis A virus (anti-HAV) and anti-hepatitis A virus (anti-HAV) and anti-hepatitis A virus (anti-HAV) and anti-hepatitis A virus (anti-HAV) and anti-hepatitis A virus (anti-HAV) and anti-hepatitis A virus (anti-HAV) and anti-hepatitis A virus (anti-HAV) and anti-hepatitis A virus (anti-HAV) and anti-hepatitis A-virus (anti-HAV) -anti-</seg>
<seg id="2742">"it is not completely secured, whether it is not secured by the immune system, which need to be protected against a hepatitis-A- which may need to be protected from the immunological memory, as they are not protected against immunological memory."</seg>
<seg id="2743">"3 As in all injection moulding materials should be available for the rare case of an anaphylaktic reaction to the gift of the vaccine, corresponding opportunities of medical treatment and monitoring."</seg>
<seg id="2744">"if a faster protection against hepatitis B is necessary, the total range of hepatitis B units is recommended, the 360 ELISA units formalinactivated hepatitis A virus and 10 µg recombined hepatitis B surface surface."</seg>
<seg id="2745">"if the immune system is treated with the immune system, there is no sufficient anti-HAV- and anti-hbs anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti</seg>
<seg id="2746">"as a intravitreous injtion or inhibition of injections to a subtle impetus could lead to a suboptimal impetus, should these injections should be avoided."</seg>
<seg id="2747">"when Thrombozytopenie or blood flow disturbances can be carried out in these cases, since it may occur in these cases."</seg>
<seg id="2748">Firm of the Year for Compliance Audits and Investigations Gibson Dunn & Crutcher Firm of the Year for Private Construction Luther</seg>
<seg id="2749">Patients with immune disease treatment or patients with immune system must be achieved in patients that may not be sufficient sufficient immunotherapy.</seg>
<seg id="2750">"in a clinical study, which was observed with 3 vaccination in adults, the frequency of pain, redness, body, body, and fever, headache, and fibrosis, headache, and preservatives with the frequency that was observed in the previous Thibausaline and preservative vaccination."</seg>
<seg id="2751">"in clinical trials, 2029 vaccine Ambient to a total of 1027 vaccines in the age of 1 to 15 years."</seg>
<seg id="2752">In a study with 300 participants were compared to the age of 12 to 15 years.</seg>
<seg id="2753">"the only exceptions were the higher number of pain and sailors at a calculation center, but not on a calculation basis per person."</seg>
<seg id="2754">"pain was observed after the gift of Ambidexat by 50.7% of the test purposes, compared with 39.1% during the trial of a dose of 3-cans combination."</seg>
<seg id="2755">"after the complete vacccycle, 66,4% of the subjects, the Ambiance had to get lost, over pain, compared to 63.8%, with the 3-Doscope combination."</seg>
<seg id="2756">"however, the frequency of Mats was comparable to 39.6% of the proxy, compared with 36.2% in the subjects that received the 3-cans combination."</seg>
<seg id="2757">The frequency of pain and body was low and comparable to the administration of the combination of combination with the 3-cans vaccination.</seg>
<seg id="2758">"in a comparison study at 1-11-year vaccines, the occurrence of local actions and general conditions in the Ambient of hepatitis A virus and 10 µg recombinant hepatitis B surface treatment was observed."</seg>
<seg id="2759">"during the 6- up to 11- year, however, however, after the age with Ambient, an increase of pain (at the injector office) per dose, not per sample, reports."</seg>
<seg id="2760">The share of vaccines that have more severe side effects during the 2-cans vaccine with the combination of 360 ELISA- units and 10 µg recombinant of hepatitis A virus and 10 µg recombinant of hepatitis A virus and 10 µg recombinant of hepatitis B vaccine.</seg>
<seg id="2761">"clinical trials, which were carried out in clinical trials, were carried out for anti-HAV 99.1% one month after the first dose and 100% one month after the second half of 6 years."</seg>
<seg id="2762">The Seroitte rates for anti-hbs were 74.2% one month after the first dose and 100% one month after the second half of 6% (i.e. in month 7).</seg>
<seg id="2763">"7 In a comparative study, which was carried out in 12- until the 15-year was carried out, 142 two cans Ambient and 147 the standard combined with three cans."</seg>
<seg id="2764">"at the 289 individuals, their immunogenic rates were significantly higher than in the month 2 and 6 after the gift of the 3-Dosenimum hydrogen sulphies significantly higher than with Ambient."</seg>
<seg id="2765">"in the following table, the immune system was observed in a clinical study study at a month after the end of the full vaccine (i.e. in month 7), are listed in the following table."</seg>
<seg id="2766">In both studies the vaccinations will be either a 2-bit vaccine with Ambient or 3-cans vaccine with a combination of 360 ELISA units and 10µg recombinant hepatitis B surface surface.</seg>
<seg id="2767">"at least 24 months, the persistence of anti-HAV- and anti-hbs anti-anti-anti-anti-anti-anti-vaccinations will be demonstrated at least 24 months after the Immunisation with Ambient in 0-6 months vaccination."</seg>
<seg id="2768">"this study was comparable to both antioxidant action against both antigens, consisting of 360 ELISA units in hepatitis B-virus and 10 µg recombinant hepatitis B surface in a Dosisex volume of 0.5 ml."</seg>
<seg id="2769">"in a clinical study at 12- to including 15-year-old, the performer of anti-HAV- and anti-hbs-anti-vaccination was comparable to the 0-12 months vaccination."</seg>
<seg id="2770">"if the first dose of Ambient in the second half of the year at the same time, the immune system (DTPa-IPV / Hib) or with the first dose of a combined Masks, inactivating polishing (DTPa-IPV / Hib) or with the first dose of a combined masculoskeles (DTPa-IPV / Hib), was the immune response to all antioxidants."</seg>
<seg id="2771">"clinical study, which was carried out with 3 doses of the formulation on adults, showed that the current formulation similar to Seroprotron and Seroconverters rates as for the earlier formulation."</seg>
<seg id="2772">The vaccine is known as well as after the resusation of the eye on any foreign particles and / or physiological changes.</seg>
<seg id="2773">"in accordance with Article 114 of Directive 2001 / 83 / EC of the Act, the state of the state shall be made from a state laboratory or to this end authorized laboratory."</seg>
<seg id="2774">Privacy policy: your entries are only used to answer this enquiry.</seg>
<seg id="2775">"suspension springs for the injunction 1 ready-to-use needle 1 ready for needle 1 prefilled with needle 10-injection moulds with Nadal 1 cup, without fat 1 dose (1 ml)"</seg>
<seg id="2776">Categories / 1 / 02 / 224 / 224 / 224 / 224 / 224 / 224 / 224 / 224 / 224 / 224 / 224 / 224 / 224 / 224 / 224 / 224 / 224 / 224 / 224 / 224 / 224 / 224 / 224 / 224 / 224 / 224 / 224 / 224 / 224 / 224 / 224 / 224 / 224 / 224 / 224 / 224 / 224 / 224 / 224</seg>
<seg id="2777">"the hepatitis A virus is usually referred to by viral foods and drinks, but can also be transmitted by other ways such as bathing in the barrels of contamination."</seg>
<seg id="2778">"you can feel tired, have a dark urine, a blow-face, yellow and / or eyes (Gelbán) and other symptoms that may need a stationary treatment."</seg>
<seg id="2779">"as with all vaccines, Ambient can not protect against a infection with hepatitis C or hepatitis B virus, even if the full vaccine series was completed with 2 cans."</seg>
<seg id="2780">"if you are infected with your child before the adoption of both vaccinations, or hepatitis B virus are infected with hepatitis C or hepatitis B virus."</seg>
<seg id="2781">"protection against other infections, which cause the liver damage or symptoms which are similar to which after a hepatitis-A- or hepatitis B infection can not be found."</seg>
<seg id="2782">"• If you already have an allergic reaction to Ambient or any part of this vaccine, including Neomycin (a research)."</seg>
<seg id="2783">"• If you have an allergic reaction to an earlier amnesty to hepatitis A or hepatitis B or hepatitis B. • if you have an allergic reaction to hepatitis A or hepatitis B or hepatitis B. • If you have an allergic reaction to hepatitis A or hepatitis B or hepatitis B. • If you have an allergic reaction to hepatitis A or hepatitis B."</seg>
<seg id="2784">• if you want to have a protection against hepatitis B (i.e. within 6 months and prior to the applicable administration of the second vaccine).</seg>
<seg id="2785">"during a possible risk of infection with hepatitis B between the first and second Image, the doctor will help you / your child from a beholding with Ambient rates."</seg>
<seg id="2786">"instead, it will also recommend you / your child 3 injections for combined hepatitis A virus and 10 microgram of a recombinable hepatitis B-virus and 10 microgram of a recombinable hepatitis B surface treatment."</seg>
<seg id="2787">The second vaccdosis of this vaccine is usually used for the first dose. usually one month after the first dose is usually usually one month after the first dose.</seg>
<seg id="2788">"sometimes, Ambient with persons who suffer from severe blood cells, under the skin and not in the muscle. • If you are looking for your child because of a disease or treatment in your / her body's body."</seg>
<seg id="2789">"Ambidexs can be given in these cases, but the immune response may not be sufficient so that a blood test can be required to see how strong the reaction to the age."</seg>
<seg id="2790">"21 Saints your doctor if you take care of your child (including those that you can get without loss) or if you have recently bought or Immunglobuline (antibodies), or this is planned in the near future."</seg>
<seg id="2791">"it may be that in this case the immune response to the vaccine is not sufficient, and the person is not protected against one or both hepatitis A and B virus."</seg>
<seg id="2792">"if a other vaccine can be given with a Ambient, should be given to separate places and as possible as possible as possible."</seg>
<seg id="2793">"if you are working on the same time or shortly before or after a injector of Immunglobulines, it is likely that the reaction to the vaccine is still adequate."</seg>
<seg id="2794">"as a result, Ambidexs or relieving women is not necessary, except in hepatitis A as well as hepatitis B as well as hepatitis B."</seg>
<seg id="2795">Important information about certain other components of Ambient Please inform your doctor if you already have an allergic reaction to Neomycin (antibiotic).</seg>
<seg id="2796">"if you miss the agreed date for the second time, talk with your doctor and arrange a new date as soon as possible."</seg>
<seg id="2797">"if you have any questions, please contact us on Tel.: + 49 5764 318 444. or contact us per email."</seg>
<seg id="2798">Firm of the Year for White Collar Crime Redeker Sellner Dahs Order JUVE German Commercial Law Firms Order the print version of JUVE German Commercial Law Firms</seg>
<seg id="2799">"other side effects, days or weeks after the age with comparable combination or single-dimensional combination of hepatitis A and hepatitis B very rare (less than 1 case per 10,000 vered cans) are:"</seg>
<seg id="2800">"these include fixed or broad scale, which can be fixed or burned-shaped, swelling of the eye and the face, swelling of the eye and the face, sudden blood pressure and consciousness."</seg>
<seg id="2801">"swing-related complaints, including bulk, muscular, muscle and joint pain", "multiple sclerosis, loss of tendons, loss of tendons, loss of tendons, loss of tendon, interruption of the neck, interruption of normal brain functions"</seg>
<seg id="2802">"the inflammation of the blood vessels of the blood vessels, caused by the blood vessels or blood vessels, caused to blood vessels or blood vessels (blue spots), caused by waste of blood sugar."</seg>
<seg id="2803">23 Informing your doctor or pharmacist if one of the linked side effects or side effects that are not specified in this package site.</seg>
<seg id="2804">"Ambient is available in packing up to 1 and 10 with or without head, and packing in packaging."</seg>
<seg id="2805">"on the basis of the data that have been known since the creation of the first permit, the CHMP show that the benefit-risk ratio of Ambient remains positive."</seg>
<seg id="2806">"but in a member state (in the Netherlands since May 2003), the available safety data for this medicine has been limited due to the low degree of patient."</seg>
<seg id="2807">Ammonia can also be used in patients at age of over one month with a complete Enzymphs or hyperammonary opathy (brain damage due to high ammonium concentration) in the prehistory.</seg>
<seg id="2808">Ammonia is divided - split by several single species to the meals - split under the stomach or a nose (through the abdominal hose) or a nose (through the nose into the stomach leading tube).</seg>
<seg id="2809">"it was not a comparable study, since Ammonia does not have to be compared with any other treatment or with Placebo (a headaches, i.e. without agent)."</seg>
<seg id="2810">"ammonia can also be used for appraisal, an abductive mammate in blood, depression, mucation, headache, smell, constipation, skin, constipation, skin irritation, skin irritation, skin irritation, skin irritation, skin or weight loss."</seg>
<seg id="2811">The Committee for Humanities (CHMP) corresponds to the conclusion that ammong in patients with malfunction of the urinary cycle to high ammonia treatment.</seg>
<seg id="2812">Ammonia was approved under "exceptional circumstances" as due to the selection of the disease at the time of approval only limited information about this medicine.</seg>
<seg id="2813">The use of all patients who have a complete endothelial deficiency in the first 28 liver (within the first 28 Lebenstage).</seg>
<seg id="2814">"in patients with a late study solid form (inappropriate Enzymphs, after the first life balance) is then an indication for the use when in Anamnese Enters."</seg>
<seg id="2815">"for infants, for children, who are not able to swallow or for patients with gorckdisorders, AMMONAPS also available in granular form."</seg>
<seg id="2816">The daily dose is individually tolerated under consideration of the protein tolerant and the development of the daily protein absorption of the patients.</seg>
<seg id="2817">"after the existing clinical experience, the normal daily dose is sodium polyphenylbutyrat: • 450 - 600 mg / kg / day for children with a weight of less than 20 kg • 9.9 - 13.0 g / m ² / day for children with a body weight of 20 kg, as well as a growing and adult adults."</seg>
<seg id="2818">"in case of patients who suffer an early treatment of Carbamylliatulamylase, the substitution of Citron or Arginine is required in a dosage of 0,17 g / kg / day or 3.8 g / m ² / day."</seg>
<seg id="2819">Patients with an argininosuccinatsynthetase deficiency must be toxic in a dosage of 0.4 - 0.7 kg / kg / day or 8.8 - 15.4 g / m ² / day.</seg>
<seg id="2820">AMMONAPS tablets may not exceed patients with gorckdisorders because there is a risk for the formation of Ösophagulzera if the tablets not immediately get into the stomach.</seg>
<seg id="2821">Each tablet ® AMMONAPS contains 62 mg (2.7 mmol) sodium around 2.5 g (108 mmol) sodium per 20 g sodium chloride tablets which corresponds to the maximum daily dose.</seg>
<seg id="2822">AMMONAPS should therefore be applied to patients with condensation or severe kidney disease as well as with sodium.</seg>
<seg id="2823">Since Metabolism and exchanger of sodium chloride in patients with liver and kidney disease should only be applied to patients with liver or kidney disease.</seg>
<seg id="2824">The importance of these results in relation to pregnant women is not known; the use of AMMONAPS during pregnancy is therefore a Indian (see 4.3).</seg>
<seg id="2825">"at subcutouts of phenylmethate at young rats in high dosage (190 - 474 mg / kg), it came to a slowing of neuronal distortion and an increased loss of neurons."</seg>
<seg id="2826">"it was also a delayed restitution of cerebral synapsen, and a reduced number of functional nervous disorders in the brain and thus a disability of brain users."</seg>
<seg id="2827">"the use of AMMONAPS during the breastfeeding is the use of AMMONAPS during the downtime, the use of AMMONAPS during the downtime (see 4.3)."</seg>
<seg id="2828">"in clinical trials with AMMONAPS stood at 56% of the patient's undesirable event (AE) and at 78% of this unwanted events, that it was not with AMMONAPS."</seg>
<seg id="2829">"the frequency is defined as follows: very often (Acts 1 / 10, &lt; 1 / 10) and occasionally (Acts 1 / 1,000, &lt; 1 / 100)."</seg>
<seg id="2830">"a significant toxic reaction to AMMONAPS (450 mg / kg / day) was developed by a 18 years old abnormal tumor in combination with liquoriot, armytopenie, peripheral neuropathy and Pankreatitis."</seg>
<seg id="2831">A case of an overdose occurred at a 5 months old small children with a certain single dose of 10 g (1370 mg / kg).</seg>
<seg id="2832">"this symptoms occur with accumulation of phenylmethate, which showed a intravenous adoption of cans up to 400 mg / kg / day."</seg>
<seg id="2833">"Phenylbenat is a metabolic-active connection that is used by Acetyloid with glylamine-glutamine, condensate about the kidneys."</seg>
<seg id="2834">"phenylmethyl glutamine with urea (both connections contain 2 nitrogen oxide); Phenylmethylglutamine is therefore suitable as an alternative carrier of excess of excess nitrogen."</seg>
<seg id="2835">5 patients with disturbances of the urine cycle can be accepted for each gram of sodium carbonate hardness between 0.12 and 0.15 g phenylmethyl glutamine-nitrogen.</seg>
<seg id="2836">It is important to improve the diagnosis at an early stage and treatment to improve the survival opportunities and the clinical result.</seg>
<seg id="2837">"the forecast of the early childhood in the early childhood was almost always infant, and the disease led to treatment with Peritonealdialysis and essential amino acids within the first half of the year."</seg>
<seg id="2838">"it is possible to increase the reduction of alternative ways of nitrogen oxide (sodium polyphenylmethylmethylate), proteinated Kost and the substance of essential amino acids, it possible to increase the survival rate of life in postpartal (however within the first life of the age of 80%)."</seg>
<seg id="2839">"in patients, their disease in the course of pregnancy was diagnosed, and the survival rate of 100%, but even in these patients, it came with time for many to mental disabilities or other neurological deficits."</seg>
<seg id="2840">"in patients with a delay of the disease, including female patients with the heterocyclerscotamylase-managers, which were treated by a hyperammonylasamylase-maneusis, which have been treated with sodium polyphenylbutyl and a proteindimentary diet, the survival rate 98%."</seg>
<seg id="2841">"the neurological deficits of neurological deficits are hardly resealed and in some patients, a further deterioration of neurological resistance can occur."</seg>
<seg id="2842">"Phenylbutyate is known for Phenylbutyate, which is used in liver and nuts."</seg>
<seg id="2843">"the concentration of phenylbutyloid and its metabolite in plasma and urine were treated according to the gift of a single dose of 5 g sodium polyphenylbutyl acetylene, as well as repetition of org. cans from up to 20 g / day (not controlled trials)."</seg>
<seg id="2844">The behavior of phenylbutyrat and its metabolite was also examined in cancer patients with intravenous fruits of sodium polyphenylbutyl (up to 2 g / m ²) or phenylmethyl.</seg>
<seg id="2845">After a orical single dose of 5 g sodium polysis in Tablaps have been found 15 minutes after taking the contamination of phenylbutyrate.</seg>
<seg id="2846">"in the majority of patients with urine cycloxide (300-650 mg / kg / day) at the next morning after the next morning, no Phenylmethylat in plasma is possible."</seg>
<seg id="2847">"in three cases, patients were treated with sodium polyphenols (20 g / day) which were treated with sodium phenylbutyrat (20 g / day), the medium phenylated concentration in the third day five times higher than after the first ones."</seg>
<seg id="2848">Exchanges The drug will take place within 24 hours to about 80 - 100% in the form of condensate product Phenylle glutamine about the kidneys.</seg>
<seg id="2849">"after the results of the micronucleus tests, sodium polyphenylmethylated with toxic and non toxic substances (study 24 and 48 h) according to a single dose of 878 to 2800 mg / kg)."</seg>
<seg id="2850">AMMONAPS granulate is used either oral (infants and children who have no tablets) or for patients with gorckdisorders) or a nose for a veneer or a nose.</seg>
<seg id="2851">"after the existing clinical experience, the normal daily dose is sodium polyphenylbutyrat: • 450 - 600 mg / kg / day with a body weight of less than 20 kg • 9.9 - 13.0 g / m ² / day for children with a body weight of 20 kg, as well as a growing and adult adults."</seg>
<seg id="2852">"the concentration of Ammonia, Arginine, essential amino acids (in particular edible amino acids), Carnitin and Serum proteinases in the plasma should be kept within the normal range."</seg>
<seg id="2853">"in case of patients who suffer an early treatment of Carbamylliatulamylase, the substitution of Citron or Arginine is required in a dosage of 0,17 g / kg / day or 3.8 g / m ² / day."</seg>
<seg id="2854">AMMONAPS granulate contains 124 mg (5.4 mmol) sodium for a gram of sodium polyphenylbutyloid what is equivalent to maximum daily dose.</seg>
<seg id="2855">"if you were exposed to the birth Phenylacetate (active Metabolism by phenylbutyate), it came to the pyramid cells of the brain cells."</seg>
<seg id="2856">"a significant toxic reaction to AMMONAPS (450 mg / kg / day) was developed by a 18 years old abnormal tumor in combination with liquoriot, armytopenie, peripheral neuropathy and Pankreatitis."</seg>
<seg id="2857">"pylmethylamine is a Phenylactic glutamine with urea (both connections contain 2 nitrogen oxide); Phenylmethylglutamine is therefore suitable as an alternative to excess of excess of excess of excess weight."</seg>
<seg id="2858">In patients with disturbances of phenylglyglutamine in patients with disturbances of the urine cycle can be accepted for each gram of sodium carbonate hardness between 0.12 and 0.15 g phenylmethyl glutamine-nitrogen.</seg>
<seg id="2859">"the neurological deficits of neurological deficits are hardly resealed, and in some patients a further deterioration of neurological resistance can occur."</seg>
<seg id="2860">After a orical single dose of 5 g sodium polyphenysis in granular form have been found 15 minutes after taking the contamination of phenylbutyrate.</seg>
<seg id="2861">"during the duration of the durability, the patient can be adjusted for a period of 3 months for a period of 3 months in a temperature of not over 25 ° C."</seg>
<seg id="2862">This method contains the small measuring spoon 0.95 g. the middle measuring spoon 2.9 g and the large measuring spoon 8.6 g sodium polyphenylmethylate.</seg>
<seg id="2863">"if a patient has to get the medication about a Sonde, AMMONAPS can be used in water (the solvent of sodium polyphenylbutyrat is up to 5 g in 10 ml water)."</seg>
<seg id="2864">"in patients with these rare diseases, certain liver enzymes, so that they may not fail the sticking waste products that could not be treated after the consumption of proteins."</seg>
<seg id="2865">"if your laboratory tests have to be made, you must take AMMONAPS, since sodium polyphenylbutyl results can influence the results of certain laboratory tests."</seg>
<seg id="2866">"when taking AMMONAPS with other medicines, please inform your doctor or pharmacist if you have other medicines or pharmacist, even if it is not non-prescription drugs."</seg>
<seg id="2867">During the downtime you may not use AMMONAPS.</seg>
<seg id="2868">"in rare cases, addiction, headaches, taste of the ear, dissemination of the ear, disorientated, joints and deterioration of existing neurological conditions observed."</seg>
<seg id="2869">"if you find one of these symptoms, please contact your doctor or with the notebooks of your hospital in a corresponding treatment."</seg>
<seg id="2870">If you have forgotten AMMONAPS please take the appropriate dose as soon as possible with the next meal.</seg>
<seg id="2871">"changes of blood body (red blood cells, white blood cells, orombocytes), snorkeling, depression, constipation, headache, constipation, kidney disorders, kidney disorders, kidney disorders, weight gain and anomale laboratory values."</seg>
<seg id="2872">Please inform your doctor or pharmacist if one of the adverse side effects or side effects that are not specified in this form information.</seg>
<seg id="2873">"you may not use AMMONAPS according to the box on the carton and the containers according to" "marked up to" "date."</seg>
<seg id="2874">"as AMMONAPS looks and content of the AMMONAPS tablets are of welded color and oval shape, and they are supplied with the embossing" UCY 500. "</seg>
<seg id="2875">"30 If your laboratory tests have to be made, you must take the doctor to use AMMONAPS, since sodium polyphenylbutyl results can influence the results of certain laboratory tests."</seg>
<seg id="2876">"when taking AMMONAPS with other medicines, please inform your doctor or pharmacist if you have other medicines or pharmacist, even if it is not non-prescription drugs."</seg>
<seg id="2877">"the AMMONAPS is distributed to the same single supplement, or via a stomach wall (tube, which will be brought directly into the stomach wall) or a nose (hose which is led by the nose into the stomach)."</seg>
<seg id="2878">"31 • Discover a straight edge, e.g. a knife to remove excess paint on the edge of the measuring spoon. • Discover the recommended number of measuring spoon granulate out of the container. • Discover the recommended number of measuring spoon granulate from the container. • Discover the recommended number of measuring spoon granulate out of the container. • Discover the recommended number of measuring spoon granulate from the container. • Discover the recommended number of measuring spoon granulate from the container. • Discover the recommended number of measuring spoon granulate from the container. • Discover the recommended number of measuring spoon granulate from the container. • Discover the recommended number of measuring spoon granulate from the container. • Discover the recommended number of measuring spoon granulate from the container. • Discover the recommended number of measuring spoon granulate from the container. • Discover the recommended number of measuring spoon granulate from the container. • Discover the recommended number of measuring spoon granulate from the container. • Discover the recommended number of measuring spoon granulate from the container. • Discover the recommended number of measuring spoon granulate from the container. • Discover the recommended number of measuring spoon granulate from the container.</seg>
<seg id="2879">"Angiox treatment will be applied to treat adult patients with" acute coronarsyndrome "(ACS, reduced blood supply to heart), for example in instabilty Angina (a form of pain in chest strap with different strength) or Myokardinfants (heart failure) or Myokardust (heart failure)."</seg>
<seg id="2880">Angiox is used for prevention of blood clauses in patients who are used to take a higher dose and the infusion can be continued until four hours after operation.</seg>
<seg id="2881">This can contribute to patients with Angina or heart failure to maintain blood flow to the heart and increase the effectiveness of a PCI.</seg>
<seg id="2882">About 14 000 patients have been compared to the main study on the treatment of Angiox / IIIA-Incinor (GPI) which was compared with a glycoagulation (GPI) and a GPI-inhibitor (GPI).</seg>
<seg id="2883">"during the PCI, patients often used a trient (a short tube that remains in the Arterie in order to prevent a lock in order to prevent a lock in order to prevent blood pressure, such as Abciximab and Aspirin."</seg>
<seg id="2884">"in treatment of ACS, Angiox - with or without a gift of GPI - in the failure of new events (deaths, heart failure or Reveals) after 30 days or a year, as effective as the traditional treatment."</seg>
<seg id="2885">"in the case of patients who were signed a PCI, Angiox was in relation to all indicators like heparin, except in severe blood vessels, in which it was considerably more effective than Heparin."</seg>
<seg id="2886">"Angiox may not be used in patients that may be sensitive (allergic) against Bivalirudin, other shudine or other components."</seg>
<seg id="2887">"it may also be used in patients with strong blood pressure or severe kidney problems, or a heart attack."</seg>
<seg id="2888">The Committee for Humanities (CHMP) corresponds to the conclusion that Angiox in treatment of ACS and during a PCI is a acceptable substitute for Heparin.</seg>
<seg id="2889">"September 2004, the European Commission published the company The Medicines Company UK Ltd, a permit for the Instruction of Angiox in the whole European Union."</seg>
<seg id="2890">"for treatment of adult patients with acute coronarrays (instabile Angina / non - ST-midrange infants (IA / NSTEMI), for a emergency stop or when a early intervention is scheduled."</seg>
<seg id="2891">The recommended initialdosis of Angiox in patients with ACS is an intravenous bolt from 0.1 mg / kg followed by a Infusion of 0.25 mg / kg / h.</seg>
<seg id="2892">"if the patient is performed in another episode, an additional bolts of 0.5 mg / kg, and the Infusion for the duration of the surgery on 1.75 mg / kg / h can be increased."</seg>
<seg id="2893">After the PCI can be added to clinical requirements the reduced induction dose from 0.25 mg / kg / h for 4 to 12 hours.</seg>
<seg id="2894">"directly before the procedure, a bolt of 0.5 mg / kg, followed by a Infusion of 1,75 mg / kg / h for the duration of the input."</seg>
<seg id="2895">The recommended dosage of Angiox in patients with a PCI consists of 0.75 mg / kg weight and one of the following intravenous infusion with a dose of 1.75 mg / kg weight weight / h at least for the duration of the surgery.</seg>
<seg id="2896">The safety and efficacy of a allotus gift of Angiox was not examined and is not recommended if a short PCI procedure is planned.</seg>
<seg id="2897">This value (mainpage after 5 minutes) can be shortened to 225 seconds. a second bolt from 0.3 mg / kg / body weight are done.</seg>
<seg id="2898">"in order to reduce the appearance of low power values, the refractionable and diluted drugs should be carefully mixed and the Bolusdosis can be replaced with intravenous membrane."</seg>
<seg id="2899">"as soon as the mainvalue is more than 225 seconds, a further monitoring is no longer required, the 1.75 mg / kg infusionsis is right correctly."</seg>
<seg id="2900">"for patients with medium severe kidney function (GFR 30-59 ml / min), which are used to be treated with Bivalirudin against ACS or not), should be a lower infusion rate of 1.4 mg / kg / h."</seg>
<seg id="2901">The mainvalue of 225 seconds is a second Bolusdosis of 0.3 mg / kg and the main5 minutes after the second Bolusdosis.</seg>
<seg id="2902">"in patients with medium severe kidney treatment, which were included in the phase III- PCI study (Remove-2) that were included in the phase III- PCI study (Remove-2) that were included for the approval of the Bivalirudin-Bolus without Dosisadjustable in average 366 ± 89 seconds."</seg>
<seg id="2903">Three Constitutional Complaints Lodged Against the Minimum Wage Act Inadmissible</seg>
<seg id="2904">Treatment with Angiox can be 30 minutes after the end of the intravenous disarmin or 8 hours after the age of subcutaneous heparin.</seg>
<seg id="2905">• sensitive hypersensitivity to the active substance or other components or increased blood vessels or increased blood circulation (GFR &lt; 30 ml / min) and for dialysis of patients.</seg>
<seg id="2906">Patients are carefully treated with regard to symptoms and signs of a blood circulation, especially when Bivalirudin in combination with another anagulans (see section 4.5). "</seg>
<seg id="2907">"even if the PCI patient under Bivalirudin, most of the blood vessels, may occur in patients that occur in a permalignite Koronarotti (PCI), while the treatment can occur anywhere in any blood vessels."</seg>
<seg id="2908">"in addition to patients who are treated with Bivalirudin, a monitoring of the INR value (International Standards Agency) should be moved to ensure that the value of treatment with Bivalirudin is achieved before the treatment of the treatment."</seg>
<seg id="2909">"starting from the knowledge about the active mechanism of anti-agulanules (Heparin, Warmbin, Thrombite or Thrombocytenure) can be determined to increase the blood circulation."</seg>
<seg id="2910">"in combination of bivalirudin with thrombocyclical units, the clinical and biological tests are the clinical and biological pathology parameters in any case regularly."</seg>
<seg id="2911">"in terms of effect on the effects of pregnancy, embryonic development, the embryonic development, the connection or postnatal development are insufficient (see under section 5.3)."</seg>
<seg id="2912">"in addition to Bivalirudin, 4604 were randomized to Bivalirudin plus GPIIb / IIIA Incinor and 4603 were randomized to either unbitionable heparin or Enoxapapy plus GPIIb / IIIA Inducor."</seg>
<seg id="2913">"both in the Bivalirc group, as well as in with Heparin-treated groups, it came to women and patients over 65 years more frequently seen in treatment than male or younger patients."</seg>
<seg id="2914">Severe blood vessels were defined according to the ACUITY and Timi dimensional as in the footnotes of table 2.</seg>
<seg id="2915">"both lightweight as well as heavy bleedings was significantly less frequently than in the groups with Heparin plus GPIIb / IIIA-Incinor, and Bivaliddin plus GPIIb / IIIOP Ingelor (see table 2)."</seg>
<seg id="2916">"a ACUITY heavy bleeding was defined as one of the following events: Incorporates, intraocular blood circulation or blood circulation in the point area which causes a radiological or surgical intervention, which caused a radiological or surgical intervention, caused by blood pressure, use of blood products for transfusion."</seg>
<seg id="2917">"further, less frequently observed blood vessels, which were only 0.1% (occasionally), were" other "points, retroperitoneal, gastrophoneal, ear, ear, nose or neck."</seg>
<seg id="2918">The following information on the side effects are based on the data of a clinical study with Bivalirudin in 6000 patients.</seg>
<seg id="2919">"both in the Bivaliro Group, as well as with heparin-treated groups, it came to women as well as in patients over 65 years more frequently seen in treatment than male or younger patients."</seg>
<seg id="2920">"both lightweight and heavy bleedings was significantly lower than in the comparison group under heparin plus GPIIb / IIIA-inhibitor."</seg>
<seg id="2921">"the following side effects, which are not listed below are listed according to the comprehensive application in practice, and are ordered by system organic classes in table 6."</seg>
<seg id="2922">"in the event of an overdose, the treatment with Bivalirt is immediately to break and break the patient with regard to signs of blood circulation."</seg>
<seg id="2923">"Angiox contains Bivalirudin, a direct and specific thrombinor, which is bound by the Catalonia Center of Thrombin, regardless of whether thrombin is bound in the liquid phase."</seg>
<seg id="2924">"the Binder of Bivalirudin at Thrombin, and thus its effect, is resealed, because thrombin in turn the binding of Bivalirudin-Arg3-Pro4 slow, making the function of the active center of thrombin."</seg>
<seg id="2925">"in addition, Bivalirudin (HIT / HITTS) did not come to Thrombozytopensis syndrome (HIT / HITTS), no Thrombocytes-aggregation action."</seg>
<seg id="2926">"in healthy subjects and patients, Bivalirudin is a class and concentration-dependent power-dependent effect that is supported by the extension of the mainboard, aPTT, PT, INR and TT."</seg>
<seg id="2927">"if the patient has been done, an additional bolt is given by 0.5mg / kg Bivalirudin and the Infusion for the duration of the input to 1,75mg / kg / h."</seg>
<seg id="2928">"in the arm A the ACUITY study was unacceptable in accordance with the relevant guidelines for the treatment of acute coronarsyndrome (ACS) in patients with instabilty Angina / non-ST-midrange infants (IA / NSTEMI)."</seg>
<seg id="2929">Patients in arm A and B were randomised to obtain a GPIIb / IIIA Incinor.</seg>
<seg id="2930">"in the ACUITY study, the characteristics of high-risk patients, which distributed a angiography within 72 hours, evenly distributed across the 3 treatment stages."</seg>
<seg id="2931">"about 77% of the patients had a recurring effect, 70% dynamic EKG- changes or increased kardiale Biomarker, 28% diabetes and about 99% of all patients were charged within 72 hours of a Angiography."</seg>
<seg id="2932">"the primary analysis and results from the ACUITY study for the total population (ITT) and for the total population (ITT) and for the patient, the Aspirin and Clopidogrel according to protocol (prior to the angiography or before the PCI), are shown in table 7 and 8."</seg>
<seg id="2933">ACUITY study; 30-days and 1 year of risk for combined endothelial endpoint and its components for patients who received Aspirin and Clopidogrel according to protocol *</seg>
<seg id="2934">Patients who received the Aspirin and Clopidogrel according to protocol the arm A arm B C UFH / Enox Bival - A C- A Bival + GPIIb / IIIA Risk Diff.</seg>
<seg id="2935">"the frequency of blood vessels, both in the ACUITY- as well as in Timi-scale up to 30 for the total population (ITT) and for patients who received Aspirin and Clopidogrel according to protocol, is represented in table 9."</seg>
<seg id="2936">"inhibitor inhibitors (N = 4612) GPIIb / IIIA / IIIA / IIIA / IIIA by Innox Bival Bival Bival + + + GPIIb / IIIA / IIIA / IIIA / IIIA / IIIA Intra (N = 2924)% (N = 2924)% (N = 2942)% (N = 2942)% (N = 2942)% (N = 2942)% (N = 2942)% (N = 2942)% (N = 2942)% (N = 2942)% (N = 2942)% (N = 2942)% (N = 2942)% (N = 2942)% (N = 2942)% (N = 2942)% (N = 2942)% (N = 2942)% (N = 2942)% (N = 2942)% (N = 2942)% (N = 2942)% (N = 2942)% (N = 2942)% (N = 2942)% (N = 2942)% (N = 2942)% (N = 2942)% (N = 2942)% (N = 2942)% (N = 2942)% (N = 2942)% (N = 2942)% (N = 2942)% (N = 2942)% (N = 2942)% (N = 2942)% (N = 2942)% (N = 2942)% (N = 2942)% (N = 2942)% (N = 2942)% (N = 2942)% (N = 2942)% (N = 2942)% (N = 2942)% (N = 29</seg>
<seg id="2937">"* Clopidogrel before Angiography or before PCI 1 A ACUITY, intraocular blood circulation, intraocular blood circulation or blood circulation in the point area that caused a radiological or surgical intervention, the reduction of the hemorphbinder of corn 3 g / dl with well known blood circulation, reproduction of blood circulation, use of blood products for transfusion."</seg>
<seg id="2938">"the 30-days results, based on four-channel and three-times endpoints of a prospective double blind study with more than 6,000 patients, are shown in table 10, are displayed in table 10."</seg>
<seg id="2939">Clinical trials with a small number of patients have limited information about the application of Angiox in patients with HIT / HITTS.</seg>
<seg id="2940">The pharmacokinetic properties of Bivalirudin were randomised in patients who underwent a permalignite Koronar.de (PCI) as well as in patients with ACS.</seg>
<seg id="2941">It is expected that Bivalirudin is expected to be a catabolism in its amino acids in its amino acids in its amino acids in the body pool.</seg>
<seg id="2942">The primary metabolition which is produced from the Arg3-Pro4 Binder of the N-date sequences by Thrombin are not effective due to the loss of its Affinity to the Catalan Centre of Thrombin.</seg>
<seg id="2943">Elimination takes place in patients with normal kidney function according to a process first order with a date half-value of 25 ± 12 minutes.</seg>
<seg id="2944">"based on conventional studies on safety spicology, toxicity with repetition of repetition, genotoxicity or reproduction of reproduction."</seg>
<seg id="2945">The toxicity of animals with repeated or continuous Exposition (1 day until 4 weeks with an Exposition up to 10 or more of the clinical Steady concentration) limited to excessive inflammatory effects.</seg>
<seg id="2946">Side effects due to a long-term physiological burden as reaction to a non-homectious coagulation were comparable to the clinical application, even at very much higher dosage, even at very much higher dosage. "</seg>
<seg id="2947">"if the production of used use is 17 not under controlled and validated conditions, this is no longer than 24 hours at 2 ° C to 8 ° C."</seg>
<seg id="2948">Angiox powder is a gey powder powder in single dosis bottles of type-1-glass to 10 ml which sealed with a Butt rubber hard foam and sealed a cap out of pressed aluminum.</seg>
<seg id="2949">"5 ml sterile water for injection purposes are given in a penetration bottle of Angiox, and easily moved up to everything completely dissolved and the solution is clear."</seg>
<seg id="2950">"5 ml glucose oxidation with 5% of glucose solution to injectors, or with 9 mg / ml (0.9%) sodium chloride solution to the injtion in a total volume of 50 ml to get a final concentration of 4mg / ml Bivalirudin."</seg>
<seg id="2951">"the owner of the permit is agreed, as in version 4 of the risk management plan, as in version 4 of the risk management plan, as in version 4 of the risk management plan (RMP), as in version 4 of the risk management plan (RMP), as in version 4 of the risk management plan (RMP)."</seg>
<seg id="2952">"according to the CHMP leader in risk management systems for humanities, the revised RMP is filed with the next periodic Safety Update Report (PSUR)."</seg>
<seg id="2953">• Patients with breast pain due to a heart disease (acute coronarisation - ACS) • patients treated treatment of closures in the blood vessels (Angitistia and / or or perk Koronarangiopathy - PCI).</seg>
<seg id="2954">• You are pregnant or suggest that you may be pregnant • you intend to be pregnant.</seg>
<seg id="2955">"however, the effects of the impact on the traffic and the ability to serve machines, but you know that the effects of this drug may only be short notice."</seg>
<seg id="2956">"if a blood flow should occur, the treatment with Angiox is broken. • Before the start of the injection or Infusion, your doctor will inform your doctor about the potential sign of an allergic reaction."</seg>
<seg id="2957">• A particularly careful monitoring will be carried out in less than 1 of 1000 patients. • A particularly careful monitoring will be carried out in less than 1 of 1000 patients. • The dose which you will receive from your body weight and type of therapy you will receive.</seg>
<seg id="2958">• 0.1 mg / kg body weight as a injector followed by an Infusion (dripping solution) with 0.25 mg / kg body weight means a tenth of a milligrams of the drug using any kg weight of the drug using any kg of body weight per hour.</seg>
<seg id="2959">"on the other hand, if Angiox occurs in combination with other mutations or anti-thrombotic drugs, (see section 2" on application of Angiox with other medicines). "</seg>
<seg id="2960">It is possible side effects (less than 1 of 100 patients). • Thrombose (blood flow) that could lead to serious complications like a heart failure.</seg>
<seg id="2961">It is an immediate side effect (less than 1 of 100 patients). • pain, blood circulation and blood cast at the point level (according to a PCI treatment). "</seg>
<seg id="2962">Please inform your doctor if one of the adverse side effects or side effects that are not specified in this form information.</seg>
<seg id="2963">"Angiox may not be applied according to the label and the carton after" "marked up to" "marked up to" "marked date" "date."</seg>
<seg id="2964">Polska The Medicines Company UK Ltd.: + 800 843 633 26 LUB + 41 61 564 1320 T-mail: + 30 210 5281700 E-mail:</seg>
<seg id="2965">"Apidra is used for treatment of adults, adolescents and children from six years with diabetes who need a treatment with insulin."</seg>
<seg id="2966">Apidra is subcutan (under the skin) in the pancreas or upper arm or the upper arm or as a permanent fusion of insulin.</seg>
<seg id="2967">Diabetes is an illness in which the body does not have enough insulin in the regulation of glucose (sugar) in blood or insulin.</seg>
<seg id="2968">"insulin pens are very slightly significant of humanities, and the change means that it is faster than a short-effective human consumption than a short-effective humanities."</seg>
<seg id="2969">"Apidra has been studied in combination with a long-effective insulin for patients with type 1 diabetes, in which the body does not produce insulin in patients with a total of 572 adults and in a study with 572 children aged between four and 17 years."</seg>
<seg id="2970">Type-2 diabetes in which the body insulin are not effective in a study with 878 adults.</seg>
<seg id="2971">The main indikator for the effectiveness was the change of the concentration of the substance of cosmic glymoglobin (HbA1c) in the blood that shows how good the blood sugar is set.</seg>
<seg id="2972">"in the first study with adults with type 1 diabetes, after six months a decrease of 0.14% (from 7.2% to 7.2%) compared to insulin resistance by 0.14%."</seg>
<seg id="2973">"for adults with type-2 diabetes, the decrease of HbA1c concentration 0.046% after six months with Apidra compared with Apidra compared with Apidra compared to 0,30%."</seg>
<seg id="2974">"Apidra must not be used in patients that may be sensitive (allergic) against insulin resistance or one of the other components, or in patients who suffer from a hypoglycemia."</seg>
<seg id="2975">"the cans of Apidra must be adjusted when it is together with a number of other medicines, which may affect blood cells."</seg>
<seg id="2976">"in September 2004 the European Commission adopted Sanofi-Aventis Germany GmbH, a permit for the Instruction of Apidra in the whole European Union."</seg>
<seg id="2977">"Apidra is available as subcutaneous injectors either in the area of the abdomen, the upper jaw or the dolite, or subcutout by continuous Infusion in the area of the pande-."</seg>
<seg id="2978">Due to reduced glucose capacity and reduced insulin treatment can be reduced in patients with a restriction of the liver function.</seg>
<seg id="2979">"any change of the operation, the brand (heron), of insulin (normal, NPH, zinction etc.), the type of insulin (e.g. insulin in) and / or the production method can change a change of insulin."</seg>
<seg id="2980">"3 A insufficient dosage or the collapse of a treatment, especially in patients with an adult diabetes, may lead to hyperglycemia and a diabetic cetoonics; these conditions are potential life-threatening."</seg>
<seg id="2981">The conversion of a patient should be carried out on another insulin type or insulin in another manufacturer in close medical supervision and can be necessary to take a change of dosage.</seg>
<seg id="2982">The treatment of a hypoglycemia depends on the treatment of the insulin used and can therefore change the treatment of the treatment.</seg>
<seg id="2983">"anti-oxidase inhibitors may increase blood sugar levels and inclination of hypods, fluoride, fluoride, fluoride, fluoride, fluoride, and sulfonyl acetate antibiotics."</seg>
<seg id="2984">"in addition, among the effect of Sympathia like Betabling, Clonidin, Guanethidin and reserve the symptoms of adrename-regulation or missing."</seg>
<seg id="2985">Animal studies showed no differences between Insu- linglulisine and humanities in relation to pregnancy, embryonic development, birth or postnatal development (see section 5.3). "</seg>
<seg id="2986">"it is not known whether insulin lulisle in the human breast milk, but in general occurs insulin in neither those in the mother's milk, nor will be resumed according to orderly application."</seg>
<seg id="2987">"below they are listed by clinical trials, they are listed in clinical trials (very often:) 1 / 10, &lt; 1 / 10; otherwise: &lt; 1 / 10; rare: &lt; 1 / 10,000, &lt; 1 / 10; very rare: &lt; 1 / 10,000); not known (frequency based on the basis of the available bays data)."</seg>
<seg id="2988">"cold - welding, cool and blet skin, fatigue, Nervosity or Trey, anxiety, unusual creation or weakness, confusion, concentration disorders, Benommenity, excessive rain, headache, and heart attack."</seg>
<seg id="2989">Liacystrophie does not collect the injector of the injections within the injections within the injector process can occur in a sequence of liposystrophie at the injector office.</seg>
<seg id="2990">Heavy Hypods with consciousness can be made by glukagon (0.5 to 1 mg) which will be treated by a prescribed person or by intravenous gift of gluten by a physician.</seg>
<seg id="2991">The patient should be monitored in a hospital in order to identify the urine effects for heavy Hypoglycemia.</seg>
<seg id="2992">Insulin lowers blood sugar levels (especially due to skeletal muscular muscles and fat) as well as the inhibition of glucose production in the liver.</seg>
<seg id="2993">Studies with healthy volunteers and patients with diabetes have shown that at subcutaneous Ga- be done by insulin resistance and the active duration is shorter than a hug normal normal fat.</seg>
<seg id="2994">"in a study with 18 male persons aged 21 to 50 years with type 1 diabetes melli- TuS showed insulin dosing range from 0,075 to 0.15 E / kg, or a lower weight of a cosmic effect, precisely as humanoid."</seg>
<seg id="2995">"insulin resistance has a double as fast efficiency, such as normal humanities and the complete isolation of the effect about 2 hours earlier than humanities."</seg>
<seg id="2996">"from the data it was obvious that in an application of insulin resistance in 2 minutes before the meal a comparable posture control will be achieved, such as human normal normal dose, 30 minutes before the meal."</seg>
<seg id="2997">"insulin resistance in 2 minutes before the meal, a better posture control is given a better posture control than with human normal normal fat, which was given 2 minutes before the meal."</seg>
<seg id="2998">"insulin resistance in 15 minutes after the beginning of the meal, a comparable glycation control such as human normal normal fat, the 2 miths of the meal will be given (see Figure 1)."</seg>
<seg id="2999">Insulin resistance in a meal 2 minutes (GLULISIN - prior) before the beginning of the meal in comparison to human normal normal normal dose, 30 minutes (normal - 30 min) before beginning of the meal was given (Figure 1B). "</seg>
<seg id="3000">Insulin resistance in a gift of 15 minutes (GLULISIN - after the beginning of the meal in comparison to humanem days (Figure 1C) before the beginning of the meal (figure 1C).</seg>
</doc>
</tstset>
